original_sentence	e1	e2	relation_type	metadata	preprocessed_sentence
The intestinal absorption of arsenate(As(V)) has been investigated in the chick by means of the in situ ligated duodenal loop technique. 	arsenate	As(V)	none	{'e1': {'word': 'arsenate', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d82.s1.e0'}, 'e2': {'word': 'As(V)', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d82.s1.e1'}, 'sentence_id': 'DDI-MedLine.d82.s1'}	The intestinal absorption of DRUG ( DRUGOTHER ) has been investigated in the chick by means of the in situ ligated duodenal loop technique .
By this procedure, it was observed that arsenate is rapidly and essentially completely absorbed (80-95%) from the lumen at As(V) concentrations up to 5 mM, declining to about 50% absorption at 50 mM. 	arsenate	As(V)	none	{'e1': {'word': 'arsenate', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d82.s2.e0'}, 'e2': {'word': 'As(V)', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d82.s2.e1'}, 'sentence_id': 'DDI-MedLine.d82.s2'}	By this procedure , it was observed that DRUG is rapidly and essentially completely absorbed ( 80 - 95 % ) from the lumen at DRUGOTHER concentrations up to 5 mM , declining to about 50 % absorption at 50 mM .
At stable As(V) concentrations greater than 1 mM, fractional mucosal cell accumulation of As(V) remains constant, while fractional transfer to the body declines. 	As(V)	As(V)	none	{'e1': {'word': 'As(V)', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d82.s4.e0'}, 'e2': {'word': 'As(V)', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d82.s4.e1'}, 'sentence_id': 'DDI-MedLine.d82.s4'}	At stable DRUG concentrations greater than 1 mM , fractional mucosal cell accumulation of DRUGOTHER remains constant , while fractional transfer to the body declines .
However, total mucosal accumulation of As(V) and that transferred to the body increase in a linear logarithmic fashion from 0.05 to 5 mm As(V). 	As(V)	As(V)	none	{'e1': {'word': 'As(V)', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d82.s5.e0'}, 'e2': {'word': 'As(V)', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d82.s5.e1'}, 'sentence_id': 'DDI-MedLine.d82.s5'}	However , total mucosal accumulation of DRUG and that transferred to the body increase in a linear logarithmic fashion from 0.05 to 5 mm DRUGOTHER .
Furthermore, arsenate and phosphate do not appear to share a common transport pathway in the duodenum and no evidence was obtained for any interaction between the two at this level. 	arsenate	phosphate	none	{'e1': {'word': 'arsenate', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d82.s7.e0'}, 'e2': {'word': 'phosphate', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d82.s7.e1'}, 'sentence_id': 'DDI-MedLine.d82.s7'}	Furthermore , DRUG and DRUGOTHER do not appear to share a common transport pathway in the duodenum and no evidence was obtained for any interaction between the two at this level .
Vitamin D3 administration to rachitic chicks was effective in significantly elevating duodenal arsenate absorption, acting primarily to enhance serosal transport.	Vitamin D3	arsenate	mechanism	{'e1': {'word': 'Vitamin D3', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d82.s8.e0'}, 'e2': {'word': 'arsenate', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d82.s8.e1'}, 'sentence_id': 'DDI-MedLine.d82.s8'}	DRUG administration to rachitic chicks was effective in significantly elevating duodenal DRUGOTHER absorption , acting primarily to enhance serosal transport .
The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.	non-nucleoside reverse transcriptase inhibitors	antiretroviral	none	{'e1': {'word': 'non-nucleoside reverse transcriptase inhibitors', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d132.s0.e0'}, 'e2': {'word': 'antiretroviral', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d132.s0.e1'}, 'sentence_id': 'DDI-MedLine.d132.s0'}	The emerging roles of DRUG in DRUGOTHER therapy .
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	non-nucleoside reverse transcriptase inhibitor	NNRTI	none	{'e1': {'word': 'non-nucleoside reverse transcriptase inhibitor', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d132.s1.e0'}, 'e2': {'word': 'NNRTI', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d132.s1.e1'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	The availability of potent DRUG ( DRUGOTHER ) - based regimens for DRUGUNRELATED therapy and concerns regarding DRUGUNRELATED ( DRUGUNRELATED ) - related metabolic disturbances have led to significant shifts in treatment practices in HIV infection .
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	non-nucleoside reverse transcriptase inhibitor	antiretroviral	none	{'e1': {'word': 'non-nucleoside reverse transcriptase inhibitor', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d132.s1.e0'}, 'e2': {'word': 'antiretroviral', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d132.s1.e2'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	The availability of potent DRUG ( DRUGUNRELATED ) - based regimens for DRUGOTHER therapy and concerns regarding DRUGUNRELATED ( DRUGUNRELATED ) - related metabolic disturbances have led to significant shifts in treatment practices in HIV infection .
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	non-nucleoside reverse transcriptase inhibitor	protease inhibitor	none	{'e1': {'word': 'non-nucleoside reverse transcriptase inhibitor', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d132.s1.e0'}, 'e2': {'word': 'protease inhibitor', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d132.s1.e3'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	The availability of potent DRUG ( DRUGUNRELATED ) - based regimens for DRUGUNRELATED therapy and concerns regarding DRUGOTHER ( DRUGUNRELATED ) - related metabolic disturbances have led to significant shifts in treatment practices in HIV infection .
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	non-nucleoside reverse transcriptase inhibitor	PI	none	{'e1': {'word': 'non-nucleoside reverse transcriptase inhibitor', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d132.s1.e0'}, 'e2': {'word': 'PI', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d132.s1.e4'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	The availability of potent DRUG ( DRUGUNRELATED ) - based regimens for DRUGUNRELATED therapy and concerns regarding DRUGUNRELATED ( DRUGOTHER ) - related metabolic disturbances have led to significant shifts in treatment practices in HIV infection .
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	NNRTI	antiretroviral	none	{'e1': {'word': 'NNRTI', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d132.s1.e1'}, 'e2': {'word': 'antiretroviral', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d132.s1.e2'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	The availability of potent DRUGUNRELATED ( DRUG ) - based regimens for DRUGOTHER therapy and concerns regarding DRUGUNRELATED ( DRUGUNRELATED ) - related metabolic disturbances have led to significant shifts in treatment practices in HIV infection .
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	NNRTI	protease inhibitor	none	{'e1': {'word': 'NNRTI', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d132.s1.e1'}, 'e2': {'word': 'protease inhibitor', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d132.s1.e3'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	The availability of potent DRUGUNRELATED ( DRUG ) - based regimens for DRUGUNRELATED therapy and concerns regarding DRUGOTHER ( DRUGUNRELATED ) - related metabolic disturbances have led to significant shifts in treatment practices in HIV infection .
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	NNRTI	PI	none	{'e1': {'word': 'NNRTI', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d132.s1.e1'}, 'e2': {'word': 'PI', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d132.s1.e4'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	The availability of potent DRUGUNRELATED ( DRUG ) - based regimens for DRUGUNRELATED therapy and concerns regarding DRUGUNRELATED ( DRUGOTHER ) - related metabolic disturbances have led to significant shifts in treatment practices in HIV infection .
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	antiretroviral	protease inhibitor	none	{'e1': {'word': 'antiretroviral', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d132.s1.e2'}, 'e2': {'word': 'protease inhibitor', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d132.s1.e3'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	The availability of potent DRUGUNRELATED ( DRUGUNRELATED ) - based regimens for DRUG therapy and concerns regarding DRUGOTHER ( DRUGUNRELATED ) - related metabolic disturbances have led to significant shifts in treatment practices in HIV infection .
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	antiretroviral	PI	none	{'e1': {'word': 'antiretroviral', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d132.s1.e2'}, 'e2': {'word': 'PI', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d132.s1.e4'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	The availability of potent DRUGUNRELATED ( DRUGUNRELATED ) - based regimens for DRUG therapy and concerns regarding DRUGUNRELATED ( DRUGOTHER ) - related metabolic disturbances have led to significant shifts in treatment practices in HIV infection .
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	protease inhibitor	PI	none	{'e1': {'word': 'protease inhibitor', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d132.s1.e3'}, 'e2': {'word': 'PI', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d132.s1.e4'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	The availability of potent DRUGUNRELATED ( DRUGUNRELATED ) - based regimens for DRUGUNRELATED therapy and concerns regarding DRUG ( DRUGOTHER ) - related metabolic disturbances have led to significant shifts in treatment practices in HIV infection .
NNRTI-based regimens may have several advantages over PI-based therapy for initial or prolonged therapy, including more convenient administration regimens, lower tablet volume, fewer drug interactions, and central nervous system penetration. 	NNRTI	PI	none	{'e1': {'word': 'NNRTI', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d132.s2.e0'}, 'e2': {'word': 'PI', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d132.s2.e1'}, 'sentence_id': 'DDI-MedLine.d132.s2'}	DRUG - based regimens may have several advantages over DRUGOTHER - based therapy for initial or prolonged therapy , including more convenient administration regimens , lower tablet volume , fewer drug interactions , and central nervous system penetration .
No data from prospective clinical trials currently exist comparing the 3 approved agents (efavirenz, nevirapine or delavirdine). 	efavirenz	nevirapine	none	{'e1': {'word': 'efavirenz', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d132.s3.e0'}, 'e2': {'word': 'nevirapine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d132.s3.e1'}, 'sentence_id': 'DDI-MedLine.d132.s3'}	No data from prospective clinical trials currently exist comparing the 3 approved agents ( DRUG , DRUGOTHER or DRUGUNRELATED ) .
No data from prospective clinical trials currently exist comparing the 3 approved agents (efavirenz, nevirapine or delavirdine). 	efavirenz	delavirdine	none	{'e1': {'word': 'efavirenz', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d132.s3.e0'}, 'e2': {'word': 'delavirdine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d132.s3.e2'}, 'sentence_id': 'DDI-MedLine.d132.s3'}	No data from prospective clinical trials currently exist comparing the 3 approved agents ( DRUG , DRUGUNRELATED or DRUGOTHER ) .
No data from prospective clinical trials currently exist comparing the 3 approved agents (efavirenz, nevirapine or delavirdine). 	nevirapine	delavirdine	none	{'e1': {'word': 'nevirapine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d132.s3.e1'}, 'e2': {'word': 'delavirdine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d132.s3.e2'}, 'sentence_id': 'DDI-MedLine.d132.s3'}	No data from prospective clinical trials currently exist comparing the 3 approved agents ( DRUGUNRELATED , DRUG or DRUGOTHER ) .
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	efavirenz	nevirapine	none	{'e1': {'word': 'efavirenz', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d132.s4.e0'}, 'e2': {'word': 'nevirapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s4.e1'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both DRUG and DRUGOTHER have been compared to triple therapy with the DRUGUNRELATED DRUGUNRELATED over 48 weeks as initial therapy , with similar responses being observed with DRUGUNRELATED regimens and superiority observed with DRUGUNRELATED .
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	efavirenz	PI	none	{'e1': {'word': 'efavirenz', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d132.s4.e0'}, 'e2': {'word': 'PI', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d132.s4.e2'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both DRUG and DRUGUNRELATED have been compared to triple therapy with the DRUGOTHER DRUGUNRELATED over 48 weeks as initial therapy , with similar responses being observed with DRUGUNRELATED regimens and superiority observed with DRUGUNRELATED .
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	efavirenz	indinavir	none	{'e1': {'word': 'efavirenz', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d132.s4.e0'}, 'e2': {'word': 'indinavir', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d132.s4.e3'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both DRUG and DRUGUNRELATED have been compared to triple therapy with the DRUGUNRELATED DRUGOTHER over 48 weeks as initial therapy , with similar responses being observed with DRUGUNRELATED regimens and superiority observed with DRUGUNRELATED .
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	efavirenz	nevirapine	none	{'e1': {'word': 'efavirenz', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d132.s4.e0'}, 'e2': {'word': 'nevirapine', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d132.s4.e4'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both DRUG and DRUGUNRELATED have been compared to triple therapy with the DRUGUNRELATED DRUGUNRELATED over 48 weeks as initial therapy , with similar responses being observed with DRUGOTHER regimens and superiority observed with DRUGUNRELATED .
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	efavirenz	efavirenz	none	{'e1': {'word': 'efavirenz', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d132.s4.e0'}, 'e2': {'word': 'efavirenz', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d132.s4.e5'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both DRUG and DRUGUNRELATED have been compared to triple therapy with the DRUGUNRELATED DRUGUNRELATED over 48 weeks as initial therapy , with similar responses being observed with DRUGUNRELATED regimens and superiority observed with DRUGOTHER .
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	nevirapine	PI	none	{'e1': {'word': 'nevirapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s4.e1'}, 'e2': {'word': 'PI', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d132.s4.e2'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both DRUGUNRELATED and DRUG have been compared to triple therapy with the DRUGOTHER DRUGUNRELATED over 48 weeks as initial therapy , with similar responses being observed with DRUGUNRELATED regimens and superiority observed with DRUGUNRELATED .
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	nevirapine	indinavir	none	{'e1': {'word': 'nevirapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s4.e1'}, 'e2': {'word': 'indinavir', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d132.s4.e3'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both DRUGUNRELATED and DRUG have been compared to triple therapy with the DRUGUNRELATED DRUGOTHER over 48 weeks as initial therapy , with similar responses being observed with DRUGUNRELATED regimens and superiority observed with DRUGUNRELATED .
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	nevirapine	nevirapine	none	{'e1': {'word': 'nevirapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s4.e1'}, 'e2': {'word': 'nevirapine', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d132.s4.e4'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both DRUGUNRELATED and DRUG have been compared to triple therapy with the DRUGUNRELATED DRUGUNRELATED over 48 weeks as initial therapy , with similar responses being observed with DRUGOTHER regimens and superiority observed with DRUGUNRELATED .
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	nevirapine	efavirenz	none	{'e1': {'word': 'nevirapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s4.e1'}, 'e2': {'word': 'efavirenz', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d132.s4.e5'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both DRUGUNRELATED and DRUG have been compared to triple therapy with the DRUGUNRELATED DRUGUNRELATED over 48 weeks as initial therapy , with similar responses being observed with DRUGUNRELATED regimens and superiority observed with DRUGOTHER .
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	PI	indinavir	none	{'e1': {'word': 'PI', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d132.s4.e2'}, 'e2': {'word': 'indinavir', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d132.s4.e3'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both DRUGUNRELATED and DRUGUNRELATED have been compared to triple therapy with the DRUG DRUGOTHER over 48 weeks as initial therapy , with similar responses being observed with DRUGUNRELATED regimens and superiority observed with DRUGUNRELATED .
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	PI	nevirapine	none	{'e1': {'word': 'PI', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d132.s4.e2'}, 'e2': {'word': 'nevirapine', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d132.s4.e4'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both DRUGUNRELATED and DRUGUNRELATED have been compared to triple therapy with the DRUG DRUGUNRELATED over 48 weeks as initial therapy , with similar responses being observed with DRUGOTHER regimens and superiority observed with DRUGUNRELATED .
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	PI	efavirenz	none	{'e1': {'word': 'PI', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d132.s4.e2'}, 'e2': {'word': 'efavirenz', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d132.s4.e5'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both DRUGUNRELATED and DRUGUNRELATED have been compared to triple therapy with the DRUG DRUGUNRELATED over 48 weeks as initial therapy , with similar responses being observed with DRUGUNRELATED regimens and superiority observed with DRUGOTHER .
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	indinavir	nevirapine	none	{'e1': {'word': 'indinavir', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d132.s4.e3'}, 'e2': {'word': 'nevirapine', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d132.s4.e4'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both DRUGUNRELATED and DRUGUNRELATED have been compared to triple therapy with the DRUGUNRELATED DRUG over 48 weeks as initial therapy , with similar responses being observed with DRUGOTHER regimens and superiority observed with DRUGUNRELATED .
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	indinavir	efavirenz	none	{'e1': {'word': 'indinavir', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d132.s4.e3'}, 'e2': {'word': 'efavirenz', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d132.s4.e5'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both DRUGUNRELATED and DRUGUNRELATED have been compared to triple therapy with the DRUGUNRELATED DRUG over 48 weeks as initial therapy , with similar responses being observed with DRUGUNRELATED regimens and superiority observed with DRUGOTHER .
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	nevirapine	efavirenz	none	{'e1': {'word': 'nevirapine', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d132.s4.e4'}, 'e2': {'word': 'efavirenz', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d132.s4.e5'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both DRUGUNRELATED and DRUGUNRELATED have been compared to triple therapy with the DRUGUNRELATED DRUGUNRELATED over 48 weeks as initial therapy , with similar responses being observed with DRUG regimens and superiority observed with DRUGOTHER .
A smaller 24-week study has suggested nevirapine may be superior to the PI nelfinavir. 	nevirapine	PI	none	{'e1': {'word': 'nevirapine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d132.s5.e0'}, 'e2': {'word': 'PI', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d132.s5.e1'}, 'sentence_id': 'DDI-MedLine.d132.s5'}	A smaller 24 - week study has suggested DRUG may be superior to the DRUGOTHER DRUGUNRELATED .
A smaller 24-week study has suggested nevirapine may be superior to the PI nelfinavir. 	nevirapine	nelfinavir	none	{'e1': {'word': 'nevirapine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d132.s5.e0'}, 'e2': {'word': 'nelfinavir', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d132.s5.e2'}, 'sentence_id': 'DDI-MedLine.d132.s5'}	A smaller 24 - week study has suggested DRUG may be superior to the DRUGUNRELATED DRUGOTHER .
A smaller 24-week study has suggested nevirapine may be superior to the PI nelfinavir. 	PI	nelfinavir	none	{'e1': {'word': 'PI', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d132.s5.e1'}, 'e2': {'word': 'nelfinavir', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d132.s5.e2'}, 'sentence_id': 'DDI-MedLine.d132.s5'}	A smaller 24 - week study has suggested DRUGUNRELATED may be superior to the DRUG DRUGOTHER .
Limited comparative data in patients with high viral loads treated with nevirapine- or delavirdine-based regimens currently exist. 	nevirapine	delavirdine	none	{'e1': {'word': 'nevirapine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d132.s6.e0'}, 'e2': {'word': 'delavirdine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d132.s6.e1'}, 'sentence_id': 'DDI-MedLine.d132.s6'}	Limited comparative data in patients with high viral loads treated with DRUG - or DRUGOTHER - based regimens currently exist .
The superiority of efavirenz over indinavir-based regimens has been observed in comparative data in a subset of patients with high viral loads. 	efavirenz	indinavir	none	{'e1': {'word': 'efavirenz', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s8.e0'}, 'e2': {'word': 'indinavir', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d132.s8.e1'}, 'sentence_id': 'DDI-MedLine.d132.s8'}	The superiority of DRUG over DRUGOTHER - based regimens has been observed in comparative data in a subset of patients with high viral loads .
Efavirenz has demonstrated superiority over nelfinavir in nucleoside-experienced patients, although combining these 2 agents may represent the best approach in these circumstances. 	Efavirenz	nelfinavir	none	{'e1': {'word': 'Efavirenz', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d132.s10.e0'}, 'e2': {'word': 'nelfinavir', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d132.s10.e1'}, 'sentence_id': 'DDI-MedLine.d132.s10'}	DRUG has demonstrated superiority over DRUGOTHER in nucleoside - experienced patients , although combining these 2 agents may represent the best approach in these circumstances .
"Enhanced theophylline clearance secondary to phenytoin therapy.
"	theophylline	phenytoin	mechanism	{'e1': {'word': 'theophylline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d7.s0.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d7.s0.e1'}, 'sentence_id': 'DDI-MedLine.d7.s0'}	Enhanced DRUG clearance secondary to DRUGOTHER therapy .
This report describes two cases in which theophylline clearance accelerated markedly with concomitant phenytoin administration. 	theophylline	phenytoin	mechanism	{'e1': {'word': 'theophylline', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d7.s1.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d7.s1.e1'}, 'sentence_id': 'DDI-MedLine.d7.s1'}	This report describes two cases in which DRUG clearance accelerated markedly with concomitant DRUGOTHER administration .
With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.	phenytoin	theophylline	effect	{'e1': {'word': 'phenytoin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d7.s4.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d7.s4.e1'}, 'sentence_id': 'DDI-MedLine.d7.s4'}	With combined use , clinicians should be aware , when DRUG is added , of the potential for reexacerbation of pulmonary symptomatology due to lowered serum DRUGOTHER concentrations .
"Selective survival in pentazocine and tripelennamine of Pseudomonas aeruginosa serotype O11 from drug addicts.
"	pentazocine	tripelennamine	none	{'e1': {'word': 'pentazocine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d45.s0.e0'}, 'e2': {'word': 'tripelennamine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d45.s0.e1'}, 'sentence_id': 'DDI-MedLine.d45.s0'}	Selective survival in DRUG and DRUGOTHER of Pseudomonas aeruginosa serotype O11 from drug addicts .
The growth of Pseudomonas aeruginosa, particularly serotype O11, in pentazocine and tripelennamine 	pentazocine	tripelennamine	none	{'e1': {'word': 'pentazocine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d45.s1.e0'}, 'e2': {'word': 'tripelennamine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d45.s1.e1'}, 'sentence_id': 'DDI-MedLine.d45.s1'}	The growth of Pseudomonas aeruginosa , particularly serotype O11 , in DRUG and DRUGOTHER
Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination. 	heroin	pentazocine	none	{'e1': {'word': 'heroin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d45.s5.e0'}, 'e2': {'word': 'pentazocine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d45.s5.e1'}, 'sentence_id': 'DDI-MedLine.d45.s5'}	Twelve strains of Staphylococcus aureus ( a frequent cause of infection in DRUG , but not in DRUGOTHER and DRUGUNRELATED , addicts ) were completely inhibited by the drug combination .
Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination. 	heroin	tripelennamine	none	{'e1': {'word': 'heroin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d45.s5.e0'}, 'e2': {'word': 'tripelennamine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d45.s5.e2'}, 'sentence_id': 'DDI-MedLine.d45.s5'}	Twelve strains of Staphylococcus aureus ( a frequent cause of infection in DRUG , but not in DRUGUNRELATED and DRUGOTHER , addicts ) were completely inhibited by the drug combination .
Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination. 	pentazocine	tripelennamine	effect	{'e1': {'word': 'pentazocine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d45.s5.e1'}, 'e2': {'word': 'tripelennamine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d45.s5.e2'}, 'sentence_id': 'DDI-MedLine.d45.s5'}	Twelve strains of Staphylococcus aureus ( a frequent cause of infection in DRUGUNRELATED , but not in DRUG and DRUGOTHER , addicts ) were completely inhibited by the drug combination .
Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine. 	tripelennamine	pentazocine	effect	{'e1': {'word': 'tripelennamine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d45.s6.e0'}, 'e2': {'word': 'pentazocine', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d45.s6.e1'}, 'sentence_id': 'DDI-MedLine.d45.s6'}	Dose - response curves ( derived from the results of using the tablets as well as pure powders ) showed that DRUG was responsible for the inhibitory activity , which was partially antagonized by DRUGOTHER .
aureus, to survive in pentazocine and tripelennamine may explain in part a shift from S. 	pentazocine	tripelennamine	none	{'e1': {'word': 'pentazocine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d45.s9.e0'}, 'e2': {'word': 'tripelennamine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d45.s9.e1'}, 'sentence_id': 'DDI-MedLine.d45.s9'}	aureus , to survive in DRUG and DRUGOTHER may explain in part a shift from S.
Since the arrival of oral erection-supporting medication, patients want to know how safe sexual activity is in cardiovascular disease in general and during use of erection-supporting medication in particular. 	erection-supporting medication	erection-supporting medication	none	{'e1': {'word': 'erection-supporting medication', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d1.s1.e0'}, 'e2': {'word': 'erection-supporting medication', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d1.s1.e1'}, 'sentence_id': 'DDI-MedLine.d1.s1'}	Since the arrival of oral DRUG , patients want to know how safe sexual activity is in cardiovascular disease in general and during use of DRUGOTHER in particular .
Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure. 	Sildenafil	long-acting nitrates	advise	{'e1': {'word': 'Sildenafil', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d1.s5.e0'}, 'e2': {'word': 'long-acting nitrates', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d1.s5.e1'}, 'sentence_id': 'DDI-MedLine.d1.s5'}	DRUG is contraindicated in patients using DRUGOTHER or who may need to use DRUGUNRELATED , because the combination may cause a sharp fall of the blood pressure .
Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure. 	Sildenafil	short-acting nitrates	advise	{'e1': {'word': 'Sildenafil', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d1.s5.e0'}, 'e2': {'word': 'short-acting nitrates', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d1.s5.e2'}, 'sentence_id': 'DDI-MedLine.d1.s5'}	DRUG is contraindicated in patients using DRUGUNRELATED or who may need to use DRUGOTHER , because the combination may cause a sharp fall of the blood pressure .
Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure. 	long-acting nitrates	short-acting nitrates	none	{'e1': {'word': 'long-acting nitrates', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d1.s5.e1'}, 'e2': {'word': 'short-acting nitrates', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d1.s5.e2'}, 'sentence_id': 'DDI-MedLine.d1.s5'}	DRUGUNRELATED is contraindicated in patients using DRUG or who may need to use DRUGOTHER , because the combination may cause a sharp fall of the blood pressure .
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	beta-receptor blockers	calcium antagonists	none	{'e1': {'word': 'beta-receptor blockers', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d1.s6.e0'}, 'e2': {'word': 'calcium antagonists', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d1.s6.e1'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	No interactions have been observed with DRUG , DRUGOTHER , DRUGUNRELATED and DRUGUNRELATED DRUGUNRELATED and DRUGUNRELATED .
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	beta-receptor blockers	thiazide diuretics	none	{'e1': {'word': 'beta-receptor blockers', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d1.s6.e0'}, 'e2': {'word': 'thiazide diuretics', 'word_index': [(10, 10), (13, 13)], 'id': 'DDI-MedLine.d1.s6.e2'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	No interactions have been observed with DRUG , DRUGUNRELATED , DRUGOTHER and DRUGUNRELATED DRUGOTHER and DRUGUNRELATED .
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	beta-receptor blockers	loop diuretics	none	{'e1': {'word': 'beta-receptor blockers', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d1.s6.e0'}, 'e2': {'word': 'loop diuretics', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d1.s6.e3'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	No interactions have been observed with DRUG , DRUGUNRELATED , DRUGUNRELATED and DRUGOTHER DRUGUNRELATED and DRUGUNRELATED .
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	beta-receptor blockers	ACE inhibitors	none	{'e1': {'word': 'beta-receptor blockers', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d1.s6.e0'}, 'e2': {'word': 'ACE inhibitors', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d1.s6.e4'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	No interactions have been observed with DRUG , DRUGUNRELATED , DRUGUNRELATED and DRUGUNRELATED DRUGUNRELATED and DRUGOTHER .
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	calcium antagonists	thiazide diuretics	none	{'e1': {'word': 'calcium antagonists', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d1.s6.e1'}, 'e2': {'word': 'thiazide diuretics', 'word_index': [(10, 10), (13, 13)], 'id': 'DDI-MedLine.d1.s6.e2'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	No interactions have been observed with DRUGUNRELATED , DRUG , DRUGOTHER and DRUGUNRELATED DRUGOTHER and DRUGUNRELATED .
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	calcium antagonists	loop diuretics	none	{'e1': {'word': 'calcium antagonists', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d1.s6.e1'}, 'e2': {'word': 'loop diuretics', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d1.s6.e3'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	No interactions have been observed with DRUGUNRELATED , DRUG , DRUGUNRELATED and DRUGOTHER DRUGUNRELATED and DRUGUNRELATED .
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	calcium antagonists	ACE inhibitors	none	{'e1': {'word': 'calcium antagonists', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d1.s6.e1'}, 'e2': {'word': 'ACE inhibitors', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d1.s6.e4'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	No interactions have been observed with DRUGUNRELATED , DRUG , DRUGUNRELATED and DRUGUNRELATED DRUGUNRELATED and DRUGOTHER .
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	thiazide diuretics	loop diuretics	none	{'e1': {'word': 'thiazide diuretics', 'word_index': [(10, 10), (13, 13)], 'id': 'DDI-MedLine.d1.s6.e2'}, 'e2': {'word': 'loop diuretics', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d1.s6.e3'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	No interactions have been observed with DRUGUNRELATED , DRUGUNRELATED , DRUG and DRUGOTHER DRUG and DRUGUNRELATED .
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	thiazide diuretics	ACE inhibitors	none	{'e1': {'word': 'thiazide diuretics', 'word_index': [(10, 10), (13, 13)], 'id': 'DDI-MedLine.d1.s6.e2'}, 'e2': {'word': 'ACE inhibitors', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d1.s6.e4'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	No interactions have been observed with DRUGUNRELATED , DRUGUNRELATED , DRUG and DRUGUNRELATED DRUG and DRUGOTHER .
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	loop diuretics	ACE inhibitors	none	{'e1': {'word': 'loop diuretics', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d1.s6.e3'}, 'e2': {'word': 'ACE inhibitors', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d1.s6.e4'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	No interactions have been observed with DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED and DRUG DRUGUNRELATED and DRUGOTHER .
"Interaction of gentamycin and atracurium in anaesthetised horses.
"	gentamycin	atracurium	int	{'e1': {'word': 'gentamycin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d90.s0.e0'}, 'e2': {'word': 'atracurium', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d90.s0.e1'}, 'sentence_id': 'DDI-MedLine.d90.s0'}	Interaction of DRUG and DRUGOTHER in anaesthetised horses .
Evoked hind limb digital extensor tension (hoof twitch) was maintained at 40% of baseline for 1 h by atracurium infusion in 7 horses anaesthetised with halothane. 	atracurium	halothane	none	{'e1': {'word': 'atracurium', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d90.s1.e0'}, 'e2': {'word': 'halothane', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d90.s1.e1'}, 'sentence_id': 'DDI-MedLine.d90.s1'}	Evoked hind limb digital extensor tension ( hoof twitch ) was maintained at 40 % of baseline for 1 h by DRUG infusion in 7 horses anaesthetised with DRUGOTHER .
Atracurium was again given by infusion to maintain 40% twitch for a second hour, then 2 mg gentamycin/kg bwt were given i.v. 	Atracurium	gentamycin	none	{'e1': {'word': 'Atracurium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d90.s3.e0'}, 'e2': {'word': 'gentamycin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d90.s3.e1'}, 'sentence_id': 'DDI-MedLine.d90.s3'}	DRUG was again given by infusion to maintain 40 % twitch for a second hour , then 2 mg DRUGOTHER / kg bwt were given i.v.
Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for atracurium alone and 11.5 +/- 2.7 min for atracurium plus gentamycin (P = 0.03). 	atracurium	atracurium	none	{'e1': {'word': 'atracurium', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d90.s7.e0'}, 'e2': {'word': 'atracurium', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d90.s7.e1'}, 'sentence_id': 'DDI-MedLine.d90.s7'}	Recovery of hoof twitch from 50 % to 75 % took 7.7 + / - 0.7 min for DRUG alone and 11.5 + / - 2.7 min for DRUGOTHER plus DRUGUNRELATED ( P = 0.03 ) .
Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for atracurium alone and 11.5 +/- 2.7 min for atracurium plus gentamycin (P = 0.03). 	atracurium	gentamycin	none	{'e1': {'word': 'atracurium', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d90.s7.e0'}, 'e2': {'word': 'gentamycin', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d90.s7.e2'}, 'sentence_id': 'DDI-MedLine.d90.s7'}	Recovery of hoof twitch from 50 % to 75 % took 7.7 + / - 0.7 min for DRUG alone and 11.5 + / - 2.7 min for DRUGUNRELATED plus DRUGOTHER ( P = 0.03 ) .
Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for atracurium alone and 11.5 +/- 2.7 min for atracurium plus gentamycin (P = 0.03). 	atracurium	gentamycin	effect	{'e1': {'word': 'atracurium', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d90.s7.e1'}, 'e2': {'word': 'gentamycin', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d90.s7.e2'}, 'sentence_id': 'DDI-MedLine.d90.s7'}	Recovery of hoof twitch from 50 % to 75 % took 7.7 + / - 0.7 min for DRUGUNRELATED alone and 11.5 + / - 2.7 min for DRUG plus DRUGOTHER ( P = 0.03 ) .
Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for atracurium alone and 13.7 +/- 1.2 min for atracurium plus gentamycin. 	atracurium	atracurium	none	{'e1': {'word': 'atracurium', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d90.s8.e0'}, 'e2': {'word': 'atracurium', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d90.s8.e1'}, 'sentence_id': 'DDI-MedLine.d90.s8'}	Recovery from 50 % twitch to 75 % fade recovery took 13.8 + / - 0.8 min for DRUG alone and 13.7 + / - 1.2 min for DRUGOTHER plus DRUGUNRELATED .
Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for atracurium alone and 13.7 +/- 1.2 min for atracurium plus gentamycin. 	atracurium	gentamycin	none	{'e1': {'word': 'atracurium', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d90.s8.e0'}, 'e2': {'word': 'gentamycin', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d90.s8.e2'}, 'sentence_id': 'DDI-MedLine.d90.s8'}	Recovery from 50 % twitch to 75 % fade recovery took 13.8 + / - 0.8 min for DRUG alone and 13.7 + / - 1.2 min for DRUGUNRELATED plus DRUGOTHER .
Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for atracurium alone and 13.7 +/- 1.2 min for atracurium plus gentamycin. 	atracurium	gentamycin	effect	{'e1': {'word': 'atracurium', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d90.s8.e1'}, 'e2': {'word': 'gentamycin', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d90.s8.e2'}, 'sentence_id': 'DDI-MedLine.d90.s8'}	Recovery from 50 % twitch to 75 % fade recovery took 13.8 + / - 0.8 min for DRUGUNRELATED alone and 13.7 + / - 1.2 min for DRUG plus DRUGOTHER .
At 75% recovery of fade, hoof twitch was 87 +/- 3% for atracurium alone and 82 +/- 4% for atracurium plus gentamycin. 	atracurium	atracurium	none	{'e1': {'word': 'atracurium', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d90.s9.e0'}, 'e2': {'word': 'atracurium', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d90.s9.e1'}, 'sentence_id': 'DDI-MedLine.d90.s9'}	At 75 % recovery of fade , hoof twitch was 87 + / - 3 % for DRUG alone and 82 + / - 4 % for DRUGOTHER plus DRUGUNRELATED .
At 75% recovery of fade, hoof twitch was 87 +/- 3% for atracurium alone and 82 +/- 4% for atracurium plus gentamycin. 	atracurium	gentamycin	none	{'e1': {'word': 'atracurium', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d90.s9.e0'}, 'e2': {'word': 'gentamycin', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d90.s9.e2'}, 'sentence_id': 'DDI-MedLine.d90.s9'}	At 75 % recovery of fade , hoof twitch was 87 + / - 3 % for DRUG alone and 82 + / - 4 % for DRUGUNRELATED plus DRUGOTHER .
At 75% recovery of fade, hoof twitch was 87 +/- 3% for atracurium alone and 82 +/- 4% for atracurium plus gentamycin. 	atracurium	gentamycin	effect	{'e1': {'word': 'atracurium', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d90.s9.e1'}, 'e2': {'word': 'gentamycin', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d90.s9.e2'}, 'sentence_id': 'DDI-MedLine.d90.s9'}	At 75 % recovery of fade , hoof twitch was 87 + / - 3 % for DRUGUNRELATED alone and 82 + / - 4 % for DRUG plus DRUGOTHER .
It was concluded that, although gentamycin did augment the neuromuscular blockade of atracurium, the effect was minimal.	gentamycin	atracurium	effect	{'e1': {'word': 'gentamycin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d90.s11.e0'}, 'e2': {'word': 'atracurium', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d90.s11.e1'}, 'sentence_id': 'DDI-MedLine.d90.s11'}	It was concluded that , although DRUG did augment the neuromuscular blockade of DRUGOTHER , the effect was minimal .
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	immunosuppressive drugs	corticosteroids	none	{'e1': {'word': 'immunosuppressive drugs', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d11.s4.e0'}, 'e2': {'word': 'corticosteroids', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d11.s4.e1'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at five commonly used DRUG in turn ( DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED ) , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	immunosuppressive drugs	cyclosporin	none	{'e1': {'word': 'immunosuppressive drugs', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d11.s4.e0'}, 'e2': {'word': 'cyclosporin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d11.s4.e2'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at five commonly used DRUG in turn ( DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED ) , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	immunosuppressive drugs	azathioprine	none	{'e1': {'word': 'immunosuppressive drugs', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d11.s4.e0'}, 'e2': {'word': 'azathioprine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d11.s4.e3'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at five commonly used DRUG in turn ( DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED ) , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	immunosuppressive drugs	methotrexate	none	{'e1': {'word': 'immunosuppressive drugs', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d11.s4.e0'}, 'e2': {'word': 'methotrexate', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d11.s4.e4'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at five commonly used DRUG in turn ( DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED ) , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	immunosuppressive drugs	cyclophosphamide	none	{'e1': {'word': 'immunosuppressive drugs', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d11.s4.e0'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d11.s4.e5'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at five commonly used DRUG in turn ( DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER ) , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	corticosteroids	cyclosporin	none	{'e1': {'word': 'corticosteroids', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d11.s4.e1'}, 'e2': {'word': 'cyclosporin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d11.s4.e2'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at five commonly used DRUGUNRELATED in turn ( DRUG , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED ) , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	corticosteroids	azathioprine	none	{'e1': {'word': 'corticosteroids', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d11.s4.e1'}, 'e2': {'word': 'azathioprine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d11.s4.e3'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at five commonly used DRUGUNRELATED in turn ( DRUG , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED ) , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	corticosteroids	methotrexate	none	{'e1': {'word': 'corticosteroids', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d11.s4.e1'}, 'e2': {'word': 'methotrexate', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d11.s4.e4'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at five commonly used DRUGUNRELATED in turn ( DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED ) , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	corticosteroids	cyclophosphamide	none	{'e1': {'word': 'corticosteroids', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d11.s4.e1'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d11.s4.e5'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at five commonly used DRUGUNRELATED in turn ( DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER ) , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	cyclosporin	azathioprine	none	{'e1': {'word': 'cyclosporin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d11.s4.e2'}, 'e2': {'word': 'azathioprine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d11.s4.e3'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at five commonly used DRUGUNRELATED in turn ( DRUGUNRELATED , DRUG , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED ) , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	cyclosporin	methotrexate	none	{'e1': {'word': 'cyclosporin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d11.s4.e2'}, 'e2': {'word': 'methotrexate', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d11.s4.e4'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at five commonly used DRUGUNRELATED in turn ( DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED ) , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	cyclosporin	cyclophosphamide	none	{'e1': {'word': 'cyclosporin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d11.s4.e2'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d11.s4.e5'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at five commonly used DRUGUNRELATED in turn ( DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER ) , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	azathioprine	methotrexate	none	{'e1': {'word': 'azathioprine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d11.s4.e3'}, 'e2': {'word': 'methotrexate', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d11.s4.e4'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at five commonly used DRUGUNRELATED in turn ( DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGOTHER , DRUGUNRELATED ) , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	azathioprine	cyclophosphamide	none	{'e1': {'word': 'azathioprine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d11.s4.e3'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d11.s4.e5'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at five commonly used DRUGUNRELATED in turn ( DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGOTHER ) , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	methotrexate	cyclophosphamide	none	{'e1': {'word': 'methotrexate', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d11.s4.e4'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d11.s4.e5'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at five commonly used DRUGUNRELATED in turn ( DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGOTHER ) , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .
Thirty male rats of the Fischer-344 strain were divided into three equal groups and were given injections of trimethyl lead (TML) (8.0 or 17.0 mg/kg/ml SC) or the saline vehicle. 	trimethyl lead	TML	none	{'e1': {'word': 'trimethyl lead', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d93.s4.e0'}, 'e2': {'word': 'TML', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d93.s4.e1'}, 'sentence_id': 'DDI-MedLine.d93.s4'}	Thirty male rats of the Fischer - 344 strain were divided into three equal groups and were given injections of DRUG ( DRUGOTHER ) ( 8.0 or 17.0 mg / kg / ml SC ) or the saline vehicle .
The 20% v/v solution of alcohol was prepared in water from a stock solution of 95% ethanol. 	alcohol	ethanol	none	{'e1': {'word': 'alcohol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d93.s6.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d93.s6.e1'}, 'sentence_id': 'DDI-MedLine.d93.s6'}	The 20 % v / v solution of DRUG was prepared in water from a stock solution of 95 % DRUGOTHER .
These results suggest that exposure to environmental lead may alter the biological and behavioral responsiveness of an animal to alcohol.	lead	alcohol	effect	{'e1': {'word': 'lead', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d93.s9.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d93.s9.e1'}, 'sentence_id': 'DDI-MedLine.d93.s9'}	These results suggest that exposure to environmental DRUG may alter the biological and behavioral responsiveness of an animal to DRUGOTHER .
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	diazepam	midazolam	none	{'e1': {'word': 'diazepam', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d67.s0.e0'}, 'e2': {'word': 'midazolam', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d67.s0.e1'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	Effect of DRUG and DRUGOTHER on the antinociceptive effect of DRUGUNRELATED , DRUGUNRELATED and DRUGUNRELATED in mice .
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	diazepam	morphine	none	{'e1': {'word': 'diazepam', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d67.s0.e0'}, 'e2': {'word': 'morphine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d67.s0.e2'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	Effect of DRUG and DRUGUNRELATED on the antinociceptive effect of DRUGOTHER , DRUGUNRELATED and DRUGUNRELATED in mice .
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	diazepam	metamizol	none	{'e1': {'word': 'diazepam', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d67.s0.e0'}, 'e2': {'word': 'metamizol', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d67.s0.e3'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	Effect of DRUG and DRUGUNRELATED on the antinociceptive effect of DRUGUNRELATED , DRUGOTHER and DRUGUNRELATED in mice .
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	diazepam	indomethacin	none	{'e1': {'word': 'diazepam', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d67.s0.e0'}, 'e2': {'word': 'indomethacin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d67.s0.e4'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	Effect of DRUG and DRUGUNRELATED on the antinociceptive effect of DRUGUNRELATED , DRUGUNRELATED and DRUGOTHER in mice .
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	midazolam	morphine	none	{'e1': {'word': 'midazolam', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d67.s0.e1'}, 'e2': {'word': 'morphine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d67.s0.e2'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	Effect of DRUGUNRELATED and DRUG on the antinociceptive effect of DRUGOTHER , DRUGUNRELATED and DRUGUNRELATED in mice .
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	midazolam	metamizol	none	{'e1': {'word': 'midazolam', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d67.s0.e1'}, 'e2': {'word': 'metamizol', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d67.s0.e3'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	Effect of DRUGUNRELATED and DRUG on the antinociceptive effect of DRUGUNRELATED , DRUGOTHER and DRUGUNRELATED in mice .
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	midazolam	indomethacin	none	{'e1': {'word': 'midazolam', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d67.s0.e1'}, 'e2': {'word': 'indomethacin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d67.s0.e4'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	Effect of DRUGUNRELATED and DRUG on the antinociceptive effect of DRUGUNRELATED , DRUGUNRELATED and DRUGOTHER in mice .
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	morphine	metamizol	none	{'e1': {'word': 'morphine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d67.s0.e2'}, 'e2': {'word': 'metamizol', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d67.s0.e3'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	Effect of DRUGUNRELATED and DRUGUNRELATED on the antinociceptive effect of DRUG , DRUGOTHER and DRUGUNRELATED in mice .
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	morphine	indomethacin	none	{'e1': {'word': 'morphine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d67.s0.e2'}, 'e2': {'word': 'indomethacin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d67.s0.e4'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	Effect of DRUGUNRELATED and DRUGUNRELATED on the antinociceptive effect of DRUG , DRUGUNRELATED and DRUGOTHER in mice .
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	metamizol	indomethacin	none	{'e1': {'word': 'metamizol', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d67.s0.e3'}, 'e2': {'word': 'indomethacin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d67.s0.e4'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	Effect of DRUGUNRELATED and DRUGUNRELATED on the antinociceptive effect of DRUGUNRELATED , DRUG and DRUGOTHER in mice .
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	midazolam	diazepam	none	{'e1': {'word': 'midazolam', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d67.s1.e0'}, 'e2': {'word': 'diazepam', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d67.s1.e1'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	The influence of DRUG and DRUGOTHER on antinociceptive effect of DRUGUNRELATED ( 10 mg / kg ) , DRUGUNRELATED ( 500 mg / kg ) and DRUGUNRELATED ( 10 mg / kg ) was investigated in a mouse model using the tail - flick and hot-plate tests .
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	midazolam	morphine	none	{'e1': {'word': 'midazolam', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d67.s1.e0'}, 'e2': {'word': 'morphine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d67.s1.e2'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	The influence of DRUG and DRUGUNRELATED on antinociceptive effect of DRUGOTHER ( 10 mg / kg ) , DRUGUNRELATED ( 500 mg / kg ) and DRUGUNRELATED ( 10 mg / kg ) was investigated in a mouse model using the tail - flick and hot-plate tests .
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	midazolam	metamizol	none	{'e1': {'word': 'midazolam', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d67.s1.e0'}, 'e2': {'word': 'metamizol', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d67.s1.e3'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	The influence of DRUG and DRUGUNRELATED on antinociceptive effect of DRUGUNRELATED ( 10 mg / kg ) , DRUGOTHER ( 500 mg / kg ) and DRUGUNRELATED ( 10 mg / kg ) was investigated in a mouse model using the tail - flick and hot-plate tests .
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	midazolam	indomethacin	none	{'e1': {'word': 'midazolam', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d67.s1.e0'}, 'e2': {'word': 'indomethacin', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d67.s1.e4'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	The influence of DRUG and DRUGUNRELATED on antinociceptive effect of DRUGUNRELATED ( 10 mg / kg ) , DRUGUNRELATED ( 500 mg / kg ) and DRUGOTHER ( 10 mg / kg ) was investigated in a mouse model using the tail - flick and hot-plate tests .
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	diazepam	morphine	none	{'e1': {'word': 'diazepam', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d67.s1.e1'}, 'e2': {'word': 'morphine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d67.s1.e2'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	The influence of DRUGUNRELATED and DRUG on antinociceptive effect of DRUGOTHER ( 10 mg / kg ) , DRUGUNRELATED ( 500 mg / kg ) and DRUGUNRELATED ( 10 mg / kg ) was investigated in a mouse model using the tail - flick and hot-plate tests .
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	diazepam	metamizol	none	{'e1': {'word': 'diazepam', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d67.s1.e1'}, 'e2': {'word': 'metamizol', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d67.s1.e3'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	The influence of DRUGUNRELATED and DRUG on antinociceptive effect of DRUGUNRELATED ( 10 mg / kg ) , DRUGOTHER ( 500 mg / kg ) and DRUGUNRELATED ( 10 mg / kg ) was investigated in a mouse model using the tail - flick and hot-plate tests .
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	diazepam	indomethacin	none	{'e1': {'word': 'diazepam', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d67.s1.e1'}, 'e2': {'word': 'indomethacin', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d67.s1.e4'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	The influence of DRUGUNRELATED and DRUG on antinociceptive effect of DRUGUNRELATED ( 10 mg / kg ) , DRUGUNRELATED ( 500 mg / kg ) and DRUGOTHER ( 10 mg / kg ) was investigated in a mouse model using the tail - flick and hot-plate tests .
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	morphine	metamizol	none	{'e1': {'word': 'morphine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d67.s1.e2'}, 'e2': {'word': 'metamizol', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d67.s1.e3'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	The influence of DRUGUNRELATED and DRUGUNRELATED on antinociceptive effect of DRUG ( 10 mg / kg ) , DRUGOTHER ( 500 mg / kg ) and DRUGUNRELATED ( 10 mg / kg ) was investigated in a mouse model using the tail - flick and hot-plate tests .
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	morphine	indomethacin	none	{'e1': {'word': 'morphine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d67.s1.e2'}, 'e2': {'word': 'indomethacin', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d67.s1.e4'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	The influence of DRUGUNRELATED and DRUGUNRELATED on antinociceptive effect of DRUG ( 10 mg / kg ) , DRUGUNRELATED ( 500 mg / kg ) and DRUGOTHER ( 10 mg / kg ) was investigated in a mouse model using the tail - flick and hot-plate tests .
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	metamizol	indomethacin	none	{'e1': {'word': 'metamizol', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d67.s1.e3'}, 'e2': {'word': 'indomethacin', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d67.s1.e4'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	The influence of DRUGUNRELATED and DRUGUNRELATED on antinociceptive effect of DRUGUNRELATED ( 10 mg / kg ) , DRUG ( 500 mg / kg ) and DRUGOTHER ( 10 mg / kg ) was investigated in a mouse model using the tail - flick and hot-plate tests .
Benzodiazepines were administered to mice 30 min before applying the analgesic drugs. 	Benzodiazepines	analgesic drugs	none	{'e1': {'word': 'Benzodiazepines', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s3.e0'}, 'e2': {'word': 'analgesic drugs', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d67.s3.e1'}, 'sentence_id': 'DDI-MedLine.d67.s3'}	DRUG were administered to mice 30 min before applying the DRUGOTHER .
Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine. 	Diazepam	morphine	effect	{'e1': {'word': 'Diazepam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s5.e0'}, 'e2': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d67.s5.e1'}, 'sentence_id': 'DDI-MedLine.d67.s5'}	DRUG at doses of 0.25 mg / kg and 2.5 mg / kg injected with DRUGOTHER was found to decrease the antinociceptive effect of DRUGUNRELATED .
Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine. 	Diazepam	morphine	none	{'e1': {'word': 'Diazepam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s5.e0'}, 'e2': {'word': 'morphine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d67.s5.e2'}, 'sentence_id': 'DDI-MedLine.d67.s5'}	DRUG at doses of 0.25 mg / kg and 2.5 mg / kg injected with DRUGUNRELATED was found to decrease the antinociceptive effect of DRUGOTHER .
Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine. 	morphine	morphine	none	{'e1': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d67.s5.e1'}, 'e2': {'word': 'morphine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d67.s5.e2'}, 'sentence_id': 'DDI-MedLine.d67.s5'}	DRUGUNRELATED at doses of 0.25 mg / kg and 2.5 mg / kg injected with DRUG was found to decrease the antinociceptive effect of DRUGOTHER .
Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin. 	diazepam	metamizol	effect	{'e1': {'word': 'diazepam', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d67.s6.e0'}, 'e2': {'word': 'metamizol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d67.s6.e1'}, 'sentence_id': 'DDI-MedLine.d67.s6'}	Similarly , DRUG decreased the antinociceptive effect of DRUGOTHER ( only in the tail - flick test ) and DRUGUNRELATED .
Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin. 	diazepam	indomethacin	effect	{'e1': {'word': 'diazepam', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d67.s6.e0'}, 'e2': {'word': 'indomethacin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d67.s6.e2'}, 'sentence_id': 'DDI-MedLine.d67.s6'}	Similarly , DRUG decreased the antinociceptive effect of DRUGUNRELATED ( only in the tail - flick test ) and DRUGOTHER .
Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin. 	metamizol	indomethacin	none	{'e1': {'word': 'metamizol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d67.s6.e1'}, 'e2': {'word': 'indomethacin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d67.s6.e2'}, 'sentence_id': 'DDI-MedLine.d67.s6'}	Similarly , DRUGUNRELATED decreased the antinociceptive effect of DRUG ( only in the tail - flick test ) and DRUGOTHER .
Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.	Midazolam	morphine	effect	{'e1': {'word': 'Midazolam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s7.e0'}, 'e2': {'word': 'morphine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d67.s7.e1'}, 'sentence_id': 'DDI-MedLine.d67.s7'}	DRUG used at doses of 1.25 mg / kg and 2.5 mg / kg decreased the antinociceptive effect of DRUGOTHER , DRUGUNRELATED ( only in the tail - flick test ) and DRUGUNRELATED .
Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.	Midazolam	metamizol	effect	{'e1': {'word': 'Midazolam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s7.e0'}, 'e2': {'word': 'metamizol', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d67.s7.e2'}, 'sentence_id': 'DDI-MedLine.d67.s7'}	DRUG used at doses of 1.25 mg / kg and 2.5 mg / kg decreased the antinociceptive effect of DRUGUNRELATED , DRUGOTHER ( only in the tail - flick test ) and DRUGUNRELATED .
Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.	Midazolam	indomethacin	effect	{'e1': {'word': 'Midazolam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s7.e0'}, 'e2': {'word': 'indomethacin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d67.s7.e3'}, 'sentence_id': 'DDI-MedLine.d67.s7'}	DRUG used at doses of 1.25 mg / kg and 2.5 mg / kg decreased the antinociceptive effect of DRUGUNRELATED , DRUGUNRELATED ( only in the tail - flick test ) and DRUGOTHER .
Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.	morphine	metamizol	none	{'e1': {'word': 'morphine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d67.s7.e1'}, 'e2': {'word': 'metamizol', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d67.s7.e2'}, 'sentence_id': 'DDI-MedLine.d67.s7'}	DRUGUNRELATED used at doses of 1.25 mg / kg and 2.5 mg / kg decreased the antinociceptive effect of DRUG , DRUGOTHER ( only in the tail - flick test ) and DRUGUNRELATED .
Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.	morphine	indomethacin	none	{'e1': {'word': 'morphine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d67.s7.e1'}, 'e2': {'word': 'indomethacin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d67.s7.e3'}, 'sentence_id': 'DDI-MedLine.d67.s7'}	DRUGUNRELATED used at doses of 1.25 mg / kg and 2.5 mg / kg decreased the antinociceptive effect of DRUG , DRUGUNRELATED ( only in the tail - flick test ) and DRUGOTHER .
Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.	metamizol	indomethacin	none	{'e1': {'word': 'metamizol', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d67.s7.e2'}, 'e2': {'word': 'indomethacin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d67.s7.e3'}, 'sentence_id': 'DDI-MedLine.d67.s7'}	DRUGUNRELATED used at doses of 1.25 mg / kg and 2.5 mg / kg decreased the antinociceptive effect of DRUGUNRELATED , DRUG ( only in the tail - flick test ) and DRUGOTHER .
"Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.
"	simvastatin	clarithromycin	effect	{'e1': {'word': 'simvastatin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d25.s0.e0'}, 'e2': {'word': 'clarithromycin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d25.s0.e1'}, 'sentence_id': 'DDI-MedLine.d25.s0'}	Rhabdomyolysis secondary to a drug interaction between DRUG and DRUGOTHER .
OBJECTIVE: To report a case of rhabdomyolysis resulting from concomitant use of clarithromycin and simvastatin. 	clarithromycin	simvastatin	none	{'e1': {'word': 'clarithromycin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d25.s1.e0'}, 'e2': {'word': 'simvastatin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d25.s1.e1'}, 'sentence_id': 'DDI-MedLine.d25.s1'}	OBJECTIVE : To report a case of rhabdomyolysis resulting from concomitant use of DRUG and DRUGOTHER .
DISCUSSION: Clarithromycin is a potent inhibitor of CYP3A4, the major enzyme responsible for simvastatin metabolism. 	Clarithromycin	simvastatin	mechanism	{'e1': {'word': 'Clarithromycin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d25.s9.e0'}, 'e2': {'word': 'simvastatin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d25.s9.e1'}, 'sentence_id': 'DDI-MedLine.d25.s9'}	DISCUSSION : DRUG is a potent inhibitor of CYP3A4 , the major enzyme responsible for DRUGOTHER metabolism .
The concomitant administration of macrolide antibiotics and other hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have resulted in previous reports of rhabdomyolysis. 	macrolide antibiotics	hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors	effect	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d25.s10.e0'}, 'e2': {'word': 'hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d25.s10.e1'}, 'sentence_id': 'DDI-MedLine.d25.s10'}	The concomitant administration of DRUG and other DRUGOTHER have resulted in previous reports of rhabdomyolysis .
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	Macrolide antibiotics	HMG-CoA reductase inhibitors	none	{'e1': {'word': 'Macrolide antibiotics', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d25.s12.e0'}, 'e2': {'word': 'HMG-CoA reductase inhibitors', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d25.s12.e1'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS : DRUG inhibit the metabolism of DRUGOTHER that are metabolized by CYP3A4 ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED ) .
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	Macrolide antibiotics	atorvastatin	mechanism	{'e1': {'word': 'Macrolide antibiotics', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d25.s12.e0'}, 'e2': {'word': 'atorvastatin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d25.s12.e2'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS : DRUG inhibit the metabolism of DRUGUNRELATED that are metabolized by CYP3A4 ( i.e. , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED ) .
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	Macrolide antibiotics	cerivastatin	mechanism	{'e1': {'word': 'Macrolide antibiotics', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d25.s12.e0'}, 'e2': {'word': 'cerivastatin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d25.s12.e3'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS : DRUG inhibit the metabolism of DRUGUNRELATED that are metabolized by CYP3A4 ( i.e. , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED ) .
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	Macrolide antibiotics	lovastatin	mechanism	{'e1': {'word': 'Macrolide antibiotics', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d25.s12.e0'}, 'e2': {'word': 'lovastatin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d25.s12.e4'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS : DRUG inhibit the metabolism of DRUGUNRELATED that are metabolized by CYP3A4 ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED ) .
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	Macrolide antibiotics	simvastatin	mechanism	{'e1': {'word': 'Macrolide antibiotics', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d25.s12.e0'}, 'e2': {'word': 'simvastatin', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d25.s12.e5'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS : DRUG inhibit the metabolism of DRUGUNRELATED that are metabolized by CYP3A4 ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER ) .
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	HMG-CoA reductase inhibitors	atorvastatin	none	{'e1': {'word': 'HMG-CoA reductase inhibitors', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d25.s12.e1'}, 'e2': {'word': 'atorvastatin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d25.s12.e2'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS : DRUGUNRELATED inhibit the metabolism of DRUG that are metabolized by CYP3A4 ( i.e. , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED ) .
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	HMG-CoA reductase inhibitors	cerivastatin	none	{'e1': {'word': 'HMG-CoA reductase inhibitors', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d25.s12.e1'}, 'e2': {'word': 'cerivastatin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d25.s12.e3'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS : DRUGUNRELATED inhibit the metabolism of DRUG that are metabolized by CYP3A4 ( i.e. , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED ) .
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	HMG-CoA reductase inhibitors	lovastatin	none	{'e1': {'word': 'HMG-CoA reductase inhibitors', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d25.s12.e1'}, 'e2': {'word': 'lovastatin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d25.s12.e4'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS : DRUGUNRELATED inhibit the metabolism of DRUG that are metabolized by CYP3A4 ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED ) .
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	HMG-CoA reductase inhibitors	simvastatin	none	{'e1': {'word': 'HMG-CoA reductase inhibitors', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d25.s12.e1'}, 'e2': {'word': 'simvastatin', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d25.s12.e5'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS : DRUGUNRELATED inhibit the metabolism of DRUG that are metabolized by CYP3A4 ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER ) .
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	atorvastatin	cerivastatin	none	{'e1': {'word': 'atorvastatin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d25.s12.e2'}, 'e2': {'word': 'cerivastatin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d25.s12.e3'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS : DRUGUNRELATED inhibit the metabolism of DRUGUNRELATED that are metabolized by CYP3A4 ( i.e. , DRUG , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED ) .
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	atorvastatin	lovastatin	none	{'e1': {'word': 'atorvastatin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d25.s12.e2'}, 'e2': {'word': 'lovastatin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d25.s12.e4'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS : DRUGUNRELATED inhibit the metabolism of DRUGUNRELATED that are metabolized by CYP3A4 ( i.e. , DRUG , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED ) .
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	atorvastatin	simvastatin	none	{'e1': {'word': 'atorvastatin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d25.s12.e2'}, 'e2': {'word': 'simvastatin', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d25.s12.e5'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS : DRUGUNRELATED inhibit the metabolism of DRUGUNRELATED that are metabolized by CYP3A4 ( i.e. , DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER ) .
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	cerivastatin	lovastatin	none	{'e1': {'word': 'cerivastatin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d25.s12.e3'}, 'e2': {'word': 'lovastatin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d25.s12.e4'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS : DRUGUNRELATED inhibit the metabolism of DRUGUNRELATED that are metabolized by CYP3A4 ( i.e. , DRUGUNRELATED , DRUG , DRUGOTHER , DRUGUNRELATED ) .
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	cerivastatin	simvastatin	none	{'e1': {'word': 'cerivastatin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d25.s12.e3'}, 'e2': {'word': 'simvastatin', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d25.s12.e5'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS : DRUGUNRELATED inhibit the metabolism of DRUGUNRELATED that are metabolized by CYP3A4 ( i.e. , DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGOTHER ) .
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	lovastatin	simvastatin	none	{'e1': {'word': 'lovastatin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d25.s12.e4'}, 'e2': {'word': 'simvastatin', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d25.s12.e5'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS : DRUGUNRELATED inhibit the metabolism of DRUGUNRELATED that are metabolized by CYP3A4 ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGOTHER ) .
To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine (20mM), glucose (100 or 150 mg. per 100 ml.), and theophylline (10 mM). 	arginine	glucose	none	{'e1': {'word': 'arginine', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d74.s2.e0'}, 'e2': {'word': 'glucose', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d74.s2.e1'}, 'sentence_id': 'DDI-MedLine.d74.s2'}	To study the pancreatic effects of other agents , dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of DRUG ( 20 mM ) , DRUGOTHER ( 100 or 150 mg. per 100 ml. ) , and DRUGUNRELATED ( 10 mM ) .
To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine (20mM), glucose (100 or 150 mg. per 100 ml.), and theophylline (10 mM). 	arginine	theophylline	none	{'e1': {'word': 'arginine', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d74.s2.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(52, 52)], 'id': 'DDI-MedLine.d74.s2.e2'}, 'sentence_id': 'DDI-MedLine.d74.s2'}	To study the pancreatic effects of other agents , dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of DRUG ( 20 mM ) , DRUGUNRELATED ( 100 or 150 mg. per 100 ml. ) , and DRUGOTHER ( 10 mM ) .
To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine (20mM), glucose (100 or 150 mg. per 100 ml.), and theophylline (10 mM). 	glucose	theophylline	none	{'e1': {'word': 'glucose', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d74.s2.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(52, 52)], 'id': 'DDI-MedLine.d74.s2.e2'}, 'sentence_id': 'DDI-MedLine.d74.s2'}	To study the pancreatic effects of other agents , dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of DRUGUNRELATED ( 20 mM ) , DRUG ( 100 or 150 mg. per 100 ml. ) , and DRUGOTHER ( 10 mM ) .
Glucose, alone and in the presence of theophylline, caused subnormal insulin release and less suppression of glucagon release in the diabectics than in the normals. 	Glucose	theophylline	none	{'e1': {'word': 'Glucose', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d74.s4.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d74.s4.e1'}, 'sentence_id': 'DDI-MedLine.d74.s4'}	DRUG , alone and in the presence of DRUGOTHER , caused subnormal insulin release and less suppression of glucagon release in the diabectics than in the normals .
Arginine, in the presence of glucose and theophylline, caused excessive glucagon release but nearly normal insulin release in the diabetics. 	Arginine	glucose	none	{'e1': {'word': 'Arginine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d74.s5.e0'}, 'e2': {'word': 'glucose', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d74.s5.e1'}, 'sentence_id': 'DDI-MedLine.d74.s5'}	DRUG , in the presence of DRUGOTHER and DRUGUNRELATED , caused excessive glucagon release but nearly normal insulin release in the diabetics .
Arginine, in the presence of glucose and theophylline, caused excessive glucagon release but nearly normal insulin release in the diabetics. 	Arginine	theophylline	none	{'e1': {'word': 'Arginine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d74.s5.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d74.s5.e2'}, 'sentence_id': 'DDI-MedLine.d74.s5'}	DRUG , in the presence of DRUGUNRELATED and DRUGOTHER , caused excessive glucagon release but nearly normal insulin release in the diabetics .
Arginine, in the presence of glucose and theophylline, caused excessive glucagon release but nearly normal insulin release in the diabetics. 	glucose	theophylline	none	{'e1': {'word': 'glucose', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d74.s5.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d74.s5.e2'}, 'sentence_id': 'DDI-MedLine.d74.s5'}	DRUGUNRELATED , in the presence of DRUG and DRUGOTHER , caused excessive glucagon release but nearly normal insulin release in the diabetics .
Arginine, in the absence of glucose or theophylline, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals. 	Arginine	glucose	none	{'e1': {'word': 'Arginine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d74.s6.e0'}, 'e2': {'word': 'glucose', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d74.s6.e1'}, 'sentence_id': 'DDI-MedLine.d74.s6'}	DRUG , in the absence of DRUGOTHER or DRUGUNRELATED , caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals .
Arginine, in the absence of glucose or theophylline, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals. 	Arginine	theophylline	none	{'e1': {'word': 'Arginine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d74.s6.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d74.s6.e2'}, 'sentence_id': 'DDI-MedLine.d74.s6'}	DRUG , in the absence of DRUGUNRELATED or DRUGOTHER , caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals .
Arginine, in the absence of glucose or theophylline, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals. 	glucose	theophylline	none	{'e1': {'word': 'glucose', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d74.s6.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d74.s6.e2'}, 'sentence_id': 'DDI-MedLine.d74.s6'}	DRUGUNRELATED , in the absence of DRUG or DRUGOTHER , caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals .
Further, these results confirm that the diabetic Chinese hamster's alpha and beta cells respond normally to theophylline, but are relatively insensitive to glucose.	theophylline	glucose	none	{'e1': {'word': 'theophylline', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d74.s11.e0'}, 'e2': {'word': 'glucose', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d74.s11.e1'}, 'sentence_id': 'DDI-MedLine.d74.s11'}	Further , these results confirm that the diabetic Chinese hamster 's alpha and beta cells respond normally to DRUG , but are relatively insensitive to DRUGOTHER .
"Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats.
"	naloxone	beta-endorphin	none	{'e1': {'word': 'naloxone', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d63.s0.e0'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d63.s0.e1'}, 'sentence_id': 'DDI-MedLine.d63.s0'}	Differential actions of intrathecal DRUG on blocking the tail - flick inhibition induced by intraventricular DRUGOTHER and DRUGUNRELATED in rats .
"Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats.
"	naloxone	morphine	none	{'e1': {'word': 'naloxone', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d63.s0.e0'}, 'e2': {'word': 'morphine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d63.s0.e2'}, 'sentence_id': 'DDI-MedLine.d63.s0'}	Differential actions of intrathecal DRUG on blocking the tail - flick inhibition induced by intraventricular DRUGUNRELATED and DRUGOTHER in rats .
"Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats.
"	beta-endorphin	morphine	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d63.s0.e1'}, 'e2': {'word': 'morphine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d63.s0.e2'}, 'sentence_id': 'DDI-MedLine.d63.s0'}	Differential actions of intrathecal DRUGUNRELATED on blocking the tail - flick inhibition induced by intraventricular DRUG and DRUGOTHER in rats .
The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied. 	naloxone	beta-endorphin	none	{'e1': {'word': 'naloxone', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d63.s2.e0'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d63.s2.e1'}, 'sentence_id': 'DDI-MedLine.d63.s2'}	The blockade of the spinal endorphinergic system by intrathecal DRUG on the production of tail - flick inhibition induced by intraventricular DRUGOTHER and DRUGUNRELATED was then studied .
The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied. 	naloxone	morphine	none	{'e1': {'word': 'naloxone', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d63.s2.e0'}, 'e2': {'word': 'morphine', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d63.s2.e2'}, 'sentence_id': 'DDI-MedLine.d63.s2'}	The blockade of the spinal endorphinergic system by intrathecal DRUG on the production of tail - flick inhibition induced by intraventricular DRUGUNRELATED and DRUGOTHER was then studied .
The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied. 	beta-endorphin	morphine	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d63.s2.e1'}, 'e2': {'word': 'morphine', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d63.s2.e2'}, 'sentence_id': 'DDI-MedLine.d63.s2'}	The blockade of the spinal endorphinergic system by intrathecal DRUGUNRELATED on the production of tail - flick inhibition induced by intraventricular DRUG and DRUGOTHER was then studied .
Intraventricular injection of beta-endorphin and morphine produced an inhibition of the tail-flick response to the heat stimulus in rats. 	beta-endorphin	morphine	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d63.s3.e0'}, 'e2': {'word': 'morphine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d63.s3.e1'}, 'sentence_id': 'DDI-MedLine.d63.s3'}	Intraventricular injection of DRUG and DRUGOTHER produced an inhibition of the tail - flick response to the heat stimulus in rats .
Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). 	naloxone	beta-endorphin	effect	{'e1': {'word': 'naloxone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d63.s4.e0'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d63.s4.e1'}, 'sentence_id': 'DDI-MedLine.d63.s4'}	Intrathecal injection of DRUG at doses of 0.4 to 40 micrograms caused a dose - related blockade of the inhibition of the tail - flick response induced by intraventricular injection of DRUGOTHER , and a high dose of DRUGUNRELATED ( 40 micrograms ) completely blocked the tail - flick inhibition induced by intraventricular DRUGUNRELATED ( 16 micrograms ) .
Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). 	naloxone	naloxone	none	{'e1': {'word': 'naloxone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d63.s4.e0'}, 'e2': {'word': 'naloxone', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d63.s4.e2'}, 'sentence_id': 'DDI-MedLine.d63.s4'}	Intrathecal injection of DRUG at doses of 0.4 to 40 micrograms caused a dose - related blockade of the inhibition of the tail - flick response induced by intraventricular injection of DRUGUNRELATED , and a high dose of DRUGOTHER ( 40 micrograms ) completely blocked the tail - flick inhibition induced by intraventricular DRUGUNRELATED ( 16 micrograms ) .
Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). 	naloxone	beta-endorphin	none	{'e1': {'word': 'naloxone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d63.s4.e0'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(53, 53)], 'id': 'DDI-MedLine.d63.s4.e3'}, 'sentence_id': 'DDI-MedLine.d63.s4'}	Intrathecal injection of DRUG at doses of 0.4 to 40 micrograms caused a dose - related blockade of the inhibition of the tail - flick response induced by intraventricular injection of DRUGUNRELATED , and a high dose of DRUGUNRELATED ( 40 micrograms ) completely blocked the tail - flick inhibition induced by intraventricular DRUGOTHER ( 16 micrograms ) .
Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). 	beta-endorphin	naloxone	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d63.s4.e1'}, 'e2': {'word': 'naloxone', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d63.s4.e2'}, 'sentence_id': 'DDI-MedLine.d63.s4'}	Intrathecal injection of DRUGUNRELATED at doses of 0.4 to 40 micrograms caused a dose - related blockade of the inhibition of the tail - flick response induced by intraventricular injection of DRUG , and a high dose of DRUGOTHER ( 40 micrograms ) completely blocked the tail - flick inhibition induced by intraventricular DRUGUNRELATED ( 16 micrograms ) .
Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). 	beta-endorphin	beta-endorphin	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d63.s4.e1'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(53, 53)], 'id': 'DDI-MedLine.d63.s4.e3'}, 'sentence_id': 'DDI-MedLine.d63.s4'}	Intrathecal injection of DRUGUNRELATED at doses of 0.4 to 40 micrograms caused a dose - related blockade of the inhibition of the tail - flick response induced by intraventricular injection of DRUG , and a high dose of DRUGUNRELATED ( 40 micrograms ) completely blocked the tail - flick inhibition induced by intraventricular DRUGOTHER ( 16 micrograms ) .
Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). 	naloxone	beta-endorphin	effect	{'e1': {'word': 'naloxone', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d63.s4.e2'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(53, 53)], 'id': 'DDI-MedLine.d63.s4.e3'}, 'sentence_id': 'DDI-MedLine.d63.s4'}	Intrathecal injection of DRUGUNRELATED at doses of 0.4 to 40 micrograms caused a dose - related blockade of the inhibition of the tail - flick response induced by intraventricular injection of DRUGUNRELATED , and a high dose of DRUG ( 40 micrograms ) completely blocked the tail - flick inhibition induced by intraventricular DRUGOTHER ( 16 micrograms ) .
On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms). 	naloxone	morphine	effect	{'e1': {'word': 'naloxone', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d63.s5.e0'}, 'e2': {'word': 'morphine', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d63.s5.e1'}, 'sentence_id': 'DDI-MedLine.d63.s5'}	On the other hand , intrathecal DRUG ( 12 - 120 micrograms ) had only a very weak effect on the tail - flick inhibition induced by intraventricular DRUGOTHER ( 40 micrograms ) .
Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. 	naloxone	beta-endorphin	effect	{'e1': {'word': 'naloxone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d63.s6.e0'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d63.s6.e1'}, 'sentence_id': 'DDI-MedLine.d63.s6'}	Intraventricular injection of DRUG at doses of 1.2 to 12 micrograms equally antagonized in a dose - dependent manner the tail - flick inhibition induced by intraventricular DRUGOTHER and DRUGUNRELATED .
Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. 	naloxone	morphine	effect	{'e1': {'word': 'naloxone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d63.s6.e0'}, 'e2': {'word': 'morphine', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d63.s6.e2'}, 'sentence_id': 'DDI-MedLine.d63.s6'}	Intraventricular injection of DRUG at doses of 1.2 to 12 micrograms equally antagonized in a dose - dependent manner the tail - flick inhibition induced by intraventricular DRUGUNRELATED and DRUGOTHER .
Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. 	beta-endorphin	morphine	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d63.s6.e1'}, 'e2': {'word': 'morphine', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d63.s6.e2'}, 'sentence_id': 'DDI-MedLine.d63.s6'}	Intraventricular injection of DRUGUNRELATED at doses of 1.2 to 12 micrograms equally antagonized in a dose - dependent manner the tail - flick inhibition induced by intraventricular DRUG and DRUGOTHER .
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	naloxone	beta-endorphin	none	{'e1': {'word': 'naloxone', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d63.s7.e0'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d63.s7.e1'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	The results indicate that a spinal DRUG - sensitive endorphinergic system is involved in the production of DRUGOTHER but not DRUGUNRELATED - induced tail - flick inhibition , and suggest that intraventricular DRUGUNRELATED and DRUGUNRELATED elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	naloxone	morphine	none	{'e1': {'word': 'naloxone', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d63.s7.e0'}, 'e2': {'word': 'morphine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d63.s7.e2'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	The results indicate that a spinal DRUG - sensitive endorphinergic system is involved in the production of DRUGUNRELATED but not DRUGOTHER - induced tail - flick inhibition , and suggest that intraventricular DRUGUNRELATED and DRUGUNRELATED elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	naloxone	beta-endorphin	none	{'e1': {'word': 'naloxone', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d63.s7.e0'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d63.s7.e3'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	The results indicate that a spinal DRUG - sensitive endorphinergic system is involved in the production of DRUGUNRELATED but not DRUGUNRELATED - induced tail - flick inhibition , and suggest that intraventricular DRUGOTHER and DRUGUNRELATED elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	naloxone	morphine	none	{'e1': {'word': 'naloxone', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d63.s7.e0'}, 'e2': {'word': 'morphine', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d63.s7.e4'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	The results indicate that a spinal DRUG - sensitive endorphinergic system is involved in the production of DRUGUNRELATED but not DRUGUNRELATED - induced tail - flick inhibition , and suggest that intraventricular DRUGUNRELATED and DRUGOTHER elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	beta-endorphin	morphine	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d63.s7.e1'}, 'e2': {'word': 'morphine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d63.s7.e2'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	The results indicate that a spinal DRUGUNRELATED - sensitive endorphinergic system is involved in the production of DRUG but not DRUGOTHER - induced tail - flick inhibition , and suggest that intraventricular DRUGUNRELATED and DRUGUNRELATED elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	beta-endorphin	beta-endorphin	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d63.s7.e1'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d63.s7.e3'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	The results indicate that a spinal DRUGUNRELATED - sensitive endorphinergic system is involved in the production of DRUG but not DRUGUNRELATED - induced tail - flick inhibition , and suggest that intraventricular DRUGOTHER and DRUGUNRELATED elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	beta-endorphin	morphine	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d63.s7.e1'}, 'e2': {'word': 'morphine', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d63.s7.e4'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	The results indicate that a spinal DRUGUNRELATED - sensitive endorphinergic system is involved in the production of DRUG but not DRUGUNRELATED - induced tail - flick inhibition , and suggest that intraventricular DRUGUNRELATED and DRUGOTHER elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	morphine	beta-endorphin	none	{'e1': {'word': 'morphine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d63.s7.e2'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d63.s7.e3'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	The results indicate that a spinal DRUGUNRELATED - sensitive endorphinergic system is involved in the production of DRUGUNRELATED but not DRUG - induced tail - flick inhibition , and suggest that intraventricular DRUGOTHER and DRUGUNRELATED elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	morphine	morphine	none	{'e1': {'word': 'morphine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d63.s7.e2'}, 'e2': {'word': 'morphine', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d63.s7.e4'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	The results indicate that a spinal DRUGUNRELATED - sensitive endorphinergic system is involved in the production of DRUGUNRELATED but not DRUG - induced tail - flick inhibition , and suggest that intraventricular DRUGUNRELATED and DRUGOTHER elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	beta-endorphin	morphine	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d63.s7.e3'}, 'e2': {'word': 'morphine', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d63.s7.e4'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	The results indicate that a spinal DRUGUNRELATED - sensitive endorphinergic system is involved in the production of DRUGUNRELATED but not DRUGUNRELATED - induced tail - flick inhibition , and suggest that intraventricular DRUG and DRUGOTHER elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
descending epsilon and mu systems for beta-endorphin and morphine, respectively, are proposed.	beta-endorphin	morphine	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d63.s8.e0'}, 'e2': {'word': 'morphine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d63.s8.e1'}, 'sentence_id': 'DDI-MedLine.d63.s8'}	descending epsilon and mu systems for DRUG and DRUGOTHER , respectively , are proposed .
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	picrotoxin	diazepam	effect	{'e1': {'word': 'picrotoxin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d27.s0.e0'}, 'e2': {'word': 'diazepam', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d27.s0.e1'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	[ The GABA - ergic system and brain edema ] It has been shown in rats with experimental toxic and traumatic edemas that DRUG ( 1 mg / kg ) removes the antiedematous action of DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED and DRUGUNRELATED and reduces the action of DRUGUNRELATED .
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	picrotoxin	phenazepam	effect	{'e1': {'word': 'picrotoxin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d27.s0.e0'}, 'e2': {'word': 'phenazepam', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d27.s0.e2'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	[ The GABA - ergic system and brain edema ] It has been shown in rats with experimental toxic and traumatic edemas that DRUG ( 1 mg / kg ) removes the antiedematous action of DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED and DRUGUNRELATED and reduces the action of DRUGUNRELATED .
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	picrotoxin	phenibut	effect	{'e1': {'word': 'picrotoxin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d27.s0.e0'}, 'e2': {'word': 'phenibut', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d27.s0.e3'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	[ The GABA - ergic system and brain edema ] It has been shown in rats with experimental toxic and traumatic edemas that DRUG ( 1 mg / kg ) removes the antiedematous action of DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER and DRUGUNRELATED and reduces the action of DRUGUNRELATED .
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	picrotoxin	amizyl	effect	{'e1': {'word': 'picrotoxin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d27.s0.e0'}, 'e2': {'word': 'amizyl', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d27.s0.e4'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	[ The GABA - ergic system and brain edema ] It has been shown in rats with experimental toxic and traumatic edemas that DRUG ( 1 mg / kg ) removes the antiedematous action of DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED and DRUGOTHER and reduces the action of DRUGUNRELATED .
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	picrotoxin	phentolamine	effect	{'e1': {'word': 'picrotoxin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d27.s0.e0'}, 'e2': {'word': 'phentolamine', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d27.s0.e5'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	[ The GABA - ergic system and brain edema ] It has been shown in rats with experimental toxic and traumatic edemas that DRUG ( 1 mg / kg ) removes the antiedematous action of DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED and DRUGUNRELATED and reduces the action of DRUGOTHER .
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	diazepam	phenazepam	none	{'e1': {'word': 'diazepam', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d27.s0.e1'}, 'e2': {'word': 'phenazepam', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d27.s0.e2'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	[ The GABA - ergic system and brain edema ] It has been shown in rats with experimental toxic and traumatic edemas that DRUGUNRELATED ( 1 mg / kg ) removes the antiedematous action of DRUG , DRUGOTHER , DRUGUNRELATED and DRUGUNRELATED and reduces the action of DRUGUNRELATED .
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	diazepam	phenibut	none	{'e1': {'word': 'diazepam', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d27.s0.e1'}, 'e2': {'word': 'phenibut', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d27.s0.e3'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	[ The GABA - ergic system and brain edema ] It has been shown in rats with experimental toxic and traumatic edemas that DRUGUNRELATED ( 1 mg / kg ) removes the antiedematous action of DRUG , DRUGUNRELATED , DRUGOTHER and DRUGUNRELATED and reduces the action of DRUGUNRELATED .
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	diazepam	amizyl	none	{'e1': {'word': 'diazepam', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d27.s0.e1'}, 'e2': {'word': 'amizyl', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d27.s0.e4'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	[ The GABA - ergic system and brain edema ] It has been shown in rats with experimental toxic and traumatic edemas that DRUGUNRELATED ( 1 mg / kg ) removes the antiedematous action of DRUG , DRUGUNRELATED , DRUGUNRELATED and DRUGOTHER and reduces the action of DRUGUNRELATED .
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	diazepam	phentolamine	none	{'e1': {'word': 'diazepam', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d27.s0.e1'}, 'e2': {'word': 'phentolamine', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d27.s0.e5'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	[ The GABA - ergic system and brain edema ] It has been shown in rats with experimental toxic and traumatic edemas that DRUGUNRELATED ( 1 mg / kg ) removes the antiedematous action of DRUG , DRUGUNRELATED , DRUGUNRELATED and DRUGUNRELATED and reduces the action of DRUGOTHER .
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	phenazepam	phenibut	none	{'e1': {'word': 'phenazepam', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d27.s0.e2'}, 'e2': {'word': 'phenibut', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d27.s0.e3'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	[ The GABA - ergic system and brain edema ] It has been shown in rats with experimental toxic and traumatic edemas that DRUGUNRELATED ( 1 mg / kg ) removes the antiedematous action of DRUGUNRELATED , DRUG , DRUGOTHER and DRUGUNRELATED and reduces the action of DRUGUNRELATED .
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	phenazepam	amizyl	none	{'e1': {'word': 'phenazepam', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d27.s0.e2'}, 'e2': {'word': 'amizyl', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d27.s0.e4'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	[ The GABA - ergic system and brain edema ] It has been shown in rats with experimental toxic and traumatic edemas that DRUGUNRELATED ( 1 mg / kg ) removes the antiedematous action of DRUGUNRELATED , DRUG , DRUGUNRELATED and DRUGOTHER and reduces the action of DRUGUNRELATED .
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	phenazepam	phentolamine	none	{'e1': {'word': 'phenazepam', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d27.s0.e2'}, 'e2': {'word': 'phentolamine', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d27.s0.e5'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	[ The GABA - ergic system and brain edema ] It has been shown in rats with experimental toxic and traumatic edemas that DRUGUNRELATED ( 1 mg / kg ) removes the antiedematous action of DRUGUNRELATED , DRUG , DRUGUNRELATED and DRUGUNRELATED and reduces the action of DRUGOTHER .
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	phenibut	amizyl	none	{'e1': {'word': 'phenibut', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d27.s0.e3'}, 'e2': {'word': 'amizyl', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d27.s0.e4'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	[ The GABA - ergic system and brain edema ] It has been shown in rats with experimental toxic and traumatic edemas that DRUGUNRELATED ( 1 mg / kg ) removes the antiedematous action of DRUGUNRELATED , DRUGUNRELATED , DRUG and DRUGOTHER and reduces the action of DRUGUNRELATED .
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	phenibut	phentolamine	none	{'e1': {'word': 'phenibut', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d27.s0.e3'}, 'e2': {'word': 'phentolamine', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d27.s0.e5'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	[ The GABA - ergic system and brain edema ] It has been shown in rats with experimental toxic and traumatic edemas that DRUGUNRELATED ( 1 mg / kg ) removes the antiedematous action of DRUGUNRELATED , DRUGUNRELATED , DRUG and DRUGUNRELATED and reduces the action of DRUGOTHER .
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	amizyl	phentolamine	none	{'e1': {'word': 'amizyl', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d27.s0.e4'}, 'e2': {'word': 'phentolamine', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d27.s0.e5'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	[ The GABA - ergic system and brain edema ] It has been shown in rats with experimental toxic and traumatic edemas that DRUGUNRELATED ( 1 mg / kg ) removes the antiedematous action of DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED and DRUG and reduces the action of DRUGOTHER .
"Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens.
"	vitamin D	antiestrogens	none	{'e1': {'word': 'vitamin D', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d53.s0.e0'}, 'e2': {'word': 'antiestrogens', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d53.s0.e1'}, 'sentence_id': 'DDI-MedLine.d53.s0'}	Induction of apoptosis in breast cancer cells in response to DRUG and DRUGOTHER .
1,25-Dihydroxycholecalciferol D3 (1,25(OH)2D3), the active metabolite of vitamin D, is a potent inhibitor of breast cancer cell growth both in vivo and in vitro. 	25-Dihydroxycholecalciferol D3	1,25(OH)2D3	none	{'e1': {'word': '25-Dihydroxycholecalciferol D3', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d53.s1.e0'}, 'e2': {'word': '1,25(OH)2D3', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d53.s1.e1'}, 'sentence_id': 'DDI-MedLine.d53.s1'}	1 , DRUG ( DRUGOTHER ) , the active metabolite of DRUGUNRELATED , is a potent inhibitor of breast cancer cell growth both in vivo and in vitro .
1,25-Dihydroxycholecalciferol D3 (1,25(OH)2D3), the active metabolite of vitamin D, is a potent inhibitor of breast cancer cell growth both in vivo and in vitro. 	25-Dihydroxycholecalciferol D3	vitamin D	none	{'e1': {'word': '25-Dihydroxycholecalciferol D3', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d53.s1.e0'}, 'e2': {'word': 'vitamin D', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d53.s1.e2'}, 'sentence_id': 'DDI-MedLine.d53.s1'}	1 , DRUG ( DRUGUNRELATED ) , the active metabolite of DRUGOTHER , is a potent inhibitor of breast cancer cell growth both in vivo and in vitro .
1,25-Dihydroxycholecalciferol D3 (1,25(OH)2D3), the active metabolite of vitamin D, is a potent inhibitor of breast cancer cell growth both in vivo and in vitro. 	1,25(OH)2D3	vitamin D	none	{'e1': {'word': '1,25(OH)2D3', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d53.s1.e1'}, 'e2': {'word': 'vitamin D', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d53.s1.e2'}, 'sentence_id': 'DDI-MedLine.d53.s1'}	1 , DRUGUNRELATED ( DRUG ) , the active metabolite of DRUGOTHER , is a potent inhibitor of breast cancer cell growth both in vivo and in vitro .
In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. 	1,25(OH)2D3	antiestrogen	none	{'e1': {'word': '1,25(OH)2D3', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d53.s3.e0'}, 'e2': {'word': 'antiestrogen', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d53.s3.e1'}, 'sentence_id': 'DDI-MedLine.d53.s3'}	In the experiments reported here , we examined the interactions between DRUG and the DRUGOTHER DRUGUNRELATED ( DRUGUNRELATED ) , which also induces apoptosis in MCF - 7 cells .
In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. 	1,25(OH)2D3	4-hydroxytamoxifen	none	{'e1': {'word': '1,25(OH)2D3', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d53.s3.e0'}, 'e2': {'word': '4-hydroxytamoxifen', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d53.s3.e2'}, 'sentence_id': 'DDI-MedLine.d53.s3'}	In the experiments reported here , we examined the interactions between DRUG and the DRUGUNRELATED DRUGOTHER ( DRUGUNRELATED ) , which also induces apoptosis in MCF - 7 cells .
In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. 	1,25(OH)2D3	TAM	none	{'e1': {'word': '1,25(OH)2D3', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d53.s3.e0'}, 'e2': {'word': 'TAM', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d53.s3.e3'}, 'sentence_id': 'DDI-MedLine.d53.s3'}	In the experiments reported here , we examined the interactions between DRUG and the DRUGUNRELATED DRUGUNRELATED ( DRUGOTHER ) , which also induces apoptosis in MCF - 7 cells .
In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. 	antiestrogen	4-hydroxytamoxifen	none	{'e1': {'word': 'antiestrogen', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d53.s3.e1'}, 'e2': {'word': '4-hydroxytamoxifen', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d53.s3.e2'}, 'sentence_id': 'DDI-MedLine.d53.s3'}	In the experiments reported here , we examined the interactions between DRUGUNRELATED and the DRUG DRUGOTHER ( DRUGUNRELATED ) , which also induces apoptosis in MCF - 7 cells .
In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. 	antiestrogen	TAM	none	{'e1': {'word': 'antiestrogen', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d53.s3.e1'}, 'e2': {'word': 'TAM', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d53.s3.e3'}, 'sentence_id': 'DDI-MedLine.d53.s3'}	In the experiments reported here , we examined the interactions between DRUGUNRELATED and the DRUG DRUGUNRELATED ( DRUGOTHER ) , which also induces apoptosis in MCF - 7 cells .
In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. 	4-hydroxytamoxifen	TAM	none	{'e1': {'word': '4-hydroxytamoxifen', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d53.s3.e2'}, 'e2': {'word': 'TAM', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d53.s3.e3'}, 'sentence_id': 'DDI-MedLine.d53.s3'}	In the experiments reported here , we examined the interactions between DRUGUNRELATED and the DRUGUNRELATED DRUG ( DRUGOTHER ) , which also induces apoptosis in MCF - 7 cells .
Our data suggest that TAM significantly potentiates the reduction in cell number induced by 1,25(OH)2D3 alone. 	TAM	1,25(OH)2D3	effect	{'e1': {'word': 'TAM', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d53.s4.e0'}, 'e2': {'word': '1,25(OH)2D3', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d53.s4.e1'}, 'sentence_id': 'DDI-MedLine.d53.s4'}	Our data suggest that DRUG significantly potentiates the reduction in cell number induced by DRUGOTHER alone .
Combined treatment with 1,25(OH)2D3 and TAM enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation. 	1,25(OH)2D3	TAM	effect	{'e1': {'word': '1,25(OH)2D3', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d53.s5.e0'}, 'e2': {'word': 'TAM', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d53.s5.e1'}, 'sentence_id': 'DDI-MedLine.d53.s5'}	Combined treatment with DRUG and DRUGOTHER enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation .
These data emphasize that apoptosis can be induced in MCF-7 cells either by activation of vitamin-D-mediated signalling or disruption of estrogen-dependent signalling.	vitamin-D	estrogen	none	{'e1': {'word': 'vitamin-D', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d53.s9.e0'}, 'e2': {'word': 'estrogen', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d53.s9.e1'}, 'sentence_id': 'DDI-MedLine.d53.s9'}	These data emphasize that apoptosis can be induced in MCF - 7 cells either by activation of DRUG - mediated signalling or disruption of DRUGOTHER - dependent signalling .
The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. 	phenytoin	fluvoxamine	none	{'e1': {'word': 'phenytoin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d60.s2.e0'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d60.s2.e1'}, 'sentence_id': 'DDI-MedLine.d60.s2'}	The serum concentration of DRUG increased dramatically from 16.6 to 49.1 microg / mL when DRUGOTHER was coadministered , although the daily dosage of DRUGUNRELATED and other DRUGUNRELATED had not changed .
The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. 	phenytoin	phenytoin	none	{'e1': {'word': 'phenytoin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d60.s2.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d60.s2.e2'}, 'sentence_id': 'DDI-MedLine.d60.s2'}	The serum concentration of DRUG increased dramatically from 16.6 to 49.1 microg / mL when DRUGUNRELATED was coadministered , although the daily dosage of DRUGOTHER and other DRUGUNRELATED had not changed .
The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. 	phenytoin	drugs	none	{'e1': {'word': 'phenytoin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d60.s2.e0'}, 'e2': {'word': 'drugs', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d60.s2.e3'}, 'sentence_id': 'DDI-MedLine.d60.s2'}	The serum concentration of DRUG increased dramatically from 16.6 to 49.1 microg / mL when DRUGUNRELATED was coadministered , although the daily dosage of DRUGUNRELATED and other DRUGOTHER had not changed .
The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. 	fluvoxamine	phenytoin	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d60.s2.e1'}, 'e2': {'word': 'phenytoin', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d60.s2.e2'}, 'sentence_id': 'DDI-MedLine.d60.s2'}	The serum concentration of DRUGUNRELATED increased dramatically from 16.6 to 49.1 microg / mL when DRUG was coadministered , although the daily dosage of DRUGOTHER and other DRUGUNRELATED had not changed .
The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. 	fluvoxamine	drugs	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d60.s2.e1'}, 'e2': {'word': 'drugs', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d60.s2.e3'}, 'sentence_id': 'DDI-MedLine.d60.s2'}	The serum concentration of DRUGUNRELATED increased dramatically from 16.6 to 49.1 microg / mL when DRUG was coadministered , although the daily dosage of DRUGUNRELATED and other DRUGOTHER had not changed .
The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. 	phenytoin	drugs	none	{'e1': {'word': 'phenytoin', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d60.s2.e2'}, 'e2': {'word': 'drugs', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d60.s2.e3'}, 'sentence_id': 'DDI-MedLine.d60.s2'}	The serum concentration of DRUGUNRELATED increased dramatically from 16.6 to 49.1 microg / mL when DRUGUNRELATED was coadministered , although the daily dosage of DRUG and other DRUGOTHER had not changed .
During phenytoin and fluvoxamine treatment, ataxia, a typical side effect of phenytoin, was observed. 	phenytoin	phenytoin	none	{'e1': {'word': 'phenytoin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d60.s3.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d60.s3.e1'}, 'sentence_id': 'DDI-MedLine.d60.s3'}	During DRUG and fluvoxamine treatment , ataxia , a typical side effect of DRUGOTHER , was observed .
The genotypes of CYP2C9 and 2C19, the enzymes responsible for phenytoin metabolism, were homozygous for the wild-type alleles (CYP2C9*1/*1 and 2C19*1/ *1). 	CYP2C9	CYP2C9	none	{'e1': {'word': 'CYP2C9', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d60.s4.e0'}, 'e2': {'word': 'CYP2C9', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d60.s4.e1'}, 'sentence_id': 'DDI-MedLine.d60.s4'}	The genotypes of DRUG and 2C19 , the enzymes responsible for phenytoin metabolism , were homozygous for the wild - type alleles ( DRUGOTHER * 1 / * 1 and 2C19 * 1 / * 1 ) .
The interaction may be a result of inhibition of both CYP2C9 and 2C19 by fluvoxamine.	CYP2C9	fluvoxamine	none	{'e1': {'word': 'CYP2C9', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d60.s5.e0'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d60.s5.e1'}, 'sentence_id': 'DDI-MedLine.d60.s5'}	The interaction may be a result of inhibition of both DRUG and 2C19 by DRUGOTHER .
"High-dose cisplatin with sodium thiosulfate protection.
"	cisplatin	sodium thiosulfate	effect	{'e1': {'word': 'cisplatin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d130.s0.e0'}, 'e2': {'word': 'sodium thiosulfate', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d130.s0.e1'}, 'sentence_id': 'DDI-MedLine.d130.s0'}	High - dose DRUG with DRUGOTHER protection .
Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage. 	Sodium thiosulfate	cisplatin	effect	{'e1': {'word': 'Sodium thiosulfate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d130.s2.e0'}, 'e2': {'word': 'cisplatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d130.s2.e1'}, 'sentence_id': 'DDI-MedLine.d130.s2'}	DRUG is a neutralizing agent for DRUGOTHER that protects against renal damage .
To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin. 	thiosulfate	cisplatin	none	{'e1': {'word': 'thiosulfate', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d130.s3.e0'}, 'e2': {'word': 'cisplatin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d130.s3.e1'}, 'sentence_id': 'DDI-MedLine.d130.s3'}	To determine whether injection of DRUG would permit larger doses of DRUGOTHER to be administered , a fixed 9.9 - g / m2 dose of DRUGUNRELATED was given intravenously over three hours concurrently with escalating doses of DRUGUNRELATED .
To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin. 	thiosulfate	thiosulfate	none	{'e1': {'word': 'thiosulfate', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d130.s3.e0'}, 'e2': {'word': 'thiosulfate', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d130.s3.e2'}, 'sentence_id': 'DDI-MedLine.d130.s3'}	To determine whether injection of DRUG would permit larger doses of DRUGUNRELATED to be administered , a fixed 9.9 - g / m2 dose of DRUGOTHER was given intravenously over three hours concurrently with escalating doses of DRUGUNRELATED .
To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin. 	thiosulfate	cisplatin	none	{'e1': {'word': 'thiosulfate', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d130.s3.e0'}, 'e2': {'word': 'cisplatin', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d130.s3.e3'}, 'sentence_id': 'DDI-MedLine.d130.s3'}	To determine whether injection of DRUG would permit larger doses of DRUGUNRELATED to be administered , a fixed 9.9 - g / m2 dose of DRUGUNRELATED was given intravenously over three hours concurrently with escalating doses of DRUGOTHER .
To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin. 	cisplatin	thiosulfate	none	{'e1': {'word': 'cisplatin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d130.s3.e1'}, 'e2': {'word': 'thiosulfate', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d130.s3.e2'}, 'sentence_id': 'DDI-MedLine.d130.s3'}	To determine whether injection of DRUGUNRELATED would permit larger doses of DRUG to be administered , a fixed 9.9 - g / m2 dose of DRUGOTHER was given intravenously over three hours concurrently with escalating doses of DRUGUNRELATED .
To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin. 	cisplatin	cisplatin	none	{'e1': {'word': 'cisplatin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d130.s3.e1'}, 'e2': {'word': 'cisplatin', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d130.s3.e3'}, 'sentence_id': 'DDI-MedLine.d130.s3'}	To determine whether injection of DRUGUNRELATED would permit larger doses of DRUG to be administered , a fixed 9.9 - g / m2 dose of DRUGUNRELATED was given intravenously over three hours concurrently with escalating doses of DRUGOTHER .
To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin. 	thiosulfate	cisplatin	none	{'e1': {'word': 'thiosulfate', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d130.s3.e2'}, 'e2': {'word': 'cisplatin', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d130.s3.e3'}, 'sentence_id': 'DDI-MedLine.d130.s3'}	To determine whether injection of DRUGUNRELATED would permit larger doses of DRUGUNRELATED to be administered , a fixed 9.9 - g / m2 dose of DRUG was given intravenously over three hours concurrently with escalating doses of DRUGOTHER .
Cisplatin was administered over the last two hours of the thiosulfate infusion. 	Cisplatin	thiosulfate	none	{'e1': {'word': 'Cisplatin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d130.s4.e0'}, 'e2': {'word': 'thiosulfate', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d130.s4.e1'}, 'sentence_id': 'DDI-MedLine.d130.s4'}	DRUG was administered over the last two hours of the DRUGOTHER infusion .
Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. 	cisplatin	thiosulfate	none	{'e1': {'word': 'cisplatin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d130.s6.e0'}, 'e2': {'word': 'thiosulfate', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d130.s6.e1'}, 'sentence_id': 'DDI-MedLine.d130.s6'}	Comparison of DRUG pharmacokinetics in patients treated with 202.5 mg / m2 plus DRUGOTHER to those in patients treated with 100 mg / m2 without DRUGUNRELATED indicated that there were no changes in the elimination rate constant , volume of distribution , or total body clearance of DRUGUNRELATED .
Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. 	cisplatin	thiosulfate	none	{'e1': {'word': 'cisplatin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d130.s6.e0'}, 'e2': {'word': 'thiosulfate', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d130.s6.e2'}, 'sentence_id': 'DDI-MedLine.d130.s6'}	Comparison of DRUG pharmacokinetics in patients treated with 202.5 mg / m2 plus DRUGUNRELATED to those in patients treated with 100 mg / m2 without DRUGOTHER indicated that there were no changes in the elimination rate constant , volume of distribution , or total body clearance of DRUGUNRELATED .
Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. 	cisplatin	cisplatin	none	{'e1': {'word': 'cisplatin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d130.s6.e0'}, 'e2': {'word': 'cisplatin', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d130.s6.e3'}, 'sentence_id': 'DDI-MedLine.d130.s6'}	Comparison of DRUG pharmacokinetics in patients treated with 202.5 mg / m2 plus DRUGUNRELATED to those in patients treated with 100 mg / m2 without DRUGUNRELATED indicated that there were no changes in the elimination rate constant , volume of distribution , or total body clearance of DRUGOTHER .
Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. 	thiosulfate	thiosulfate	none	{'e1': {'word': 'thiosulfate', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d130.s6.e1'}, 'e2': {'word': 'thiosulfate', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d130.s6.e2'}, 'sentence_id': 'DDI-MedLine.d130.s6'}	Comparison of DRUGUNRELATED pharmacokinetics in patients treated with 202.5 mg / m2 plus DRUG to those in patients treated with 100 mg / m2 without DRUGOTHER indicated that there were no changes in the elimination rate constant , volume of distribution , or total body clearance of DRUGUNRELATED .
Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. 	thiosulfate	cisplatin	none	{'e1': {'word': 'thiosulfate', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d130.s6.e1'}, 'e2': {'word': 'cisplatin', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d130.s6.e3'}, 'sentence_id': 'DDI-MedLine.d130.s6'}	Comparison of DRUGUNRELATED pharmacokinetics in patients treated with 202.5 mg / m2 plus DRUG to those in patients treated with 100 mg / m2 without DRUGUNRELATED indicated that there were no changes in the elimination rate constant , volume of distribution , or total body clearance of DRUGOTHER .
Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. 	thiosulfate	cisplatin	none	{'e1': {'word': 'thiosulfate', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d130.s6.e2'}, 'e2': {'word': 'cisplatin', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d130.s6.e3'}, 'sentence_id': 'DDI-MedLine.d130.s6'}	Comparison of DRUGUNRELATED pharmacokinetics in patients treated with 202.5 mg / m2 plus DRUGUNRELATED to those in patients treated with 100 mg / m2 without DRUG indicated that there were no changes in the elimination rate constant , volume of distribution , or total body clearance of DRUGOTHER .
This study demonstrates that concurrent administration of thiosulfate permits at least a twofold increase in dose and total exposure to cisplatin.	thiosulfate	cisplatin	mechanism	{'e1': {'word': 'thiosulfate', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d130.s8.e0'}, 'e2': {'word': 'cisplatin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d130.s8.e1'}, 'sentence_id': 'DDI-MedLine.d130.s8'}	This study demonstrates that concurrent administration of DRUG permits at least a two fold increase in dose and total exposure to DRUGOTHER .
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d103.s1.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d103.s1.e1'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	Two different types of therapy with DRUG are used : physiological oral DRUGOTHER supplementation which is totally atoxic since it palliates DRUGUNRELATED deficiencies by simply normalizing the DRUGUNRELATED intake and pharmacological DRUGUNRELATED therapy which may induce toxicity since it creates iatrogenic DRUGUNRELATED overload .
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d103.s1.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d103.s1.e2'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	Two different types of therapy with DRUG are used : physiological oral DRUGUNRELATED supplementation which is totally atoxic since it palliates DRUGOTHER deficiencies by simply normalizing the DRUGUNRELATED intake and pharmacological DRUGUNRELATED therapy which may induce toxicity since it creates iatrogenic DRUGUNRELATED overload .
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d103.s1.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d103.s1.e3'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	Two different types of therapy with DRUG are used : physiological oral DRUGUNRELATED supplementation which is totally atoxic since it palliates DRUGUNRELATED deficiencies by simply normalizing the DRUGOTHER intake and pharmacological DRUGUNRELATED therapy which may induce toxicity since it creates iatrogenic DRUGUNRELATED overload .
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d103.s1.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d103.s1.e4'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	Two different types of therapy with DRUG are used : physiological oral DRUGUNRELATED supplementation which is totally atoxic since it palliates DRUGUNRELATED deficiencies by simply normalizing the DRUGUNRELATED intake and pharmacological DRUGOTHER therapy which may induce toxicity since it creates iatrogenic DRUGUNRELATED overload .
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d103.s1.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d103.s1.e5'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	Two different types of therapy with DRUG are used : physiological oral DRUGUNRELATED supplementation which is totally atoxic since it palliates DRUGUNRELATED deficiencies by simply normalizing the DRUGUNRELATED intake and pharmacological DRUGUNRELATED therapy which may induce toxicity since it creates iatrogenic DRUGOTHER overload .
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d103.s1.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d103.s1.e2'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	Two different types of therapy with DRUGUNRELATED are used : physiological oral DRUG supplementation which is totally atoxic since it palliates DRUGOTHER deficiencies by simply normalizing the DRUGUNRELATED intake and pharmacological DRUGUNRELATED therapy which may induce toxicity since it creates iatrogenic DRUGUNRELATED overload .
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d103.s1.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d103.s1.e3'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	Two different types of therapy with DRUGUNRELATED are used : physiological oral DRUG supplementation which is totally atoxic since it palliates DRUGUNRELATED deficiencies by simply normalizing the DRUGOTHER intake and pharmacological DRUGUNRELATED therapy which may induce toxicity since it creates iatrogenic DRUGUNRELATED overload .
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d103.s1.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d103.s1.e4'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	Two different types of therapy with DRUGUNRELATED are used : physiological oral DRUG supplementation which is totally atoxic since it palliates DRUGUNRELATED deficiencies by simply normalizing the DRUGUNRELATED intake and pharmacological DRUGOTHER therapy which may induce toxicity since it creates iatrogenic DRUGUNRELATED overload .
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d103.s1.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d103.s1.e5'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	Two different types of therapy with DRUGUNRELATED are used : physiological oral DRUG supplementation which is totally atoxic since it palliates DRUGUNRELATED deficiencies by simply normalizing the DRUGUNRELATED intake and pharmacological DRUGUNRELATED therapy which may induce toxicity since it creates iatrogenic DRUGOTHER overload .
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d103.s1.e2'}, 'e2': {'word': 'magnesium', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d103.s1.e3'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	Two different types of therapy with DRUGUNRELATED are used : physiological oral DRUGUNRELATED supplementation which is totally atoxic since it palliates DRUG deficiencies by simply normalizing the DRUGOTHER intake and pharmacological DRUGUNRELATED therapy which may induce toxicity since it creates iatrogenic DRUGUNRELATED overload .
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d103.s1.e2'}, 'e2': {'word': 'magnesium', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d103.s1.e4'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	Two different types of therapy with DRUGUNRELATED are used : physiological oral DRUGUNRELATED supplementation which is totally atoxic since it palliates DRUG deficiencies by simply normalizing the DRUGUNRELATED intake and pharmacological DRUGOTHER therapy which may induce toxicity since it creates iatrogenic DRUGUNRELATED overload .
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d103.s1.e2'}, 'e2': {'word': 'magnesium', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d103.s1.e5'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	Two different types of therapy with DRUGUNRELATED are used : physiological oral DRUGUNRELATED supplementation which is totally atoxic since it palliates DRUG deficiencies by simply normalizing the DRUGUNRELATED intake and pharmacological DRUGUNRELATED therapy which may induce toxicity since it creates iatrogenic DRUGOTHER overload .
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d103.s1.e3'}, 'e2': {'word': 'magnesium', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d103.s1.e4'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	Two different types of therapy with DRUGUNRELATED are used : physiological oral DRUGUNRELATED supplementation which is totally atoxic since it palliates DRUGUNRELATED deficiencies by simply normalizing the DRUG intake and pharmacological DRUGOTHER therapy which may induce toxicity since it creates iatrogenic DRUGUNRELATED overload .
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d103.s1.e3'}, 'e2': {'word': 'magnesium', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d103.s1.e5'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	Two different types of therapy with DRUGUNRELATED are used : physiological oral DRUGUNRELATED supplementation which is totally atoxic since it palliates DRUGUNRELATED deficiencies by simply normalizing the DRUG intake and pharmacological DRUGUNRELATED therapy which may induce toxicity since it creates iatrogenic DRUGOTHER overload .
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d103.s1.e4'}, 'e2': {'word': 'magnesium', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d103.s1.e5'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	Two different types of therapy with DRUGUNRELATED are used : physiological oral DRUGUNRELATED supplementation which is totally atoxic since it palliates DRUGUNRELATED deficiencies by simply normalizing the DRUGUNRELATED intake and pharmacological DRUG therapy which may induce toxicity since it creates iatrogenic DRUGOTHER overload .
Primary and secondary magnesium deficiencies constitute the sole indication of physiological oral magnesium therapy. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d103.s2.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d103.s2.e1'}, 'sentence_id': 'DDI-MedLine.d103.s2'}	Primary and secondary DRUG deficiencies constitute the sole indication of physiological oral DRUGOTHER therapy .
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d103.s3.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d103.s3.e1'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of DRUG deficit and to discriminate between DRUGOTHER deficiency due to an insufficient DRUGUNRELATED intake which only requires oral physiological supplementation and DRUGUNRELATED depletion related to a dysregulation of the control mechanisms of DRUGUNRELATED status which requires more or less specific regulation of its causal dysregulation .
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d103.s3.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d103.s3.e2'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of DRUG deficit and to discriminate between DRUGUNRELATED deficiency due to an insufficient DRUGOTHER intake which only requires oral physiological supplementation and DRUGUNRELATED depletion related to a dysregulation of the control mechanisms of DRUGUNRELATED status which requires more or less specific regulation of its causal dysregulation .
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d103.s3.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d103.s3.e3'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of DRUG deficit and to discriminate between DRUGUNRELATED deficiency due to an insufficient DRUGUNRELATED intake which only requires oral physiological supplementation and DRUGOTHER depletion related to a dysregulation of the control mechanisms of DRUGUNRELATED status which requires more or less specific regulation of its causal dysregulation .
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d103.s3.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d103.s3.e4'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of DRUG deficit and to discriminate between DRUGUNRELATED deficiency due to an insufficient DRUGUNRELATED intake which only requires oral physiological supplementation and DRUGUNRELATED depletion related to a dysregulation of the control mechanisms of DRUGOTHER status which requires more or less specific regulation of its causal dysregulation .
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d103.s3.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d103.s3.e2'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of DRUGUNRELATED deficit and to discriminate between DRUG deficiency due to an insufficient DRUGOTHER intake which only requires oral physiological supplementation and DRUGUNRELATED depletion related to a dysregulation of the control mechanisms of DRUGUNRELATED status which requires more or less specific regulation of its causal dysregulation .
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d103.s3.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d103.s3.e3'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of DRUGUNRELATED deficit and to discriminate between DRUG deficiency due to an insufficient DRUGUNRELATED intake which only requires oral physiological supplementation and DRUGOTHER depletion related to a dysregulation of the control mechanisms of DRUGUNRELATED status which requires more or less specific regulation of its causal dysregulation .
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d103.s3.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d103.s3.e4'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of DRUGUNRELATED deficit and to discriminate between DRUG deficiency due to an insufficient DRUGUNRELATED intake which only requires oral physiological supplementation and DRUGUNRELATED depletion related to a dysregulation of the control mechanisms of DRUGOTHER status which requires more or less specific regulation of its causal dysregulation .
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d103.s3.e2'}, 'e2': {'word': 'magnesium', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d103.s3.e3'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of DRUGUNRELATED deficit and to discriminate between DRUGUNRELATED deficiency due to an insufficient DRUG intake which only requires oral physiological supplementation and DRUGOTHER depletion related to a dysregulation of the control mechanisms of DRUGUNRELATED status which requires more or less specific regulation of its causal dysregulation .
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d103.s3.e2'}, 'e2': {'word': 'magnesium', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d103.s3.e4'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of DRUGUNRELATED deficit and to discriminate between DRUGUNRELATED deficiency due to an insufficient DRUG intake which only requires oral physiological supplementation and DRUGUNRELATED depletion related to a dysregulation of the control mechanisms of DRUGOTHER status which requires more or less specific regulation of its causal dysregulation .
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d103.s3.e3'}, 'e2': {'word': 'magnesium', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d103.s3.e4'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of DRUGUNRELATED deficit and to discriminate between DRUGUNRELATED deficiency due to an insufficient DRUGUNRELATED intake which only requires oral physiological supplementation and DRUG depletion related to a dysregulation of the control mechanisms of DRUGOTHER status which requires more or less specific regulation of its causal dysregulation .
Physiological oral magnesium load constitutes the best tool for diagnosis of magnesium deficiency and the first step of its treatment. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d103.s4.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d103.s4.e1'}, 'sentence_id': 'DDI-MedLine.d103.s4'}	Physiological oral DRUG load constitutes the best tool for diagnosis of DRUGOTHER deficiency and the first step of its treatment .
Physiological oral magnesium supplementation (5 mg/kg/day) is easy and can be carried out in the diet or with magnesium salts, with practically only one contra-indication: overt renal failure. 	magnesium	magnesium salt	none	{'e1': {'word': 'magnesium', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d103.s5.e0'}, 'e2': {'word': 'magnesium salt', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d103.s5.e1'}, 'sentence_id': 'DDI-MedLine.d103.s5'}	Physiological oral DRUG supplementation ( 5 mg / kg / day ) is easy and can be carried out in the diet or with DRUGOTHER s , with practically only one contra-indication : overt renal failure .
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	magnesium	magnesium sparing diuretics	none	{'e1': {'word': 'magnesium', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d103.s6.e0'}, 'e2': {'word': 'magnesium sparing diuretics', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d103.s6.e1'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	Specific and aspecific treatments of DRUG depletion are tricky using for example DRUGOTHER , pharmacological doses of DRUGUNRELATED , physiological doses of DRUGUNRELATED and of DRUGUNRELATED .
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	magnesium	vitamin B6	none	{'e1': {'word': 'magnesium', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d103.s6.e0'}, 'e2': {'word': 'vitamin B6', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d103.s6.e2'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	Specific and aspecific treatments of DRUG depletion are tricky using for example DRUGUNRELATED , pharmacological doses of DRUGOTHER , physiological doses of DRUGUNRELATED and of DRUGUNRELATED .
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	magnesium	vitamin D	none	{'e1': {'word': 'magnesium', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d103.s6.e0'}, 'e2': {'word': 'vitamin D', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d103.s6.e3'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	Specific and aspecific treatments of DRUG depletion are tricky using for example DRUGUNRELATED , pharmacological doses of DRUGUNRELATED , physiological doses of DRUGOTHER and of DRUGUNRELATED .
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	magnesium	selenium	none	{'e1': {'word': 'magnesium', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d103.s6.e0'}, 'e2': {'word': 'selenium', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d103.s6.e4'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	Specific and aspecific treatments of DRUG depletion are tricky using for example DRUGUNRELATED , pharmacological doses of DRUGUNRELATED , physiological doses of DRUGUNRELATED and of DRUGOTHER .
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	magnesium sparing diuretics	vitamin B6	none	{'e1': {'word': 'magnesium sparing diuretics', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d103.s6.e1'}, 'e2': {'word': 'vitamin B6', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d103.s6.e2'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	Specific and aspecific treatments of DRUGUNRELATED depletion are tricky using for example DRUG , pharmacological doses of DRUGOTHER , physiological doses of DRUGUNRELATED and of DRUGUNRELATED .
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	magnesium sparing diuretics	vitamin D	none	{'e1': {'word': 'magnesium sparing diuretics', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d103.s6.e1'}, 'e2': {'word': 'vitamin D', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d103.s6.e3'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	Specific and aspecific treatments of DRUGUNRELATED depletion are tricky using for example DRUG , pharmacological doses of DRUGUNRELATED , physiological doses of DRUGOTHER and of DRUGUNRELATED .
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	magnesium sparing diuretics	selenium	none	{'e1': {'word': 'magnesium sparing diuretics', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d103.s6.e1'}, 'e2': {'word': 'selenium', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d103.s6.e4'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	Specific and aspecific treatments of DRUGUNRELATED depletion are tricky using for example DRUG , pharmacological doses of DRUGUNRELATED , physiological doses of DRUGUNRELATED and of DRUGOTHER .
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	vitamin B6	vitamin D	none	{'e1': {'word': 'vitamin B6', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d103.s6.e2'}, 'e2': {'word': 'vitamin D', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d103.s6.e3'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	Specific and aspecific treatments of DRUGUNRELATED depletion are tricky using for example DRUGUNRELATED , pharmacological doses of DRUG , physiological doses of DRUGOTHER and of DRUGUNRELATED .
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	vitamin B6	selenium	none	{'e1': {'word': 'vitamin B6', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d103.s6.e2'}, 'e2': {'word': 'selenium', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d103.s6.e4'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	Specific and aspecific treatments of DRUGUNRELATED depletion are tricky using for example DRUGUNRELATED , pharmacological doses of DRUG , physiological doses of DRUGUNRELATED and of DRUGOTHER .
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	vitamin D	selenium	none	{'e1': {'word': 'vitamin D', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d103.s6.e3'}, 'e2': {'word': 'selenium', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d103.s6.e4'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	Specific and aspecific treatments of DRUGUNRELATED depletion are tricky using for example DRUGUNRELATED , pharmacological doses of DRUGUNRELATED , physiological doses of DRUG and of DRUGOTHER .
There are 3 types of indications: specific (for the treatment of some forms of magnesium deficit i.e. acute), pharmacological (i.e. without alterations of magnesium status) and mixed--pharmacological and aetiopathogenic--(for example complications of chronic alcoholism). 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d103.s8.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d103.s8.e1'}, 'sentence_id': 'DDI-MedLine.d103.s8'}	There are 3 types of indications : specific ( for the treatment of some forms of DRUG deficit i.e. acute ) , pharmacological ( i.e. without alterations of DRUGOTHER status ) and mixed - - pharmacological and aetiopathogenic - - ( for example complications of chronic alcoholism ) .
Lastly local use of the mucocutaneous and cytoprotective properties of magnesium is still valid, in cardioplegic solutions and for preservation of transplants particularly.	magnesium	cardioplegic solutions	none	{'e1': {'word': 'magnesium', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d103.s15.e0'}, 'e2': {'word': 'cardioplegic solutions', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d103.s15.e1'}, 'sentence_id': 'DDI-MedLine.d103.s15'}	Lastly local use of the mucocutaneous and cytoprotective properties of DRUG is still valid , in DRUGOTHER and for preservation of transplants particularly .
"Hypothermia as an index of the disulfiram-ethanol reaction in the rat.
"	disulfiram	ethanol	none	{'e1': {'word': 'disulfiram', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d81.s0.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d81.s0.e1'}, 'sentence_id': 'DDI-MedLine.d81.s0'}	Hypothermia as an index of the DRUG - DRUGOTHER reaction in the rat .
Decreased core temperature in female rats was investigated as one possible index of the disulfiram-ethanol reaction (DER). 	disulfiram	ethanol	none	{'e1': {'word': 'disulfiram', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d81.s1.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d81.s1.e1'}, 'sentence_id': 'DDI-MedLine.d81.s1'}	Decreased core temperature in female rats was investigated as one possible index of the DRUG - DRUGOTHER reaction ( DER ) .
Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge. 	ethanol	disulfiram	effect	{'e1': {'word': 'ethanol', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d81.s2.e0'}, 'e2': {'word': 'disulfiram', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d81.s2.e1'}, 'sentence_id': 'DDI-MedLine.d81.s2'}	Core temperature was decreased in rats in a dose - dependent manner when DRUG was administered to rats treated with DRUGOTHER 8 hours before the DRUGUNRELATED challenge .
Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge. 	ethanol	ethanol	none	{'e1': {'word': 'ethanol', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d81.s2.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d81.s2.e2'}, 'sentence_id': 'DDI-MedLine.d81.s2'}	Core temperature was decreased in rats in a dose - dependent manner when DRUG was administered to rats treated with DRUGUNRELATED 8 hours before the DRUGOTHER challenge .
Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge. 	disulfiram	ethanol	none	{'e1': {'word': 'disulfiram', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d81.s2.e1'}, 'e2': {'word': 'ethanol', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d81.s2.e2'}, 'sentence_id': 'DDI-MedLine.d81.s2'}	Core temperature was decreased in rats in a dose - dependent manner when DRUGUNRELATED was administered to rats treated with DRUG 8 hours before the DRUGOTHER challenge .
The decrease in temperature began within 20 minutes after ethanol administration, reaching a maximal decrease between 60 and 120 minutes post ethanol. 	ethanol	ethanol	none	{'e1': {'word': 'ethanol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d81.s3.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d81.s3.e1'}, 'sentence_id': 'DDI-MedLine.d81.s3'}	The decrease in temperature began within 20 minutes after DRUG administration , reaching a maximal decrease between 60 and 120 minutes post DRUGOTHER .
Maximal hypotension was found 120 minutes post ethanol, and returned to normal 300 minutes after ethanol. 	ethanol	ethanol	none	{'e1': {'word': 'ethanol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d81.s6.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d81.s6.e1'}, 'sentence_id': 'DDI-MedLine.d81.s6'}	Maximal hypotension was found 120 minutes post DRUG , and returned to normal 300 minutes after DRUGOTHER .
"In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans.
"	KRM-1648	ofloxacin	none	{'e1': {'word': 'KRM-1648', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d8.s0.e0'}, 'e2': {'word': 'ofloxacin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d8.s0.e1'}, 'sentence_id': 'DDI-MedLine.d8.s0'}	In vitro activity of DRUG , either singly or in combination with DRUGOTHER , against Mycobacterium ulcerans .
The antimicrobial effect of a benzoxazinorifamycin, KRM-1648, either alone or in combination with ofloxacin, was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans. 	benzoxazinorifamycin	KRM-1648	none	{'e1': {'word': 'benzoxazinorifamycin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d8.s1.e0'}, 'e2': {'word': 'KRM-1648', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d8.s1.e1'}, 'sentence_id': 'DDI-MedLine.d8.s1'}	The antimicrobial effect of a DRUG , DRUGOTHER , either alone or in combination with DRUGUNRELATED , was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans .
The antimicrobial effect of a benzoxazinorifamycin, KRM-1648, either alone or in combination with ofloxacin, was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans. 	benzoxazinorifamycin	ofloxacin	none	{'e1': {'word': 'benzoxazinorifamycin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d8.s1.e0'}, 'e2': {'word': 'ofloxacin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d8.s1.e2'}, 'sentence_id': 'DDI-MedLine.d8.s1'}	The antimicrobial effect of a DRUG , DRUGUNRELATED , either alone or in combination with DRUGOTHER , was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans .
The antimicrobial effect of a benzoxazinorifamycin, KRM-1648, either alone or in combination with ofloxacin, was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans. 	KRM-1648	ofloxacin	none	{'e1': {'word': 'KRM-1648', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d8.s1.e1'}, 'e2': {'word': 'ofloxacin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d8.s1.e2'}, 'sentence_id': 'DDI-MedLine.d8.s1'}	The antimicrobial effect of a DRUGUNRELATED , DRUG , either alone or in combination with DRUGOTHER , was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans .
ulcerans was between 0.012 and 0.025 mg/l, while corresponding values for rifampicin and rifabutin were in the range of 0.1-0.8 mg/l and 0.1-0.4 mg/l respectively. 	rifampicin	rifabutin	none	{'e1': {'word': 'rifampicin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d8.s5.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d8.s5.e1'}, 'sentence_id': 'DDI-MedLine.d8.s5'}	ulcerans was between 0.012 and 0.025 mg / l , while corresponding values for DRUG and DRUGOTHER were in the range of 0.1 - 0.8 mg / l and 0.1 - 0.4 mg / l respectively .
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	ofloxacin	KRM-1648	effect	{'e1': {'word': 'ofloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d8.s6.e0'}, 'e2': {'word': 'KRM-1648', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d8.s6.e1'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	When combined with DRUG , DRUGOTHER exhibited strong synergistic activity while only additive effects were observed with the combination of DRUGUNRELATED ( or DRUGUNRELATED ) and DRUGUNRELATED .
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	ofloxacin	rifampicin	none	{'e1': {'word': 'ofloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d8.s6.e0'}, 'e2': {'word': 'rifampicin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d8.s6.e2'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	When combined with DRUG , DRUGUNRELATED exhibited strong synergistic activity while only additive effects were observed with the combination of DRUGOTHER ( or DRUGUNRELATED ) and DRUGUNRELATED .
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	ofloxacin	rifabutin	none	{'e1': {'word': 'ofloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d8.s6.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d8.s6.e3'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	When combined with DRUG , DRUGUNRELATED exhibited strong synergistic activity while only additive effects were observed with the combination of DRUGUNRELATED ( or DRUGOTHER ) and DRUGUNRELATED .
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	ofloxacin	ofloxacin	none	{'e1': {'word': 'ofloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d8.s6.e0'}, 'e2': {'word': 'ofloxacin', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d8.s6.e4'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	When combined with DRUG , DRUGUNRELATED exhibited strong synergistic activity while only additive effects were observed with the combination of DRUGUNRELATED ( or DRUGUNRELATED ) and DRUGOTHER .
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	KRM-1648	rifampicin	none	{'e1': {'word': 'KRM-1648', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d8.s6.e1'}, 'e2': {'word': 'rifampicin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d8.s6.e2'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	When combined with DRUGUNRELATED , DRUG exhibited strong synergistic activity while only additive effects were observed with the combination of DRUGOTHER ( or DRUGUNRELATED ) and DRUGUNRELATED .
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	KRM-1648	rifabutin	none	{'e1': {'word': 'KRM-1648', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d8.s6.e1'}, 'e2': {'word': 'rifabutin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d8.s6.e3'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	When combined with DRUGUNRELATED , DRUG exhibited strong synergistic activity while only additive effects were observed with the combination of DRUGUNRELATED ( or DRUGOTHER ) and DRUGUNRELATED .
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	KRM-1648	ofloxacin	none	{'e1': {'word': 'KRM-1648', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d8.s6.e1'}, 'e2': {'word': 'ofloxacin', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d8.s6.e4'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	When combined with DRUGUNRELATED , DRUG exhibited strong synergistic activity while only additive effects were observed with the combination of DRUGUNRELATED ( or DRUGUNRELATED ) and DRUGOTHER .
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	rifampicin	rifabutin	none	{'e1': {'word': 'rifampicin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d8.s6.e2'}, 'e2': {'word': 'rifabutin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d8.s6.e3'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	When combined with DRUGUNRELATED , DRUGUNRELATED exhibited strong synergistic activity while only additive effects were observed with the combination of DRUG ( or DRUGOTHER ) and DRUGUNRELATED .
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	rifampicin	ofloxacin	effect	{'e1': {'word': 'rifampicin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d8.s6.e2'}, 'e2': {'word': 'ofloxacin', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d8.s6.e4'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	When combined with DRUGUNRELATED , DRUGUNRELATED exhibited strong synergistic activity while only additive effects were observed with the combination of DRUG ( or DRUGUNRELATED ) and DRUGOTHER .
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	rifabutin	ofloxacin	effect	{'e1': {'word': 'rifabutin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d8.s6.e3'}, 'e2': {'word': 'ofloxacin', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d8.s6.e4'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	When combined with DRUGUNRELATED , DRUGUNRELATED exhibited strong synergistic activity while only additive effects were observed with the combination of DRUGUNRELATED ( or DRUG ) and DRUGOTHER .
"Interaction between glycine and glutamate in the development of spontaneous motility in chick embryos.
"	glycine	glutamate	effect	{'e1': {'word': 'glycine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d20.s0.e0'}, 'e2': {'word': 'glutamate', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d20.s0.e1'}, 'sentence_id': 'DDI-MedLine.d20.s0'}	Interaction between DRUG and DRUGOTHER in the development of spontaneous motility in chick embryos .
The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone. 	glycine	glutamate	effect	{'e1': {'word': 'glycine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d20.s4.e0'}, 'e2': {'word': 'glutamate', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d20.s4.e1'}, 'sentence_id': 'DDI-MedLine.d20.s4'}	The successive application of DRUG ( 5 or 10 mg / kg egg weight ( e.w. ) and DRUGOTHER ( 15 mg / kg e.w. ) in a 10 min interval significantly increased the activation of spontaneous motility of 17 - day - old chick embryos in comparison with the effect of DRUGUNRELATED alone .
The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone. 	glycine	glutamate	none	{'e1': {'word': 'glycine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d20.s4.e0'}, 'e2': {'word': 'glutamate', 'word_index': [(52, 52)], 'id': 'DDI-MedLine.d20.s4.e2'}, 'sentence_id': 'DDI-MedLine.d20.s4'}	The successive application of DRUG ( 5 or 10 mg / kg egg weight ( e.w. ) and DRUGUNRELATED ( 15 mg / kg e.w. ) in a 10 min interval significantly increased the activation of spontaneous motility of 17 - day - old chick embryos in comparison with the effect of DRUGOTHER alone .
The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone. 	glutamate	glutamate	none	{'e1': {'word': 'glutamate', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d20.s4.e1'}, 'e2': {'word': 'glutamate', 'word_index': [(52, 52)], 'id': 'DDI-MedLine.d20.s4.e2'}, 'sentence_id': 'DDI-MedLine.d20.s4'}	The successive application of DRUGUNRELATED ( 5 or 10 mg / kg egg weight ( e.w. ) and DRUG ( 15 mg / kg e.w. ) in a 10 min interval significantly increased the activation of spontaneous motility of 17 - day - old chick embryos in comparison with the effect of DRUGOTHER alone .
"Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
"	verapamil	bombesin	effect	{'e1': {'word': 'verapamil', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d133.s0.e0'}, 'e2': {'word': 'bombesin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d133.s0.e1'}, 'sentence_id': 'DDI-MedLine.d133.s0'}	Suppression by DRUG of DRUGOTHER - enhanced peritoneal metastasis of intestinal adenocarcinomas induced by DRUGUNRELATED in wistar rats .
"Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
"	verapamil	azoxymethane	none	{'e1': {'word': 'verapamil', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d133.s0.e0'}, 'e2': {'word': 'azoxymethane', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d133.s0.e2'}, 'sentence_id': 'DDI-MedLine.d133.s0'}	Suppression by DRUG of DRUGUNRELATED - enhanced peritoneal metastasis of intestinal adenocarcinomas induced by DRUGOTHER in wistar rats .
"Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
"	bombesin	azoxymethane	none	{'e1': {'word': 'bombesin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d133.s0.e1'}, 'e2': {'word': 'azoxymethane', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d133.s0.e2'}, 'sentence_id': 'DDI-MedLine.d133.s0'}	Suppression by DRUGUNRELATED of DRUG - enhanced peritoneal metastasis of intestinal adenocarcinomas induced by DRUGOTHER in wistar rats .
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	bombesin	verapamil hydrochloride	none	{'e1': {'word': 'bombesin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d133.s1.e0'}, 'e2': {'word': 'verapamil hydrochloride', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d133.s1.e1'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND : The effects of combined administration of DRUG and DRUGOTHER ( DRUGUNRELATED ) , a DRUGUNRELATED , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGUNRELATED ( DRUGUNRELATED ) and the labeling index of intestinal cancers were investigated in male Wistar rats .
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	bombesin	verapamil	none	{'e1': {'word': 'bombesin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d133.s1.e0'}, 'e2': {'word': 'verapamil', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d133.s1.e2'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND : The effects of combined administration of DRUG and DRUGUNRELATED ( DRUGOTHER ) , a DRUGUNRELATED , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGUNRELATED ( DRUGUNRELATED ) and the labeling index of intestinal cancers were investigated in male Wistar rats .
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	bombesin	calcium channel blocker	none	{'e1': {'word': 'bombesin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d133.s1.e0'}, 'e2': {'word': 'calcium channel blocker', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d133.s1.e3'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND : The effects of combined administration of DRUG and DRUGUNRELATED ( DRUGUNRELATED ) , a DRUGOTHER , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGUNRELATED ( DRUGUNRELATED ) and the labeling index of intestinal cancers were investigated in male Wistar rats .
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	bombesin	azoxymethane	none	{'e1': {'word': 'bombesin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d133.s1.e0'}, 'e2': {'word': 'azoxymethane', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d133.s1.e4'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND : The effects of combined administration of DRUG and DRUGUNRELATED ( DRUGUNRELATED ) , a DRUGUNRELATED , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGOTHER ( DRUGUNRELATED ) and the labeling index of intestinal cancers were investigated in male Wistar rats .
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	bombesin	AOM	none	{'e1': {'word': 'bombesin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d133.s1.e0'}, 'e2': {'word': 'AOM', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d133.s1.e5'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND : The effects of combined administration of DRUG and DRUGUNRELATED ( DRUGUNRELATED ) , a DRUGUNRELATED , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGUNRELATED ( DRUGOTHER ) and the labeling index of intestinal cancers were investigated in male Wistar rats .
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	verapamil hydrochloride	verapamil	none	{'e1': {'word': 'verapamil hydrochloride', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d133.s1.e1'}, 'e2': {'word': 'verapamil', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d133.s1.e2'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND : The effects of combined administration of DRUGUNRELATED and DRUG ( DRUGOTHER ) , a DRUGUNRELATED , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGUNRELATED ( DRUGUNRELATED ) and the labeling index of intestinal cancers were investigated in male Wistar rats .
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	verapamil hydrochloride	calcium channel blocker	none	{'e1': {'word': 'verapamil hydrochloride', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d133.s1.e1'}, 'e2': {'word': 'calcium channel blocker', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d133.s1.e3'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND : The effects of combined administration of DRUGUNRELATED and DRUG ( DRUGUNRELATED ) , a DRUGOTHER , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGUNRELATED ( DRUGUNRELATED ) and the labeling index of intestinal cancers were investigated in male Wistar rats .
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	verapamil hydrochloride	azoxymethane	none	{'e1': {'word': 'verapamil hydrochloride', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d133.s1.e1'}, 'e2': {'word': 'azoxymethane', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d133.s1.e4'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND : The effects of combined administration of DRUGUNRELATED and DRUG ( DRUGUNRELATED ) , a DRUGUNRELATED , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGOTHER ( DRUGUNRELATED ) and the labeling index of intestinal cancers were investigated in male Wistar rats .
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	verapamil hydrochloride	AOM	none	{'e1': {'word': 'verapamil hydrochloride', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d133.s1.e1'}, 'e2': {'word': 'AOM', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d133.s1.e5'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND : The effects of combined administration of DRUGUNRELATED and DRUG ( DRUGUNRELATED ) , a DRUGUNRELATED , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGUNRELATED ( DRUGOTHER ) and the labeling index of intestinal cancers were investigated in male Wistar rats .
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	verapamil	calcium channel blocker	none	{'e1': {'word': 'verapamil', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d133.s1.e2'}, 'e2': {'word': 'calcium channel blocker', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d133.s1.e3'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND : The effects of combined administration of DRUGUNRELATED and DRUGUNRELATED ( DRUG ) , a DRUGOTHER , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGUNRELATED ( DRUGUNRELATED ) and the labeling index of intestinal cancers were investigated in male Wistar rats .
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	verapamil	azoxymethane	none	{'e1': {'word': 'verapamil', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d133.s1.e2'}, 'e2': {'word': 'azoxymethane', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d133.s1.e4'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND : The effects of combined administration of DRUGUNRELATED and DRUGUNRELATED ( DRUG ) , a DRUGUNRELATED , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGOTHER ( DRUGUNRELATED ) and the labeling index of intestinal cancers were investigated in male Wistar rats .
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	verapamil	AOM	none	{'e1': {'word': 'verapamil', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d133.s1.e2'}, 'e2': {'word': 'AOM', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d133.s1.e5'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND : The effects of combined administration of DRUGUNRELATED and DRUGUNRELATED ( DRUG ) , a DRUGUNRELATED , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGUNRELATED ( DRUGOTHER ) and the labeling index of intestinal cancers were investigated in male Wistar rats .
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	calcium channel blocker	azoxymethane	none	{'e1': {'word': 'calcium channel blocker', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d133.s1.e3'}, 'e2': {'word': 'azoxymethane', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d133.s1.e4'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND : The effects of combined administration of DRUGUNRELATED and DRUGUNRELATED ( DRUGUNRELATED ) , a DRUG , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGOTHER ( DRUGUNRELATED ) and the labeling index of intestinal cancers were investigated in male Wistar rats .
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	calcium channel blocker	AOM	none	{'e1': {'word': 'calcium channel blocker', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d133.s1.e3'}, 'e2': {'word': 'AOM', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d133.s1.e5'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND : The effects of combined administration of DRUGUNRELATED and DRUGUNRELATED ( DRUGUNRELATED ) , a DRUG , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGUNRELATED ( DRUGOTHER ) and the labeling index of intestinal cancers were investigated in male Wistar rats .
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	azoxymethane	AOM	none	{'e1': {'word': 'azoxymethane', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d133.s1.e4'}, 'e2': {'word': 'AOM', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d133.s1.e5'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND : The effects of combined administration of DRUGUNRELATED and DRUGUNRELATED ( DRUGUNRELATED ) , a DRUGUNRELATED , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUG ( DRUGOTHER ) and the labeling index of intestinal cancers were investigated in male Wistar rats .
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45. 	AOM	bombesin	none	{'e1': {'word': 'AOM', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d133.s2.e0'}, 'e2': {'word': 'bombesin', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d133.s2.e1'}, 'sentence_id': 'DDI-MedLine.d133.s2'}	METHODS : From the beginning of the experiment , rats were given 10 weekly subcutaneous injections of DRUG ( 7.4 mg / kg body weight ) and subcutaneous injections of DRUGOTHER ( 40 microg / kg body weight ) every other day , and from week 16 , intraperitoneal injections of DRUGUNRELATED ( 10 or 20 mg / kg body weight ) every other day until the end fo the experiment in week 45 .
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45. 	AOM	verapamil	none	{'e1': {'word': 'AOM', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d133.s2.e0'}, 'e2': {'word': 'verapamil', 'word_index': [(51, 51)], 'id': 'DDI-MedLine.d133.s2.e2'}, 'sentence_id': 'DDI-MedLine.d133.s2'}	METHODS : From the beginning of the experiment , rats were given 10 weekly subcutaneous injections of DRUG ( 7.4 mg / kg body weight ) and subcutaneous injections of DRUGUNRELATED ( 40 microg / kg body weight ) every other day , and from week 16 , intraperitoneal injections of DRUGOTHER ( 10 or 20 mg / kg body weight ) every other day until the end fo the experiment in week 45 .
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45. 	bombesin	verapamil	none	{'e1': {'word': 'bombesin', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d133.s2.e1'}, 'e2': {'word': 'verapamil', 'word_index': [(51, 51)], 'id': 'DDI-MedLine.d133.s2.e2'}, 'sentence_id': 'DDI-MedLine.d133.s2'}	METHODS : From the beginning of the experiment , rats were given 10 weekly subcutaneous injections of DRUGUNRELATED ( 7.4 mg / kg body weight ) and subcutaneous injections of DRUG ( 40 microg / kg body weight ) every other day , and from week 16 , intraperitoneal injections of DRUGOTHER ( 10 or 20 mg / kg body weight ) every other day until the end fo the experiment in week 45 .
Although verapamil administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by bombesin or on the location, histologic type, depth of involvement, labeling index, apoptotic index or tumor vascularity of intestinal cancers, it significantly decreased the incidence of cancer metastasis. 	verapamil	bombesin	none	{'e1': {'word': 'verapamil', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d133.s4.e0'}, 'e2': {'word': 'bombesin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d133.s4.e1'}, 'sentence_id': 'DDI-MedLine.d133.s4'}	Although DRUG administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by DRUGOTHER or on the location , histologic type , depth of involvement , labeling index , apoptotic index or tumor vascularity of intestinal cancers , it significantly decreased the incidence of cancer metastasis .
Verapamil also significantly decreased the incidence of lymphatic invasion of adenocarcinomas, which was enhanced by bombesin. 	Verapamil	bombesin	effect	{'e1': {'word': 'Verapamil', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d133.s5.e0'}, 'e2': {'word': 'bombesin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d133.s5.e1'}, 'sentence_id': 'DDI-MedLine.d133.s5'}	DRUG also significantly decreased the incidence of lymphatic invasion of adenocarcinomas , which was enhanced by DRUGOTHER .
The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. 	ruthenium red	RR	none	{'e1': {'word': 'ruthenium red', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d114.s1.e0'}, 'e2': {'word': 'RR', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d114.s1.e1'}, 'sentence_id': 'DDI-MedLine.d114.s1'}	The effects of DRUG ( DRUGOTHER ) on DRUGUNRELATED ( DRUGUNRELATED ) - induced responses were studied in rat bone marrow megakaryocytes with the patch - clamp whole - cell recording technique in combination with fura - 2 microfluorometry .
The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. 	ruthenium red	inositol 1,4,5-trisphosphate	none	{'e1': {'word': 'ruthenium red', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d114.s1.e0'}, 'e2': {'word': 'inositol 1,4,5-trisphosphate', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d114.s1.e2'}, 'sentence_id': 'DDI-MedLine.d114.s1'}	The effects of DRUG ( DRUGUNRELATED ) on DRUGOTHER ( DRUGUNRELATED ) - induced responses were studied in rat bone marrow megakaryocytes with the patch - clamp whole - cell recording technique in combination with fura - 2 microfluorometry .
The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. 	ruthenium red	InsP(3)	none	{'e1': {'word': 'ruthenium red', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d114.s1.e0'}, 'e2': {'word': 'InsP(3)', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d114.s1.e3'}, 'sentence_id': 'DDI-MedLine.d114.s1'}	The effects of DRUG ( DRUGUNRELATED ) on DRUGUNRELATED ( DRUGOTHER ) - induced responses were studied in rat bone marrow megakaryocytes with the patch - clamp whole - cell recording technique in combination with fura - 2 microfluorometry .
The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. 	RR	inositol 1,4,5-trisphosphate	none	{'e1': {'word': 'RR', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d114.s1.e1'}, 'e2': {'word': 'inositol 1,4,5-trisphosphate', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d114.s1.e2'}, 'sentence_id': 'DDI-MedLine.d114.s1'}	The effects of DRUGUNRELATED ( DRUG ) on DRUGOTHER ( DRUGUNRELATED ) - induced responses were studied in rat bone marrow megakaryocytes with the patch - clamp whole - cell recording technique in combination with fura - 2 microfluorometry .
The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. 	RR	InsP(3)	none	{'e1': {'word': 'RR', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d114.s1.e1'}, 'e2': {'word': 'InsP(3)', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d114.s1.e3'}, 'sentence_id': 'DDI-MedLine.d114.s1'}	The effects of DRUGUNRELATED ( DRUG ) on DRUGUNRELATED ( DRUGOTHER ) - induced responses were studied in rat bone marrow megakaryocytes with the patch - clamp whole - cell recording technique in combination with fura - 2 microfluorometry .
The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. 	inositol 1,4,5-trisphosphate	InsP(3)	none	{'e1': {'word': 'inositol 1,4,5-trisphosphate', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d114.s1.e2'}, 'e2': {'word': 'InsP(3)', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d114.s1.e3'}, 'sentence_id': 'DDI-MedLine.d114.s1'}	The effects of DRUGUNRELATED ( DRUGUNRELATED ) on DRUG ( DRUGOTHER ) - induced responses were studied in rat bone marrow megakaryocytes with the patch - clamp whole - cell recording technique in combination with fura - 2 microfluorometry .
Administering InsP(3) together with RR (100-500 microM) inhibited InsP(3)-induced responses (both Ca(2+) and current responses) in a dose-dependent fashion. 	InsP(3)	RR	effect	{'e1': {'word': 'InsP(3)', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d114.s3.e0'}, 'e2': {'word': 'RR', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d114.s3.e1'}, 'sentence_id': 'DDI-MedLine.d114.s3'}	Administering DRUG together with DRUGOTHER ( 100 - 500 microM ) inhibited InsP ( 3 ) - induced responses ( both Ca ( 2 + ) and current responses ) in a dose - dependent fashion .
Pretreatment of megakaryocytes with extracellular RR (50 microM) also inhibited InsP(3)-induced responses. 	RR	InsP(3)	effect	{'e1': {'word': 'RR', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d114.s4.e0'}, 'e2': {'word': 'InsP(3)', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d114.s4.e1'}, 'sentence_id': 'DDI-MedLine.d114.s4'}	Pretreatment of megakaryocytes with extracellular DRUG ( 50 microM ) also inhibited DRUGOTHER - induced responses .
In contrast, in isolated single pancreatic acinar cells, RR had no effect on InsP(3)-induced responses. 	RR	InsP(3)	none	{'e1': {'word': 'RR', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d114.s6.e0'}, 'e2': {'word': 'InsP(3)', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d114.s6.e1'}, 'sentence_id': 'DDI-MedLine.d114.s6'}	In contrast , in isolated single pancreatic acinar cells , DRUG had no effect on DRUGOTHER - induced responses .
In addition, we have shown that RR is a useful pharmacological tool with which to examine the InsP(3)-mediated responses of megakaryocytes.	RR	InsP(3)	none	{'e1': {'word': 'RR', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d114.s8.e0'}, 'e2': {'word': 'InsP(3)', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d114.s8.e1'}, 'sentence_id': 'DDI-MedLine.d114.s8'}	In addition , we have shown that DRUG is a useful pharmacological tool with which to examine the DRUGOTHER - mediated responses of megakaryocytes .
Dual effect of ouabain on the palytoxin-induced contraction and norepinephrine release in the guinea-pig vas deferens.	ouabain	palytoxin	none	{'e1': {'word': 'ouabain', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d56.s0.e0'}, 'e2': {'word': 'palytoxin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d56.s0.e1'}, 'sentence_id': 'DDI-MedLine.d56.s0'}	Dual effect of DRUG on the DRUGOTHER - induced contraction and norepinephrine release in the guinea - pig vas deferens .
Palytoxin (PTX), C129H223N3O54, isolated from marine coelenterates of Palythoa tuberculosa, caused a first rapid contraction followed by the slow phasic contraction of guinea-pig vas deferens. 	Palytoxin	PTX	none	{'e1': {'word': 'Palytoxin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d56.s1.e0'}, 'e2': {'word': 'PTX', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d56.s1.e1'}, 'sentence_id': 'DDI-MedLine.d56.s1'}	DRUG ( DRUGOTHER ) , C129H223N3O54 , isolated from marine coelenterates of Palythoa tuberculosa , caused a first rapid contraction followed by the slow phasic contraction of guinea - pig vas deferens .
In the presence of ouabain (10(-5) M), PTX (10(-8) M) failed to cause the first contraction; 	ouabain	PTX	effect	{'e1': {'word': 'ouabain', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d56.s2.e0'}, 'e2': {'word': 'PTX', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d56.s2.e1'}, 'sentence_id': 'DDI-MedLine.d56.s2'}	In the presence of DRUG ( 10 ( - 5 ) M ) , DRUGOTHER ( 10 ( - 8 ) M ) failed to cause the first contraction ;
When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished. 	ouabain	phentolamine	effect	{'e1': {'word': 'ouabain', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d56.s5.e0'}, 'e2': {'word': 'phentolamine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d56.s5.e1'}, 'sentence_id': 'DDI-MedLine.d56.s5'}	When DRUG was applied to the muscle in the presence of DRUGOTHER , both first and second contractile responses to DRUGUNRELATED were abolished .
When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished. 	ouabain	PTX	none	{'e1': {'word': 'ouabain', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d56.s5.e0'}, 'e2': {'word': 'PTX', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d56.s5.e2'}, 'sentence_id': 'DDI-MedLine.d56.s5'}	When DRUG was applied to the muscle in the presence of DRUGUNRELATED , both first and second contractile responses to DRUGOTHER were abolished .
When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished. 	phentolamine	PTX	none	{'e1': {'word': 'phentolamine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d56.s5.e1'}, 'e2': {'word': 'PTX', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d56.s5.e2'}, 'sentence_id': 'DDI-MedLine.d56.s5'}	When DRUGUNRELATED was applied to the muscle in the presence of DRUG , both first and second contractile responses to DRUGOTHER were abolished .
Exposure of the muscle to ouabain (10(-5) M) markedly increased the PTX-induced release. 	ouabain	PTX	effect	{'e1': {'word': 'ouabain', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d56.s8.e0'}, 'e2': {'word': 'PTX', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d56.s8.e1'}, 'sentence_id': 'DDI-MedLine.d56.s8'}	Exposure of the muscle to DRUG ( 10 ( - 5 ) M ) markedly increased the DRUGOTHER - induced release .
The second response is due to a release of norepinephrine from nerves and was potentiated by ouabain through the increase in the norepinephrine release, whereas the first response was not due to the norepinephrine release but presumably to a direct action on smooth muscle cell and was inhibited by ouabain. 	ouabain	ouabain	none	{'e1': {'word': 'ouabain', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d56.s10.e0'}, 'e2': {'word': 'ouabain', 'word_index': [(50, 50)], 'id': 'DDI-MedLine.d56.s10.e1'}, 'sentence_id': 'DDI-MedLine.d56.s10'}	The second response is due to a release of norepinephrine from nerves and was potentiated by DRUG through the increase in the norepinephrine release , whereas the first response was not due to the norepinephrine release but presumably to a direct action on smooth muscle cell and was inhibited by DRUGOTHER .
Diethyl pyrocarbonate, at pH 7.0, was used to chemically modify exposed histidine residues on toxin A. 	Diethyl pyrocarbonate	toxin A	none	{'e1': {'word': 'Diethyl pyrocarbonate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d48.s3.e0'}, 'e2': {'word': 'toxin A', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d48.s3.e1'}, 'sentence_id': 'DDI-MedLine.d48.s3'}	DRUG , at pH 7.0 , was used to chemically modify exposed histidine residues on DRUGOTHER .
Modification of toxin A with diethyl pyrocarbonate abolished both its cytotoxic activity and the ability of the toxin to bind Zn-Sepharose gel. 	toxin A	diethyl pyrocarbonate	none	{'e1': {'word': 'toxin A', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d48.s4.e0'}, 'e2': {'word': 'diethyl pyrocarbonate', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d48.s4.e1'}, 'sentence_id': 'DDI-MedLine.d48.s4'}	Modification of DRUG with DRUGOTHER abolished both its cytotoxic activity and the ability of the toxin to bind Zn - Sepharose gel .
Treatment of toxin A with [(14)C]-diethyl pyrocarbonate revealed concentration dependent labelling of histidine residues on the toxin molecules. 	toxin A	diethyl pyrocarbonate	none	{'e1': {'word': 'toxin A', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d48.s5.e0'}, 'e2': {'word': 'diethyl pyrocarbonate', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d48.s5.e1'}, 'sentence_id': 'DDI-MedLine.d48.s5'}	Treatment of DRUG with [ ( 14 ) C ] - DRUGOTHER revealed concentration dependent labelling of histidine residues on the toxin molecules .
The effects of diethyl pyrocarbonate could be reversed by hydroxylamine treatment. 	diethyl pyrocarbonate	hydroxylamine	none	{'e1': {'word': 'diethyl pyrocarbonate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d48.s6.e0'}, 'e2': {'word': 'hydroxylamine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d48.s6.e1'}, 'sentence_id': 'DDI-MedLine.d48.s6'}	The effects of DRUG could be reversed by DRUGOTHER treatment .
Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.	toxin A	zinc	none	{'e1': {'word': 'toxin A', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d48.s11.e0'}, 'e2': {'word': 'zinc', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d48.s11.e1'}, 'sentence_id': 'DDI-MedLine.d48.s11'}	Exposed histidines on DRUG are available for DRUGOTHER chelation , and these have been exploited in the development of a novel purification protocol for DRUGUNRELATED using DRUGUNRELATED - chelating chromatography .
Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.	toxin A	toxin A	none	{'e1': {'word': 'toxin A', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d48.s11.e0'}, 'e2': {'word': 'toxin A', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d48.s11.e2'}, 'sentence_id': 'DDI-MedLine.d48.s11'}	Exposed histidines on DRUG are available for DRUGUNRELATED chelation , and these have been exploited in the development of a novel purification protocol for DRUGOTHER using DRUGUNRELATED - chelating chromatography .
Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.	toxin A	zinc	none	{'e1': {'word': 'toxin A', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d48.s11.e0'}, 'e2': {'word': 'zinc', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d48.s11.e3'}, 'sentence_id': 'DDI-MedLine.d48.s11'}	Exposed histidines on DRUG are available for DRUGUNRELATED chelation , and these have been exploited in the development of a novel purification protocol for DRUGUNRELATED using DRUGOTHER - chelating chromatography .
Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.	zinc	toxin A	none	{'e1': {'word': 'zinc', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d48.s11.e1'}, 'e2': {'word': 'toxin A', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d48.s11.e2'}, 'sentence_id': 'DDI-MedLine.d48.s11'}	Exposed histidines on DRUGUNRELATED are available for DRUG chelation , and these have been exploited in the development of a novel purification protocol for DRUGOTHER using DRUGUNRELATED - chelating chromatography .
Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.	zinc	zinc	none	{'e1': {'word': 'zinc', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d48.s11.e1'}, 'e2': {'word': 'zinc', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d48.s11.e3'}, 'sentence_id': 'DDI-MedLine.d48.s11'}	Exposed histidines on DRUGUNRELATED are available for DRUG chelation , and these have been exploited in the development of a novel purification protocol for DRUGUNRELATED using DRUGOTHER - chelating chromatography .
Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.	toxin A	zinc	none	{'e1': {'word': 'toxin A', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d48.s11.e2'}, 'e2': {'word': 'zinc', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d48.s11.e3'}, 'sentence_id': 'DDI-MedLine.d48.s11'}	Exposed histidines on DRUGUNRELATED are available for DRUGUNRELATED chelation , and these have been exploited in the development of a novel purification protocol for DRUG using DRUGOTHER - chelating chromatography .
Slow-channel calcium blockers, such as verapamil, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. 	Slow-channel calcium blockers	verapamil	none	{'e1': {'word': 'Slow-channel calcium blockers', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d100.s5.e0'}, 'e2': {'word': 'verapamil', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d100.s5.e1'}, 'sentence_id': 'DDI-MedLine.d100.s5'}	DRUG , such as DRUGOTHER , DRUGUNRELATED and DRUGUNRELATED , inhibit platelet activation in vitro , and decrease platelet adhesion intravascularly .
Slow-channel calcium blockers, such as verapamil, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. 	Slow-channel calcium blockers	diltiazem	none	{'e1': {'word': 'Slow-channel calcium blockers', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d100.s5.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d100.s5.e2'}, 'sentence_id': 'DDI-MedLine.d100.s5'}	DRUG , such as DRUGUNRELATED , DRUGOTHER and DRUGUNRELATED , inhibit platelet activation in vitro , and decrease platelet adhesion intravascularly .
Slow-channel calcium blockers, such as verapamil, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. 	Slow-channel calcium blockers	nifedipine	none	{'e1': {'word': 'Slow-channel calcium blockers', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d100.s5.e0'}, 'e2': {'word': 'nifedipine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d100.s5.e3'}, 'sentence_id': 'DDI-MedLine.d100.s5'}	DRUG , such as DRUGUNRELATED , DRUGUNRELATED and DRUGOTHER , inhibit platelet activation in vitro , and decrease platelet adhesion intravascularly .
Slow-channel calcium blockers, such as verapamil, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. 	verapamil	diltiazem	none	{'e1': {'word': 'verapamil', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d100.s5.e1'}, 'e2': {'word': 'diltiazem', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d100.s5.e2'}, 'sentence_id': 'DDI-MedLine.d100.s5'}	DRUGUNRELATED , such as DRUG , DRUGOTHER and DRUGUNRELATED , inhibit platelet activation in vitro , and decrease platelet adhesion intravascularly .
Slow-channel calcium blockers, such as verapamil, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. 	verapamil	nifedipine	none	{'e1': {'word': 'verapamil', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d100.s5.e1'}, 'e2': {'word': 'nifedipine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d100.s5.e3'}, 'sentence_id': 'DDI-MedLine.d100.s5'}	DRUGUNRELATED , such as DRUG , DRUGUNRELATED and DRUGOTHER , inhibit platelet activation in vitro , and decrease platelet adhesion intravascularly .
Slow-channel calcium blockers, such as verapamil, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. 	diltiazem	nifedipine	none	{'e1': {'word': 'diltiazem', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d100.s5.e2'}, 'e2': {'word': 'nifedipine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d100.s5.e3'}, 'sentence_id': 'DDI-MedLine.d100.s5'}	DRUGUNRELATED , such as DRUGUNRELATED , DRUG and DRUGOTHER , inhibit platelet activation in vitro , and decrease platelet adhesion intravascularly .
"Cypermethrin-induced oxidative stress in rat brain and liver is prevented by vitamin E or allopurinol.
"	Cypermethrin	vitamin E	effect	{'e1': {'word': 'Cypermethrin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d126.s0.e0'}, 'e2': {'word': 'vitamin E', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d126.s0.e1'}, 'sentence_id': 'DDI-MedLine.d126.s0'}	DRUG - induced oxidative stress in rat brain and liver is prevented by DRUGOTHER or DRUGUNRELATED .
"Cypermethrin-induced oxidative stress in rat brain and liver is prevented by vitamin E or allopurinol.
"	Cypermethrin	allopurinol	effect	{'e1': {'word': 'Cypermethrin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d126.s0.e0'}, 'e2': {'word': 'allopurinol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d126.s0.e2'}, 'sentence_id': 'DDI-MedLine.d126.s0'}	DRUG - induced oxidative stress in rat brain and liver is prevented by DRUGUNRELATED or DRUGOTHER .
"Cypermethrin-induced oxidative stress in rat brain and liver is prevented by vitamin E or allopurinol.
"	vitamin E	allopurinol	none	{'e1': {'word': 'vitamin E', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d126.s0.e1'}, 'e2': {'word': 'allopurinol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d126.s0.e2'}, 'sentence_id': 'DDI-MedLine.d126.s0'}	DRUGUNRELATED - induced oxidative stress in rat brain and liver is prevented by DRUG or DRUGOTHER .
Considering that the involvement of reactive oxygen species (ROS) has been implicated in the toxicity of various pesticides, this study was designed to investigate the possibility of oxidative stress induction by cypermethrin, a Type II pyrethroid. 	cypermethrin	Type II pyrethroid	none	{'e1': {'word': 'cypermethrin', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d126.s1.e0'}, 'e2': {'word': 'Type II pyrethroid', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d126.s1.e1'}, 'sentence_id': 'DDI-MedLine.d126.s1'}	Considering that the involvement of reactive oxygen species ( ROS ) has been implicated in the toxicity of various pesticides , this study was designed to investigate the possibility of oxidative stress induction by DRUG , a DRUGOTHER .
Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within 4 h. 	allopurinol	Vitamin E	none	{'e1': {'word': 'allopurinol', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d126.s6.e0'}, 'e2': {'word': 'Vitamin E', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d126.s6.e1'}, 'sentence_id': 'DDI-MedLine.d126.s6'}	Pretreatment of rats with DRUG ( 100 mg / kg , ip ) or DRUGOTHER ( 100 mg / kg per day , ig , for 3 days and a dose of 40 mg / kg on the 4th day ) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues , induced by single high dose of oral DRUGUNRELATED administration within 4 h .
Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within 4 h. 	allopurinol	cypermethrin	effect	{'e1': {'word': 'allopurinol', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d126.s6.e0'}, 'e2': {'word': 'cypermethrin', 'word_index': [(63, 63)], 'id': 'DDI-MedLine.d126.s6.e2'}, 'sentence_id': 'DDI-MedLine.d126.s6'}	Pretreatment of rats with DRUG ( 100 mg / kg , ip ) or DRUGUNRELATED ( 100 mg / kg per day , ig , for 3 days and a dose of 40 mg / kg on the 4th day ) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues , induced by single high dose of oral DRUGOTHER administration within 4 h .
Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within 4 h. 	Vitamin E	cypermethrin	effect	{'e1': {'word': 'Vitamin E', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d126.s6.e1'}, 'e2': {'word': 'cypermethrin', 'word_index': [(63, 63)], 'id': 'DDI-MedLine.d126.s6.e2'}, 'sentence_id': 'DDI-MedLine.d126.s6'}	Pretreatment of rats with DRUGUNRELATED ( 100 mg / kg , ip ) or DRUG ( 100 mg / kg per day , ig , for 3 days and a dose of 40 mg / kg on the 4th day ) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues , induced by single high dose of oral DRUGOTHER administration within 4 h .
Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin E.	cypermethrin	allopurinol	effect	{'e1': {'word': 'cypermethrin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d126.s7.e0'}, 'e2': {'word': 'allopurinol', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d126.s7.e1'}, 'sentence_id': 'DDI-MedLine.d126.s7'}	Thus , the results suggest that DRUG exposure of rats results in free radical - mediated tissue damage , as indicated by elevated cerebral and hepatic lipid peroxidation , which was prevented by DRUGOTHER and DRUGUNRELATED .
Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin E.	cypermethrin	Vitamin E	effect	{'e1': {'word': 'cypermethrin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d126.s7.e0'}, 'e2': {'word': 'Vitamin E', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d126.s7.e2'}, 'sentence_id': 'DDI-MedLine.d126.s7'}	Thus , the results suggest that DRUG exposure of rats results in free radical - mediated tissue damage , as indicated by elevated cerebral and hepatic lipid peroxidation , which was prevented by DRUGUNRELATED and DRUGOTHER .
Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin E.	allopurinol	Vitamin E	none	{'e1': {'word': 'allopurinol', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d126.s7.e1'}, 'e2': {'word': 'Vitamin E', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d126.s7.e2'}, 'sentence_id': 'DDI-MedLine.d126.s7'}	Thus , the results suggest that DRUGUNRELATED exposure of rats results in free radical - mediated tissue damage , as indicated by elevated cerebral and hepatic lipid peroxidation , which was prevented by DRUG and DRUGOTHER .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	cerulein	3H-spiroperidol	none	{'e1': {'word': 'cerulein', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d15.s0.e0'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d15.s0.e1'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUG - - an analog of the octapeptide cholecystokinin - - of DRUGOTHER binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	cerulein	neuroleptics	none	{'e1': {'word': 'cerulein', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d15.s0.e0'}, 'e2': {'word': 'neuroleptics', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d15.s0.e2'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUG - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUGOTHER ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	cerulein	haloperidol	none	{'e1': {'word': 'cerulein', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d15.s0.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(48, 48)], 'id': 'DDI-MedLine.d15.s0.e3'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUG - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGOTHER ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	cerulein	pyreneperone	none	{'e1': {'word': 'cerulein', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d15.s0.e0'}, 'e2': {'word': 'pyreneperone', 'word_index': [(56, 56)], 'id': 'DDI-MedLine.d15.s0.e4'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUG - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUGOTHER ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	cerulein	3H-spiroperidol	none	{'e1': {'word': 'cerulein', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d15.s0.e0'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(69, 69)], 'id': 'DDI-MedLine.d15.s0.e5'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUG - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGOTHER and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	cerulein	apomorphine	none	{'e1': {'word': 'cerulein', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d15.s0.e0'}, 'e2': {'word': 'apomorphine', 'word_index': [(76, 76)], 'id': 'DDI-MedLine.d15.s0.e6'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUG - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGOTHER in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	cerulein	3H-spiroperidol	none	{'e1': {'word': 'cerulein', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d15.s0.e0'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(82, 82)], 'id': 'DDI-MedLine.d15.s0.e7'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUG - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGOTHER binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	cerulein	apomorphine	none	{'e1': {'word': 'cerulein', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d15.s0.e0'}, 'e2': {'word': 'apomorphine', 'word_index': [(90, 90)], 'id': 'DDI-MedLine.d15.s0.e8'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUG - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGOTHER increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	neuroleptics	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d15.s0.e1'}, 'e2': {'word': 'neuroleptics', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d15.s0.e2'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUG binding after the long - term administration of DRUGOTHER ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	haloperidol	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d15.s0.e1'}, 'e2': {'word': 'haloperidol', 'word_index': [(48, 48)], 'id': 'DDI-MedLine.d15.s0.e3'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUG binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGOTHER ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	pyreneperone	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d15.s0.e1'}, 'e2': {'word': 'pyreneperone', 'word_index': [(56, 56)], 'id': 'DDI-MedLine.d15.s0.e4'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUG binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUGOTHER ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	3H-spiroperidol	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d15.s0.e1'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(69, 69)], 'id': 'DDI-MedLine.d15.s0.e5'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUG binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGOTHER and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	apomorphine	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d15.s0.e1'}, 'e2': {'word': 'apomorphine', 'word_index': [(76, 76)], 'id': 'DDI-MedLine.d15.s0.e6'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUG binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGOTHER in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	3H-spiroperidol	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d15.s0.e1'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(82, 82)], 'id': 'DDI-MedLine.d15.s0.e7'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUG binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGOTHER binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	apomorphine	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d15.s0.e1'}, 'e2': {'word': 'apomorphine', 'word_index': [(90, 90)], 'id': 'DDI-MedLine.d15.s0.e8'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUG binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGOTHER increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	neuroleptics	haloperidol	none	{'e1': {'word': 'neuroleptics', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d15.s0.e2'}, 'e2': {'word': 'haloperidol', 'word_index': [(48, 48)], 'id': 'DDI-MedLine.d15.s0.e3'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUG ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGOTHER ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	neuroleptics	pyreneperone	none	{'e1': {'word': 'neuroleptics', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d15.s0.e2'}, 'e2': {'word': 'pyreneperone', 'word_index': [(56, 56)], 'id': 'DDI-MedLine.d15.s0.e4'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUG ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUGOTHER ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	neuroleptics	3H-spiroperidol	none	{'e1': {'word': 'neuroleptics', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d15.s0.e2'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(69, 69)], 'id': 'DDI-MedLine.d15.s0.e5'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUG ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGOTHER and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	neuroleptics	apomorphine	none	{'e1': {'word': 'neuroleptics', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d15.s0.e2'}, 'e2': {'word': 'apomorphine', 'word_index': [(76, 76)], 'id': 'DDI-MedLine.d15.s0.e6'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUG ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGOTHER in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	neuroleptics	3H-spiroperidol	none	{'e1': {'word': 'neuroleptics', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d15.s0.e2'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(82, 82)], 'id': 'DDI-MedLine.d15.s0.e7'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUG ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGOTHER binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	neuroleptics	apomorphine	none	{'e1': {'word': 'neuroleptics', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d15.s0.e2'}, 'e2': {'word': 'apomorphine', 'word_index': [(90, 90)], 'id': 'DDI-MedLine.d15.s0.e8'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUG ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGOTHER increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	haloperidol	pyreneperone	none	{'e1': {'word': 'haloperidol', 'word_index': [(48, 48)], 'id': 'DDI-MedLine.d15.s0.e3'}, 'e2': {'word': 'pyreneperone', 'word_index': [(56, 56)], 'id': 'DDI-MedLine.d15.s0.e4'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUG ( 0.25 mg / kg ) and DRUGOTHER ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	haloperidol	3H-spiroperidol	none	{'e1': {'word': 'haloperidol', 'word_index': [(48, 48)], 'id': 'DDI-MedLine.d15.s0.e3'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(69, 69)], 'id': 'DDI-MedLine.d15.s0.e5'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUG ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGOTHER and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	haloperidol	apomorphine	none	{'e1': {'word': 'haloperidol', 'word_index': [(48, 48)], 'id': 'DDI-MedLine.d15.s0.e3'}, 'e2': {'word': 'apomorphine', 'word_index': [(76, 76)], 'id': 'DDI-MedLine.d15.s0.e6'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUG ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGOTHER in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	haloperidol	3H-spiroperidol	none	{'e1': {'word': 'haloperidol', 'word_index': [(48, 48)], 'id': 'DDI-MedLine.d15.s0.e3'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(82, 82)], 'id': 'DDI-MedLine.d15.s0.e7'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUG ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGOTHER binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	haloperidol	apomorphine	none	{'e1': {'word': 'haloperidol', 'word_index': [(48, 48)], 'id': 'DDI-MedLine.d15.s0.e3'}, 'e2': {'word': 'apomorphine', 'word_index': [(90, 90)], 'id': 'DDI-MedLine.d15.s0.e8'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUG ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGOTHER increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	pyreneperone	3H-spiroperidol	none	{'e1': {'word': 'pyreneperone', 'word_index': [(56, 56)], 'id': 'DDI-MedLine.d15.s0.e4'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(69, 69)], 'id': 'DDI-MedLine.d15.s0.e5'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUG ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGOTHER and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	pyreneperone	apomorphine	none	{'e1': {'word': 'pyreneperone', 'word_index': [(56, 56)], 'id': 'DDI-MedLine.d15.s0.e4'}, 'e2': {'word': 'apomorphine', 'word_index': [(76, 76)], 'id': 'DDI-MedLine.d15.s0.e6'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUG ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGOTHER in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	pyreneperone	3H-spiroperidol	none	{'e1': {'word': 'pyreneperone', 'word_index': [(56, 56)], 'id': 'DDI-MedLine.d15.s0.e4'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(82, 82)], 'id': 'DDI-MedLine.d15.s0.e7'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUG ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGOTHER binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	pyreneperone	apomorphine	none	{'e1': {'word': 'pyreneperone', 'word_index': [(56, 56)], 'id': 'DDI-MedLine.d15.s0.e4'}, 'e2': {'word': 'apomorphine', 'word_index': [(90, 90)], 'id': 'DDI-MedLine.d15.s0.e8'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUG ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGOTHER increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	apomorphine	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(69, 69)], 'id': 'DDI-MedLine.d15.s0.e5'}, 'e2': {'word': 'apomorphine', 'word_index': [(76, 76)], 'id': 'DDI-MedLine.d15.s0.e6'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUG and low affinity binding sites for DRUGOTHER in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	3H-spiroperidol	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(69, 69)], 'id': 'DDI-MedLine.d15.s0.e5'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(82, 82)], 'id': 'DDI-MedLine.d15.s0.e7'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUG and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGOTHER binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	apomorphine	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(69, 69)], 'id': 'DDI-MedLine.d15.s0.e5'}, 'e2': {'word': 'apomorphine', 'word_index': [(90, 90)], 'id': 'DDI-MedLine.d15.s0.e8'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUG and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGOTHER increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	apomorphine	3H-spiroperidol	none	{'e1': {'word': 'apomorphine', 'word_index': [(76, 76)], 'id': 'DDI-MedLine.d15.s0.e6'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(82, 82)], 'id': 'DDI-MedLine.d15.s0.e7'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUG in subcortical structures , whereas DRUGOTHER binding with high affinity binding sites for DRUGUNRELATED increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	apomorphine	apomorphine	none	{'e1': {'word': 'apomorphine', 'word_index': [(76, 76)], 'id': 'DDI-MedLine.d15.s0.e6'}, 'e2': {'word': 'apomorphine', 'word_index': [(90, 90)], 'id': 'DDI-MedLine.d15.s0.e8'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUG in subcortical structures , whereas DRUGUNRELATED binding with high affinity binding sites for DRUGOTHER increased both in the frontal cortex and subcortical structures of the forebrain .
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	apomorphine	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(82, 82)], 'id': 'DDI-MedLine.d15.s0.e7'}, 'e2': {'word': 'apomorphine', 'word_index': [(90, 90)], 'id': 'DDI-MedLine.d15.s0.e8'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	[ Stimulation by DRUGUNRELATED - - an analog of the octapeptide cholecystokinin - - of DRUGUNRELATED binding after the long - term administration of DRUGUNRELATED ] It has been established in experiments on white male rats that prolonged administration ( twice a day for 14 days ) of DRUGUNRELATED ( 0.25 mg / kg ) and DRUGUNRELATED ( 0.25 mg / kg ) resulted in the reduced interaction between DRUGUNRELATED and low affinity binding sites for DRUGUNRELATED in subcortical structures , whereas DRUG binding with high affinity binding sites for DRUGOTHER increased both in the frontal cortex and subcortical structures of the forebrain .
After prolonged administration of neuroleptics the displacing effect of cerulein, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on 3H-spiroperidol binding. 	neuroleptics	cerulein	none	{'e1': {'word': 'neuroleptics', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d15.s1.e0'}, 'e2': {'word': 'cerulein', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d15.s1.e1'}, 'sentence_id': 'DDI-MedLine.d15.s1'}	After prolonged administration of DRUG the displacing effect of DRUGOTHER , an analog of cholecystokinin octapeptide , was replaced by the stimulant action on DRUGUNRELATED binding .
After prolonged administration of neuroleptics the displacing effect of cerulein, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on 3H-spiroperidol binding. 	neuroleptics	3H-spiroperidol	none	{'e1': {'word': 'neuroleptics', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d15.s1.e0'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d15.s1.e2'}, 'sentence_id': 'DDI-MedLine.d15.s1'}	After prolonged administration of DRUG the displacing effect of DRUGUNRELATED , an analog of cholecystokinin octapeptide , was replaced by the stimulant action on DRUGOTHER binding .
After prolonged administration of neuroleptics the displacing effect of cerulein, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on 3H-spiroperidol binding. 	cerulein	3H-spiroperidol	none	{'e1': {'word': 'cerulein', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d15.s1.e1'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d15.s1.e2'}, 'sentence_id': 'DDI-MedLine.d15.s1'}	After prolonged administration of DRUGUNRELATED the displacing effect of DRUG , an analog of cholecystokinin octapeptide , was replaced by the stimulant action on DRUGOTHER binding .
It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration. 	3H-spiroperidol	apomorphine	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d15.s2.e0'}, 'e2': {'word': 'apomorphine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d15.s2.e1'}, 'sentence_id': 'DDI-MedLine.d15.s2'}	It is assumed that increased interaction between DRUG and high affinity binding sites for DRUGOTHER on dopamine2 - and serotonin2 - receptors underlies the antipsychotic action of DRUGUNRELATED after their prolonged administration .
It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration. 	3H-spiroperidol	neuroleptics	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d15.s2.e0'}, 'e2': {'word': 'neuroleptics', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d15.s2.e2'}, 'sentence_id': 'DDI-MedLine.d15.s2'}	It is assumed that increased interaction between DRUG and high affinity binding sites for DRUGUNRELATED on dopamine2 - and serotonin2 - receptors underlies the antipsychotic action of DRUGOTHER after their prolonged administration .
It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration. 	apomorphine	neuroleptics	none	{'e1': {'word': 'apomorphine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d15.s2.e1'}, 'e2': {'word': 'neuroleptics', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d15.s2.e2'}, 'sentence_id': 'DDI-MedLine.d15.s2'}	It is assumed that increased interaction between DRUGUNRELATED and high affinity binding sites for DRUG on dopamine2 - and serotonin2 - receptors underlies the antipsychotic action of DRUGOTHER after their prolonged administration .
"Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine.
"	1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine	MPTP	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d73.s0.e0'}, 'e2': {'word': 'MPTP', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d73.s0.e1'}, 'sentence_id': 'DDI-MedLine.d73.s0'}	Neurochemical and functional consequences following DRUG ( DRUGOTHER ) and DRUGUNRELATED .
"Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine.
"	1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine	methamphetamine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d73.s0.e0'}, 'e2': {'word': 'methamphetamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d73.s0.e2'}, 'sentence_id': 'DDI-MedLine.d73.s0'}	Neurochemical and functional consequences following DRUG ( DRUGUNRELATED ) and DRUGOTHER .
"Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine.
"	MPTP	methamphetamine	none	{'e1': {'word': 'MPTP', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d73.s0.e1'}, 'e2': {'word': 'methamphetamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d73.s0.e2'}, 'sentence_id': 'DDI-MedLine.d73.s0'}	Neurochemical and functional consequences following DRUGUNRELATED ( DRUG ) and DRUGOTHER .
The neurochemical and functional consequences following MPTP administration to the rat were evaluated and compared to similar effects following methamphetamine administration. 	MPTP	methamphetamine	none	{'e1': {'word': 'MPTP', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d73.s1.e0'}, 'e2': {'word': 'methamphetamine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d73.s1.e1'}, 'sentence_id': 'DDI-MedLine.d73.s1'}	The neurochemical and functional consequences following DRUG administration to the rat were evaluated and compared to similar effects following DRUGOTHER administration .
It was observed that MPTP induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by pargyline pretreatment. 	MPTP	pargyline	effect	{'e1': {'word': 'MPTP', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d73.s2.e0'}, 'e2': {'word': 'pargyline', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d73.s2.e1'}, 'sentence_id': 'DDI-MedLine.d73.s2'}	It was observed that DRUG induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by DRUGOTHER pretreatment .
The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm. 	MPTP	amphetamine	effect	{'e1': {'word': 'MPTP', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d73.s3.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d73.s3.e1'}, 'sentence_id': 'DDI-MedLine.d73.s3'}	The DRUG - induced neuronal damage produced a tolerance to the disruptive effects of DRUGOTHER and a supersensitivity to the disruptive effects of DRUGUNRELATED in rats responding in a schedule controlled paradigm .
The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm. 	MPTP	apomorphine	effect	{'e1': {'word': 'MPTP', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d73.s3.e0'}, 'e2': {'word': 'apomorphine', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d73.s3.e2'}, 'sentence_id': 'DDI-MedLine.d73.s3'}	The DRUG - induced neuronal damage produced a tolerance to the disruptive effects of DRUGUNRELATED and a supersensitivity to the disruptive effects of DRUGOTHER in rats responding in a schedule controlled paradigm .
The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm. 	amphetamine	apomorphine	none	{'e1': {'word': 'amphetamine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d73.s3.e1'}, 'e2': {'word': 'apomorphine', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d73.s3.e2'}, 'sentence_id': 'DDI-MedLine.d73.s3'}	The DRUGUNRELATED - induced neuronal damage produced a tolerance to the disruptive effects of DRUG and a supersensitivity to the disruptive effects of DRUGOTHER in rats responding in a schedule controlled paradigm .
Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment. 	Methamphetamine	MPTP	none	{'e1': {'word': 'Methamphetamine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d73.s4.e0'}, 'e2': {'word': 'MPTP', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d73.s4.e1'}, 'sentence_id': 'DDI-MedLine.d73.s4'}	DRUG , like DRUGOTHER , produced depletions of striatal dopamine but these actions were potentiated by DRUGUNRELATED pretreatment .
Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment. 	Methamphetamine	pargyline	effect	{'e1': {'word': 'Methamphetamine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d73.s4.e0'}, 'e2': {'word': 'pargyline', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d73.s4.e2'}, 'sentence_id': 'DDI-MedLine.d73.s4'}	DRUG , like DRUGUNRELATED , produced depletions of striatal dopamine but these actions were potentiated by DRUGOTHER pretreatment .
Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment. 	MPTP	pargyline	none	{'e1': {'word': 'MPTP', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d73.s4.e1'}, 'e2': {'word': 'pargyline', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d73.s4.e2'}, 'sentence_id': 'DDI-MedLine.d73.s4'}	DRUGUNRELATED , like DRUG , produced depletions of striatal dopamine but these actions were potentiated by DRUGOTHER pretreatment .
"Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition.
"	levofloxacin	oxycodone	none	{'e1': {'word': 'levofloxacin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d124.s0.e0'}, 'e2': {'word': 'oxycodone', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d124.s0.e1'}, 'sentence_id': 'DDI-MedLine.d124.s0'}	Lack of interaction between DRUG and DRUGOTHER : pharmacokinetics and drug disposition .
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. 	trovafloxacin	ciprofloxacin	none	{'e1': {'word': 'trovafloxacin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d124.s1.e0'}, 'e2': {'word': 'ciprofloxacin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d124.s1.e1'}, 'sentence_id': 'DDI-MedLine.d124.s1'}	Previous studies have demonstrated a significant reduction in the oral bioavailability of DRUG and DRUGOTHER when administered concomitantly with an intravenous DRUGUNRELATED such as DRUGUNRELATED .
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. 	trovafloxacin	opiate	mechanism	{'e1': {'word': 'trovafloxacin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d124.s1.e0'}, 'e2': {'word': 'opiate', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d124.s1.e2'}, 'sentence_id': 'DDI-MedLine.d124.s1'}	Previous studies have demonstrated a significant reduction in the oral bioavailability of DRUG and DRUGUNRELATED when administered concomitantly with an intravenous DRUGOTHER such as DRUGUNRELATED .
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. 	trovafloxacin	morphine	mechanism	{'e1': {'word': 'trovafloxacin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d124.s1.e0'}, 'e2': {'word': 'morphine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d124.s1.e3'}, 'sentence_id': 'DDI-MedLine.d124.s1'}	Previous studies have demonstrated a significant reduction in the oral bioavailability of DRUG and DRUGUNRELATED when administered concomitantly with an intravenous DRUGUNRELATED such as DRUGOTHER .
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. 	ciprofloxacin	opiate	mechanism	{'e1': {'word': 'ciprofloxacin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d124.s1.e1'}, 'e2': {'word': 'opiate', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d124.s1.e2'}, 'sentence_id': 'DDI-MedLine.d124.s1'}	Previous studies have demonstrated a significant reduction in the oral bioavailability of DRUGUNRELATED and DRUG when administered concomitantly with an intravenous DRUGOTHER such as DRUGUNRELATED .
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. 	ciprofloxacin	morphine	mechanism	{'e1': {'word': 'ciprofloxacin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d124.s1.e1'}, 'e2': {'word': 'morphine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d124.s1.e3'}, 'sentence_id': 'DDI-MedLine.d124.s1'}	Previous studies have demonstrated a significant reduction in the oral bioavailability of DRUGUNRELATED and DRUG when administered concomitantly with an intravenous DRUGUNRELATED such as DRUGOTHER .
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. 	opiate	morphine	none	{'e1': {'word': 'opiate', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d124.s1.e2'}, 'e2': {'word': 'morphine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d124.s1.e3'}, 'sentence_id': 'DDI-MedLine.d124.s1'}	Previous studies have demonstrated a significant reduction in the oral bioavailability of DRUGUNRELATED and DRUGUNRELATED when administered concomitantly with an intravenous DRUG such as DRUGOTHER .
This decrease in absorption results in a 36% and 50% lower AUC for trovafloxacin and ciprofloxacin, respectively, which could cause clinical failures. 	trovafloxacin	ciprofloxacin	none	{'e1': {'word': 'trovafloxacin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d124.s2.e0'}, 'e2': {'word': 'ciprofloxacin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d124.s2.e1'}, 'sentence_id': 'DDI-MedLine.d124.s2'}	This decrease in absorption results in a 36 % and 50 % lower AUC for DRUG and DRUGOTHER , respectively , which could cause clinical failures .
The authors investigated the possibility of a similar interaction between oxycodone and levofloxacin. 	oxycodone	levofloxacin	none	{'e1': {'word': 'oxycodone', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d124.s3.e0'}, 'e2': {'word': 'levofloxacin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d124.s3.e1'}, 'sentence_id': 'DDI-MedLine.d124.s3'}	The authors investigated the possibility of a similar interaction between DRUG and DRUGOTHER .
1 hour after starting the oxycodone or levofloxacin 500 mg p.o. 	oxycodone	levofloxacin	none	{'e1': {'word': 'oxycodone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d124.s6.e0'}, 'e2': {'word': 'levofloxacin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d124.s6.e1'}, 'sentence_id': 'DDI-MedLine.d124.s6'}	1 hour after starting the DRUG or DRUGOTHER 500 mg p.o.
There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens. 	levofloxacin	levofloxacin	none	{'e1': {'word': 'levofloxacin', 'word_index': [(61, 61)], 'id': 'DDI-MedLine.d124.s9.e0'}, 'e2': {'word': 'levofloxacin', 'word_index': [(63, 63)], 'id': 'DDI-MedLine.d124.s9.e1'}, 'sentence_id': 'DDI-MedLine.d124.s9'}	There was not a significant difference ( p > 0.05 ) in AUC ( 48.59 + / - 8.52 vs . 49.9 + / - 9.93 ) , Cmax ( 7.73 + / - 2.6 vs . 6.6 + / - 2.0 ) , and tmax ( 1.1 + / - 0.6 vs . 1.6 + / - 1.1 ) for DRUG versus DRUGOTHER / DRUGUNRELATED regimens .
There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens. 	levofloxacin	oxycodone	none	{'e1': {'word': 'levofloxacin', 'word_index': [(61, 61)], 'id': 'DDI-MedLine.d124.s9.e0'}, 'e2': {'word': 'oxycodone', 'word_index': [(65, 65)], 'id': 'DDI-MedLine.d124.s9.e2'}, 'sentence_id': 'DDI-MedLine.d124.s9'}	There was not a significant difference ( p > 0.05 ) in AUC ( 48.59 + / - 8.52 vs . 49.9 + / - 9.93 ) , Cmax ( 7.73 + / - 2.6 vs . 6.6 + / - 2.0 ) , and tmax ( 1.1 + / - 0.6 vs . 1.6 + / - 1.1 ) for DRUG versus DRUGUNRELATED / DRUGOTHER regimens .
There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens. 	levofloxacin	oxycodone	none	{'e1': {'word': 'levofloxacin', 'word_index': [(63, 63)], 'id': 'DDI-MedLine.d124.s9.e1'}, 'e2': {'word': 'oxycodone', 'word_index': [(65, 65)], 'id': 'DDI-MedLine.d124.s9.e2'}, 'sentence_id': 'DDI-MedLine.d124.s9'}	There was not a significant difference ( p > 0.05 ) in AUC ( 48.59 + / - 8.52 vs . 49.9 + / - 9.93 ) , Cmax ( 7.73 + / - 2.6 vs . 6.6 + / - 2.0 ) , and tmax ( 1.1 + / - 0.6 vs . 1.6 + / - 1.1 ) for DRUGUNRELATED versus DRUG / DRUGOTHER regimens .
It was concluded that oral oxycodone and levofloxacin can be administered concomitantly without a significant decrease in AUC, Cmax, or tmax.	oxycodone	levofloxacin	none	{'e1': {'word': 'oxycodone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d124.s10.e0'}, 'e2': {'word': 'levofloxacin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d124.s10.e1'}, 'sentence_id': 'DDI-MedLine.d124.s10'}	It was concluded that oral DRUG and DRUGOTHER can be administered concomitantly without a significant decrease in AUC , Cmax , or tmax .
"Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection.
"	Sirolimus	rapamycin	none	{'e1': {'word': 'Sirolimus', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d118.s0.e0'}, 'e2': {'word': 'rapamycin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d118.s0.e1'}, 'sentence_id': 'DDI-MedLine.d118.s0'}	DRUG : mammalian target of DRUGOTHER inhibitor to prevent kidney rejection .
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	Sirolimus	immunosuppressants	none	{'e1': {'word': 'Sirolimus', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d118.s2.e0'}, 'e2': {'word': 'immunosuppressants', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d118.s2.e1'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	DRUG works differently from the DRUGOTHER currently available , and except for increased lipid levels , the adverse reaction profile of DRUGUNRELATED does not appear to overlap to any great extent with that associated with DRUGUNRELATED or DRUGUNRELATED .
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	Sirolimus	sirolimus	none	{'e1': {'word': 'Sirolimus', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d118.s2.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d118.s2.e2'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	DRUG works differently from the DRUGUNRELATED currently available , and except for increased lipid levels , the adverse reaction profile of DRUGOTHER does not appear to overlap to any great extent with that associated with DRUGUNRELATED or DRUGUNRELATED .
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	Sirolimus	cyclosporine	none	{'e1': {'word': 'Sirolimus', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d118.s2.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d118.s2.e3'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	DRUG works differently from the DRUGUNRELATED currently available , and except for increased lipid levels , the adverse reaction profile of DRUGUNRELATED does not appear to overlap to any great extent with that associated with DRUGOTHER or DRUGUNRELATED .
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	Sirolimus	tacrolimus	none	{'e1': {'word': 'Sirolimus', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d118.s2.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d118.s2.e4'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	DRUG works differently from the DRUGUNRELATED currently available , and except for increased lipid levels , the adverse reaction profile of DRUGUNRELATED does not appear to overlap to any great extent with that associated with DRUGUNRELATED or DRUGOTHER .
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	immunosuppressants	sirolimus	none	{'e1': {'word': 'immunosuppressants', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d118.s2.e1'}, 'e2': {'word': 'sirolimus', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d118.s2.e2'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	DRUGUNRELATED works differently from the DRUG currently available , and except for increased lipid levels , the adverse reaction profile of DRUGOTHER does not appear to overlap to any great extent with that associated with DRUGUNRELATED or DRUGUNRELATED .
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	immunosuppressants	cyclosporine	none	{'e1': {'word': 'immunosuppressants', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d118.s2.e1'}, 'e2': {'word': 'cyclosporine', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d118.s2.e3'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	DRUGUNRELATED works differently from the DRUG currently available , and except for increased lipid levels , the adverse reaction profile of DRUGUNRELATED does not appear to overlap to any great extent with that associated with DRUGOTHER or DRUGUNRELATED .
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	immunosuppressants	tacrolimus	none	{'e1': {'word': 'immunosuppressants', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d118.s2.e1'}, 'e2': {'word': 'tacrolimus', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d118.s2.e4'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	DRUGUNRELATED works differently from the DRUG currently available , and except for increased lipid levels , the adverse reaction profile of DRUGUNRELATED does not appear to overlap to any great extent with that associated with DRUGUNRELATED or DRUGOTHER .
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	sirolimus	cyclosporine	none	{'e1': {'word': 'sirolimus', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d118.s2.e2'}, 'e2': {'word': 'cyclosporine', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d118.s2.e3'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	DRUGUNRELATED works differently from the DRUGUNRELATED currently available , and except for increased lipid levels , the adverse reaction profile of DRUG does not appear to overlap to any great extent with that associated with DRUGOTHER or DRUGUNRELATED .
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	sirolimus	tacrolimus	none	{'e1': {'word': 'sirolimus', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d118.s2.e2'}, 'e2': {'word': 'tacrolimus', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d118.s2.e4'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	DRUGUNRELATED works differently from the DRUGUNRELATED currently available , and except for increased lipid levels , the adverse reaction profile of DRUG does not appear to overlap to any great extent with that associated with DRUGUNRELATED or DRUGOTHER .
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d118.s2.e3'}, 'e2': {'word': 'tacrolimus', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d118.s2.e4'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	DRUGUNRELATED works differently from the DRUGUNRELATED currently available , and except for increased lipid levels , the adverse reaction profile of DRUGUNRELATED does not appear to overlap to any great extent with that associated with DRUG or DRUGOTHER .
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	sirolimus	cyclosporine	none	{'e1': {'word': 'sirolimus', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d118.s3.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d118.s3.e1'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	While additional research is needed , the initial clinical data in kidney recipients suggest that DRUG , in combination with DRUGOTHER or DRUGUNRELATED , might have the potential to reduce the frequency of rejection episodes , permit reductions in DRUGUNRELATED or DRUGUNRELATED dosage , and permit steroid withdrawal ( Kelly , 1999 ) .
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	sirolimus	tacrolimus	none	{'e1': {'word': 'sirolimus', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d118.s3.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d118.s3.e2'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	While additional research is needed , the initial clinical data in kidney recipients suggest that DRUG , in combination with DRUGUNRELATED or DRUGOTHER , might have the potential to reduce the frequency of rejection episodes , permit reductions in DRUGUNRELATED or DRUGUNRELATED dosage , and permit steroid withdrawal ( Kelly , 1999 ) .
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	sirolimus	cyclosporine	none	{'e1': {'word': 'sirolimus', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d118.s3.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d118.s3.e3'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	While additional research is needed , the initial clinical data in kidney recipients suggest that DRUG , in combination with DRUGUNRELATED or DRUGUNRELATED , might have the potential to reduce the frequency of rejection episodes , permit reductions in DRUGOTHER or DRUGUNRELATED dosage , and permit steroid withdrawal ( Kelly , 1999 ) .
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	sirolimus	tacrolimus	none	{'e1': {'word': 'sirolimus', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d118.s3.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d118.s3.e4'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	While additional research is needed , the initial clinical data in kidney recipients suggest that DRUG , in combination with DRUGUNRELATED or DRUGUNRELATED , might have the potential to reduce the frequency of rejection episodes , permit reductions in DRUGUNRELATED or DRUGOTHER dosage , and permit steroid withdrawal ( Kelly , 1999 ) .
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d118.s3.e1'}, 'e2': {'word': 'tacrolimus', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d118.s3.e2'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	While additional research is needed , the initial clinical data in kidney recipients suggest that DRUGUNRELATED , in combination with DRUG or DRUGOTHER , might have the potential to reduce the frequency of rejection episodes , permit reductions in DRUGUNRELATED or DRUGUNRELATED dosage , and permit steroid withdrawal ( Kelly , 1999 ) .
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	cyclosporine	cyclosporine	none	{'e1': {'word': 'cyclosporine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d118.s3.e1'}, 'e2': {'word': 'cyclosporine', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d118.s3.e3'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	While additional research is needed , the initial clinical data in kidney recipients suggest that DRUGUNRELATED , in combination with DRUG or DRUGUNRELATED , might have the potential to reduce the frequency of rejection episodes , permit reductions in DRUGOTHER or DRUGUNRELATED dosage , and permit steroid withdrawal ( Kelly , 1999 ) .
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d118.s3.e1'}, 'e2': {'word': 'tacrolimus', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d118.s3.e4'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	While additional research is needed , the initial clinical data in kidney recipients suggest that DRUGUNRELATED , in combination with DRUG or DRUGUNRELATED , might have the potential to reduce the frequency of rejection episodes , permit reductions in DRUGUNRELATED or DRUGOTHER dosage , and permit steroid withdrawal ( Kelly , 1999 ) .
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	tacrolimus	cyclosporine	none	{'e1': {'word': 'tacrolimus', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d118.s3.e2'}, 'e2': {'word': 'cyclosporine', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d118.s3.e3'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	While additional research is needed , the initial clinical data in kidney recipients suggest that DRUGUNRELATED , in combination with DRUGUNRELATED or DRUG , might have the potential to reduce the frequency of rejection episodes , permit reductions in DRUGOTHER or DRUGUNRELATED dosage , and permit steroid withdrawal ( Kelly , 1999 ) .
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	tacrolimus	tacrolimus	none	{'e1': {'word': 'tacrolimus', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d118.s3.e2'}, 'e2': {'word': 'tacrolimus', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d118.s3.e4'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	While additional research is needed , the initial clinical data in kidney recipients suggest that DRUGUNRELATED , in combination with DRUGUNRELATED or DRUG , might have the potential to reduce the frequency of rejection episodes , permit reductions in DRUGUNRELATED or DRUGOTHER dosage , and permit steroid withdrawal ( Kelly , 1999 ) .
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d118.s3.e3'}, 'e2': {'word': 'tacrolimus', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d118.s3.e4'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	While additional research is needed , the initial clinical data in kidney recipients suggest that DRUGUNRELATED , in combination with DRUGUNRELATED or DRUGUNRELATED , might have the potential to reduce the frequency of rejection episodes , permit reductions in DRUG or DRUGOTHER dosage , and permit steroid withdrawal ( Kelly , 1999 ) .
The EC50 values for isoproterenol, which is not a substrate for norepinephrine uptake-1, were reduced in myocardium in functional classes II to III and IV compared with those in nonfailing myocardium. 	isoproterenol	norepinephrine	none	{'e1': {'word': 'isoproterenol', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d94.s11.e0'}, 'e2': {'word': 'norepinephrine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d94.s11.e1'}, 'sentence_id': 'DDI-MedLine.d94.s11'}	The EC50 values for DRUG , which is not a substrate for DRUGOTHER uptake - 1 , were reduced in myocardium in functional classes II to III and IV compared with those in nonfailing myocardium .
The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. 	cocaine	desipramine	none	{'e1': {'word': 'cocaine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d94.s12.e0'}, 'e2': {'word': 'desipramine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d94.s12.e1'}, 'sentence_id': 'DDI-MedLine.d94.s12'}	The uptake inhibitors DRUG and DRUGOTHER ( 3 mumol / liter ) potentiated the positive inotropic effects of DRUGUNRELATED in nonfailing myocardium ( p < 0.05 ) but not in functional class IV myocardium .
The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. 	cocaine	norepinephrine	effect	{'e1': {'word': 'cocaine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d94.s12.e0'}, 'e2': {'word': 'norepinephrine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d94.s12.e2'}, 'sentence_id': 'DDI-MedLine.d94.s12'}	The uptake inhibitors DRUG and DRUGUNRELATED ( 3 mumol / liter ) potentiated the positive inotropic effects of DRUGOTHER in nonfailing myocardium ( p < 0.05 ) but not in functional class IV myocardium .
The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. 	desipramine	norepinephrine	effect	{'e1': {'word': 'desipramine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d94.s12.e1'}, 'e2': {'word': 'norepinephrine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d94.s12.e2'}, 'sentence_id': 'DDI-MedLine.d94.s12'}	The uptake inhibitors DRUGUNRELATED and DRUG ( 3 mumol / liter ) potentiated the positive inotropic effects of DRUGOTHER in nonfailing myocardium ( p < 0.05 ) but not in functional class IV myocardium .
Radioligand binding experiments using the uptake inhibitor hydrogen-3 mazindol revealed a significant decrease by approximately 30% in norepinephrine uptake-1 carrier density in functional classes II to III and IV myocardium versus nonfailing myocardium (p < 0.05). 	mazindol	norepinephrine	none	{'e1': {'word': 'mazindol', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d94.s13.e0'}, 'e2': {'word': 'norepinephrine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d94.s13.e1'}, 'sentence_id': 'DDI-MedLine.d94.s13'}	Radioligand binding experiments using the uptake inhibitor hydrogen - 3 DRUG revealed a significant decrease by approximately 30 % in DRUGOTHER uptake - 1 carrier density in functional classes II to III and IV myocardium versus nonfailing myocardium ( p < 0.05 ) .
This defect in the failing heart can be mimicked by the effects of uptake blocking agents, such as cocaine and desipramine, in the nonfailing heart only. 	cocaine	desipramine	none	{'e1': {'word': 'cocaine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d94.s16.e0'}, 'e2': {'word': 'desipramine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d94.s16.e1'}, 'sentence_id': 'DDI-MedLine.d94.s16'}	This defect in the failing heart can be mimicked by the effects of uptake blocking agents , such as DRUG and DRUGOTHER , in the nonfailing heart only .
Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by cocaine and desipramine. 	norepinephrine	cocaine	none	{'e1': {'word': 'norepinephrine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d94.s17.e0'}, 'e2': {'word': 'cocaine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d94.s17.e1'}, 'sentence_id': 'DDI-MedLine.d94.s17'}	Compromised DRUG uptake - 1 in functional class IV can not be further increased by DRUGOTHER and DRUGUNRELATED .
Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by cocaine and desipramine. 	norepinephrine	desipramine	none	{'e1': {'word': 'norepinephrine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d94.s17.e0'}, 'e2': {'word': 'desipramine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d94.s17.e2'}, 'sentence_id': 'DDI-MedLine.d94.s17'}	Compromised DRUG uptake - 1 in functional class IV can not be further increased by DRUGUNRELATED and DRUGOTHER .
Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by cocaine and desipramine. 	cocaine	desipramine	none	{'e1': {'word': 'cocaine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d94.s17.e1'}, 'e2': {'word': 'desipramine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d94.s17.e2'}, 'sentence_id': 'DDI-MedLine.d94.s17'}	Compromised DRUGUNRELATED uptake - 1 in functional class IV can not be further increased by DRUG and DRUGOTHER .
Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia. 	Olanzapine	thienobenzodiazepine derivative	none	{'e1': {'word': 'Olanzapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s1.e0'}, 'e2': {'word': 'thienobenzodiazepine derivative', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d83.s1.e1'}, 'sentence_id': 'DDI-MedLine.d83.s1'}	DRUG , a DRUGOTHER , is a DRUGUNRELATED which has proven efficacy against the positive and negative symptoms of schizophrenia .
Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia. 	Olanzapine	second generation (atypical) antipsychotic agent	none	{'e1': {'word': 'Olanzapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s1.e0'}, 'e2': {'word': 'second generation (atypical) antipsychotic agent', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d83.s1.e2'}, 'sentence_id': 'DDI-MedLine.d83.s1'}	DRUG , a DRUGUNRELATED , is a DRUGOTHER which has proven efficacy against the positive and negative symptoms of schizophrenia .
Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia. 	thienobenzodiazepine derivative	second generation (atypical) antipsychotic agent	none	{'e1': {'word': 'thienobenzodiazepine derivative', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d83.s1.e1'}, 'e2': {'word': 'second generation (atypical) antipsychotic agent', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d83.s1.e2'}, 'sentence_id': 'DDI-MedLine.d83.s1'}	DRUGUNRELATED , a DRUG , is a DRUGOTHER which has proven efficacy against the positive and negative symptoms of schizophrenia .
In large, well controlled trials in patients with schizophrenia or related psychoses, olanzapine 5 to 20 mg/day was significantly superior to haloperidol 5 to 20 mg/day in overall improvements in psychopathology rating scales and in the treatment of depressive and negative symptoms, and was comparable in effects on positive psychotic symptoms. 	olanzapine	haloperidol	none	{'e1': {'word': 'olanzapine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d83.s3.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d83.s3.e1'}, 'sentence_id': 'DDI-MedLine.d83.s3'}	In large , well controlled trials in patients with schizophrenia or related psychoses , DRUG 5 to 20 mg / day was significantly superior to DRUGOTHER 5 to 20 mg / day in overall improvements in psychopathology rating scales and in the treatment of depressive and negative symptoms , and was comparable in effects on positive psychotic symptoms .
The 1-year risk of relapse (rehospitalisation) was significantly lower with olanzapine than with haloperidol treatment. 	olanzapine	haloperidol	none	{'e1': {'word': 'olanzapine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d83.s4.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d83.s4.e1'}, 'sentence_id': 'DDI-MedLine.d83.s4'}	The 1 - year risk of relapse ( rehospitalisation ) was significantly lower with DRUG than with DRUGOTHER treatment .
In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. 	olanzapine	risperidone	none	{'e1': {'word': 'olanzapine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d83.s5.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d83.s5.e1'}, 'sentence_id': 'DDI-MedLine.d83.s5'}	In the first double - blind comparative study ( 28 - week ) of DRUG and DRUGOTHER , DRUGUNRELATED 10 to 20 mg / day proved to be significantly more effective than DRUGUNRELATED 4 to 12 mg / day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms .
In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. 	olanzapine	olanzapine	none	{'e1': {'word': 'olanzapine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d83.s5.e0'}, 'e2': {'word': 'olanzapine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d83.s5.e2'}, 'sentence_id': 'DDI-MedLine.d83.s5'}	In the first double - blind comparative study ( 28 - week ) of DRUG and DRUGUNRELATED , DRUGOTHER 10 to 20 mg / day proved to be significantly more effective than DRUGUNRELATED 4 to 12 mg / day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms .
In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. 	olanzapine	risperidone	none	{'e1': {'word': 'olanzapine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d83.s5.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d83.s5.e3'}, 'sentence_id': 'DDI-MedLine.d83.s5'}	In the first double - blind comparative study ( 28 - week ) of DRUG and DRUGUNRELATED , DRUGUNRELATED 10 to 20 mg / day proved to be significantly more effective than DRUGOTHER 4 to 12 mg / day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms .
In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. 	risperidone	olanzapine	none	{'e1': {'word': 'risperidone', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d83.s5.e1'}, 'e2': {'word': 'olanzapine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d83.s5.e2'}, 'sentence_id': 'DDI-MedLine.d83.s5'}	In the first double - blind comparative study ( 28 - week ) of DRUGUNRELATED and DRUG , DRUGOTHER 10 to 20 mg / day proved to be significantly more effective than DRUGUNRELATED 4 to 12 mg / day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms .
In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. 	risperidone	risperidone	none	{'e1': {'word': 'risperidone', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d83.s5.e1'}, 'e2': {'word': 'risperidone', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d83.s5.e3'}, 'sentence_id': 'DDI-MedLine.d83.s5'}	In the first double - blind comparative study ( 28 - week ) of DRUGUNRELATED and DRUG , DRUGUNRELATED 10 to 20 mg / day proved to be significantly more effective than DRUGOTHER 4 to 12 mg / day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms .
In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. 	olanzapine	risperidone	none	{'e1': {'word': 'olanzapine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d83.s5.e2'}, 'e2': {'word': 'risperidone', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d83.s5.e3'}, 'sentence_id': 'DDI-MedLine.d83.s5'}	In the first double - blind comparative study ( 28 - week ) of DRUGUNRELATED and DRUGUNRELATED , DRUG 10 to 20 mg / day proved to be significantly more effective than DRUGOTHER 4 to 12 mg / day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms .
In contrast, preliminary results from an 8-week controlled study suggested risperidone 2 to 6 mg/day was superior to olanzapine 5 to 20 mg/day against positive and anxiety/depressive symptoms (p < 0.05), although consistent with the first study, both agents demonstrated similar efficacy on measures of overall psychopathology. 	risperidone	olanzapine	none	{'e1': {'word': 'risperidone', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d83.s6.e0'}, 'e2': {'word': 'olanzapine', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d83.s6.e1'}, 'sentence_id': 'DDI-MedLine.d83.s6'}	In contrast , preliminary results from an 8 - week controlled study suggested DRUG 2 to 6 mg / day was superior to DRUGOTHER 5 to 20 mg / day against positive and anxiety / depressive symptoms ( p < 0.05 ) , although consistent with the first study , both agents demonstrated similar efficacy on measures of overall psychopathology .
Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol. 	olanzapine	risperidone	none	{'e1': {'word': 'olanzapine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d83.s7.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d83.s7.e1'}, 'sentence_id': 'DDI-MedLine.d83.s7'}	Improvements in general cognitive function seen with DRUG treatment in a 1 - year controlled study of patients with early - phase schizophrenia , were significantly greater than changes seen with either DRUGOTHER or DRUGUNRELATED .
Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol. 	olanzapine	haloperidol	none	{'e1': {'word': 'olanzapine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d83.s7.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d83.s7.e2'}, 'sentence_id': 'DDI-MedLine.d83.s7'}	Improvements in general cognitive function seen with DRUG treatment in a 1 - year controlled study of patients with early - phase schizophrenia , were significantly greater than changes seen with either DRUGUNRELATED or DRUGOTHER .
Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol. 	risperidone	haloperidol	none	{'e1': {'word': 'risperidone', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d83.s7.e1'}, 'e2': {'word': 'haloperidol', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d83.s7.e2'}, 'sentence_id': 'DDI-MedLine.d83.s7'}	Improvements in general cognitive function seen with DRUGUNRELATED treatment in a 1 - year controlled study of patients with early - phase schizophrenia , were significantly greater than changes seen with either DRUG or DRUGOTHER .
However, preliminary results from an 8-week trial showed comparable cognitive enhancing effects of olanzapine and risperidone treatment in patients with schizophrenia or schizoaffective disorder. 	olanzapine	risperidone	none	{'e1': {'word': 'olanzapine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d83.s8.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d83.s8.e1'}, 'sentence_id': 'DDI-MedLine.d83.s8'}	However , preliminary results from an 8 - week trial showed comparable cognitive enhancing effects of DRUG and DRUGOTHER treatment in patients with schizophrenia or schizoaffective disorder .
Several studies indicate that olanzapine has benefits against symptoms of aggression and agitation, while other studies strongly support the effectiveness of olanzapine in the treatment of depressive symptomatology. 	olanzapine	olanzapine	none	{'e1': {'word': 'olanzapine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d83.s9.e0'}, 'e2': {'word': 'olanzapine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d83.s9.e1'}, 'sentence_id': 'DDI-MedLine.d83.s9'}	Several studies indicate that DRUG has benefits against symptoms of aggression and agitation , while other studies strongly support the effectiveness of DRUGOTHER in the treatment of depressive symptomatology .
Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone. 	Olanzapine	haloperidol	none	{'e1': {'word': 'Olanzapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s10.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d83.s10.e1'}, 'sentence_id': 'DDI-MedLine.d83.s10'}	DRUG is associated with significantly fewer extrapyramidal symptoms than DRUGOTHER and DRUGUNRELATED .
Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone. 	Olanzapine	risperidone	none	{'e1': {'word': 'Olanzapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s10.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d83.s10.e2'}, 'sentence_id': 'DDI-MedLine.d83.s10'}	DRUG is associated with significantly fewer extrapyramidal symptoms than DRUGUNRELATED and DRUGOTHER .
Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone. 	haloperidol	risperidone	none	{'e1': {'word': 'haloperidol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d83.s10.e1'}, 'e2': {'word': 'risperidone', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d83.s10.e2'}, 'sentence_id': 'DDI-MedLine.d83.s10'}	DRUGUNRELATED is associated with significantly fewer extrapyramidal symptoms than DRUG and DRUGOTHER .
In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval. 	olanzapine	clozapine	none	{'e1': {'word': 'olanzapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d83.s11.e0'}, 'e2': {'word': 'clozapine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d83.s11.e1'}, 'sentence_id': 'DDI-MedLine.d83.s11'}	In addition , DRUG is not associated with a risk of agranulocytosis as seen with DRUGOTHER or clinically significant hyperprolactinaemia as seen with DRUGUNRELATED or prolongation of the QT interval .
In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval. 	olanzapine	risperidone	none	{'e1': {'word': 'olanzapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d83.s11.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d83.s11.e2'}, 'sentence_id': 'DDI-MedLine.d83.s11'}	In addition , DRUG is not associated with a risk of agranulocytosis as seen with DRUGUNRELATED or clinically significant hyperprolactinaemia as seen with DRUGOTHER or prolongation of the QT interval .
In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval. 	clozapine	risperidone	none	{'e1': {'word': 'clozapine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d83.s11.e1'}, 'e2': {'word': 'risperidone', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d83.s11.e2'}, 'sentence_id': 'DDI-MedLine.d83.s11'}	In addition , DRUGUNRELATED is not associated with a risk of agranulocytosis as seen with DRUG or clinically significant hyperprolactinaemia as seen with DRUGOTHER or prolongation of the QT interval .
In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. 	haloperidol	olanzapine	none	{'e1': {'word': 'haloperidol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d83.s13.e0'}, 'e2': {'word': 'olanzapine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d83.s13.e1'}, 'sentence_id': 'DDI-MedLine.d83.s13'}	In comparison with DRUG , the adverse events reported significantly more frequently with DRUGOTHER in > or = 3.5 % of patients were dry mouth , bodyweight gain and increased appetite and compared with DRUGUNRELATED , only bodyweight gain occurred significantly more frequently with DRUGUNRELATED .
In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. 	haloperidol	risperidone	none	{'e1': {'word': 'haloperidol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d83.s13.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d83.s13.e2'}, 'sentence_id': 'DDI-MedLine.d83.s13'}	In comparison with DRUG , the adverse events reported significantly more frequently with DRUGUNRELATED in > or = 3.5 % of patients were dry mouth , bodyweight gain and increased appetite and compared with DRUGOTHER , only bodyweight gain occurred significantly more frequently with DRUGUNRELATED .
In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. 	haloperidol	olanzapine	none	{'e1': {'word': 'haloperidol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d83.s13.e0'}, 'e2': {'word': 'olanzapine', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d83.s13.e3'}, 'sentence_id': 'DDI-MedLine.d83.s13'}	In comparison with DRUG , the adverse events reported significantly more frequently with DRUGUNRELATED in > or = 3.5 % of patients were dry mouth , bodyweight gain and increased appetite and compared with DRUGUNRELATED , only bodyweight gain occurred significantly more frequently with DRUGOTHER .
In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. 	olanzapine	risperidone	none	{'e1': {'word': 'olanzapine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d83.s13.e1'}, 'e2': {'word': 'risperidone', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d83.s13.e2'}, 'sentence_id': 'DDI-MedLine.d83.s13'}	In comparison with DRUGUNRELATED , the adverse events reported significantly more frequently with DRUG in > or = 3.5 % of patients were dry mouth , bodyweight gain and increased appetite and compared with DRUGOTHER , only bodyweight gain occurred significantly more frequently with DRUGUNRELATED .
In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. 	olanzapine	olanzapine	none	{'e1': {'word': 'olanzapine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d83.s13.e1'}, 'e2': {'word': 'olanzapine', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d83.s13.e3'}, 'sentence_id': 'DDI-MedLine.d83.s13'}	In comparison with DRUGUNRELATED , the adverse events reported significantly more frequently with DRUG in > or = 3.5 % of patients were dry mouth , bodyweight gain and increased appetite and compared with DRUGUNRELATED , only bodyweight gain occurred significantly more frequently with DRUGOTHER .
In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. 	risperidone	olanzapine	none	{'e1': {'word': 'risperidone', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d83.s13.e2'}, 'e2': {'word': 'olanzapine', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d83.s13.e3'}, 'sentence_id': 'DDI-MedLine.d83.s13'}	In comparison with DRUGUNRELATED , the adverse events reported significantly more frequently with DRUGUNRELATED in > or = 3.5 % of patients were dry mouth , bodyweight gain and increased appetite and compared with DRUG , only bodyweight gain occurred significantly more frequently with DRUGOTHER .
Pharmacoeconomic analyses indicate that olanzapine does not significantly increase, and may even decrease, the overall direct treatment costs of schizophrenia, compared with haloperidol. 	olanzapine	haloperidol	none	{'e1': {'word': 'olanzapine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d83.s15.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d83.s15.e1'}, 'sentence_id': 'DDI-MedLine.d83.s15'}	Pharmacoeconomic analyses indicate that DRUG does not significantly increase , and may even decrease , the overall direct treatment costs of schizophrenia , compared with DRUGOTHER .
Compared with risperidone, olanzapine has also been reported to decrease overall treatment costs, despite the several-fold higher daily acquisition cost of the drug. 	risperidone	olanzapine	none	{'e1': {'word': 'risperidone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d83.s16.e0'}, 'e2': {'word': 'olanzapine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d83.s16.e1'}, 'sentence_id': 'DDI-MedLine.d83.s16'}	Compared with DRUG , DRUGOTHER has also been reported to decrease overall treatment costs , despite the several - fold higher daily acquisition cost of the drug .
Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol, and to broadly the same extent as risperidone. 	Olanzapine	haloperidol	none	{'e1': {'word': 'Olanzapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s17.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d83.s17.e1'}, 'sentence_id': 'DDI-MedLine.d83.s17'}	DRUG treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than DRUGOTHER , and to broadly the same extent as DRUGUNRELATED .
Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol, and to broadly the same extent as risperidone. 	Olanzapine	risperidone	none	{'e1': {'word': 'Olanzapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s17.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d83.s17.e2'}, 'sentence_id': 'DDI-MedLine.d83.s17'}	DRUG treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than DRUGUNRELATED , and to broadly the same extent as DRUGOTHER .
Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol, and to broadly the same extent as risperidone. 	haloperidol	risperidone	none	{'e1': {'word': 'haloperidol', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d83.s17.e1'}, 'e2': {'word': 'risperidone', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d83.s17.e2'}, 'sentence_id': 'DDI-MedLine.d83.s17'}	DRUGUNRELATED treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than DRUG , and to broadly the same extent as DRUGOTHER .
CONCLUSIONS: Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia. 	Olanzapine	haloperidol	none	{'e1': {'word': 'Olanzapine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d83.s18.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d83.s18.e1'}, 'sentence_id': 'DDI-MedLine.d83.s18'}	CONCLUSIONS : DRUG demonstrated superior antipsychotic efficacy compared with DRUGOTHER in the treatment of acute phase schizophrenia , and in the treatment of some patients with first - episode or treatment - resistant schizophrenia .
The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.	haloperidol	risperidone	none	{'e1': {'word': 'haloperidol', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d83.s19.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d83.s19.e1'}, 'sentence_id': 'DDI-MedLine.d83.s19'}	The reduced risk of adverse events and therapeutic superiority compared with DRUG and DRUGOTHER in the treatment of negative and depressive symptoms support the choice of DRUGUNRELATED as a first - line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response .
The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.	haloperidol	olanzapine	none	{'e1': {'word': 'haloperidol', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d83.s19.e0'}, 'e2': {'word': 'olanzapine', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d83.s19.e2'}, 'sentence_id': 'DDI-MedLine.d83.s19'}	The reduced risk of adverse events and therapeutic superiority compared with DRUG and DRUGUNRELATED in the treatment of negative and depressive symptoms support the choice of DRUGOTHER as a first - line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response .
The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.	risperidone	olanzapine	none	{'e1': {'word': 'risperidone', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d83.s19.e1'}, 'e2': {'word': 'olanzapine', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d83.s19.e2'}, 'sentence_id': 'DDI-MedLine.d83.s19'}	The reduced risk of adverse events and therapeutic superiority compared with DRUGUNRELATED and DRUG in the treatment of negative and depressive symptoms support the choice of DRUGOTHER as a first - line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response .
Numerous drug interactions are possible with some anticonvulsant agents, such as phenobarbitone and phenytoin, which affect hepatic microsomal enzyme systems. 	anticonvulsant agents	phenobarbitone	none	{'e1': {'word': 'anticonvulsant agents', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d19.s4.e0'}, 'e2': {'word': 'phenobarbitone', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d19.s4.e1'}, 'sentence_id': 'DDI-MedLine.d19.s4'}	Numerous drug interactions are possible with some DRUG , such as DRUGOTHER and DRUGUNRELATED , which affect hepatic microsomal enzyme systems .
Numerous drug interactions are possible with some anticonvulsant agents, such as phenobarbitone and phenytoin, which affect hepatic microsomal enzyme systems. 	anticonvulsant agents	phenytoin	none	{'e1': {'word': 'anticonvulsant agents', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d19.s4.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d19.s4.e2'}, 'sentence_id': 'DDI-MedLine.d19.s4'}	Numerous drug interactions are possible with some DRUG , such as DRUGUNRELATED and DRUGOTHER , which affect hepatic microsomal enzyme systems .
Numerous drug interactions are possible with some anticonvulsant agents, such as phenobarbitone and phenytoin, which affect hepatic microsomal enzyme systems. 	phenobarbitone	phenytoin	none	{'e1': {'word': 'phenobarbitone', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d19.s4.e1'}, 'e2': {'word': 'phenytoin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d19.s4.e2'}, 'sentence_id': 'DDI-MedLine.d19.s4'}	Numerous drug interactions are possible with some DRUGUNRELATED , such as DRUG and DRUGOTHER , which affect hepatic microsomal enzyme systems .
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	cyclophosphamide	doxorubicin	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d115.s0.e0'}, 'e2': {'word': 'doxorubicin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d115.s0.e1'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	Concomitant DRUG , DRUGOTHER , DRUGUNRELATED , and DRUGUNRELATED chemotherapy plus DRUGUNRELATED therapy in patients with human immunodeficiency virus - related , non-Hodgkin lymphoma .
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	cyclophosphamide	vincristine	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d115.s0.e0'}, 'e2': {'word': 'vincristine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d115.s0.e2'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	Concomitant DRUG , DRUGUNRELATED , DRUGOTHER , and DRUGUNRELATED chemotherapy plus DRUGUNRELATED therapy in patients with human immunodeficiency virus - related , non-Hodgkin lymphoma .
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	cyclophosphamide	prednisone	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d115.s0.e0'}, 'e2': {'word': 'prednisone', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d115.s0.e3'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	Concomitant DRUG , DRUGUNRELATED , DRUGUNRELATED , and DRUGOTHER chemotherapy plus DRUGUNRELATED therapy in patients with human immunodeficiency virus - related , non-Hodgkin lymphoma .
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	cyclophosphamide	highly active antiretroviral	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d115.s0.e0'}, 'e2': {'word': 'highly active antiretroviral', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d115.s0.e4'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	Concomitant DRUG , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED chemotherapy plus DRUGOTHER therapy in patients with human immunodeficiency virus - related , non-Hodgkin lymphoma .
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	doxorubicin	vincristine	none	{'e1': {'word': 'doxorubicin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d115.s0.e1'}, 'e2': {'word': 'vincristine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d115.s0.e2'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	Concomitant DRUGUNRELATED , DRUG , DRUGOTHER , and DRUGUNRELATED chemotherapy plus DRUGUNRELATED therapy in patients with human immunodeficiency virus - related , non-Hodgkin lymphoma .
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	doxorubicin	prednisone	none	{'e1': {'word': 'doxorubicin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d115.s0.e1'}, 'e2': {'word': 'prednisone', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d115.s0.e3'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	Concomitant DRUGUNRELATED , DRUG , DRUGUNRELATED , and DRUGOTHER chemotherapy plus DRUGUNRELATED therapy in patients with human immunodeficiency virus - related , non-Hodgkin lymphoma .
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	doxorubicin	highly active antiretroviral	none	{'e1': {'word': 'doxorubicin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d115.s0.e1'}, 'e2': {'word': 'highly active antiretroviral', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d115.s0.e4'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	Concomitant DRUGUNRELATED , DRUG , DRUGUNRELATED , and DRUGUNRELATED chemotherapy plus DRUGOTHER therapy in patients with human immunodeficiency virus - related , non-Hodgkin lymphoma .
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	vincristine	prednisone	none	{'e1': {'word': 'vincristine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d115.s0.e2'}, 'e2': {'word': 'prednisone', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d115.s0.e3'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	Concomitant DRUGUNRELATED , DRUGUNRELATED , DRUG , and DRUGOTHER chemotherapy plus DRUGUNRELATED therapy in patients with human immunodeficiency virus - related , non-Hodgkin lymphoma .
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	vincristine	highly active antiretroviral	none	{'e1': {'word': 'vincristine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d115.s0.e2'}, 'e2': {'word': 'highly active antiretroviral', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d115.s0.e4'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	Concomitant DRUGUNRELATED , DRUGUNRELATED , DRUG , and DRUGUNRELATED chemotherapy plus DRUGOTHER therapy in patients with human immunodeficiency virus - related , non-Hodgkin lymphoma .
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	prednisone	highly active antiretroviral	none	{'e1': {'word': 'prednisone', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d115.s0.e3'}, 'e2': {'word': 'highly active antiretroviral', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d115.s0.e4'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	Concomitant DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUG chemotherapy plus DRUGOTHER therapy in patients with human immunodeficiency virus - related , non-Hodgkin lymphoma .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	doxorubicin	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'doxorubicin', 'word_index': [(49, 49)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUG , DRUGOTHER , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	vincristine	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'vincristine', 'word_index': [(51, 51)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUG , DRUGUNRELATED , DRUGOTHER , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	prednisone	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'prednisone', 'word_index': [(54, 54)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUG , DRUGUNRELATED , DRUGUNRELATED , and DRUGOTHER ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	cyclophosphamide	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(83, 83)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUG , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	doxorubicin	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'doxorubicin', 'word_index': [(85, 85)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUG , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	teniposide	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'teniposide', 'word_index': [(87, 87)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUG , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	prednisone	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'prednisone', 'word_index': [(90, 90)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUG , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGOTHER with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	vincristine	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'vincristine', 'word_index': [(92, 92)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUG , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGOTHER plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	bleomycin	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'bleomycin', 'word_index': [(94, 94)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUG , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGOTHER ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	antiretroviral	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'antiretroviral', 'word_index': [(98, 98)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUG , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGOTHER therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	vincristine	none	{'e1': {'word': 'doxorubicin', 'word_index': [(49, 49)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'vincristine', 'word_index': [(51, 51)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUG , DRUGOTHER , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	prednisone	none	{'e1': {'word': 'doxorubicin', 'word_index': [(49, 49)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'prednisone', 'word_index': [(54, 54)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUG , DRUGUNRELATED , and DRUGOTHER ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	cyclophosphamide	none	{'e1': {'word': 'doxorubicin', 'word_index': [(49, 49)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(83, 83)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUG , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	doxorubicin	none	{'e1': {'word': 'doxorubicin', 'word_index': [(49, 49)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'doxorubicin', 'word_index': [(85, 85)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUG , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	teniposide	none	{'e1': {'word': 'doxorubicin', 'word_index': [(49, 49)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'teniposide', 'word_index': [(87, 87)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUG , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	prednisone	none	{'e1': {'word': 'doxorubicin', 'word_index': [(49, 49)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'prednisone', 'word_index': [(90, 90)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUG , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGOTHER with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	vincristine	none	{'e1': {'word': 'doxorubicin', 'word_index': [(49, 49)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'vincristine', 'word_index': [(92, 92)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUG , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGOTHER plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	bleomycin	none	{'e1': {'word': 'doxorubicin', 'word_index': [(49, 49)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'bleomycin', 'word_index': [(94, 94)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUG , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGOTHER ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	antiretroviral	none	{'e1': {'word': 'doxorubicin', 'word_index': [(49, 49)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'antiretroviral', 'word_index': [(98, 98)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUG , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGOTHER therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	prednisone	none	{'e1': {'word': 'vincristine', 'word_index': [(51, 51)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'e2': {'word': 'prednisone', 'word_index': [(54, 54)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUG , and DRUGOTHER ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	cyclophosphamide	none	{'e1': {'word': 'vincristine', 'word_index': [(51, 51)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(83, 83)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUG , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	doxorubicin	none	{'e1': {'word': 'vincristine', 'word_index': [(51, 51)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'e2': {'word': 'doxorubicin', 'word_index': [(85, 85)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUG , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	teniposide	none	{'e1': {'word': 'vincristine', 'word_index': [(51, 51)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'e2': {'word': 'teniposide', 'word_index': [(87, 87)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUG , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	prednisone	none	{'e1': {'word': 'vincristine', 'word_index': [(51, 51)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'e2': {'word': 'prednisone', 'word_index': [(90, 90)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUG , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGOTHER with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	vincristine	none	{'e1': {'word': 'vincristine', 'word_index': [(51, 51)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'e2': {'word': 'vincristine', 'word_index': [(92, 92)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUG , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGOTHER plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	bleomycin	none	{'e1': {'word': 'vincristine', 'word_index': [(51, 51)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'e2': {'word': 'bleomycin', 'word_index': [(94, 94)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUG , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGOTHER ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	antiretroviral	none	{'e1': {'word': 'vincristine', 'word_index': [(51, 51)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'e2': {'word': 'antiretroviral', 'word_index': [(98, 98)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUG , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGOTHER therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	cyclophosphamide	none	{'e1': {'word': 'prednisone', 'word_index': [(54, 54)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(83, 83)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUG ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	doxorubicin	none	{'e1': {'word': 'prednisone', 'word_index': [(54, 54)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'e2': {'word': 'doxorubicin', 'word_index': [(85, 85)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUG ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	teniposide	none	{'e1': {'word': 'prednisone', 'word_index': [(54, 54)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'e2': {'word': 'teniposide', 'word_index': [(87, 87)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUG ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	prednisone	none	{'e1': {'word': 'prednisone', 'word_index': [(54, 54)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'e2': {'word': 'prednisone', 'word_index': [(90, 90)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUG ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGOTHER with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	vincristine	none	{'e1': {'word': 'prednisone', 'word_index': [(54, 54)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'e2': {'word': 'vincristine', 'word_index': [(92, 92)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUG ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGOTHER plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	bleomycin	none	{'e1': {'word': 'prednisone', 'word_index': [(54, 54)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'e2': {'word': 'bleomycin', 'word_index': [(94, 94)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUG ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGOTHER ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	antiretroviral	none	{'e1': {'word': 'prednisone', 'word_index': [(54, 54)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'e2': {'word': 'antiretroviral', 'word_index': [(98, 98)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUG ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGOTHER therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	doxorubicin	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(83, 83)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'e2': {'word': 'doxorubicin', 'word_index': [(85, 85)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUG , DRUGOTHER , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	teniposide	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(83, 83)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'e2': {'word': 'teniposide', 'word_index': [(87, 87)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUG , DRUGUNRELATED , DRUGOTHER , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	prednisone	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(83, 83)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'e2': {'word': 'prednisone', 'word_index': [(90, 90)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUG , DRUGUNRELATED , DRUGUNRELATED , and DRUGOTHER with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	vincristine	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(83, 83)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'e2': {'word': 'vincristine', 'word_index': [(92, 92)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUG , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGOTHER plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	bleomycin	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(83, 83)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'e2': {'word': 'bleomycin', 'word_index': [(94, 94)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUG , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGOTHER ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	antiretroviral	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(83, 83)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'e2': {'word': 'antiretroviral', 'word_index': [(98, 98)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUG , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGOTHER therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	teniposide	none	{'e1': {'word': 'doxorubicin', 'word_index': [(85, 85)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'e2': {'word': 'teniposide', 'word_index': [(87, 87)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUG , DRUGOTHER , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	prednisone	none	{'e1': {'word': 'doxorubicin', 'word_index': [(85, 85)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'e2': {'word': 'prednisone', 'word_index': [(90, 90)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUG , DRUGUNRELATED , and DRUGOTHER with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	vincristine	none	{'e1': {'word': 'doxorubicin', 'word_index': [(85, 85)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'e2': {'word': 'vincristine', 'word_index': [(92, 92)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUG , DRUGUNRELATED , and DRUGUNRELATED with DRUGOTHER plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	bleomycin	none	{'e1': {'word': 'doxorubicin', 'word_index': [(85, 85)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'e2': {'word': 'bleomycin', 'word_index': [(94, 94)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUG , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGOTHER ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	antiretroviral	none	{'e1': {'word': 'doxorubicin', 'word_index': [(85, 85)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'e2': {'word': 'antiretroviral', 'word_index': [(98, 98)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUG , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGOTHER therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	teniposide	prednisone	none	{'e1': {'word': 'teniposide', 'word_index': [(87, 87)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'e2': {'word': 'prednisone', 'word_index': [(90, 90)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUG , and DRUGOTHER with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	teniposide	vincristine	none	{'e1': {'word': 'teniposide', 'word_index': [(87, 87)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'e2': {'word': 'vincristine', 'word_index': [(92, 92)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUG , and DRUGUNRELATED with DRUGOTHER plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	teniposide	bleomycin	none	{'e1': {'word': 'teniposide', 'word_index': [(87, 87)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'e2': {'word': 'bleomycin', 'word_index': [(94, 94)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUG , and DRUGUNRELATED with DRUGUNRELATED plus DRUGOTHER ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	teniposide	antiretroviral	none	{'e1': {'word': 'teniposide', 'word_index': [(87, 87)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'e2': {'word': 'antiretroviral', 'word_index': [(98, 98)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUG , and DRUGUNRELATED with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGOTHER therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	vincristine	none	{'e1': {'word': 'prednisone', 'word_index': [(90, 90)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'e2': {'word': 'vincristine', 'word_index': [(92, 92)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUG with DRUGOTHER plus DRUGUNRELATED ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	bleomycin	none	{'e1': {'word': 'prednisone', 'word_index': [(90, 90)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'e2': {'word': 'bleomycin', 'word_index': [(94, 94)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUG with DRUGUNRELATED plus DRUGOTHER ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	antiretroviral	none	{'e1': {'word': 'prednisone', 'word_index': [(90, 90)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'e2': {'word': 'antiretroviral', 'word_index': [(98, 98)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUG with DRUGUNRELATED plus DRUGUNRELATED ) without receiving DRUGOTHER therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	bleomycin	none	{'e1': {'word': 'vincristine', 'word_index': [(92, 92)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'e2': {'word': 'bleomycin', 'word_index': [(94, 94)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUG plus DRUGOTHER ) without receiving DRUGUNRELATED therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	antiretroviral	none	{'e1': {'word': 'vincristine', 'word_index': [(92, 92)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'e2': {'word': 'antiretroviral', 'word_index': [(98, 98)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUG plus DRUGUNRELATED ) without receiving DRUGOTHER therapy .
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	bleomycin	antiretroviral	none	{'e1': {'word': 'bleomycin', 'word_index': [(94, 94)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'e2': {'word': 'antiretroviral', 'word_index': [(98, 98)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV - related , systemic , non-Hodgkin lymphoma ( HIV - NHL ) , the authors compared retrospectively a group of 24 patients with HIV - NHL who were treated with the DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP - like regimen ( i.e. , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED plus DRUG ) without receiving DRUGOTHER therapy .
Antiretroviral regimens consisted of two reverse transcriptase inhibitors and one protease inhibitor. 	Antiretroviral	reverse transcriptase inhibitors	none	{'e1': {'word': 'Antiretroviral', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s5.e0'}, 'e2': {'word': 'reverse transcriptase inhibitors', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d115.s5.e1'}, 'sentence_id': 'DDI-MedLine.d115.s5'}	DRUG regimens consisted of two DRUGOTHER and one DRUGUNRELATED .
Antiretroviral regimens consisted of two reverse transcriptase inhibitors and one protease inhibitor. 	Antiretroviral	protease inhibitor	none	{'e1': {'word': 'Antiretroviral', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s5.e0'}, 'e2': {'word': 'protease inhibitor', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d115.s5.e2'}, 'sentence_id': 'DDI-MedLine.d115.s5'}	DRUG regimens consisted of two DRUGUNRELATED and one DRUGOTHER .
Antiretroviral regimens consisted of two reverse transcriptase inhibitors and one protease inhibitor. 	reverse transcriptase inhibitors	protease inhibitor	none	{'e1': {'word': 'reverse transcriptase inhibitors', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d115.s5.e1'}, 'e2': {'word': 'protease inhibitor', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d115.s5.e2'}, 'sentence_id': 'DDI-MedLine.d115.s5'}	DRUGUNRELATED regimens consisted of two DRUG and one DRUGOTHER .
However, careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between antiretroviral and antineoplastic drugs. 	antiretroviral drugs	antineoplastic drugs	advise	{'e1': {'word': 'antiretroviral drugs', 'word_index': [(15, 15), (18, 18)], 'id': 'DDI-MedLine.d115.s14.e0'}, 'e2': {'word': 'antineoplastic drugs', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d115.s14.e1'}, 'sentence_id': 'DDI-MedLine.d115.s14'}	However , careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between DRUG and DRUGOTHER DRUG .
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	cimetidine	verografin	none	{'e1': {'word': 'cimetidine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d68.s0.e0'}, 'e2': {'word': 'verografin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d68.s0.e1'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	[ The effect of DRUG on the renal excretion of DRUGOTHER and DRUGUNRELATED in dogs ] The intravenous injection of DRUGUNRELATED in a dose of 20 mg / kg enhanced DRUGUNRELATED and DRUGUNRELATED excretion in chronic canine experiments .
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	cimetidine	iodamide	none	{'e1': {'word': 'cimetidine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d68.s0.e0'}, 'e2': {'word': 'iodamide', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d68.s0.e2'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	[ The effect of DRUG on the renal excretion of DRUGUNRELATED and DRUGOTHER in dogs ] The intravenous injection of DRUGUNRELATED in a dose of 20 mg / kg enhanced DRUGUNRELATED and DRUGUNRELATED excretion in chronic canine experiments .
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	cimetidine	cimetidine	none	{'e1': {'word': 'cimetidine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d68.s0.e0'}, 'e2': {'word': 'cimetidine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d68.s0.e3'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	[ The effect of DRUG on the renal excretion of DRUGUNRELATED and DRUGUNRELATED in dogs ] The intravenous injection of DRUGOTHER in a dose of 20 mg / kg enhanced DRUGUNRELATED and DRUGUNRELATED excretion in chronic canine experiments .
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	cimetidine	verografine	none	{'e1': {'word': 'cimetidine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d68.s0.e0'}, 'e2': {'word': 'verografine', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d68.s0.e4'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	[ The effect of DRUG on the renal excretion of DRUGUNRELATED and DRUGUNRELATED in dogs ] The intravenous injection of DRUGUNRELATED in a dose of 20 mg / kg enhanced DRUGOTHER and DRUGUNRELATED excretion in chronic canine experiments .
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	cimetidine	iodamide	none	{'e1': {'word': 'cimetidine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d68.s0.e0'}, 'e2': {'word': 'iodamide', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d68.s0.e5'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	[ The effect of DRUG on the renal excretion of DRUGUNRELATED and DRUGUNRELATED in dogs ] The intravenous injection of DRUGUNRELATED in a dose of 20 mg / kg enhanced DRUGUNRELATED and DRUGOTHER excretion in chronic canine experiments .
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	verografin	iodamide	none	{'e1': {'word': 'verografin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d68.s0.e1'}, 'e2': {'word': 'iodamide', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d68.s0.e2'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	[ The effect of DRUGUNRELATED on the renal excretion of DRUG and DRUGOTHER in dogs ] The intravenous injection of DRUGUNRELATED in a dose of 20 mg / kg enhanced DRUGUNRELATED and DRUGUNRELATED excretion in chronic canine experiments .
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	verografin	cimetidine	none	{'e1': {'word': 'verografin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d68.s0.e1'}, 'e2': {'word': 'cimetidine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d68.s0.e3'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	[ The effect of DRUGUNRELATED on the renal excretion of DRUG and DRUGUNRELATED in dogs ] The intravenous injection of DRUGOTHER in a dose of 20 mg / kg enhanced DRUGUNRELATED and DRUGUNRELATED excretion in chronic canine experiments .
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	verografin	verografine	none	{'e1': {'word': 'verografin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d68.s0.e1'}, 'e2': {'word': 'verografine', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d68.s0.e4'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	[ The effect of DRUGUNRELATED on the renal excretion of DRUG and DRUGUNRELATED in dogs ] The intravenous injection of DRUGUNRELATED in a dose of 20 mg / kg enhanced DRUGOTHER and DRUGUNRELATED excretion in chronic canine experiments .
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	verografin	iodamide	none	{'e1': {'word': 'verografin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d68.s0.e1'}, 'e2': {'word': 'iodamide', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d68.s0.e5'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	[ The effect of DRUGUNRELATED on the renal excretion of DRUG and DRUGUNRELATED in dogs ] The intravenous injection of DRUGUNRELATED in a dose of 20 mg / kg enhanced DRUGUNRELATED and DRUGOTHER excretion in chronic canine experiments .
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	iodamide	cimetidine	none	{'e1': {'word': 'iodamide', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d68.s0.e2'}, 'e2': {'word': 'cimetidine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d68.s0.e3'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	[ The effect of DRUGUNRELATED on the renal excretion of DRUGUNRELATED and DRUG in dogs ] The intravenous injection of DRUGOTHER in a dose of 20 mg / kg enhanced DRUGUNRELATED and DRUGUNRELATED excretion in chronic canine experiments .
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	iodamide	verografine	none	{'e1': {'word': 'iodamide', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d68.s0.e2'}, 'e2': {'word': 'verografine', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d68.s0.e4'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	[ The effect of DRUGUNRELATED on the renal excretion of DRUGUNRELATED and DRUG in dogs ] The intravenous injection of DRUGUNRELATED in a dose of 20 mg / kg enhanced DRUGOTHER and DRUGUNRELATED excretion in chronic canine experiments .
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	iodamide	iodamide	none	{'e1': {'word': 'iodamide', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d68.s0.e2'}, 'e2': {'word': 'iodamide', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d68.s0.e5'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	[ The effect of DRUGUNRELATED on the renal excretion of DRUGUNRELATED and DRUG in dogs ] The intravenous injection of DRUGUNRELATED in a dose of 20 mg / kg enhanced DRUGUNRELATED and DRUGOTHER excretion in chronic canine experiments .
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	cimetidine	verografine	mechanism	{'e1': {'word': 'cimetidine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d68.s0.e3'}, 'e2': {'word': 'verografine', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d68.s0.e4'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	[ The effect of DRUGUNRELATED on the renal excretion of DRUGUNRELATED and DRUGUNRELATED in dogs ] The intravenous injection of DRUG in a dose of 20 mg / kg enhanced DRUGOTHER and DRUGUNRELATED excretion in chronic canine experiments .
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	cimetidine	iodamide	mechanism	{'e1': {'word': 'cimetidine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d68.s0.e3'}, 'e2': {'word': 'iodamide', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d68.s0.e5'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	[ The effect of DRUGUNRELATED on the renal excretion of DRUGUNRELATED and DRUGUNRELATED in dogs ] The intravenous injection of DRUG in a dose of 20 mg / kg enhanced DRUGUNRELATED and DRUGOTHER excretion in chronic canine experiments .
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	verografine	iodamide	none	{'e1': {'word': 'verografine', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d68.s0.e4'}, 'e2': {'word': 'iodamide', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d68.s0.e5'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	[ The effect of DRUGUNRELATED on the renal excretion of DRUGUNRELATED and DRUGUNRELATED in dogs ] The intravenous injection of DRUGUNRELATED in a dose of 20 mg / kg enhanced DRUG and DRUGOTHER excretion in chronic canine experiments .
The higher verografine and iodamide excretion was due to their increased renal tubular secretion. 	verografine	iodamide	none	{'e1': {'word': 'verografine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d68.s1.e0'}, 'e2': {'word': 'iodamide', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d68.s1.e1'}, 'sentence_id': 'DDI-MedLine.d68.s1'}	The higher DRUG and DRUGOTHER excretion was due to their increased renal tubular secretion .
In dogs, cimetidine unchanged the secretion of cardiotrast, a test agent for anionic transport. 	cimetidine	cardiotrast	none	{'e1': {'word': 'cimetidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d68.s2.e0'}, 'e2': {'word': 'cardiotrast', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d68.s2.e1'}, 'sentence_id': 'DDI-MedLine.d68.s2'}	In dogs , DRUG unchanged the secretion of DRUGOTHER , a test agent for anionic transport .
Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined.	cimetidine	verografine	none	{'e1': {'word': 'cimetidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d68.s3.e0'}, 'e2': {'word': 'verografine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d68.s3.e1'}, 'sentence_id': 'DDI-MedLine.d68.s3'}	Possible extrarenal mechanisms of action of DRUG on DRUGOTHER and DRUGUNRELATED transport were also examined .
Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined.	cimetidine	iodamide	none	{'e1': {'word': 'cimetidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d68.s3.e0'}, 'e2': {'word': 'iodamide', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d68.s3.e2'}, 'sentence_id': 'DDI-MedLine.d68.s3'}	Possible extrarenal mechanisms of action of DRUG on DRUGUNRELATED and DRUGOTHER transport were also examined .
Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined.	verografine	iodamide	none	{'e1': {'word': 'verografine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d68.s3.e1'}, 'e2': {'word': 'iodamide', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d68.s3.e2'}, 'sentence_id': 'DDI-MedLine.d68.s3'}	Possible extrarenal mechanisms of action of DRUGUNRELATED on DRUG and DRUGOTHER transport were also examined .
"Acute hydrocortisone administration does not affect subjective responses to d-amphetamine in humans.
"	hydrocortisone	d-amphetamine	none	{'e1': {'word': 'hydrocortisone', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d38.s0.e0'}, 'e2': {'word': 'd-amphetamine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d38.s0.e1'}, 'sentence_id': 'DDI-MedLine.d38.s0'}	Acute DRUG administration does not affect subjective responses to DRUGOTHER in humans .
However, the effects of stress and glucocorticoids on the subjective and behavioral effects of psychostimulants have not been well studied in humans. 	glucocorticoids	psychostimulants	none	{'e1': {'word': 'glucocorticoids', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d38.s2.e0'}, 'e2': {'word': 'psychostimulants', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d38.s2.e1'}, 'sentence_id': 'DDI-MedLine.d38.s2'}	However , the effects of stress and DRUG on the subjective and behavioral effects of DRUGOTHER have not been well studied in humans .
OBJECTIVES: To examine the effects of acute hydrocortisone pretreatment on the subjective and behavioral effects of d-amphetamine. 	hydrocortisone	d-amphetamine	none	{'e1': {'word': 'hydrocortisone', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d38.s3.e0'}, 'e2': {'word': 'd-amphetamine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d38.s3.e1'}, 'sentence_id': 'DDI-MedLine.d38.s3'}	OBJECTIVES : To examine the effects of acute DRUG pretreatment on the subjective and behavioral effects of DRUGOTHER .
METHODS: Hydrocortisone (100 mg) and d-amphetamine (20 mg) were administered orally to 16 healthy male and female volunteers in a four-session, placebo-controlled, within-subject, crossover design. 	Hydrocortisone	d-amphetamine	none	{'e1': {'word': 'Hydrocortisone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d38.s4.e0'}, 'e2': {'word': 'd-amphetamine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d38.s4.e1'}, 'sentence_id': 'DDI-MedLine.d38.s4'}	METHODS : DRUG ( 100 mg ) and DRUGOTHER ( 20 mg ) were administered orally to 16 healthy male and female volunteers in a four - session , placebo - controlled , within - subject , crossover design .
However, hydrocortisone pretreatment did not affect any of the physiological, behavioral, or subjective effects of d-amphetamine. 	hydrocortisone	d-amphetamine	none	{'e1': {'word': 'hydrocortisone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d38.s8.e0'}, 'e2': {'word': 'd-amphetamine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d38.s8.e1'}, 'sentence_id': 'DDI-MedLine.d38.s8'}	However , DRUG pretreatment did not affect any of the physiological , behavioral , or subjective effects of DRUGOTHER .
CONCLUSIONS: In contrast to the effects of glucocorticoids in rodent studies, these results indicate that an acute increase in cortisol does not enhance the psychostimulant effects of d-amphetamine in humans.	glucocorticoids	d-amphetamine	none	{'e1': {'word': 'glucocorticoids', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d38.s9.e0'}, 'e2': {'word': 'd-amphetamine', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d38.s9.e1'}, 'sentence_id': 'DDI-MedLine.d38.s9'}	CONCLUSIONS : In contrast to the effects of DRUG in rodent studies , these results indicate that an acute increase in cortisol does not enhance the psychostimulant effects of DRUGOTHER in humans .
[Quantitative approach to treatment with incisive neuroleptics by therapeutic monitoring]; The problems encountered during the longterm treatment of psychotic patients with neuroleptics are illustrated by six typical case reports. 	neuroleptics	neuroleptics	none	{'e1': {'word': 'neuroleptics', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d139.s0.e0'}, 'e2': {'word': 'neuroleptics', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d139.s0.e1'}, 'sentence_id': 'DDI-MedLine.d139.s0'}	[ Quantitative approach to treatment with incisive DRUG by therapeutic monitoring ] ; The problems encountered during the longterm treatment of psychotic patients with DRUGOTHER are illustrated by six typical case reports .
"Combinations of clozapine and phencyclidine: effects on drug discrimination and behavioral inhibition in rats.
"	clozapine	phencyclidine	none	{'e1': {'word': 'clozapine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d135.s0.e0'}, 'e2': {'word': 'phencyclidine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d135.s0.e1'}, 'sentence_id': 'DDI-MedLine.d135.s0'}	Combinations of DRUG and DRUGOTHER : effects on drug discrimination and behavioral inhibition in rats .
Phencyclidine (PCP) produces psychotomimetic effects in humans that resemble schizophrenia symptoms. 	Phencyclidine	PCP	none	{'e1': {'word': 'Phencyclidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d135.s1.e0'}, 'e2': {'word': 'PCP', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d135.s1.e1'}, 'sentence_id': 'DDI-MedLine.d135.s1'}	DRUG ( DRUGOTHER ) produces psychotomimetic effects in humans that resemble schizophrenia symptoms .
In the present study, the atypical antipsychotic clozapine was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures. 	atypical antipsychotic	clozapine	none	{'e1': {'word': 'atypical antipsychotic', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d135.s3.e0'}, 'e2': {'word': 'clozapine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d135.s3.e1'}, 'sentence_id': 'DDI-MedLine.d135.s3'}	In the present study , the DRUG DRUGOTHER was tested in combination with an active dose of DRUGUNRELATED in two - lever drug discrimination and mixed signalled - unsignalled differential - reinforcement - of - low - rates ( DRL ) procedures .
In the present study, the atypical antipsychotic clozapine was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures. 	atypical antipsychotic	PCP	none	{'e1': {'word': 'atypical antipsychotic', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d135.s3.e0'}, 'e2': {'word': 'PCP', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d135.s3.e2'}, 'sentence_id': 'DDI-MedLine.d135.s3'}	In the present study , the DRUG DRUGUNRELATED was tested in combination with an active dose of DRUGOTHER in two - lever drug discrimination and mixed signalled - unsignalled differential - reinforcement - of - low - rates ( DRL ) procedures .
In the present study, the atypical antipsychotic clozapine was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures. 	clozapine	PCP	none	{'e1': {'word': 'clozapine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d135.s3.e1'}, 'e2': {'word': 'PCP', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d135.s3.e2'}, 'sentence_id': 'DDI-MedLine.d135.s3'}	In the present study , the DRUGUNRELATED DRUG was tested in combination with an active dose of DRUGOTHER in two - lever drug discrimination and mixed signalled - unsignalled differential - reinforcement - of - low - rates ( DRL ) procedures .
PCP produced distinctive effects in each task: it substituted for the training dose in PCP discrimination and it increased the number of responses with short (<3 s) interresponse times as well as increasing overall response rates in the DRL schedule. 	PCP	PCP	none	{'e1': {'word': 'PCP', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d135.s4.e0'}, 'e2': {'word': 'PCP', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d135.s4.e1'}, 'sentence_id': 'DDI-MedLine.d135.s4'}	DRUG produced distinctive effects in each task : it substituted for the training dose in DRUGOTHER discrimination and it increased the number of responses with short ( < 3 s ) interresponse times as well as increasing overall response rates in the DRL schedule .
Acute dosing with clozapine failed to alter the behavioral effects of PCP in either procedure even when tested up to doses that produced pharmacological effects alone. 	clozapine	PCP	none	{'e1': {'word': 'clozapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d135.s5.e0'}, 'e2': {'word': 'PCP', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d135.s5.e1'}, 'sentence_id': 'DDI-MedLine.d135.s5'}	Acute dosing with DRUG failed to alter the behavioral effects of DRUGOTHER in either procedure even when tested up to doses that produced pharmacological effects alone .
These results suggest that acute dosing with clozapine would not affect behaviors most closely associated with PCP intoxication. 	clozapine	PCP	none	{'e1': {'word': 'clozapine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d135.s6.e0'}, 'e2': {'word': 'PCP', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d135.s6.e1'}, 'sentence_id': 'DDI-MedLine.d135.s6'}	These results suggest that acute dosing with DRUG would not affect behaviors most closely associated with DRUGOTHER intoxication .
Since chronic dosing is required for therapeutic efficacy of antipsychotics, future studies should focus on investigation of chronic dosing effects of these drugs in combination with PCP.	antipsychotics	PCP	none	{'e1': {'word': 'antipsychotics', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d135.s8.e0'}, 'e2': {'word': 'PCP', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d135.s8.e1'}, 'sentence_id': 'DDI-MedLine.d135.s8'}	Since chronic dosing is required for therapeutic efficacy of DRUG , future studies should focus on investigation of chronic dosing effects of these drugs in combination with DRUGOTHER .
"Pharmacokinetic evaluation of the digoxin-amiodarone interaction.
"	digoxin	amiodarone	none	{'e1': {'word': 'digoxin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d61.s0.e0'}, 'e2': {'word': 'amiodarone', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d61.s0.e1'}, 'sentence_id': 'DDI-MedLine.d61.s0'}	Pharmacokinetic evaluation of the DRUG - DRUGOTHER interaction .
Amiodarone is known to raise serum digoxin levels. 	Amiodarone	digoxin	mechanism	{'e1': {'word': 'Amiodarone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d61.s1.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d61.s1.e1'}, 'sentence_id': 'DDI-MedLine.d61.s1'}	DRUG is known to raise serum DRUGOTHER levels .
The pharmacokinetic variables for digoxin were determined after a 1.0 mg intravenous dose of digoxin in each subject, before and after oral amiodarone, 400 mg daily for 3 weeks. 	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d61.s3.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d61.s3.e1'}, 'sentence_id': 'DDI-MedLine.d61.s3'}	The pharmacokinetic variables for DRUG were determined after a 1.0 mg intravenous dose of DRUGOTHER in each subject , before and after oral DRUGUNRELATED , 400 mg daily for 3 weeks .
The pharmacokinetic variables for digoxin were determined after a 1.0 mg intravenous dose of digoxin in each subject, before and after oral amiodarone, 400 mg daily for 3 weeks. 	digoxin	amiodarone	none	{'e1': {'word': 'digoxin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d61.s3.e0'}, 'e2': {'word': 'amiodarone', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d61.s3.e2'}, 'sentence_id': 'DDI-MedLine.d61.s3'}	The pharmacokinetic variables for DRUG were determined after a 1.0 mg intravenous dose of DRUGUNRELATED in each subject , before and after oral DRUGOTHER , 400 mg daily for 3 weeks .
The pharmacokinetic variables for digoxin were determined after a 1.0 mg intravenous dose of digoxin in each subject, before and after oral amiodarone, 400 mg daily for 3 weeks. 	digoxin	amiodarone	none	{'e1': {'word': 'digoxin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d61.s3.e1'}, 'e2': {'word': 'amiodarone', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d61.s3.e2'}, 'sentence_id': 'DDI-MedLine.d61.s3'}	The pharmacokinetic variables for DRUGUNRELATED were determined after a 1.0 mg intravenous dose of DRUG in each subject , before and after oral DRUGOTHER , 400 mg daily for 3 weeks .
During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01). 	amiodarone	digoxin	mechanism	{'e1': {'word': 'amiodarone', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d61.s4.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d61.s4.e1'}, 'sentence_id': 'DDI-MedLine.d61.s4'}	During DRUG administration , systemic clearance of DRUGOTHER was reduced from 234 + / - 72 ml / min ( mean + / - standard deviation ) to 172 + / - 33 ml / min ( p less than 0.01 ) .
Amiodarone caused a three- to fivefold increase in serum reverse triiodothyronine levels, but changes in thyroid function were not quantitatively related to the changes in digoxin pharmacokinetics. 	Amiodarone	digoxin	none	{'e1': {'word': 'Amiodarone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d61.s8.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d61.s8.e1'}, 'sentence_id': 'DDI-MedLine.d61.s8'}	DRUG caused a three - to fivefold increase in serum reverse triiodothyronine levels , but changes in thyroid function were not quantitatively related to the changes in DRUGOTHER pharmacokinetics .
These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.	digoxin	amiodarone	mechanism	{'e1': {'word': 'digoxin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d61.s9.e0'}, 'e2': {'word': 'amiodarone', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d61.s9.e1'}, 'sentence_id': 'DDI-MedLine.d61.s9'}	These alterations in DRUG pharmacokinetics produced by DRUGOTHER explain the increase in serum DRUGUNRELATED level that has been observed when this drug combination has been used clinically .
These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d61.s9.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d61.s9.e2'}, 'sentence_id': 'DDI-MedLine.d61.s9'}	These alterations in DRUG pharmacokinetics produced by DRUGUNRELATED explain the increase in serum DRUGOTHER level that has been observed when this drug combination has been used clinically .
These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.	amiodarone	digoxin	none	{'e1': {'word': 'amiodarone', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d61.s9.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d61.s9.e2'}, 'sentence_id': 'DDI-MedLine.d61.s9'}	These alterations in DRUGUNRELATED pharmacokinetics produced by DRUG explain the increase in serum DRUGOTHER level that has been observed when this drug combination has been used clinically .
Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin, a homodimeric disintegrin, and monomeric disintegrins echistatin and flavoridin.	contortrostatin	echistatin	none	{'e1': {'word': 'contortrostatin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d69.s0.e0'}, 'e2': {'word': 'echistatin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d69.s0.e1'}, 'sentence_id': 'DDI-MedLine.d69.s0'}	Differential regulation of tyrosine phosphorylation in tumor cells by DRUG , a homodimeric disintegrin , and monomeric disintegrins DRUGOTHER and DRUGUNRELATED .
Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin, a homodimeric disintegrin, and monomeric disintegrins echistatin and flavoridin.	contortrostatin	flavoridin	none	{'e1': {'word': 'contortrostatin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d69.s0.e0'}, 'e2': {'word': 'flavoridin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d69.s0.e2'}, 'sentence_id': 'DDI-MedLine.d69.s0'}	Differential regulation of tyrosine phosphorylation in tumor cells by DRUG , a homodimeric disintegrin , and monomeric disintegrins DRUGUNRELATED and DRUGOTHER .
Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin, a homodimeric disintegrin, and monomeric disintegrins echistatin and flavoridin.	echistatin	flavoridin	none	{'e1': {'word': 'echistatin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d69.s0.e1'}, 'e2': {'word': 'flavoridin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d69.s0.e2'}, 'sentence_id': 'DDI-MedLine.d69.s0'}	Differential regulation of tyrosine phosphorylation in tumor cells by DRUGUNRELATED , a homodimeric disintegrin , and monomeric disintegrins DRUG and DRUGOTHER .
The homodimeric disintegrin contortrostatin was compared directly to the monomeric disintegrins echistatin and flavoridin for the ability to affect protein tyrosine phosphorylation in tumor cells. 	contortrostatin	echistatin	none	{'e1': {'word': 'contortrostatin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d69.s1.e0'}, 'e2': {'word': 'echistatin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d69.s1.e1'}, 'sentence_id': 'DDI-MedLine.d69.s1'}	The homodimeric disintegrin DRUG was compared directly to the monomeric disintegrins DRUGOTHER and DRUGUNRELATED for the ability to affect protein tyrosine phosphorylation in tumor cells .
The homodimeric disintegrin contortrostatin was compared directly to the monomeric disintegrins echistatin and flavoridin for the ability to affect protein tyrosine phosphorylation in tumor cells. 	contortrostatin	flavoridin	none	{'e1': {'word': 'contortrostatin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d69.s1.e0'}, 'e2': {'word': 'flavoridin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d69.s1.e2'}, 'sentence_id': 'DDI-MedLine.d69.s1'}	The homodimeric disintegrin DRUG was compared directly to the monomeric disintegrins DRUGUNRELATED and DRUGOTHER for the ability to affect protein tyrosine phosphorylation in tumor cells .
The homodimeric disintegrin contortrostatin was compared directly to the monomeric disintegrins echistatin and flavoridin for the ability to affect protein tyrosine phosphorylation in tumor cells. 	echistatin	flavoridin	none	{'e1': {'word': 'echistatin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d69.s1.e1'}, 'e2': {'word': 'flavoridin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d69.s1.e2'}, 'sentence_id': 'DDI-MedLine.d69.s1'}	The homodimeric disintegrin DRUGUNRELATED was compared directly to the monomeric disintegrins DRUG and DRUGOTHER for the ability to affect protein tyrosine phosphorylation in tumor cells .
Echistatin alone had no effect on tyrosine phosphorylation in T24 cells, but dose-dependently inhibits the effects of contortrostatin when both are added simultaneously. 	Echistatin	contortrostatin	effect	{'e1': {'word': 'Echistatin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d69.s3.e0'}, 'e2': {'word': 'contortrostatin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d69.s3.e1'}, 'sentence_id': 'DDI-MedLine.d69.s3'}	DRUG alone had no effect on tyrosine phosphorylation in T24 cells , but dose - dependently inhibits the effects of DRUGOTHER when both are added simultaneously .
Flavoridin alone was found to have no effect on CAS, but can completely block contortrostatin-induced phosphorylation of this protein in MDA-MB-435 cells. 	Flavoridin	contortrostatin	effect	{'e1': {'word': 'Flavoridin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d69.s5.e0'}, 'e2': {'word': 'contortrostatin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d69.s5.e1'}, 'sentence_id': 'DDI-MedLine.d69.s5'}	DRUG alone was found to have no effect on CAS , but can completely block DRUGOTHER - induced phosphorylation of this protein in MDA - MB - 435 cells .
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	coumaphos	coumaphos	none	{'e1': {'word': 'coumaphos', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d5.s0.e0'}, 'e2': {'word': 'coumaphos', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d5.s0.e1'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	Repeated oral administration of DRUG in sheep : interactions of DRUGOTHER with DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED .
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	coumaphos	bishydroxycoumarin	none	{'e1': {'word': 'coumaphos', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d5.s0.e0'}, 'e2': {'word': 'bishydroxycoumarin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d5.s0.e2'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	Repeated oral administration of DRUG in sheep : interactions of DRUGUNRELATED with DRUGOTHER , DRUGUNRELATED , and DRUGUNRELATED .
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	coumaphos	trichlorfon	none	{'e1': {'word': 'coumaphos', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d5.s0.e0'}, 'e2': {'word': 'trichlorfon', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d5.s0.e3'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	Repeated oral administration of DRUG in sheep : interactions of DRUGUNRELATED with DRUGUNRELATED , DRUGOTHER , and DRUGUNRELATED .
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	coumaphos	phenobarbital sodium	none	{'e1': {'word': 'coumaphos', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d5.s0.e0'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d5.s0.e4'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	Repeated oral administration of DRUG in sheep : interactions of DRUGUNRELATED with DRUGUNRELATED , DRUGUNRELATED , and DRUGOTHER .
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	coumaphos	bishydroxycoumarin	none	{'e1': {'word': 'coumaphos', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d5.s0.e1'}, 'e2': {'word': 'bishydroxycoumarin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d5.s0.e2'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	Repeated oral administration of DRUGUNRELATED in sheep : interactions of DRUG with DRUGOTHER , DRUGUNRELATED , and DRUGUNRELATED .
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	coumaphos	trichlorfon	none	{'e1': {'word': 'coumaphos', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d5.s0.e1'}, 'e2': {'word': 'trichlorfon', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d5.s0.e3'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	Repeated oral administration of DRUGUNRELATED in sheep : interactions of DRUG with DRUGUNRELATED , DRUGOTHER , and DRUGUNRELATED .
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	coumaphos	phenobarbital sodium	none	{'e1': {'word': 'coumaphos', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d5.s0.e1'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d5.s0.e4'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	Repeated oral administration of DRUGUNRELATED in sheep : interactions of DRUG with DRUGUNRELATED , DRUGUNRELATED , and DRUGOTHER .
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	bishydroxycoumarin	trichlorfon	none	{'e1': {'word': 'bishydroxycoumarin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d5.s0.e2'}, 'e2': {'word': 'trichlorfon', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d5.s0.e3'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	Repeated oral administration of DRUGUNRELATED in sheep : interactions of DRUGUNRELATED with DRUG , DRUGOTHER , and DRUGUNRELATED .
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	bishydroxycoumarin	phenobarbital sodium	none	{'e1': {'word': 'bishydroxycoumarin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d5.s0.e2'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d5.s0.e4'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	Repeated oral administration of DRUGUNRELATED in sheep : interactions of DRUGUNRELATED with DRUG , DRUGUNRELATED , and DRUGOTHER .
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	trichlorfon	phenobarbital sodium	none	{'e1': {'word': 'trichlorfon', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d5.s0.e3'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d5.s0.e4'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	Repeated oral administration of DRUGUNRELATED in sheep : interactions of DRUGUNRELATED with DRUGUNRELATED , DRUG , and DRUGOTHER .
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	coumaphos	bishydroxycoumarin	none	{'e1': {'word': 'coumaphos', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d5.s1.e0'}, 'e2': {'word': 'bishydroxycoumarin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d5.s1.e1'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with DRUG , DRUGOTHER ( an DRUGUNRELATED ) , DRUGUNRELATED ( an DRUGUNRELATED ) , and DRUGUNRELATED ( an inducer of microsomal enzymes ) were investigated in sheep .
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	coumaphos	anticoagulant	none	{'e1': {'word': 'coumaphos', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d5.s1.e0'}, 'e2': {'word': 'anticoagulant', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d5.s1.e2'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with DRUG , DRUGUNRELATED ( an DRUGOTHER ) , DRUGUNRELATED ( an DRUGUNRELATED ) , and DRUGUNRELATED ( an inducer of microsomal enzymes ) were investigated in sheep .
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	coumaphos	trichlorfon	none	{'e1': {'word': 'coumaphos', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d5.s1.e0'}, 'e2': {'word': 'trichlorfon', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d5.s1.e3'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with DRUG , DRUGUNRELATED ( an DRUGUNRELATED ) , DRUGOTHER ( an DRUGUNRELATED ) , and DRUGUNRELATED ( an inducer of microsomal enzymes ) were investigated in sheep .
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	coumaphos	organophosphorous compound	none	{'e1': {'word': 'coumaphos', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d5.s1.e0'}, 'e2': {'word': 'organophosphorous compound', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d5.s1.e4'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with DRUG , DRUGUNRELATED ( an DRUGUNRELATED ) , DRUGUNRELATED ( an DRUGOTHER ) , and DRUGUNRELATED ( an inducer of microsomal enzymes ) were investigated in sheep .
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	coumaphos	phenobarbital sodium	none	{'e1': {'word': 'coumaphos', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d5.s1.e0'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d5.s1.e5'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with DRUG , DRUGUNRELATED ( an DRUGUNRELATED ) , DRUGUNRELATED ( an DRUGUNRELATED ) , and DRUGOTHER ( an inducer of microsomal enzymes ) were investigated in sheep .
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	bishydroxycoumarin	anticoagulant	none	{'e1': {'word': 'bishydroxycoumarin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d5.s1.e1'}, 'e2': {'word': 'anticoagulant', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d5.s1.e2'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with DRUGUNRELATED , DRUG ( an DRUGOTHER ) , DRUGUNRELATED ( an DRUGUNRELATED ) , and DRUGUNRELATED ( an inducer of microsomal enzymes ) were investigated in sheep .
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	bishydroxycoumarin	trichlorfon	none	{'e1': {'word': 'bishydroxycoumarin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d5.s1.e1'}, 'e2': {'word': 'trichlorfon', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d5.s1.e3'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with DRUGUNRELATED , DRUG ( an DRUGUNRELATED ) , DRUGOTHER ( an DRUGUNRELATED ) , and DRUGUNRELATED ( an inducer of microsomal enzymes ) were investigated in sheep .
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	bishydroxycoumarin	organophosphorous compound	none	{'e1': {'word': 'bishydroxycoumarin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d5.s1.e1'}, 'e2': {'word': 'organophosphorous compound', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d5.s1.e4'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with DRUGUNRELATED , DRUG ( an DRUGUNRELATED ) , DRUGUNRELATED ( an DRUGOTHER ) , and DRUGUNRELATED ( an inducer of microsomal enzymes ) were investigated in sheep .
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	bishydroxycoumarin	phenobarbital sodium	none	{'e1': {'word': 'bishydroxycoumarin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d5.s1.e1'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d5.s1.e5'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with DRUGUNRELATED , DRUG ( an DRUGUNRELATED ) , DRUGUNRELATED ( an DRUGUNRELATED ) , and DRUGOTHER ( an inducer of microsomal enzymes ) were investigated in sheep .
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	anticoagulant	trichlorfon	none	{'e1': {'word': 'anticoagulant', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d5.s1.e2'}, 'e2': {'word': 'trichlorfon', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d5.s1.e3'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with DRUGUNRELATED , DRUGUNRELATED ( an DRUG ) , DRUGOTHER ( an DRUGUNRELATED ) , and DRUGUNRELATED ( an inducer of microsomal enzymes ) were investigated in sheep .
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	anticoagulant	organophosphorous compound	none	{'e1': {'word': 'anticoagulant', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d5.s1.e2'}, 'e2': {'word': 'organophosphorous compound', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d5.s1.e4'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with DRUGUNRELATED , DRUGUNRELATED ( an DRUG ) , DRUGUNRELATED ( an DRUGOTHER ) , and DRUGUNRELATED ( an inducer of microsomal enzymes ) were investigated in sheep .
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	anticoagulant	phenobarbital sodium	none	{'e1': {'word': 'anticoagulant', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d5.s1.e2'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d5.s1.e5'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with DRUGUNRELATED , DRUGUNRELATED ( an DRUG ) , DRUGUNRELATED ( an DRUGUNRELATED ) , and DRUGOTHER ( an inducer of microsomal enzymes ) were investigated in sheep .
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	trichlorfon	organophosphorous compound	none	{'e1': {'word': 'trichlorfon', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d5.s1.e3'}, 'e2': {'word': 'organophosphorous compound', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d5.s1.e4'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with DRUGUNRELATED , DRUGUNRELATED ( an DRUGUNRELATED ) , DRUG ( an DRUGOTHER ) , and DRUGUNRELATED ( an inducer of microsomal enzymes ) were investigated in sheep .
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	trichlorfon	phenobarbital sodium	none	{'e1': {'word': 'trichlorfon', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d5.s1.e3'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d5.s1.e5'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with DRUGUNRELATED , DRUGUNRELATED ( an DRUGUNRELATED ) , DRUG ( an DRUGUNRELATED ) , and DRUGOTHER ( an inducer of microsomal enzymes ) were investigated in sheep .
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	organophosphorous compound	phenobarbital sodium	none	{'e1': {'word': 'organophosphorous compound', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d5.s1.e4'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d5.s1.e5'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with DRUGUNRELATED , DRUGUNRELATED ( an DRUGUNRELATED ) , DRUGUNRELATED ( an DRUG ) , and DRUGOTHER ( an inducer of microsomal enzymes ) were investigated in sheep .
A daily dose of 2 mg of coumaphos/kg of body weight for 6 days did not affect the plasma enzymes or the antiprothrombinemic effect of bishydroxy-coumarin in wethers. 	coumaphos	bishydroxy-coumarin	none	{'e1': {'word': 'coumaphos', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d5.s2.e0'}, 'e2': {'word': 'bishydroxy-coumarin', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d5.s2.e1'}, 'sentence_id': 'DDI-MedLine.d5.s2'}	A daily dose of 2 mg of DRUG / kg of body weight for 6 days did not affect the plasma enzymes or the antiprothrombinemic effect of DRUGOTHER in wethers .
The treatment of ewes with an intravenous (IV) injection of trichlorfon, insufficient to produce significant inhibition of erythrocyte acetylcholinesterase (AChE) activity, appeared to produce additive effects with those produced by subsequent treatment with 4 mg of coumaphos/kg/day. 	trichlorfon	coumaphos	effect	{'e1': {'word': 'trichlorfon', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d5.s3.e0'}, 'e2': {'word': 'coumaphos', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d5.s3.e1'}, 'sentence_id': 'DDI-MedLine.d5.s3'}	The treatment of ewes with an intravenous ( IV ) injection of DRUG , insufficient to produce significant inhibition of erythrocyte acetylcholinesterase ( AChE ) activity , appeared to produce additive effects with those produced by subsequent treatment with 4 mg of DRUGOTHER / kg / day .
In ewes given 40 mg of phenobarbital sodium/kg for 5 days intraperitoneally (IP), the anticholinesterase effect of 4 mg of coumaphos/kg was significantly reduced and signs of toxicity were not present. 	phenobarbital sodium	coumaphos	effect	{'e1': {'word': 'phenobarbital sodium', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d5.s4.e0'}, 'e2': {'word': 'coumaphos', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d5.s4.e1'}, 'sentence_id': 'DDI-MedLine.d5.s4'}	In ewes given 40 mg of DRUG / kg for 5 days intraperitoneally ( IP ) , the anticholinesterase effect of 4 mg of DRUGOTHER / kg was significantly reduced and signs of toxicity were not present .
Molecular basis for the selective toxicity of amphotericin B for yeast and filipin for animal cells.	amphotericin B	filipin	none	{'e1': {'word': 'amphotericin B', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d120.s0.e0'}, 'e2': {'word': 'filipin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d120.s0.e1'}, 'sentence_id': 'DDI-MedLine.d120.s0'}	Molecular basis for the selective toxicity of DRUG for yeast and DRUGOTHER for animal cells .
Among the polyene antibiotics, many, like filipin, cannot be used clinically because they are toxic; 	polyene antibiotics	filipin	none	{'e1': {'word': 'polyene antibiotics', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d120.s1.e0'}, 'e2': {'word': 'filipin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d120.s1.e1'}, 'sentence_id': 'DDI-MedLine.d120.s1'}	Among the DRUG , many , like DRUGOTHER , can not be used clinically because they are toxic ;
Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells; 	filipin	amphotericin B	none	{'e1': {'word': 'filipin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d120.s3.e0'}, 'e2': {'word': 'amphotericin B', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d120.s3.e1'}, 'sentence_id': 'DDI-MedLine.d120.s3'}	Both the toxicity of DRUG and the therapeutic value of DRUGOTHER can be rationalized at the cellular and molecular level by the following observations : ( i ) these DRUGUNRELATED showed differential effects on cells ;
Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells; 	filipin	polyene antibiotics	none	{'e1': {'word': 'filipin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d120.s3.e0'}, 'e2': {'word': 'polyene antibiotics', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d120.s3.e2'}, 'sentence_id': 'DDI-MedLine.d120.s3'}	Both the toxicity of DRUG and the therapeutic value of DRUGUNRELATED can be rationalized at the cellular and molecular level by the following observations : ( i ) these DRUGOTHER showed differential effects on cells ;
Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells; 	amphotericin B	polyene antibiotics	none	{'e1': {'word': 'amphotericin B', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d120.s3.e1'}, 'e2': {'word': 'polyene antibiotics', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d120.s3.e2'}, 'sentence_id': 'DDI-MedLine.d120.s3'}	Both the toxicity of DRUGUNRELATED and the therapeutic value of DRUG can be rationalized at the cellular and molecular level by the following observations : ( i ) these DRUGOTHER showed differential effects on cells ;
filipin was more potent in lysing human red blood cells, whereas amphotericin B was more potent in inhibiting yeast cell growth; 	filipin	amphotericin B	none	{'e1': {'word': 'filipin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d120.s4.e0'}, 'e2': {'word': 'amphotericin B', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d120.s4.e1'}, 'sentence_id': 'DDI-MedLine.d120.s4'}	DRUG was more potent in lysing human red blood cells , whereas DRUGOTHER was more potent in inhibiting yeast cell growth ;
and (ii) the effects of filipin were more efficiently inhibited by added cholesterol, the major membrane sterol in human cells, whereas the effects of amphotericin B were more efficiently inhibited by ergosterol, the major membrane sterol in yeast. 	filipin	amphotericin B	none	{'e1': {'word': 'filipin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d120.s5.e0'}, 'e2': {'word': 'amphotericin B', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d120.s5.e1'}, 'sentence_id': 'DDI-MedLine.d120.s5'}	and ( ii ) the effects of DRUG were more efficiently inhibited by added cholesterol , the major membrane sterol in human cells , whereas the effects of DRUGOTHER were more efficiently inhibited by ergosterol , the major membrane sterol in yeast .
"If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
"	indinavir	IDV	none	{'e1': {'word': 'indinavir', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d79.s0.e0'}, 'e2': {'word': 'IDV', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d79.s0.e1'}, 'sentence_id': 'DDI-MedLine.d79.s0'}	If taken 1 hour before DRUG ( DRUGOTHER ) , DRUGUNRELATED does not affect DRUGUNRELATED exposure , despite persistent buffering effects .
"If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
"	indinavir	didanosine	none	{'e1': {'word': 'indinavir', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d79.s0.e0'}, 'e2': {'word': 'didanosine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d79.s0.e2'}, 'sentence_id': 'DDI-MedLine.d79.s0'}	If taken 1 hour before DRUG ( DRUGUNRELATED ) , DRUGOTHER does not affect DRUGUNRELATED exposure , despite persistent buffering effects .
"If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
"	indinavir	IDV	none	{'e1': {'word': 'indinavir', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d79.s0.e0'}, 'e2': {'word': 'IDV', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d79.s0.e3'}, 'sentence_id': 'DDI-MedLine.d79.s0'}	If taken 1 hour before DRUG ( DRUGUNRELATED ) , DRUGUNRELATED does not affect DRUGOTHER exposure , despite persistent buffering effects .
"If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
"	IDV	didanosine	none	{'e1': {'word': 'IDV', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d79.s0.e1'}, 'e2': {'word': 'didanosine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d79.s0.e2'}, 'sentence_id': 'DDI-MedLine.d79.s0'}	If taken 1 hour before DRUGUNRELATED ( DRUG ) , DRUGOTHER does not affect DRUGUNRELATED exposure , despite persistent buffering effects .
"If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
"	IDV	IDV	none	{'e1': {'word': 'IDV', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d79.s0.e1'}, 'e2': {'word': 'IDV', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d79.s0.e3'}, 'sentence_id': 'DDI-MedLine.d79.s0'}	If taken 1 hour before DRUGUNRELATED ( DRUG ) , DRUGUNRELATED does not affect DRUGOTHER exposure , despite persistent buffering effects .
"If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
"	didanosine	IDV	none	{'e1': {'word': 'didanosine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d79.s0.e2'}, 'e2': {'word': 'IDV', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d79.s0.e3'}, 'sentence_id': 'DDI-MedLine.d79.s0'}	If taken 1 hour before DRUGUNRELATED ( DRUGUNRELATED ) , DRUG does not affect DRUGOTHER exposure , despite persistent buffering effects .
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	indinavir	didanosine	mechanism	{'e1': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s1.e0'}, 'e2': {'word': 'didanosine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d79.s1.e1'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	Concurrent administration of DRUG and DRUGOTHER significantly reduces the level of exposure to DRUGUNRELATED , but it is unclear how soon after DRUGUNRELATED administration DRUGUNRELATED may be given safely .
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	indinavir	indinavir	none	{'e1': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s1.e0'}, 'e2': {'word': 'indinavir', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d79.s1.e2'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	Concurrent administration of DRUG and DRUGUNRELATED significantly reduces the level of exposure to DRUGOTHER , but it is unclear how soon after DRUGUNRELATED administration DRUGUNRELATED may be given safely .
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	indinavir	didanosine	none	{'e1': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s1.e0'}, 'e2': {'word': 'didanosine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d79.s1.e3'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	Concurrent administration of DRUG and DRUGUNRELATED significantly reduces the level of exposure to DRUGUNRELATED , but it is unclear how soon after DRUGOTHER administration DRUGUNRELATED may be given safely .
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	indinavir	indinavir	none	{'e1': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s1.e0'}, 'e2': {'word': 'indinavir', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d79.s1.e4'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	Concurrent administration of DRUG and DRUGUNRELATED significantly reduces the level of exposure to DRUGUNRELATED , but it is unclear how soon after DRUGUNRELATED administration DRUGOTHER may be given safely .
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	didanosine	indinavir	none	{'e1': {'word': 'didanosine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d79.s1.e1'}, 'e2': {'word': 'indinavir', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d79.s1.e2'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	Concurrent administration of DRUGUNRELATED and DRUG significantly reduces the level of exposure to DRUGOTHER , but it is unclear how soon after DRUGUNRELATED administration DRUGUNRELATED may be given safely .
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	didanosine	didanosine	none	{'e1': {'word': 'didanosine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d79.s1.e1'}, 'e2': {'word': 'didanosine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d79.s1.e3'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	Concurrent administration of DRUGUNRELATED and DRUG significantly reduces the level of exposure to DRUGUNRELATED , but it is unclear how soon after DRUGOTHER administration DRUGUNRELATED may be given safely .
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	didanosine	indinavir	none	{'e1': {'word': 'didanosine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d79.s1.e1'}, 'e2': {'word': 'indinavir', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d79.s1.e4'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	Concurrent administration of DRUGUNRELATED and DRUG significantly reduces the level of exposure to DRUGUNRELATED , but it is unclear how soon after DRUGUNRELATED administration DRUGOTHER may be given safely .
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	indinavir	didanosine	none	{'e1': {'word': 'indinavir', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d79.s1.e2'}, 'e2': {'word': 'didanosine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d79.s1.e3'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	Concurrent administration of DRUGUNRELATED and DRUGUNRELATED significantly reduces the level of exposure to DRUG , but it is unclear how soon after DRUGOTHER administration DRUGUNRELATED may be given safely .
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	indinavir	indinavir	none	{'e1': {'word': 'indinavir', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d79.s1.e2'}, 'e2': {'word': 'indinavir', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d79.s1.e4'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	Concurrent administration of DRUGUNRELATED and DRUGUNRELATED significantly reduces the level of exposure to DRUG , but it is unclear how soon after DRUGUNRELATED administration DRUGOTHER may be given safely .
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	didanosine	indinavir	none	{'e1': {'word': 'didanosine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d79.s1.e3'}, 'e2': {'word': 'indinavir', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d79.s1.e4'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	Concurrent administration of DRUGUNRELATED and DRUGUNRELATED significantly reduces the level of exposure to DRUGUNRELATED , but it is unclear how soon after DRUG administration DRUGOTHER may be given safely .
We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. 	indinavir	indinavir	none	{'e1': {'word': 'indinavir', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d79.s2.e0'}, 'e2': {'word': 'indinavir', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d79.s2.e1'}, 'sentence_id': 'DDI-MedLine.d79.s2'}	We compared DRUG pharmacokinetics and gastric pH in 12 human immunodeficiency virus - positive patients by use of 800 mg of DRUGOTHER alone versus 800 mg of DRUGUNRELATED administered 1 h after DRUGUNRELATED administration .
We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. 	indinavir	indinavir	none	{'e1': {'word': 'indinavir', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d79.s2.e0'}, 'e2': {'word': 'indinavir', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d79.s2.e2'}, 'sentence_id': 'DDI-MedLine.d79.s2'}	We compared DRUG pharmacokinetics and gastric pH in 12 human immunodeficiency virus - positive patients by use of 800 mg of DRUGUNRELATED alone versus 800 mg of DRUGOTHER administered 1 h after DRUGUNRELATED administration .
We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. 	indinavir	didanosine	none	{'e1': {'word': 'indinavir', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d79.s2.e0'}, 'e2': {'word': 'didanosine', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d79.s2.e3'}, 'sentence_id': 'DDI-MedLine.d79.s2'}	We compared DRUG pharmacokinetics and gastric pH in 12 human immunodeficiency virus - positive patients by use of 800 mg of DRUGUNRELATED alone versus 800 mg of DRUGUNRELATED administered 1 h after DRUGOTHER administration .
We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. 	indinavir	indinavir	none	{'e1': {'word': 'indinavir', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d79.s2.e1'}, 'e2': {'word': 'indinavir', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d79.s2.e2'}, 'sentence_id': 'DDI-MedLine.d79.s2'}	We compared DRUGUNRELATED pharmacokinetics and gastric pH in 12 human immunodeficiency virus - positive patients by use of 800 mg of DRUG alone versus 800 mg of DRUGOTHER administered 1 h after DRUGUNRELATED administration .
We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. 	indinavir	didanosine	none	{'e1': {'word': 'indinavir', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d79.s2.e1'}, 'e2': {'word': 'didanosine', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d79.s2.e3'}, 'sentence_id': 'DDI-MedLine.d79.s2'}	We compared DRUGUNRELATED pharmacokinetics and gastric pH in 12 human immunodeficiency virus - positive patients by use of 800 mg of DRUG alone versus 800 mg of DRUGUNRELATED administered 1 h after DRUGOTHER administration .
We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. 	indinavir	didanosine	none	{'e1': {'word': 'indinavir', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d79.s2.e2'}, 'e2': {'word': 'didanosine', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d79.s2.e3'}, 'sentence_id': 'DDI-MedLine.d79.s2'}	We compared DRUGUNRELATED pharmacokinetics and gastric pH in 12 human immunodeficiency virus - positive patients by use of 800 mg of DRUGUNRELATED alone versus 800 mg of DRUG administered 1 h after DRUGOTHER administration .
Median gastric pH was significantly higher when indinavir was taken after didanosine administration; 	indinavir	didanosine	mechanism	{'e1': {'word': 'indinavir', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d79.s3.e0'}, 'e2': {'word': 'didanosine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d79.s3.e1'}, 'sentence_id': 'DDI-MedLine.d79.s3'}	Median gastric pH was significantly higher when DRUG was taken after DRUGOTHER administration ;
Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.	Indinavir	didanosine	advise	{'e1': {'word': 'Indinavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d79.s5.e0'}, 'e2': {'word': 'didanosine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d79.s5.e1'}, 'sentence_id': 'DDI-MedLine.d79.s5'}	DRUG may be taken with a light meal 1 h following the administration of 400 mg of DRUGOTHER .
"Green tea polyphenols as potent enhancers of glucocorticoid-induced mouse mammary tumor virus gene expression.
"	Green tea polyphenols	enhancers	none	{'e1': {'word': 'Green tea polyphenols', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d129.s0.e0'}, 'e2': {'word': 'enhancers', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d129.s0.e1'}, 'sentence_id': 'DDI-MedLine.d129.s0'}	DRUG as potent DRUGOTHER of glucocorticoid - induced mouse mammary tumor virus gene expression .
n-dodecyl gallate showed the most potent inhibition (66% inhibition at 10 microM), which was far more potent than that of crude tannic acid. 	n-dodecyl gallate	tannic acid	none	{'e1': {'word': 'n-dodecyl gallate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d129.s3.e0'}, 'e2': {'word': 'tannic acid', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d129.s3.e1'}, 'sentence_id': 'DDI-MedLine.d129.s3'}	DRUG showed the most potent inhibition ( 66 % inhibition at 10 microM ) , which was far more potent than that of crude DRUGOTHER .
As immediate-early genes (IEGs) are thought to play a critical role in mediating stimulus-induced neural plasticity, IEG response induced by methamphetamine (METH) has been characterized to define the changes in gene expression that may underlie its long-lasting behavioral effects. 	methamphetamine	METH	none	{'e1': {'word': 'methamphetamine', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d62.s1.e0'}, 'e2': {'word': 'METH', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d62.s1.e1'}, 'sentence_id': 'DDI-MedLine.d62.s1'}	As immediate - early genes ( IEGs ) are thought to play a critical role in mediating stimulus - induced neural plasticity , IEG response induced by DRUG ( DRUGOTHER ) has been characterized to define the changes in gene expression that may underlie its long - lasting behavioral effects .
Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. 	METH	SCH-23390	effect	{'e1': {'word': 'METH', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d62.s4.e0'}, 'e2': {'word': 'SCH-23390', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d62.s4.e1'}, 'sentence_id': 'DDI-MedLine.d62.s4'}	Using in situ hybridization , we observed that DRUG caused a rapid and transient dose - dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist DRUGOTHER but not by an DRUGUNRELATED DRUGUNRELATED .
Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. 	METH	atypical neuroleptic	none	{'e1': {'word': 'METH', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d62.s4.e0'}, 'e2': {'word': 'atypical neuroleptic', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d62.s4.e2'}, 'sentence_id': 'DDI-MedLine.d62.s4'}	Using in situ hybridization , we observed that DRUG caused a rapid and transient dose - dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist DRUGUNRELATED but not by an DRUGOTHER DRUGUNRELATED .
Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. 	METH	clozapine	none	{'e1': {'word': 'METH', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d62.s4.e0'}, 'e2': {'word': 'clozapine', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d62.s4.e3'}, 'sentence_id': 'DDI-MedLine.d62.s4'}	Using in situ hybridization , we observed that DRUG caused a rapid and transient dose - dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist DRUGUNRELATED but not by an DRUGUNRELATED DRUGOTHER .
Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. 	SCH-23390	atypical neuroleptic	none	{'e1': {'word': 'SCH-23390', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d62.s4.e1'}, 'e2': {'word': 'atypical neuroleptic', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d62.s4.e2'}, 'sentence_id': 'DDI-MedLine.d62.s4'}	Using in situ hybridization , we observed that DRUGUNRELATED caused a rapid and transient dose - dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist DRUG but not by an DRUGOTHER DRUGUNRELATED .
Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. 	SCH-23390	clozapine	none	{'e1': {'word': 'SCH-23390', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d62.s4.e1'}, 'e2': {'word': 'clozapine', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d62.s4.e3'}, 'sentence_id': 'DDI-MedLine.d62.s4'}	Using in situ hybridization , we observed that DRUGUNRELATED caused a rapid and transient dose - dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist DRUG but not by an DRUGUNRELATED DRUGOTHER .
Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. 	atypical neuroleptic	clozapine	none	{'e1': {'word': 'atypical neuroleptic', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d62.s4.e2'}, 'e2': {'word': 'clozapine', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d62.s4.e3'}, 'sentence_id': 'DDI-MedLine.d62.s4'}	Using in situ hybridization , we observed that DRUGUNRELATED caused a rapid and transient dose - dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist DRUGUNRELATED but not by an DRUG DRUGOTHER .
Since photic evoked potential components are representations of neural pathways which are activated during photic stimulation, study of the effects of alcohol on these components may help to trace pathways which are affected by alcohol. 	alcohol	alcohol	none	{'e1': {'word': 'alcohol', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d54.s2.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d54.s2.e1'}, 'sentence_id': 'DDI-MedLine.d54.s2'}	Since photic evoked potential components are representations of neural pathways which are activated during photic stimulation , study of the effects of DRUG on these components may help to trace pathways which are affected by DRUGOTHER .
In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, ethanol (2.0 g/kg), physostigmine (0.6 mg/kg) or atropine (15.0 mg/kg) on separate days. 	ethanol	physostigmine	none	{'e1': {'word': 'ethanol', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d54.s3.e0'}, 'e2': {'word': 'physostigmine', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d54.s3.e1'}, 'sentence_id': 'DDI-MedLine.d54.s3'}	In the present study , evoked potentials were recorded at 5 , 20 , and 40 min following IP injections of saline , DRUG ( 2.0 g / kg ) , DRUGOTHER ( 0.6 mg / kg ) or DRUGUNRELATED ( 15.0 mg / kg ) on separate days .
In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, ethanol (2.0 g/kg), physostigmine (0.6 mg/kg) or atropine (15.0 mg/kg) on separate days. 	ethanol	atropine	none	{'e1': {'word': 'ethanol', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d54.s3.e0'}, 'e2': {'word': 'atropine', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d54.s3.e2'}, 'sentence_id': 'DDI-MedLine.d54.s3'}	In the present study , evoked potentials were recorded at 5 , 20 , and 40 min following IP injections of saline , DRUG ( 2.0 g / kg ) , DRUGUNRELATED ( 0.6 mg / kg ) or DRUGOTHER ( 15.0 mg / kg ) on separate days .
In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, ethanol (2.0 g/kg), physostigmine (0.6 mg/kg) or atropine (15.0 mg/kg) on separate days. 	physostigmine	atropine	none	{'e1': {'word': 'physostigmine', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d54.s3.e1'}, 'e2': {'word': 'atropine', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d54.s3.e2'}, 'sentence_id': 'DDI-MedLine.d54.s3'}	In the present study , evoked potentials were recorded at 5 , 20 , and 40 min following IP injections of saline , DRUGUNRELATED ( 2.0 g / kg ) , DRUG ( 0.6 mg / kg ) or DRUGOTHER ( 15.0 mg / kg ) on separate days .
Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. 	Physostigmine	alcohol	effect	{'e1': {'word': 'Physostigmine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d54.s8.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d54.s8.e1'}, 'sentence_id': 'DDI-MedLine.d54.s8'}	DRUG pretreatment augmented the depressant effect of DRUGOTHER on the early components P1 and N1 , while attenuating DRUGUNRELATED 's influence on components P2 and P3 .
Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. 	Physostigmine	alcohol	effect	{'e1': {'word': 'Physostigmine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d54.s8.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d54.s8.e2'}, 'sentence_id': 'DDI-MedLine.d54.s8'}	DRUG pretreatment augmented the depressant effect of DRUGUNRELATED on the early components P1 and N1 , while attenuating DRUGOTHER 's influence on components P2 and P3 .
Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. 	alcohol	alcohol	none	{'e1': {'word': 'alcohol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d54.s8.e1'}, 'e2': {'word': 'alcohol', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d54.s8.e2'}, 'sentence_id': 'DDI-MedLine.d54.s8'}	DRUGUNRELATED pretreatment augmented the depressant effect of DRUG on the early components P1 and N1 , while attenuating DRUGOTHER 's influence on components P2 and P3 .
Atropine, either alone or in combination with alcohol, produced approximately the same degree of enhancement of component P2. 	Atropine	alcohol	none	{'e1': {'word': 'Atropine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d54.s10.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d54.s10.e1'}, 'sentence_id': 'DDI-MedLine.d54.s10'}	DRUG , either alone or in combination with DRUGOTHER , produced approximately the same degree of enhancement of component P2 .
"Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture.
"	buforin II	azithromycin	none	{'e1': {'word': 'buforin II', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d47.s0.e0'}, 'e2': {'word': 'azithromycin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d47.s0.e1'}, 'sentence_id': 'DDI-MedLine.d47.s0'}	Activity of DRUG alone and in combination with DRUGOTHER and DRUGUNRELATED against Cryptosporidium parvum in cell culture .
"Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture.
"	buforin II	minocycline	none	{'e1': {'word': 'buforin II', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d47.s0.e0'}, 'e2': {'word': 'minocycline', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d47.s0.e2'}, 'sentence_id': 'DDI-MedLine.d47.s0'}	Activity of DRUG alone and in combination with DRUGUNRELATED and DRUGOTHER against Cryptosporidium parvum in cell culture .
"Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture.
"	azithromycin	minocycline	none	{'e1': {'word': 'azithromycin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d47.s0.e1'}, 'e2': {'word': 'minocycline', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d47.s0.e2'}, 'sentence_id': 'DDI-MedLine.d47.s0'}	Activity of DRUGUNRELATED alone and in combination with DRUG and DRUGOTHER against Cryptosporidium parvum in cell culture .
The in vitro anti-cryptosporidial activity of buforin II alone and in combination with azithromycin and minocycline was investigated. 	buforin II	azithromycin	none	{'e1': {'word': 'buforin II', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d47.s1.e0'}, 'e2': {'word': 'azithromycin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d47.s1.e1'}, 'sentence_id': 'DDI-MedLine.d47.s1'}	The in vitro anti-cryptosporidial activity of DRUG alone and in combination with DRUGOTHER and DRUGUNRELATED was investigated .
The in vitro anti-cryptosporidial activity of buforin II alone and in combination with azithromycin and minocycline was investigated. 	buforin II	minocycline	none	{'e1': {'word': 'buforin II', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d47.s1.e0'}, 'e2': {'word': 'minocycline', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d47.s1.e2'}, 'sentence_id': 'DDI-MedLine.d47.s1'}	The in vitro anti-cryptosporidial activity of DRUG alone and in combination with DRUGUNRELATED and DRUGOTHER was investigated .
The in vitro anti-cryptosporidial activity of buforin II alone and in combination with azithromycin and minocycline was investigated. 	azithromycin	minocycline	none	{'e1': {'word': 'azithromycin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d47.s1.e1'}, 'e2': {'word': 'minocycline', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d47.s1.e2'}, 'sentence_id': 'DDI-MedLine.d47.s1'}	The in vitro anti-cryptosporidial activity of DRUGUNRELATED alone and in combination with DRUG and DRUGOTHER was investigated .
Moreover, its activity was enhanced when it was combined with either azithromycin or minocycline with 90% parasite reduction at the highest concentration tested. 	azithromycin	minocycline	none	{'e1': {'word': 'azithromycin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d47.s3.e0'}, 'e2': {'word': 'minocycline', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d47.s3.e1'}, 'sentence_id': 'DDI-MedLine.d47.s3'}	Moreover , its activity was enhanced when it was combined with either DRUG or DRUGOTHER with 90 % parasite reduction at the highest concentration tested .
Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.	Buforin II	azithromycin	effect	{'e1': {'word': 'Buforin II', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d47.s4.e0'}, 'e2': {'word': 'azithromycin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d47.s4.e1'}, 'sentence_id': 'DDI-MedLine.d47.s4'}	DRUG may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either DRUGOTHER or DRUGUNRELATED .
Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.	Buforin II	minocycline	effect	{'e1': {'word': 'Buforin II', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d47.s4.e0'}, 'e2': {'word': 'minocycline', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d47.s4.e2'}, 'sentence_id': 'DDI-MedLine.d47.s4'}	DRUG may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either DRUGUNRELATED or DRUGOTHER .
Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.	azithromycin	minocycline	none	{'e1': {'word': 'azithromycin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d47.s4.e1'}, 'e2': {'word': 'minocycline', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d47.s4.e2'}, 'sentence_id': 'DDI-MedLine.d47.s4'}	DRUGUNRELATED may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either DRUG or DRUGOTHER .
"The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.
"	ketamine	Innovar	none	{'e1': {'word': 'ketamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s0.e0'}, 'e2': {'word': 'Innovar', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s0.e1'}, 'sentence_id': 'DDI-MedLine.d23.s0'}	The effects of DRUG and of DRUGOTHER anesthesia on DRUGUNRELATED tolerance in dogs .
"The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.
"	ketamine	digitalis	none	{'e1': {'word': 'ketamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s0.e0'}, 'e2': {'word': 'digitalis', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d23.s0.e2'}, 'sentence_id': 'DDI-MedLine.d23.s0'}	The effects of DRUG and of DRUGUNRELATED anesthesia on DRUGOTHER tolerance in dogs .
"The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.
"	Innovar	digitalis	none	{'e1': {'word': 'Innovar', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s0.e1'}, 'e2': {'word': 'digitalis', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d23.s0.e2'}, 'sentence_id': 'DDI-MedLine.d23.s0'}	The effects of DRUGUNRELATED and of DRUG anesthesia on DRUGOTHER tolerance in dogs .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	digitalis	ketamine	none	{'e1': {'word': 'digitalis', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s1.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d23.s1.e1'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUG tolerance in dogs anesthetized with DRUGOTHER , DRUGUNRELATED , or DRUGUNRELATED , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGUNRELATED or DRUGUNRELATED than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	digitalis	Innovar Vet	none	{'e1': {'word': 'digitalis', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s1.e0'}, 'e2': {'word': 'Innovar Vet', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d23.s1.e2'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUG tolerance in dogs anesthetized with DRUGUNRELATED , DRUGOTHER , or DRUGUNRELATED , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGUNRELATED or DRUGUNRELATED than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	digitalis	pentobarbital	none	{'e1': {'word': 'digitalis', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s1.e0'}, 'e2': {'word': 'pentobarbital', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e3'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUG tolerance in dogs anesthetized with DRUGUNRELATED , DRUGUNRELATED , or DRUGOTHER , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGUNRELATED or DRUGUNRELATED than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	digitalis	ouabain	none	{'e1': {'word': 'digitalis', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s1.e0'}, 'e2': {'word': 'ouabain', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d23.s1.e4'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUG tolerance in dogs anesthetized with DRUGUNRELATED , DRUGUNRELATED , or DRUGUNRELATED , the dosage of DRUGOTHER needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGUNRELATED or DRUGUNRELATED than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	digitalis	ouabain	none	{'e1': {'word': 'digitalis', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s1.e0'}, 'e2': {'word': 'ouabain', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d23.s1.e5'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUG tolerance in dogs anesthetized with DRUGUNRELATED , DRUGUNRELATED , or DRUGUNRELATED , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGOTHER , with DRUGUNRELATED or DRUGUNRELATED than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	digitalis	ketamine	none	{'e1': {'word': 'digitalis', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s1.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d23.s1.e6'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUG tolerance in dogs anesthetized with DRUGUNRELATED , DRUGUNRELATED , or DRUGUNRELATED , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGOTHER or DRUGUNRELATED than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	digitalis	Innovar	none	{'e1': {'word': 'digitalis', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s1.e0'}, 'e2': {'word': 'Innovar', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d23.s1.e7'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUG tolerance in dogs anesthetized with DRUGUNRELATED , DRUGUNRELATED , or DRUGUNRELATED , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGUNRELATED or DRUGOTHER than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	digitalis	pentobarbital	none	{'e1': {'word': 'digitalis', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s1.e0'}, 'e2': {'word': 'pentobarbital', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d23.s1.e8'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUG tolerance in dogs anesthetized with DRUGUNRELATED , DRUGUNRELATED , or DRUGUNRELATED , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGUNRELATED or DRUGUNRELATED than with DRUGOTHER .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	Innovar Vet	none	{'e1': {'word': 'ketamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d23.s1.e1'}, 'e2': {'word': 'Innovar Vet', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d23.s1.e2'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUG , DRUGOTHER , or DRUGUNRELATED , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGUNRELATED or DRUGUNRELATED than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	pentobarbital	none	{'e1': {'word': 'ketamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d23.s1.e1'}, 'e2': {'word': 'pentobarbital', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e3'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUG , DRUGUNRELATED , or DRUGOTHER , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGUNRELATED or DRUGUNRELATED than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	ouabain	effect	{'e1': {'word': 'ketamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d23.s1.e1'}, 'e2': {'word': 'ouabain', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d23.s1.e4'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUG , DRUGUNRELATED , or DRUGUNRELATED , the dosage of DRUGOTHER needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGUNRELATED or DRUGUNRELATED than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	ouabain	none	{'e1': {'word': 'ketamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d23.s1.e1'}, 'e2': {'word': 'ouabain', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d23.s1.e5'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUG , DRUGUNRELATED , or DRUGUNRELATED , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGOTHER , with DRUGUNRELATED or DRUGUNRELATED than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	ketamine	none	{'e1': {'word': 'ketamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d23.s1.e1'}, 'e2': {'word': 'ketamine', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d23.s1.e6'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUG , DRUGUNRELATED , or DRUGUNRELATED , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGOTHER or DRUGUNRELATED than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	Innovar	none	{'e1': {'word': 'ketamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d23.s1.e1'}, 'e2': {'word': 'Innovar', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d23.s1.e7'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUG , DRUGUNRELATED , or DRUGUNRELATED , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGUNRELATED or DRUGOTHER than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	pentobarbital	none	{'e1': {'word': 'ketamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d23.s1.e1'}, 'e2': {'word': 'pentobarbital', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d23.s1.e8'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUG , DRUGUNRELATED , or DRUGUNRELATED , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGUNRELATED or DRUGUNRELATED than with DRUGOTHER .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	Innovar Vet	pentobarbital	none	{'e1': {'word': 'Innovar Vet', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d23.s1.e2'}, 'e2': {'word': 'pentobarbital', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e3'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUGUNRELATED , DRUG , or DRUGOTHER , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGUNRELATED or DRUGUNRELATED than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	Innovar Vet	ouabain	effect	{'e1': {'word': 'Innovar Vet', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d23.s1.e2'}, 'e2': {'word': 'ouabain', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d23.s1.e4'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUGUNRELATED , DRUG , or DRUGUNRELATED , the dosage of DRUGOTHER needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGUNRELATED or DRUGUNRELATED than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	Innovar Vet	ouabain	none	{'e1': {'word': 'Innovar Vet', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d23.s1.e2'}, 'e2': {'word': 'ouabain', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d23.s1.e5'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUGUNRELATED , DRUG , or DRUGUNRELATED , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGOTHER , with DRUGUNRELATED or DRUGUNRELATED than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	Innovar Vet	ketamine	none	{'e1': {'word': 'Innovar Vet', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d23.s1.e2'}, 'e2': {'word': 'ketamine', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d23.s1.e6'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUGUNRELATED , DRUG , or DRUGUNRELATED , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGOTHER or DRUGUNRELATED than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	Innovar Vet	Innovar	none	{'e1': {'word': 'Innovar Vet', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d23.s1.e2'}, 'e2': {'word': 'Innovar', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d23.s1.e7'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUGUNRELATED , DRUG , or DRUGUNRELATED , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGUNRELATED or DRUGOTHER than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	Innovar Vet	pentobarbital	none	{'e1': {'word': 'Innovar Vet', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d23.s1.e2'}, 'e2': {'word': 'pentobarbital', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d23.s1.e8'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUGUNRELATED , DRUG , or DRUGUNRELATED , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGUNRELATED or DRUGUNRELATED than with DRUGOTHER .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	pentobarbital	ouabain	effect	{'e1': {'word': 'pentobarbital', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e3'}, 'e2': {'word': 'ouabain', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d23.s1.e4'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUGUNRELATED , DRUGUNRELATED , or DRUG , the dosage of DRUGOTHER needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGUNRELATED or DRUGUNRELATED than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	pentobarbital	ouabain	none	{'e1': {'word': 'pentobarbital', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e3'}, 'e2': {'word': 'ouabain', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d23.s1.e5'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUGUNRELATED , DRUGUNRELATED , or DRUG , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGOTHER , with DRUGUNRELATED or DRUGUNRELATED than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	pentobarbital	ketamine	none	{'e1': {'word': 'pentobarbital', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e3'}, 'e2': {'word': 'ketamine', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d23.s1.e6'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUGUNRELATED , DRUGUNRELATED , or DRUG , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGOTHER or DRUGUNRELATED than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	pentobarbital	Innovar	none	{'e1': {'word': 'pentobarbital', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e3'}, 'e2': {'word': 'Innovar', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d23.s1.e7'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUGUNRELATED , DRUGUNRELATED , or DRUG , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGUNRELATED or DRUGOTHER than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	pentobarbital	pentobarbital	none	{'e1': {'word': 'pentobarbital', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e3'}, 'e2': {'word': 'pentobarbital', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d23.s1.e8'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUGUNRELATED , DRUGUNRELATED , or DRUG , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGUNRELATED or DRUGUNRELATED than with DRUGOTHER .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ouabain	ouabain	none	{'e1': {'word': 'ouabain', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d23.s1.e4'}, 'e2': {'word': 'ouabain', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d23.s1.e5'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUGUNRELATED , DRUGUNRELATED , or DRUGUNRELATED , the dosage of DRUG needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGOTHER , with DRUGUNRELATED or DRUGUNRELATED than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ouabain	ketamine	none	{'e1': {'word': 'ouabain', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d23.s1.e4'}, 'e2': {'word': 'ketamine', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d23.s1.e6'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUGUNRELATED , DRUGUNRELATED , or DRUGUNRELATED , the dosage of DRUG needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGOTHER or DRUGUNRELATED than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ouabain	Innovar	none	{'e1': {'word': 'ouabain', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d23.s1.e4'}, 'e2': {'word': 'Innovar', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d23.s1.e7'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUGUNRELATED , DRUGUNRELATED , or DRUGUNRELATED , the dosage of DRUG needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGUNRELATED or DRUGOTHER than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ouabain	pentobarbital	none	{'e1': {'word': 'ouabain', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d23.s1.e4'}, 'e2': {'word': 'pentobarbital', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d23.s1.e8'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUGUNRELATED , DRUGUNRELATED , or DRUGUNRELATED , the dosage of DRUG needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGUNRELATED or DRUGUNRELATED than with DRUGOTHER .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ouabain	ketamine	none	{'e1': {'word': 'ouabain', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d23.s1.e5'}, 'e2': {'word': 'ketamine', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d23.s1.e6'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUGUNRELATED , DRUGUNRELATED , or DRUGUNRELATED , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUG , with DRUGOTHER or DRUGUNRELATED than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ouabain	Innovar	none	{'e1': {'word': 'ouabain', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d23.s1.e5'}, 'e2': {'word': 'Innovar', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d23.s1.e7'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUGUNRELATED , DRUGUNRELATED , or DRUGUNRELATED , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUG , with DRUGUNRELATED or DRUGOTHER than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ouabain	pentobarbital	none	{'e1': {'word': 'ouabain', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d23.s1.e5'}, 'e2': {'word': 'pentobarbital', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d23.s1.e8'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUGUNRELATED , DRUGUNRELATED , or DRUGUNRELATED , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUG , with DRUGUNRELATED or DRUGUNRELATED than with DRUGOTHER .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	Innovar	none	{'e1': {'word': 'ketamine', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d23.s1.e6'}, 'e2': {'word': 'Innovar', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d23.s1.e7'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUGUNRELATED , DRUGUNRELATED , or DRUGUNRELATED , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUG or DRUGOTHER than with DRUGUNRELATED .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	pentobarbital	none	{'e1': {'word': 'ketamine', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d23.s1.e6'}, 'e2': {'word': 'pentobarbital', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d23.s1.e8'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUGUNRELATED , DRUGUNRELATED , or DRUGUNRELATED , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUG or DRUGUNRELATED than with DRUGOTHER .
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	Innovar	pentobarbital	none	{'e1': {'word': 'Innovar', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d23.s1.e7'}, 'e2': {'word': 'pentobarbital', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d23.s1.e8'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of DRUGUNRELATED tolerance in dogs anesthetized with DRUGUNRELATED , DRUGUNRELATED , or DRUGUNRELATED , the dosage of DRUGUNRELATED needed to cause ventricular tachycardia was significantly higher , as was the LD50 of DRUGUNRELATED , with DRUGUNRELATED or DRUG than with DRUGOTHER .
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	ouabain	Innovar	effect	{'e1': {'word': 'ouabain', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s2.e0'}, 'e2': {'word': 'Innovar', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d23.s2.e1'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by DRUG was generally converted to sinus rhythm following administration of DRUGOTHER , DRUGUNRELATED , or DRUGUNRELATED but not after administration of DRUGUNRELATED alone or after DRUGUNRELATED .
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	ouabain	ketamine	effect	{'e1': {'word': 'ouabain', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s2.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d23.s2.e2'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by DRUG was generally converted to sinus rhythm following administration of DRUGUNRELATED , DRUGOTHER , or DRUGUNRELATED but not after administration of DRUGUNRELATED alone or after DRUGUNRELATED .
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	ouabain	droperidol	effect	{'e1': {'word': 'ouabain', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s2.e0'}, 'e2': {'word': 'droperidol', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d23.s2.e3'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by DRUG was generally converted to sinus rhythm following administration of DRUGUNRELATED , DRUGUNRELATED , or DRUGOTHER but not after administration of DRUGUNRELATED alone or after DRUGUNRELATED .
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	ouabain	fentayl	none	{'e1': {'word': 'ouabain', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s2.e0'}, 'e2': {'word': 'fentayl', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d23.s2.e4'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by DRUG was generally converted to sinus rhythm following administration of DRUGUNRELATED , DRUGUNRELATED , or DRUGUNRELATED but not after administration of DRUGOTHER alone or after DRUGUNRELATED .
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	ouabain	pentobarbital	none	{'e1': {'word': 'ouabain', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s2.e0'}, 'e2': {'word': 'pentobarbital', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d23.s2.e5'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by DRUG was generally converted to sinus rhythm following administration of DRUGUNRELATED , DRUGUNRELATED , or DRUGUNRELATED but not after administration of DRUGUNRELATED alone or after DRUGOTHER .
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	Innovar	ketamine	none	{'e1': {'word': 'Innovar', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d23.s2.e1'}, 'e2': {'word': 'ketamine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d23.s2.e2'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by DRUGUNRELATED was generally converted to sinus rhythm following administration of DRUG , DRUGOTHER , or DRUGUNRELATED but not after administration of DRUGUNRELATED alone or after DRUGUNRELATED .
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	Innovar	droperidol	none	{'e1': {'word': 'Innovar', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d23.s2.e1'}, 'e2': {'word': 'droperidol', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d23.s2.e3'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by DRUGUNRELATED was generally converted to sinus rhythm following administration of DRUG , DRUGUNRELATED , or DRUGOTHER but not after administration of DRUGUNRELATED alone or after DRUGUNRELATED .
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	Innovar	fentayl	none	{'e1': {'word': 'Innovar', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d23.s2.e1'}, 'e2': {'word': 'fentayl', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d23.s2.e4'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by DRUGUNRELATED was generally converted to sinus rhythm following administration of DRUG , DRUGUNRELATED , or DRUGUNRELATED but not after administration of DRUGOTHER alone or after DRUGUNRELATED .
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	Innovar	pentobarbital	none	{'e1': {'word': 'Innovar', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d23.s2.e1'}, 'e2': {'word': 'pentobarbital', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d23.s2.e5'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by DRUGUNRELATED was generally converted to sinus rhythm following administration of DRUG , DRUGUNRELATED , or DRUGUNRELATED but not after administration of DRUGUNRELATED alone or after DRUGOTHER .
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	ketamine	droperidol	none	{'e1': {'word': 'ketamine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d23.s2.e2'}, 'e2': {'word': 'droperidol', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d23.s2.e3'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by DRUGUNRELATED was generally converted to sinus rhythm following administration of DRUGUNRELATED , DRUG , or DRUGOTHER but not after administration of DRUGUNRELATED alone or after DRUGUNRELATED .
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	ketamine	fentayl	none	{'e1': {'word': 'ketamine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d23.s2.e2'}, 'e2': {'word': 'fentayl', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d23.s2.e4'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by DRUGUNRELATED was generally converted to sinus rhythm following administration of DRUGUNRELATED , DRUG , or DRUGUNRELATED but not after administration of DRUGOTHER alone or after DRUGUNRELATED .
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	ketamine	pentobarbital	none	{'e1': {'word': 'ketamine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d23.s2.e2'}, 'e2': {'word': 'pentobarbital', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d23.s2.e5'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by DRUGUNRELATED was generally converted to sinus rhythm following administration of DRUGUNRELATED , DRUG , or DRUGUNRELATED but not after administration of DRUGUNRELATED alone or after DRUGOTHER .
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	droperidol	fentayl	none	{'e1': {'word': 'droperidol', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d23.s2.e3'}, 'e2': {'word': 'fentayl', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d23.s2.e4'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by DRUGUNRELATED was generally converted to sinus rhythm following administration of DRUGUNRELATED , DRUGUNRELATED , or DRUG but not after administration of DRUGOTHER alone or after DRUGUNRELATED .
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	droperidol	pentobarbital	none	{'e1': {'word': 'droperidol', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d23.s2.e3'}, 'e2': {'word': 'pentobarbital', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d23.s2.e5'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by DRUGUNRELATED was generally converted to sinus rhythm following administration of DRUGUNRELATED , DRUGUNRELATED , or DRUG but not after administration of DRUGUNRELATED alone or after DRUGOTHER .
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	fentayl	pentobarbital	none	{'e1': {'word': 'fentayl', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d23.s2.e4'}, 'e2': {'word': 'pentobarbital', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d23.s2.e5'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by DRUGUNRELATED was generally converted to sinus rhythm following administration of DRUGUNRELATED , DRUGUNRELATED , or DRUGUNRELATED but not after administration of DRUG alone or after DRUGOTHER .
The literature provides considerable evidence indicating that several, but not all antihistaminics, are indeed analgesic agents and some are analgesic adjuvants as well.	antihistaminics	analgesic agents	none	{'e1': {'word': 'antihistaminics', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d57.s1.e0'}, 'e2': {'word': 'analgesic agents', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d57.s1.e1'}, 'sentence_id': 'DDI-MedLine.d57.s1'}	The literature provides considerable evidence indicating that several , but not all DRUG , are indeed DRUGOTHER and some are DRUGUNRELATED as well .
The literature provides considerable evidence indicating that several, but not all antihistaminics, are indeed analgesic agents and some are analgesic adjuvants as well.	antihistaminics	analgesic adjuvants	none	{'e1': {'word': 'antihistaminics', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d57.s1.e0'}, 'e2': {'word': 'analgesic adjuvants', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d57.s1.e2'}, 'sentence_id': 'DDI-MedLine.d57.s1'}	The literature provides considerable evidence indicating that several , but not all DRUG , are indeed DRUGUNRELATED and some are DRUGOTHER as well .
The literature provides considerable evidence indicating that several, but not all antihistaminics, are indeed analgesic agents and some are analgesic adjuvants as well.	analgesic agents	analgesic adjuvants	none	{'e1': {'word': 'analgesic agents', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d57.s1.e1'}, 'e2': {'word': 'analgesic adjuvants', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d57.s1.e2'}, 'sentence_id': 'DDI-MedLine.d57.s1'}	The literature provides considerable evidence indicating that several , but not all DRUGUNRELATED , are indeed DRUG and some are DRUGOTHER as well .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	diphenhydramine	hydroxyzine	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d57.s2.e0'}, 'e2': {'word': 'hydroxyzine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e1'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUG , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	diphenhydramine	orphenadrine	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d57.s2.e0'}, 'e2': {'word': 'orphenadrine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d57.s2.e2'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUG , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	diphenhydramine	pyrilamine	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d57.s2.e0'}, 'e2': {'word': 'pyrilamine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d57.s2.e3'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	diphenhydramine	phenyltoloxamine	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d57.s2.e0'}, 'e2': {'word': 'phenyltoloxamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d57.s2.e4'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	diphenhydramine	promethazine	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d57.s2.e0'}, 'e2': {'word': 'promethazine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d57.s2.e5'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , and DRUGUNRELATED .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	diphenhydramine	methdilazine	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d57.s2.e0'}, 'e2': {'word': 'methdilazine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d57.s2.e6'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , and DRUGUNRELATED .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	diphenhydramine	tripelennamine	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d57.s2.e0'}, 'e2': {'word': 'tripelennamine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d57.s2.e7'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGOTHER .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	hydroxyzine	orphenadrine	none	{'e1': {'word': 'hydroxyzine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e1'}, 'e2': {'word': 'orphenadrine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d57.s2.e2'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUGUNRELATED , DRUG , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	hydroxyzine	pyrilamine	none	{'e1': {'word': 'hydroxyzine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e1'}, 'e2': {'word': 'pyrilamine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d57.s2.e3'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	hydroxyzine	phenyltoloxamine	none	{'e1': {'word': 'hydroxyzine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e1'}, 'e2': {'word': 'phenyltoloxamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d57.s2.e4'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	hydroxyzine	promethazine	none	{'e1': {'word': 'hydroxyzine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e1'}, 'e2': {'word': 'promethazine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d57.s2.e5'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , and DRUGUNRELATED .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	hydroxyzine	methdilazine	none	{'e1': {'word': 'hydroxyzine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e1'}, 'e2': {'word': 'methdilazine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d57.s2.e6'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , and DRUGUNRELATED .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	hydroxyzine	tripelennamine	none	{'e1': {'word': 'hydroxyzine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e1'}, 'e2': {'word': 'tripelennamine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d57.s2.e7'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGOTHER .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	orphenadrine	pyrilamine	none	{'e1': {'word': 'orphenadrine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d57.s2.e2'}, 'e2': {'word': 'pyrilamine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d57.s2.e3'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	orphenadrine	phenyltoloxamine	none	{'e1': {'word': 'orphenadrine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d57.s2.e2'}, 'e2': {'word': 'phenyltoloxamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d57.s2.e4'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	orphenadrine	promethazine	none	{'e1': {'word': 'orphenadrine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d57.s2.e2'}, 'e2': {'word': 'promethazine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d57.s2.e5'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , and DRUGUNRELATED .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	orphenadrine	methdilazine	none	{'e1': {'word': 'orphenadrine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d57.s2.e2'}, 'e2': {'word': 'methdilazine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d57.s2.e6'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , and DRUGUNRELATED .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	orphenadrine	tripelennamine	none	{'e1': {'word': 'orphenadrine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d57.s2.e2'}, 'e2': {'word': 'tripelennamine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d57.s2.e7'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGOTHER .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	pyrilamine	phenyltoloxamine	none	{'e1': {'word': 'pyrilamine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d57.s2.e3'}, 'e2': {'word': 'phenyltoloxamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d57.s2.e4'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	pyrilamine	promethazine	none	{'e1': {'word': 'pyrilamine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d57.s2.e3'}, 'e2': {'word': 'promethazine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d57.s2.e5'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , and DRUGUNRELATED .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	pyrilamine	methdilazine	none	{'e1': {'word': 'pyrilamine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d57.s2.e3'}, 'e2': {'word': 'methdilazine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d57.s2.e6'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , and DRUGUNRELATED .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	pyrilamine	tripelennamine	none	{'e1': {'word': 'pyrilamine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d57.s2.e3'}, 'e2': {'word': 'tripelennamine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d57.s2.e7'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGOTHER .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	phenyltoloxamine	promethazine	none	{'e1': {'word': 'phenyltoloxamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d57.s2.e4'}, 'e2': {'word': 'promethazine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d57.s2.e5'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGOTHER , DRUGUNRELATED , and DRUGUNRELATED .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	phenyltoloxamine	methdilazine	none	{'e1': {'word': 'phenyltoloxamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d57.s2.e4'}, 'e2': {'word': 'methdilazine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d57.s2.e6'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGOTHER , and DRUGUNRELATED .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	phenyltoloxamine	tripelennamine	none	{'e1': {'word': 'phenyltoloxamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d57.s2.e4'}, 'e2': {'word': 'tripelennamine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d57.s2.e7'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGUNRELATED , and DRUGOTHER .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	promethazine	methdilazine	none	{'e1': {'word': 'promethazine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d57.s2.e5'}, 'e2': {'word': 'methdilazine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d57.s2.e6'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGOTHER , and DRUGUNRELATED .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	promethazine	tripelennamine	none	{'e1': {'word': 'promethazine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d57.s2.e5'}, 'e2': {'word': 'tripelennamine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d57.s2.e7'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGUNRELATED , and DRUGOTHER .
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	methdilazine	tripelennamine	none	{'e1': {'word': 'methdilazine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d57.s2.e6'}, 'e2': {'word': 'tripelennamine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d57.s2.e7'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUG , and DRUGOTHER .
"Influence of coadministration of fluoxetine on cisapride pharmacokinetics and QTc intervals in healthy volunteers.
"	fluoxetine	cisapride	none	{'e1': {'word': 'fluoxetine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d46.s0.e0'}, 'e2': {'word': 'cisapride', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d46.s0.e1'}, 'sentence_id': 'DDI-MedLine.d46.s0'}	Influence of coadministration of DRUG on DRUGOTHER pharmacokinetics and QTc intervals in healthy volunteers .
STUDY OBJECTIVE: To evaluate the effect of fluoxetine on the pharmacokinetics and cardiovascular safety of cisapride at steady state in healthy men. 	fluoxetine	cisapride	none	{'e1': {'word': 'fluoxetine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d46.s1.e0'}, 'e2': {'word': 'cisapride', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d46.s1.e1'}, 'sentence_id': 'DDI-MedLine.d46.s1'}	STUDY OBJECTIVE : To evaluate the effect of DRUG on the pharmacokinetics and cardiovascular safety of DRUGOTHER at steady state in healthy men .
and phase 3 (days 45-52): cisapride 10 mg 4 times/day (days 45-51) plus fluoxetine 20 mg/day (days 45-52). 	cisapride	fluoxetine	none	{'e1': {'word': 'cisapride', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d46.s9.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d46.s9.e1'}, 'sentence_id': 'DDI-MedLine.d46.s9'}	and phase 3 ( days 45 - 52 ) : DRUG 10 mg 4 times / day ( days 45 - 51 ) plus DRUGOTHER 20 mg / day ( days 45 - 52 ) .
Coadministration of fluoxetine significantly decreased cisapride plasma concentrations. 	fluoxetine	cisapride	mechanism	{'e1': {'word': 'fluoxetine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d46.s13.e0'}, 'e2': {'word': 'cisapride', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d46.s13.e1'}, 'sentence_id': 'DDI-MedLine.d46.s13'}	Coadministration of DRUG significantly decreased DRUGOTHER plasma concentrations .
There were no clinically significant changes in corrected QT intervals during administration of cisapride alone or with fluoxetine. 	cisapride	fluoxetine	none	{'e1': {'word': 'cisapride', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d46.s14.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d46.s14.e1'}, 'sentence_id': 'DDI-MedLine.d46.s14'}	There were no clinically significant changes in corrected QT intervals during administration of DRUG alone or with DRUGOTHER .
Cisapride was well tolerated when administered alone or with fluoxetine. 	Cisapride	fluoxetine	none	{'e1': {'word': 'Cisapride', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d46.s15.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d46.s15.e1'}, 'sentence_id': 'DDI-MedLine.d46.s15'}	DRUG was well tolerated when administered alone or with DRUGOTHER .
CONCLUSION: Cisapride can be administered safely to patients receiving low therapeutic dosages of fluoxetine.	Cisapride	fluoxetine	none	{'e1': {'word': 'Cisapride', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d46.s16.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d46.s16.e1'}, 'sentence_id': 'DDI-MedLine.d46.s16'}	CONCLUSION : DRUG can be administered safely to patients receiving low therapeutic dosages of DRUGOTHER .
"The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
"	DCG-IV	L-CCG-1	none	{'e1': {'word': 'DCG-IV', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d104.s0.e0'}, 'e2': {'word': 'L-CCG-1', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d104.s0.e1'}, 'sentence_id': 'DDI-MedLine.d104.s0'}	The effects of DRUG and DRUGOTHER upon DRUGUNRELATED ( DRUGUNRELATED ) - induced locomotion and behavioral changes in mice .
"The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
"	DCG-IV	phencyclidine	none	{'e1': {'word': 'DCG-IV', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d104.s0.e0'}, 'e2': {'word': 'phencyclidine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d104.s0.e2'}, 'sentence_id': 'DDI-MedLine.d104.s0'}	The effects of DRUG and DRUGUNRELATED upon DRUGOTHER ( DRUGUNRELATED ) - induced locomotion and behavioral changes in mice .
"The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
"	DCG-IV	PCP	none	{'e1': {'word': 'DCG-IV', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d104.s0.e0'}, 'e2': {'word': 'PCP', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d104.s0.e3'}, 'sentence_id': 'DDI-MedLine.d104.s0'}	The effects of DRUG and DRUGUNRELATED upon DRUGUNRELATED ( DRUGOTHER ) - induced locomotion and behavioral changes in mice .
"The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
"	L-CCG-1	phencyclidine	none	{'e1': {'word': 'L-CCG-1', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d104.s0.e1'}, 'e2': {'word': 'phencyclidine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d104.s0.e2'}, 'sentence_id': 'DDI-MedLine.d104.s0'}	The effects of DRUGUNRELATED and DRUG upon DRUGOTHER ( DRUGUNRELATED ) - induced locomotion and behavioral changes in mice .
"The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
"	L-CCG-1	PCP	none	{'e1': {'word': 'L-CCG-1', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d104.s0.e1'}, 'e2': {'word': 'PCP', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d104.s0.e3'}, 'sentence_id': 'DDI-MedLine.d104.s0'}	The effects of DRUGUNRELATED and DRUG upon DRUGUNRELATED ( DRUGOTHER ) - induced locomotion and behavioral changes in mice .
"The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
"	phencyclidine	PCP	none	{'e1': {'word': 'phencyclidine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d104.s0.e2'}, 'e2': {'word': 'PCP', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d104.s0.e3'}, 'sentence_id': 'DDI-MedLine.d104.s0'}	The effects of DRUGUNRELATED and DRUGUNRELATED upon DRUG ( DRUGOTHER ) - induced locomotion and behavioral changes in mice .
injection of phencyclidine (PCP) were observed by measuring locomotor activity and stereotyped behavior. 	phencyclidine	PCP	none	{'e1': {'word': 'phencyclidine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d104.s2.e0'}, 'e2': {'word': 'PCP', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d104.s2.e1'}, 'sentence_id': 'DDI-MedLine.d104.s2'}	injection of DRUG ( DRUGOTHER ) were observed by measuring locomotor activity and stereotyped behavior .
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and L-CCG-1, on the above behavioral changes induced by PCP were found. 	DCG-IV	L-CCG-1	none	{'e1': {'word': 'DCG-IV', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d104.s3.e0'}, 'e2': {'word': 'L-CCG-1', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d104.s3.e1'}, 'sentence_id': 'DDI-MedLine.d104.s3'}	Then , the effects of metabotropic glutamate receptor ( mGluR ) agonists , DRUG and DRUGOTHER , on the above behavioral changes induced by DRUGUNRELATED were found .
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and L-CCG-1, on the above behavioral changes induced by PCP were found. 	DCG-IV	PCP	none	{'e1': {'word': 'DCG-IV', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d104.s3.e0'}, 'e2': {'word': 'PCP', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d104.s3.e2'}, 'sentence_id': 'DDI-MedLine.d104.s3'}	Then , the effects of metabotropic glutamate receptor ( mGluR ) agonists , DRUG and DRUGUNRELATED , on the above behavioral changes induced by DRUGOTHER were found .
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and L-CCG-1, on the above behavioral changes induced by PCP were found. 	L-CCG-1	PCP	none	{'e1': {'word': 'L-CCG-1', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d104.s3.e1'}, 'e2': {'word': 'PCP', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d104.s3.e2'}, 'sentence_id': 'DDI-MedLine.d104.s3'}	Then , the effects of metabotropic glutamate receptor ( mGluR ) agonists , DRUGUNRELATED and DRUG , on the above behavioral changes induced by DRUGOTHER were found .
The effects of DCG-IV were very strong and completely depressed the PCP-induced hyperlocomotion. 	DCG-IV	PCP	effect	{'e1': {'word': 'DCG-IV', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d104.s4.e0'}, 'e2': {'word': 'PCP', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d104.s4.e1'}, 'sentence_id': 'DDI-MedLine.d104.s4'}	The effects of DRUG were very strong and completely depressed the DRUGOTHER - induced hyperlocomotion .
In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.	PCP	PCP	none	{'e1': {'word': 'PCP', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d104.s8.e0'}, 'e2': {'word': 'PCP', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d104.s8.e1'}, 'sentence_id': 'DDI-MedLine.d104.s8'}	In order to examine some molecular mechanisms of DRUG - induced behavioral changes , Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with DRUGOTHER , DRUGUNRELATED , and DRUGUNRELATED was carried out .
In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.	PCP	DCG-IV	none	{'e1': {'word': 'PCP', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d104.s8.e0'}, 'e2': {'word': 'DCG-IV', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d104.s8.e2'}, 'sentence_id': 'DDI-MedLine.d104.s8'}	In order to examine some molecular mechanisms of DRUG - induced behavioral changes , Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with DRUGUNRELATED , DRUGOTHER , and DRUGUNRELATED was carried out .
In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.	PCP	L-CCG-1	none	{'e1': {'word': 'PCP', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d104.s8.e0'}, 'e2': {'word': 'L-CCG-1', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d104.s8.e3'}, 'sentence_id': 'DDI-MedLine.d104.s8'}	In order to examine some molecular mechanisms of DRUG - induced behavioral changes , Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with DRUGUNRELATED , DRUGUNRELATED , and DRUGOTHER was carried out .
In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.	PCP	DCG-IV	none	{'e1': {'word': 'PCP', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d104.s8.e1'}, 'e2': {'word': 'DCG-IV', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d104.s8.e2'}, 'sentence_id': 'DDI-MedLine.d104.s8'}	In order to examine some molecular mechanisms of DRUGUNRELATED - induced behavioral changes , Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with DRUG , DRUGOTHER , and DRUGUNRELATED was carried out .
In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.	PCP	L-CCG-1	none	{'e1': {'word': 'PCP', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d104.s8.e1'}, 'e2': {'word': 'L-CCG-1', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d104.s8.e3'}, 'sentence_id': 'DDI-MedLine.d104.s8'}	In order to examine some molecular mechanisms of DRUGUNRELATED - induced behavioral changes , Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with DRUG , DRUGUNRELATED , and DRUGOTHER was carried out .
In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.	DCG-IV	L-CCG-1	none	{'e1': {'word': 'DCG-IV', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d104.s8.e2'}, 'e2': {'word': 'L-CCG-1', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d104.s8.e3'}, 'sentence_id': 'DDI-MedLine.d104.s8'}	In order to examine some molecular mechanisms of DRUGUNRELATED - induced behavioral changes , Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with DRUGUNRELATED , DRUG , and DRUGOTHER was carried out .
Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients.	azithromycin	zidovudine	none	{'e1': {'word': 'azithromycin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d105.s0.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d105.s0.e1'}, 'sentence_id': 'DDI-MedLine.d105.s0'}	Lack of an effect of DRUG on the disposition of DRUGOTHER and DRUGUNRELATED in HIV - infected patients .
Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients.	azithromycin	dideoxyinosine	none	{'e1': {'word': 'azithromycin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d105.s0.e0'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d105.s0.e2'}, 'sentence_id': 'DDI-MedLine.d105.s0'}	Lack of an effect of DRUG on the disposition of DRUGUNRELATED and DRUGOTHER in HIV - infected patients .
Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients.	zidovudine	dideoxyinosine	none	{'e1': {'word': 'zidovudine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d105.s0.e1'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d105.s0.e2'}, 'sentence_id': 'DDI-MedLine.d105.s0'}	Lack of an effect of DRUGUNRELATED on the disposition of DRUG and DRUGOTHER in HIV - infected patients .
Two studies were conducted in HIV-infected subjects to assess the potential for azithromycin to interact with zidovudine and dideoxyinosine. 	azithromycin	zidovudine	none	{'e1': {'word': 'azithromycin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d105.s1.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d105.s1.e1'}, 'sentence_id': 'DDI-MedLine.d105.s1'}	Two studies were conducted in HIV - infected subjects to assess the potential for DRUG to interact with DRUGOTHER and DRUGUNRELATED .
Two studies were conducted in HIV-infected subjects to assess the potential for azithromycin to interact with zidovudine and dideoxyinosine. 	azithromycin	dideoxyinosine	none	{'e1': {'word': 'azithromycin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d105.s1.e0'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d105.s1.e2'}, 'sentence_id': 'DDI-MedLine.d105.s1'}	Two studies were conducted in HIV - infected subjects to assess the potential for DRUG to interact with DRUGUNRELATED and DRUGOTHER .
Two studies were conducted in HIV-infected subjects to assess the potential for azithromycin to interact with zidovudine and dideoxyinosine. 	zidovudine	dideoxyinosine	none	{'e1': {'word': 'zidovudine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d105.s1.e1'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d105.s1.e2'}, 'sentence_id': 'DDI-MedLine.d105.s1'}	Two studies were conducted in HIV - infected subjects to assess the potential for DRUGUNRELATED to interact with DRUG and DRUGOTHER .
The zidovudine study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine. 	zidovudine	azithromycin	none	{'e1': {'word': 'zidovudine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d105.s3.e0'}, 'e2': {'word': 'azithromycin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d105.s3.e1'}, 'sentence_id': 'DDI-MedLine.d105.s3'}	The DRUG study dosed subjects with 1200 mg / day of DRUGOTHER ( n = 7 ) ( later changed to 600 mg / day [ n = 5 ] ) for Days 8 to 21 of a 21 - day course of 100 mg , five times / day of DRUGUNRELATED .
The zidovudine study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine. 	zidovudine	zidovudine	none	{'e1': {'word': 'zidovudine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d105.s3.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(51, 51)], 'id': 'DDI-MedLine.d105.s3.e2'}, 'sentence_id': 'DDI-MedLine.d105.s3'}	The DRUG study dosed subjects with 1200 mg / day of DRUGUNRELATED ( n = 7 ) ( later changed to 600 mg / day [ n = 5 ] ) for Days 8 to 21 of a 21 - day course of 100 mg , five times / day of DRUGOTHER .
The zidovudine study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine. 	azithromycin	zidovudine	none	{'e1': {'word': 'azithromycin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d105.s3.e1'}, 'e2': {'word': 'zidovudine', 'word_index': [(51, 51)], 'id': 'DDI-MedLine.d105.s3.e2'}, 'sentence_id': 'DDI-MedLine.d105.s3'}	The DRUGUNRELATED study dosed subjects with 1200 mg / day of DRUG ( n = 7 ) ( later changed to 600 mg / day [ n = 5 ] ) for Days 8 to 21 of a 21 - day course of 100 mg , five times / day of DRUGOTHER .
Subjects treated with 200 mg of dideoxyinosine twice daily for 21 days received 1200 mg of azithromycin or an equivalent amount of placebo/day for Days 8 to 21. 	dideoxyinosine	azithromycin	none	{'e1': {'word': 'dideoxyinosine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d105.s4.e0'}, 'e2': {'word': 'azithromycin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d105.s4.e1'}, 'sentence_id': 'DDI-MedLine.d105.s4'}	Subjects treated with 200 mg of DRUG twice daily for 21 days received 1200 mg of DRUGOTHER or an equivalent amount of placebo / day for Days 8 to 21 .
Antiretroviral plasma and urine sampling were conducted on Days 1, 7, and 21 for zidovudine and on Days 7 and 21 for dideoxyinosine. 	Antiretroviral	zidovudine	none	{'e1': {'word': 'Antiretroviral', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s5.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d105.s5.e1'}, 'sentence_id': 'DDI-MedLine.d105.s5'}	DRUG plasma and urine sampling were conducted on Days 1 , 7 , and 21 for DRUGOTHER and on Days 7 and 21 for DRUGUNRELATED .
Antiretroviral plasma and urine sampling were conducted on Days 1, 7, and 21 for zidovudine and on Days 7 and 21 for dideoxyinosine. 	Antiretroviral	dideoxyinosine	none	{'e1': {'word': 'Antiretroviral', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s5.e0'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d105.s5.e2'}, 'sentence_id': 'DDI-MedLine.d105.s5'}	DRUG plasma and urine sampling were conducted on Days 1 , 7 , and 21 for DRUGUNRELATED and on Days 7 and 21 for DRUGOTHER .
Antiretroviral plasma and urine sampling were conducted on Days 1, 7, and 21 for zidovudine and on Days 7 and 21 for dideoxyinosine. 	zidovudine	dideoxyinosine	none	{'e1': {'word': 'zidovudine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d105.s5.e1'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d105.s5.e2'}, 'sentence_id': 'DDI-MedLine.d105.s5'}	DRUGUNRELATED plasma and urine sampling were conducted on Days 1 , 7 , and 21 for DRUG and on Days 7 and 21 for DRUGOTHER .
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. 	Azithromycin	zidovudine	none	{'e1': {'word': 'Azithromycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s7.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d105.s7.e1'}, 'sentence_id': 'DDI-MedLine.d105.s7'}	DRUG had no significant impact on the Cmax and AUC of DRUGOTHER , although it significantly decreased the DRUGUNRELATED tmax by 44 % and increased the intracellular exposure to phosphorylated DRUGUNRELATED by 110 % .
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. 	Azithromycin	zidovudine	mechanism	{'e1': {'word': 'Azithromycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s7.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d105.s7.e2'}, 'sentence_id': 'DDI-MedLine.d105.s7'}	DRUG had no significant impact on the Cmax and AUC of DRUGUNRELATED , although it significantly decreased the DRUGOTHER tmax by 44 % and increased the intracellular exposure to phosphorylated DRUGUNRELATED by 110 % .
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. 	Azithromycin	zidovudine	mechanism	{'e1': {'word': 'Azithromycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s7.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d105.s7.e3'}, 'sentence_id': 'DDI-MedLine.d105.s7'}	DRUG had no significant impact on the Cmax and AUC of DRUGUNRELATED , although it significantly decreased the DRUGUNRELATED tmax by 44 % and increased the intracellular exposure to phosphorylated DRUGOTHER by 110 % .
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. 	zidovudine	zidovudine	none	{'e1': {'word': 'zidovudine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d105.s7.e1'}, 'e2': {'word': 'zidovudine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d105.s7.e2'}, 'sentence_id': 'DDI-MedLine.d105.s7'}	DRUGUNRELATED had no significant impact on the Cmax and AUC of DRUG , although it significantly decreased the DRUGOTHER tmax by 44 % and increased the intracellular exposure to phosphorylated DRUGUNRELATED by 110 % .
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. 	zidovudine	zidovudine	none	{'e1': {'word': 'zidovudine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d105.s7.e1'}, 'e2': {'word': 'zidovudine', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d105.s7.e3'}, 'sentence_id': 'DDI-MedLine.d105.s7'}	DRUGUNRELATED had no significant impact on the Cmax and AUC of DRUG , although it significantly decreased the DRUGUNRELATED tmax by 44 % and increased the intracellular exposure to phosphorylated DRUGOTHER by 110 % .
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. 	zidovudine	zidovudine	none	{'e1': {'word': 'zidovudine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d105.s7.e2'}, 'e2': {'word': 'zidovudine', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d105.s7.e3'}, 'sentence_id': 'DDI-MedLine.d105.s7'}	DRUGUNRELATED had no significant impact on the Cmax and AUC of DRUGUNRELATED , although it significantly decreased the DRUG tmax by 44 % and increased the intracellular exposure to phosphorylated DRUGOTHER by 110 % .
Azithromycin had no significant effect on dideoxyinosine pharmacokinetics. 	Azithromycin	dideoxyinosine	none	{'e1': {'word': 'Azithromycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s8.e0'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d105.s8.e1'}, 'sentence_id': 'DDI-MedLine.d105.s8'}	DRUG had no significant effect on DRUGOTHER pharmacokinetics .
Based on the results of these studies, it is concluded that azithromycin may be safely coadministered with both zidovudine and dideoxyinosine.	azithromycin	zidovudine	none	{'e1': {'word': 'azithromycin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d105.s9.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d105.s9.e1'}, 'sentence_id': 'DDI-MedLine.d105.s9'}	Based on the results of these studies , it is concluded that DRUG may be safely coadministered with both DRUGOTHER and DRUGUNRELATED .
Based on the results of these studies, it is concluded that azithromycin may be safely coadministered with both zidovudine and dideoxyinosine.	azithromycin	dideoxyinosine	none	{'e1': {'word': 'azithromycin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d105.s9.e0'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d105.s9.e2'}, 'sentence_id': 'DDI-MedLine.d105.s9'}	Based on the results of these studies , it is concluded that DRUG may be safely coadministered with both DRUGUNRELATED and DRUGOTHER .
Based on the results of these studies, it is concluded that azithromycin may be safely coadministered with both zidovudine and dideoxyinosine.	zidovudine	dideoxyinosine	none	{'e1': {'word': 'zidovudine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d105.s9.e1'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d105.s9.e2'}, 'sentence_id': 'DDI-MedLine.d105.s9'}	Based on the results of these studies , it is concluded that DRUGUNRELATED may be safely coadministered with both DRUG and DRUGOTHER .
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	Acetaminophen	lidocaine	none	{'e1': {'word': 'Acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e0'}, 'e2': {'word': 'lidocaine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s2.e1'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	DRUG , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED were added to pooled human serum at therapeutic concentrations .
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	Acetaminophen	phenobarbital	none	{'e1': {'word': 'Acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s2.e2'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	DRUG , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED were added to pooled human serum at therapeutic concentrations .
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	Acetaminophen	quinidine	none	{'e1': {'word': 'Acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e0'}, 'e2': {'word': 'quinidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s2.e3'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , and DRUGUNRELATED were added to pooled human serum at therapeutic concentrations .
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	Acetaminophen	theophylline	none	{'e1': {'word': 'Acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s2.e4'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , and DRUGUNRELATED were added to pooled human serum at therapeutic concentrations .
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	Acetaminophen	valproic acid	none	{'e1': {'word': 'Acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e0'}, 'e2': {'word': 'valproic acid', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d111.s2.e5'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGOTHER were added to pooled human serum at therapeutic concentrations .
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	lidocaine	phenobarbital	none	{'e1': {'word': 'lidocaine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s2.e1'}, 'e2': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s2.e2'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	DRUGUNRELATED , DRUG , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED were added to pooled human serum at therapeutic concentrations .
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	lidocaine	quinidine	none	{'e1': {'word': 'lidocaine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s2.e1'}, 'e2': {'word': 'quinidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s2.e3'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , and DRUGUNRELATED were added to pooled human serum at therapeutic concentrations .
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	lidocaine	theophylline	none	{'e1': {'word': 'lidocaine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s2.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s2.e4'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , and DRUGUNRELATED were added to pooled human serum at therapeutic concentrations .
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	lidocaine	valproic acid	none	{'e1': {'word': 'lidocaine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s2.e1'}, 'e2': {'word': 'valproic acid', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d111.s2.e5'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGOTHER were added to pooled human serum at therapeutic concentrations .
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	phenobarbital	quinidine	none	{'e1': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s2.e2'}, 'e2': {'word': 'quinidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s2.e3'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGOTHER , DRUGUNRELATED , and DRUGUNRELATED were added to pooled human serum at therapeutic concentrations .
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	phenobarbital	theophylline	none	{'e1': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s2.e2'}, 'e2': {'word': 'theophylline', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s2.e4'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGOTHER , and DRUGUNRELATED were added to pooled human serum at therapeutic concentrations .
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	phenobarbital	valproic acid	none	{'e1': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s2.e2'}, 'e2': {'word': 'valproic acid', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d111.s2.e5'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGUNRELATED , and DRUGOTHER were added to pooled human serum at therapeutic concentrations .
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	quinidine	theophylline	none	{'e1': {'word': 'quinidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s2.e3'}, 'e2': {'word': 'theophylline', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s2.e4'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGOTHER , and DRUGUNRELATED were added to pooled human serum at therapeutic concentrations .
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	quinidine	valproic acid	none	{'e1': {'word': 'quinidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s2.e3'}, 'e2': {'word': 'valproic acid', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d111.s2.e5'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGUNRELATED , and DRUGOTHER were added to pooled human serum at therapeutic concentrations .
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	theophylline	valproic acid	none	{'e1': {'word': 'theophylline', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s2.e4'}, 'e2': {'word': 'valproic acid', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d111.s2.e5'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUG , and DRUGOTHER were added to pooled human serum at therapeutic concentrations .
The following eight target drug/added drug combinations were studied: acetaminophen/phenobarbital. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s4.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d111.s4.e1'}, 'sentence_id': 'DDI-MedLine.d111.s4'}	The following eight target drug / added drug combinations were studied : DRUG / DRUGOTHER .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	theophylline	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUG / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	lidocaine	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'lidocaine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUG / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	quinidine	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'quinidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	acetaminophen	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'acetaminophen', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	valproic acid	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'valproic acid', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	quinidine	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'quinidine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	lidocaine	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'lidocaine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	theophylline	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	acetaminophen	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'acetaminophen', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	valproic acid	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'valproic acid', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGOTHER / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGOTHER .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	lidocaine	none	{'e1': {'word': 'theophylline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'lidocaine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUG , DRUGOTHER / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	quinidine	none	{'e1': {'word': 'theophylline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'quinidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	phenobarbital	none	{'e1': {'word': 'theophylline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'phenobarbital', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	acetaminophen	none	{'e1': {'word': 'theophylline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'acetaminophen', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	phenobarbital	none	{'e1': {'word': 'theophylline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	valproic acid	none	{'e1': {'word': 'theophylline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'valproic acid', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	quinidine	none	{'e1': {'word': 'theophylline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'quinidine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	lidocaine	none	{'e1': {'word': 'theophylline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'lidocaine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	theophylline	none	{'e1': {'word': 'theophylline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	acetaminophen	none	{'e1': {'word': 'theophylline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'acetaminophen', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	valproic acid	none	{'e1': {'word': 'theophylline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'valproic acid', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGOTHER / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	phenobarbital	none	{'e1': {'word': 'theophylline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'phenobarbital', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGOTHER .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	quinidine	none	{'e1': {'word': 'lidocaine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'quinidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	phenobarbital	none	{'e1': {'word': 'lidocaine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'phenobarbital', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	acetaminophen	none	{'e1': {'word': 'lidocaine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'acetaminophen', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	phenobarbital	none	{'e1': {'word': 'lidocaine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	valproic acid	none	{'e1': {'word': 'lidocaine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'valproic acid', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	quinidine	none	{'e1': {'word': 'lidocaine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'quinidine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	lidocaine	none	{'e1': {'word': 'lidocaine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'lidocaine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	theophylline	none	{'e1': {'word': 'lidocaine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'theophylline', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	acetaminophen	none	{'e1': {'word': 'lidocaine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'acetaminophen', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	valproic acid	none	{'e1': {'word': 'lidocaine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'valproic acid', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGOTHER / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	phenobarbital	none	{'e1': {'word': 'lidocaine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'phenobarbital', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGOTHER .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	phenobarbital	none	{'e1': {'word': 'quinidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'phenobarbital', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGOTHER / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	acetaminophen	none	{'e1': {'word': 'quinidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'acetaminophen', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	phenobarbital	none	{'e1': {'word': 'quinidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	valproic acid	none	{'e1': {'word': 'quinidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'valproic acid', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	quinidine	none	{'e1': {'word': 'quinidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'quinidine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	lidocaine	none	{'e1': {'word': 'quinidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'lidocaine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	theophylline	none	{'e1': {'word': 'quinidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'theophylline', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	acetaminophen	none	{'e1': {'word': 'quinidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'acetaminophen', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	valproic acid	none	{'e1': {'word': 'quinidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'valproic acid', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGOTHER / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	phenobarbital	none	{'e1': {'word': 'quinidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'phenobarbital', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGOTHER .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	acetaminophen	none	{'e1': {'word': 'phenobarbital', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'acetaminophen', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	phenobarbital	none	{'e1': {'word': 'phenobarbital', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	valproic acid	none	{'e1': {'word': 'phenobarbital', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'valproic acid', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	quinidine	none	{'e1': {'word': 'phenobarbital', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'quinidine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	lidocaine	none	{'e1': {'word': 'phenobarbital', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'lidocaine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	theophylline	none	{'e1': {'word': 'phenobarbital', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'theophylline', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	acetaminophen	none	{'e1': {'word': 'phenobarbital', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'acetaminophen', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	valproic acid	none	{'e1': {'word': 'phenobarbital', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'valproic acid', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGOTHER / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	phenobarbital	none	{'e1': {'word': 'phenobarbital', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'phenobarbital', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGOTHER .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'e2': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGOTHER / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	valproic acid	none	{'e1': {'word': 'acetaminophen', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'e2': {'word': 'valproic acid', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	quinidine	none	{'e1': {'word': 'acetaminophen', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'e2': {'word': 'quinidine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	lidocaine	none	{'e1': {'word': 'acetaminophen', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'e2': {'word': 'lidocaine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	theophylline	none	{'e1': {'word': 'acetaminophen', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'e2': {'word': 'theophylline', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	acetaminophen	none	{'e1': {'word': 'acetaminophen', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'e2': {'word': 'acetaminophen', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	valproic acid	none	{'e1': {'word': 'acetaminophen', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'e2': {'word': 'valproic acid', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGOTHER / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'e2': {'word': 'phenobarbital', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGOTHER .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	valproic acid	none	{'e1': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'e2': {'word': 'valproic acid', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	quinidine	none	{'e1': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'e2': {'word': 'quinidine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	lidocaine	none	{'e1': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'e2': {'word': 'lidocaine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	theophylline	none	{'e1': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'e2': {'word': 'theophylline', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	acetaminophen	none	{'e1': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'e2': {'word': 'acetaminophen', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	valproic acid	none	{'e1': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'e2': {'word': 'valproic acid', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGOTHER / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	phenobarbital	none	{'e1': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'e2': {'word': 'phenobarbital', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGOTHER .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	valproic acid	quinidine	none	{'e1': {'word': 'valproic acid', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'e2': {'word': 'quinidine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGOTHER / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	valproic acid	lidocaine	none	{'e1': {'word': 'valproic acid', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'e2': {'word': 'lidocaine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	valproic acid	theophylline	none	{'e1': {'word': 'valproic acid', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'e2': {'word': 'theophylline', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	valproic acid	acetaminophen	none	{'e1': {'word': 'valproic acid', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'e2': {'word': 'acetaminophen', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	valproic acid	valproic acid	none	{'e1': {'word': 'valproic acid', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'e2': {'word': 'valproic acid', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGOTHER / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	valproic acid	phenobarbital	none	{'e1': {'word': 'valproic acid', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'e2': {'word': 'phenobarbital', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGOTHER .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	lidocaine	none	{'e1': {'word': 'quinidine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'e2': {'word': 'lidocaine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGOTHER , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	theophylline	none	{'e1': {'word': 'quinidine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'e2': {'word': 'theophylline', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGOTHER / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	acetaminophen	none	{'e1': {'word': 'quinidine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'e2': {'word': 'acetaminophen', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGOTHER , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	valproic acid	none	{'e1': {'word': 'quinidine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'e2': {'word': 'valproic acid', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGOTHER / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	phenobarbital	none	{'e1': {'word': 'quinidine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'e2': {'word': 'phenobarbital', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGOTHER .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	theophylline	none	{'e1': {'word': 'lidocaine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'e2': {'word': 'theophylline', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGOTHER / DRUGUNRELATED , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	acetaminophen	none	{'e1': {'word': 'lidocaine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'e2': {'word': 'acetaminophen', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGOTHER , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	valproic acid	none	{'e1': {'word': 'lidocaine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'e2': {'word': 'valproic acid', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , and DRUGOTHER / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	phenobarbital	none	{'e1': {'word': 'lidocaine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'e2': {'word': 'phenobarbital', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , DRUGUNRELATED / DRUGUNRELATED , and DRUGUNRELATED / DRUGOTHER .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	acetaminophen	none	{'e1': {'word': 'theophylline', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'e2': {'word': 'acetaminophen', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGOTHER , and DRUGUNRELATED / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	valproic acid	none	{'e1': {'word': 'theophylline', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'e2': {'word': 'valproic acid', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , and DRUGOTHER / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	phenobarbital	none	{'e1': {'word': 'theophylline', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'e2': {'word': 'phenobarbital', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUG / DRUGUNRELATED , and DRUGUNRELATED / DRUGOTHER .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	valproic acid	none	{'e1': {'word': 'acetaminophen', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'e2': {'word': 'valproic acid', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , and DRUGOTHER / DRUGUNRELATED .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'e2': {'word': 'phenobarbital', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUG , and DRUGUNRELATED / DRUGOTHER .
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	valproic acid	phenobarbital	none	{'e1': {'word': 'valproic acid', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'e2': {'word': 'phenobarbital', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , DRUGUNRELATED / DRUGUNRELATED , and DRUG / DRUGOTHER .
Similarly dialyzed were phenobarbital, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum. 	phenobarbital	quinidine	none	{'e1': {'word': 'phenobarbital', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s7.e0'}, 'e2': {'word': 'quinidine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s7.e1'}, 'sentence_id': 'DDI-MedLine.d111.s7'}	Similarly dialyzed were DRUG , DRUGOTHER , and DRUGUNRELATED , both alone at therapeutic concentrations in serum and with DRUGUNRELATED at three different concentrations in serum .
Similarly dialyzed were phenobarbital, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum. 	phenobarbital	theophylline	none	{'e1': {'word': 'phenobarbital', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s7.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s7.e2'}, 'sentence_id': 'DDI-MedLine.d111.s7'}	Similarly dialyzed were DRUG , DRUGUNRELATED , and DRUGOTHER , both alone at therapeutic concentrations in serum and with DRUGUNRELATED at three different concentrations in serum .
Similarly dialyzed were phenobarbital, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum. 	phenobarbital	ethanol	none	{'e1': {'word': 'phenobarbital', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s7.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d111.s7.e3'}, 'sentence_id': 'DDI-MedLine.d111.s7'}	Similarly dialyzed were DRUG , DRUGUNRELATED , and DRUGUNRELATED , both alone at therapeutic concentrations in serum and with DRUGOTHER at three different concentrations in serum .
Similarly dialyzed were phenobarbital, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum. 	quinidine	theophylline	none	{'e1': {'word': 'quinidine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s7.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s7.e2'}, 'sentence_id': 'DDI-MedLine.d111.s7'}	Similarly dialyzed were DRUGUNRELATED , DRUG , and DRUGOTHER , both alone at therapeutic concentrations in serum and with DRUGUNRELATED at three different concentrations in serum .
Similarly dialyzed were phenobarbital, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum. 	quinidine	ethanol	none	{'e1': {'word': 'quinidine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s7.e1'}, 'e2': {'word': 'ethanol', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d111.s7.e3'}, 'sentence_id': 'DDI-MedLine.d111.s7'}	Similarly dialyzed were DRUGUNRELATED , DRUG , and DRUGUNRELATED , both alone at therapeutic concentrations in serum and with DRUGOTHER at three different concentrations in serum .
Similarly dialyzed were phenobarbital, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum. 	theophylline	ethanol	none	{'e1': {'word': 'theophylline', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s7.e2'}, 'e2': {'word': 'ethanol', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d111.s7.e3'}, 'sentence_id': 'DDI-MedLine.d111.s7'}	Similarly dialyzed were DRUGUNRELATED , DRUGUNRELATED , and DRUG , both alone at therapeutic concentrations in serum and with DRUGOTHER at three different concentrations in serum .
Acetaminophen diminished the binding of theophylline to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L. 	Acetaminophen	theophylline	mechanism	{'e1': {'word': 'Acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s9.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s9.e1'}, 'sentence_id': 'DDI-MedLine.d111.s9'}	DRUG diminished the binding of DRUGOTHER to human serum by a net change of 5.7 % ( percentage increase in free drug fraction [ FDF ] , 11.0 % ) at 662 micromol / L and by a net change of 7.1 % ( percentage increase in FDF , 13.7 % ) at 1324 micromol / L.
Theophylline decreased the binding of acetaminophen by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L; 	Theophylline	acetaminophen	mechanism	{'e1': {'word': 'Theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s10.e0'}, 'e2': {'word': 'acetaminophen', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s10.e1'}, 'sentence_id': 'DDI-MedLine.d111.s10'}	DRUG decreased the binding of DRUGOTHER by a net change of 6.8 % ( percentage increase in FDF , 8.8 % ) at 277.5 micromol / L ;
Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. 	Valproic acid	phenobarbital	mechanism	{'e1': {'word': 'Valproic acid', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s12.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s12.e1'}, 'sentence_id': 'DDI-MedLine.d111.s12'}	DRUG diminished binding of DRUGOTHER by a net change of 9.9 % ( percentage increase in FDF , 21.2 % ) at 1732 micromol / L.
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	acetaminophen	theophylline	effect	{'e1': {'word': 'acetaminophen', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s14.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s14.e1'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of DRUG with DRUGOTHER , DRUGUNRELATED with DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED at high to toxic concentrations decreases the binding of the target drug .
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s14.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s14.e2'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of DRUG with DRUGUNRELATED , DRUGOTHER with DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED at high to toxic concentrations decreases the binding of the target drug .
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	acetaminophen	acetaminophen	none	{'e1': {'word': 'acetaminophen', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s14.e0'}, 'e2': {'word': 'acetaminophen', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s14.e3'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of DRUG with DRUGUNRELATED , DRUGUNRELATED with DRUGOTHER , and DRUGUNRELATED with DRUGUNRELATED at high to toxic concentrations decreases the binding of the target drug .
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	acetaminophen	valproic acid	none	{'e1': {'word': 'acetaminophen', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s14.e0'}, 'e2': {'word': 'valproic acid', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d111.s14.e4'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of DRUG with DRUGUNRELATED , DRUGUNRELATED with DRUGUNRELATED , and DRUGOTHER with DRUGUNRELATED at high to toxic concentrations decreases the binding of the target drug .
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s14.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d111.s14.e5'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of DRUG with DRUGUNRELATED , DRUGUNRELATED with DRUGUNRELATED , and DRUGUNRELATED with DRUGOTHER at high to toxic concentrations decreases the binding of the target drug .
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	theophylline	phenobarbital	none	{'e1': {'word': 'theophylline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s14.e1'}, 'e2': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s14.e2'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of DRUGUNRELATED with DRUG , DRUGOTHER with DRUGUNRELATED , and DRUGUNRELATED with DRUGUNRELATED at high to toxic concentrations decreases the binding of the target drug .
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	theophylline	acetaminophen	none	{'e1': {'word': 'theophylline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s14.e1'}, 'e2': {'word': 'acetaminophen', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s14.e3'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of DRUGUNRELATED with DRUG , DRUGUNRELATED with DRUGOTHER , and DRUGUNRELATED with DRUGUNRELATED at high to toxic concentrations decreases the binding of the target drug .
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	theophylline	valproic acid	none	{'e1': {'word': 'theophylline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s14.e1'}, 'e2': {'word': 'valproic acid', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d111.s14.e4'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of DRUGUNRELATED with DRUG , DRUGUNRELATED with DRUGUNRELATED , and DRUGOTHER with DRUGUNRELATED at high to toxic concentrations decreases the binding of the target drug .
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	theophylline	phenobarbital	none	{'e1': {'word': 'theophylline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s14.e1'}, 'e2': {'word': 'phenobarbital', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d111.s14.e5'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of DRUGUNRELATED with DRUG , DRUGUNRELATED with DRUGUNRELATED , and DRUGUNRELATED with DRUGOTHER at high to toxic concentrations decreases the binding of the target drug .
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	phenobarbital	acetaminophen	effect	{'e1': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s14.e2'}, 'e2': {'word': 'acetaminophen', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s14.e3'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of DRUGUNRELATED with DRUGUNRELATED , DRUG with DRUGOTHER , and DRUGUNRELATED with DRUGUNRELATED at high to toxic concentrations decreases the binding of the target drug .
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	phenobarbital	valproic acid	none	{'e1': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s14.e2'}, 'e2': {'word': 'valproic acid', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d111.s14.e4'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of DRUGUNRELATED with DRUGUNRELATED , DRUG with DRUGUNRELATED , and DRUGOTHER with DRUGUNRELATED at high to toxic concentrations decreases the binding of the target drug .
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	phenobarbital	phenobarbital	none	{'e1': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s14.e2'}, 'e2': {'word': 'phenobarbital', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d111.s14.e5'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of DRUGUNRELATED with DRUGUNRELATED , DRUG with DRUGUNRELATED , and DRUGUNRELATED with DRUGOTHER at high to toxic concentrations decreases the binding of the target drug .
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	acetaminophen	valproic acid	none	{'e1': {'word': 'acetaminophen', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s14.e3'}, 'e2': {'word': 'valproic acid', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d111.s14.e4'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of DRUGUNRELATED with DRUGUNRELATED , DRUGUNRELATED with DRUG , and DRUGOTHER with DRUGUNRELATED at high to toxic concentrations decreases the binding of the target drug .
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d111.s14.e3'}, 'e2': {'word': 'phenobarbital', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d111.s14.e5'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of DRUGUNRELATED with DRUGUNRELATED , DRUGUNRELATED with DRUG , and DRUGUNRELATED with DRUGOTHER at high to toxic concentrations decreases the binding of the target drug .
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	valproic acid	phenobarbital	effect	{'e1': {'word': 'valproic acid', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d111.s14.e4'}, 'e2': {'word': 'phenobarbital', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d111.s14.e5'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of DRUGUNRELATED with DRUGUNRELATED , DRUGUNRELATED with DRUGUNRELATED , and DRUG with DRUGOTHER at high to toxic concentrations decreases the binding of the target drug .
"Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.
"	Fluvoxamine	tolbutamide	mechanism	{'e1': {'word': 'Fluvoxamine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d99.s0.e0'}, 'e2': {'word': 'tolbutamide', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d99.s0.e1'}, 'sentence_id': 'DDI-MedLine.d99.s0'}	DRUG inhibits the CYP2C9 catalyzed biotransformation of DRUGOTHER .
OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. 	fluvoxamine	tolbutamide	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d99.s1.e0'}, 'e2': {'word': 'tolbutamide', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d99.s1.e1'}, 'sentence_id': 'DDI-MedLine.d99.s1'}	OBJECTIVE : Our objective was to examine the interaction between DRUG and DRUGOTHER to confirm that DRUGUNRELATED inhibits CYP2C9 .
OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. 	fluvoxamine	fluvoxamine	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d99.s1.e0'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d99.s1.e2'}, 'sentence_id': 'DDI-MedLine.d99.s1'}	OBJECTIVE : Our objective was to examine the interaction between DRUG and DRUGUNRELATED to confirm that DRUGOTHER inhibits CYP2C9 .
OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. 	tolbutamide	fluvoxamine	none	{'e1': {'word': 'tolbutamide', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d99.s1.e1'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d99.s1.e2'}, 'sentence_id': 'DDI-MedLine.d99.s1'}	OBJECTIVE : Our objective was to examine the interaction between DRUGUNRELATED and DRUG to confirm that DRUGOTHER inhibits CYP2C9 .
Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. 	tolbutamide	tolbutamide	none	{'e1': {'word': 'tolbutamide', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d99.s8.e0'}, 'e2': {'word': 'tolbutamide', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d99.s8.e1'}, 'sentence_id': 'DDI-MedLine.d99.s8'}	Plasma was analyzed for DRUG , and urine was analyzed for DRUGOTHER and its two metabolites , DRUGUNRELATED and DRUGUNRELATED by means of HPLC .
Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. 	tolbutamide	4-hydroxytolbutamide	none	{'e1': {'word': 'tolbutamide', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d99.s8.e0'}, 'e2': {'word': '4-hydroxytolbutamide', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d99.s8.e2'}, 'sentence_id': 'DDI-MedLine.d99.s8'}	Plasma was analyzed for DRUG , and urine was analyzed for DRUGUNRELATED and its two metabolites , DRUGOTHER and DRUGUNRELATED by means of HPLC .
Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. 	tolbutamide	carboxytolbutamide	none	{'e1': {'word': 'tolbutamide', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d99.s8.e0'}, 'e2': {'word': 'carboxytolbutamide', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d99.s8.e3'}, 'sentence_id': 'DDI-MedLine.d99.s8'}	Plasma was analyzed for DRUG , and urine was analyzed for DRUGUNRELATED and its two metabolites , DRUGUNRELATED and DRUGOTHER by means of HPLC .
Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. 	tolbutamide	4-hydroxytolbutamide	none	{'e1': {'word': 'tolbutamide', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d99.s8.e1'}, 'e2': {'word': '4-hydroxytolbutamide', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d99.s8.e2'}, 'sentence_id': 'DDI-MedLine.d99.s8'}	Plasma was analyzed for DRUGUNRELATED , and urine was analyzed for DRUG and its two metabolites , DRUGOTHER and DRUGUNRELATED by means of HPLC .
Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. 	tolbutamide	carboxytolbutamide	none	{'e1': {'word': 'tolbutamide', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d99.s8.e1'}, 'e2': {'word': 'carboxytolbutamide', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d99.s8.e3'}, 'sentence_id': 'DDI-MedLine.d99.s8'}	Plasma was analyzed for DRUGUNRELATED , and urine was analyzed for DRUG and its two metabolites , DRUGUNRELATED and DRUGOTHER by means of HPLC .
Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. 	4-hydroxytolbutamide	carboxytolbutamide	none	{'e1': {'word': '4-hydroxytolbutamide', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d99.s8.e2'}, 'e2': {'word': 'carboxytolbutamide', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d99.s8.e3'}, 'sentence_id': 'DDI-MedLine.d99.s8'}	Plasma was analyzed for DRUGUNRELATED , and urine was analyzed for DRUGUNRELATED and its two metabolites , DRUG and DRUGOTHER by means of HPLC .
RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. 	fluvoxamine	tolbutamide	mechanism	{'e1': {'word': 'fluvoxamine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d99.s9.e0'}, 'e2': {'word': 'tolbutamide', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d99.s9.e1'}, 'sentence_id': 'DDI-MedLine.d99.s9'}	RESULTS : During treatment with DRUG , there was a statistically significant decrease in the median of the total clearance of DRUGOTHER , from 845 mL / h to 688 mL / h , among the volunteers who received 75 mg / d .
The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). 	4-hydroxytolbutamide	carboxytolbutamide	none	{'e1': {'word': '4-hydroxytolbutamide', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d99.s11.e0'}, 'e2': {'word': 'carboxytolbutamide', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d99.s11.e1'}, 'sentence_id': 'DDI-MedLine.d99.s11'}	The clearance by means of DRUG and DRUGOTHER was significantly reduced in both groups ( ie , from 901 mL / h to 318 mL / h in the group that received 150 mg of DRUGUNRELATED per day and from 723 mL / h to 457 mL / h in the group that received 75 mg of DRUGUNRELATED per day ) .
The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). 	4-hydroxytolbutamide	tolbutamide	none	{'e1': {'word': '4-hydroxytolbutamide', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d99.s11.e0'}, 'e2': {'word': 'tolbutamide', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d99.s11.e2'}, 'sentence_id': 'DDI-MedLine.d99.s11'}	The clearance by means of DRUG and DRUGUNRELATED was significantly reduced in both groups ( ie , from 901 mL / h to 318 mL / h in the group that received 150 mg of DRUGOTHER per day and from 723 mL / h to 457 mL / h in the group that received 75 mg of DRUGUNRELATED per day ) .
The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). 	4-hydroxytolbutamide	tolbutamide	none	{'e1': {'word': '4-hydroxytolbutamide', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d99.s11.e0'}, 'e2': {'word': 'tolbutamide', 'word_index': [(57, 57)], 'id': 'DDI-MedLine.d99.s11.e3'}, 'sentence_id': 'DDI-MedLine.d99.s11'}	The clearance by means of DRUG and DRUGUNRELATED was significantly reduced in both groups ( ie , from 901 mL / h to 318 mL / h in the group that received 150 mg of DRUGUNRELATED per day and from 723 mL / h to 457 mL / h in the group that received 75 mg of DRUGOTHER per day ) .
The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). 	carboxytolbutamide	tolbutamide	none	{'e1': {'word': 'carboxytolbutamide', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d99.s11.e1'}, 'e2': {'word': 'tolbutamide', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d99.s11.e2'}, 'sentence_id': 'DDI-MedLine.d99.s11'}	The clearance by means of DRUGUNRELATED and DRUG was significantly reduced in both groups ( ie , from 901 mL / h to 318 mL / h in the group that received 150 mg of DRUGOTHER per day and from 723 mL / h to 457 mL / h in the group that received 75 mg of DRUGUNRELATED per day ) .
The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). 	carboxytolbutamide	tolbutamide	none	{'e1': {'word': 'carboxytolbutamide', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d99.s11.e1'}, 'e2': {'word': 'tolbutamide', 'word_index': [(57, 57)], 'id': 'DDI-MedLine.d99.s11.e3'}, 'sentence_id': 'DDI-MedLine.d99.s11'}	The clearance by means of DRUGUNRELATED and DRUG was significantly reduced in both groups ( ie , from 901 mL / h to 318 mL / h in the group that received 150 mg of DRUGUNRELATED per day and from 723 mL / h to 457 mL / h in the group that received 75 mg of DRUGOTHER per day ) .
The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). 	tolbutamide	tolbutamide	none	{'e1': {'word': 'tolbutamide', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d99.s11.e2'}, 'e2': {'word': 'tolbutamide', 'word_index': [(57, 57)], 'id': 'DDI-MedLine.d99.s11.e3'}, 'sentence_id': 'DDI-MedLine.d99.s11'}	The clearance by means of DRUGUNRELATED and DRUGUNRELATED was significantly reduced in both groups ( ie , from 901 mL / h to 318 mL / h in the group that received 150 mg of DRUG per day and from 723 mL / h to 457 mL / h in the group that received 75 mg of DRUGOTHER per day ) .
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin	angiotensin 1	none	{'e1': {'word': 'angiotensin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d14.s0.e0'}, 'e2': {'word': 'angiotensin 1', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d14.s0.e1'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	[ A pharmacological analysis of the effect of DRUG on stimulated gastric secretion ] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of DRUGOTHER and DRUGUNRELATED on DRUGUNRELATED - and DRUGUNRELATED - induced gastric acid secretion .
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin	angiotensin 2	none	{'e1': {'word': 'angiotensin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d14.s0.e0'}, 'e2': {'word': 'angiotensin 2', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d14.s0.e2'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	[ A pharmacological analysis of the effect of DRUG on stimulated gastric secretion ] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of DRUGUNRELATED and DRUGOTHER on DRUGUNRELATED - and DRUGUNRELATED - induced gastric acid secretion .
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin	pentagastrin	none	{'e1': {'word': 'angiotensin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d14.s0.e0'}, 'e2': {'word': 'pentagastrin', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d14.s0.e3'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	[ A pharmacological analysis of the effect of DRUG on stimulated gastric secretion ] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of DRUGUNRELATED and DRUGUNRELATED on DRUGOTHER - and DRUGUNRELATED - induced gastric acid secretion .
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin	histamine	none	{'e1': {'word': 'angiotensin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d14.s0.e0'}, 'e2': {'word': 'histamine', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d14.s0.e4'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	[ A pharmacological analysis of the effect of DRUG on stimulated gastric secretion ] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of DRUGUNRELATED and DRUGUNRELATED on DRUGUNRELATED - and DRUGOTHER - induced gastric acid secretion .
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin 1	angiotensin 2	none	{'e1': {'word': 'angiotensin 1', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d14.s0.e1'}, 'e2': {'word': 'angiotensin 2', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d14.s0.e2'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	[ A pharmacological analysis of the effect of DRUGUNRELATED on stimulated gastric secretion ] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of DRUG and DRUGOTHER on DRUGUNRELATED - and DRUGUNRELATED - induced gastric acid secretion .
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin 1	pentagastrin	none	{'e1': {'word': 'angiotensin 1', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d14.s0.e1'}, 'e2': {'word': 'pentagastrin', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d14.s0.e3'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	[ A pharmacological analysis of the effect of DRUGUNRELATED on stimulated gastric secretion ] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of DRUG and DRUGUNRELATED on DRUGOTHER - and DRUGUNRELATED - induced gastric acid secretion .
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin 1	histamine	none	{'e1': {'word': 'angiotensin 1', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d14.s0.e1'}, 'e2': {'word': 'histamine', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d14.s0.e4'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	[ A pharmacological analysis of the effect of DRUGUNRELATED on stimulated gastric secretion ] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of DRUG and DRUGUNRELATED on DRUGUNRELATED - and DRUGOTHER - induced gastric acid secretion .
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin 2	pentagastrin	none	{'e1': {'word': 'angiotensin 2', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d14.s0.e2'}, 'e2': {'word': 'pentagastrin', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d14.s0.e3'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	[ A pharmacological analysis of the effect of DRUGUNRELATED on stimulated gastric secretion ] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of DRUGUNRELATED and DRUG on DRUGOTHER - and DRUGUNRELATED - induced gastric acid secretion .
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin 2	histamine	none	{'e1': {'word': 'angiotensin 2', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d14.s0.e2'}, 'e2': {'word': 'histamine', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d14.s0.e4'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	[ A pharmacological analysis of the effect of DRUGUNRELATED on stimulated gastric secretion ] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of DRUGUNRELATED and DRUG on DRUGUNRELATED - and DRUGOTHER - induced gastric acid secretion .
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	pentagastrin	histamine	none	{'e1': {'word': 'pentagastrin', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d14.s0.e3'}, 'e2': {'word': 'histamine', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d14.s0.e4'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	[ A pharmacological analysis of the effect of DRUGUNRELATED on stimulated gastric secretion ] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of DRUGUNRELATED and DRUGUNRELATED on DRUG - and DRUGOTHER - induced gastric acid secretion .
It was established that both angiotensins inhibited gastric acid secretion stimulated by pentagastrin but not by histamine. 	pentagastrin	histamine	none	{'e1': {'word': 'pentagastrin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d14.s1.e0'}, 'e2': {'word': 'histamine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d14.s1.e1'}, 'sentence_id': 'DDI-MedLine.d14.s1'}	It was established that both angiotensins inhibited gastric acid secretion stimulated by DRUG but not by DRUGOTHER .
Comparative analysis of the effects of stimulation and inhibition of cholino- and adrenoreceptors on this inhibitory action of angiotensins suggested the mediation of angiotensin influence through the modulation of cholinergic reactions of parietal cells in the stomach.	angiotensins	angiotensin	none	{'e1': {'word': 'angiotensins', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d14.s2.e0'}, 'e2': {'word': 'angiotensin', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d14.s2.e1'}, 'sentence_id': 'DDI-MedLine.d14.s2'}	Comparative analysis of the effects of stimulation and inhibition of cholino - and adrenoreceptors on this inhibitory action of DRUG suggested the mediation of DRUGOTHER influence through the modulation of cholinergic reactions of parietal cells in the stomach .
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	ginsenosides	selective Ca(2+) channel blockers	none	{'e1': {'word': 'ginsenosides', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d58.s3.e0'}, 'e2': {'word': 'selective Ca(2+) channel blockers', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d58.s3.e1'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	In this study we investigated the effect of DRUG on high threshold voltage - dependent Ca ( 2 + ) channel subtypes using their DRUGOTHER DRUGUNRELATED ( L - type ) , DRUGUNRELATED ( N - type ) , or DRUGUNRELATED ( P - type ) in bovine chromaffin cells .
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	ginsenosides	nimodipine	none	{'e1': {'word': 'ginsenosides', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d58.s3.e0'}, 'e2': {'word': 'nimodipine', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d58.s3.e2'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	In this study we investigated the effect of DRUG on high threshold voltage - dependent Ca ( 2 + ) channel subtypes using their DRUGUNRELATED DRUGOTHER ( L - type ) , DRUGUNRELATED ( N - type ) , or DRUGUNRELATED ( P - type ) in bovine chromaffin cells .
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	ginsenosides	omega-conotoxin GVIA	none	{'e1': {'word': 'ginsenosides', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d58.s3.e0'}, 'e2': {'word': 'omega-conotoxin GVIA', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d58.s3.e3'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	In this study we investigated the effect of DRUG on high threshold voltage - dependent Ca ( 2 + ) channel subtypes using their DRUGUNRELATED DRUGUNRELATED ( L - type ) , DRUGOTHER ( N - type ) , or DRUGUNRELATED ( P - type ) in bovine chromaffin cells .
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	ginsenosides	omega-agatoxin IVA	none	{'e1': {'word': 'ginsenosides', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d58.s3.e0'}, 'e2': {'word': 'omega-agatoxin IVA', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d58.s3.e4'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	In this study we investigated the effect of DRUG on high threshold voltage - dependent Ca ( 2 + ) channel subtypes using their DRUGUNRELATED DRUGUNRELATED ( L - type ) , DRUGUNRELATED ( N - type ) , or DRUGOTHER ( P - type ) in bovine chromaffin cells .
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	selective Ca(2+) channel blockers	nimodipine	none	{'e1': {'word': 'selective Ca(2+) channel blockers', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d58.s3.e1'}, 'e2': {'word': 'nimodipine', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d58.s3.e2'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	In this study we investigated the effect of DRUGUNRELATED on high threshold voltage - dependent Ca ( 2 + ) channel subtypes using their DRUG DRUGOTHER ( L - type ) , DRUGUNRELATED ( N - type ) , or DRUGUNRELATED ( P - type ) in bovine chromaffin cells .
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	selective Ca(2+) channel blockers	omega-conotoxin GVIA	none	{'e1': {'word': 'selective Ca(2+) channel blockers', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d58.s3.e1'}, 'e2': {'word': 'omega-conotoxin GVIA', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d58.s3.e3'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	In this study we investigated the effect of DRUGUNRELATED on high threshold voltage - dependent Ca ( 2 + ) channel subtypes using their DRUG DRUGUNRELATED ( L - type ) , DRUGOTHER ( N - type ) , or DRUGUNRELATED ( P - type ) in bovine chromaffin cells .
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	selective Ca(2+) channel blockers	omega-agatoxin IVA	none	{'e1': {'word': 'selective Ca(2+) channel blockers', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d58.s3.e1'}, 'e2': {'word': 'omega-agatoxin IVA', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d58.s3.e4'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	In this study we investigated the effect of DRUGUNRELATED on high threshold voltage - dependent Ca ( 2 + ) channel subtypes using their DRUG DRUGUNRELATED ( L - type ) , DRUGUNRELATED ( N - type ) , or DRUGOTHER ( P - type ) in bovine chromaffin cells .
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	nimodipine	omega-conotoxin GVIA	none	{'e1': {'word': 'nimodipine', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d58.s3.e2'}, 'e2': {'word': 'omega-conotoxin GVIA', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d58.s3.e3'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	In this study we investigated the effect of DRUGUNRELATED on high threshold voltage - dependent Ca ( 2 + ) channel subtypes using their DRUGUNRELATED DRUG ( L - type ) , DRUGOTHER ( N - type ) , or DRUGUNRELATED ( P - type ) in bovine chromaffin cells .
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	nimodipine	omega-agatoxin IVA	none	{'e1': {'word': 'nimodipine', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d58.s3.e2'}, 'e2': {'word': 'omega-agatoxin IVA', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d58.s3.e4'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	In this study we investigated the effect of DRUGUNRELATED on high threshold voltage - dependent Ca ( 2 + ) channel subtypes using their DRUGUNRELATED DRUG ( L - type ) , DRUGUNRELATED ( N - type ) , or DRUGOTHER ( P - type ) in bovine chromaffin cells .
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	omega-conotoxin GVIA	omega-agatoxin IVA	none	{'e1': {'word': 'omega-conotoxin GVIA', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d58.s3.e3'}, 'e2': {'word': 'omega-agatoxin IVA', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d58.s3.e4'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	In this study we investigated the effect of DRUGUNRELATED on high threshold voltage - dependent Ca ( 2 + ) channel subtypes using their DRUGUNRELATED DRUGUNRELATED ( L - type ) , DRUG ( N - type ) , or DRUGOTHER ( P - type ) in bovine chromaffin cells .
Nimodipine had no effect on ginsenosides response. 	Nimodipine	ginsenosides	none	{'e1': {'word': 'Nimodipine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d58.s6.e0'}, 'e2': {'word': 'ginsenosides', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d58.s6.e1'}, 'sentence_id': 'DDI-MedLine.d58.s6'}	DRUG had no effect on DRUGOTHER response .
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	ginsenosides	omega-conotoxin GVIA	none	{'e1': {'word': 'ginsenosides', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d58.s7.e0'}, 'e2': {'word': 'omega-conotoxin GVIA', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d58.s7.e1'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that DRUG are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an DRUGOTHER - sensitive ( N - type ) channel , an DRUGUNRELATED - sensitive ( P - type ) channel and DRUGUNRELATED / DRUGUNRELATED / DRUGUNRELATED - resistant ( presumptive Q - type ) channel .
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	ginsenosides	omega-agatoxin IVA	none	{'e1': {'word': 'ginsenosides', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d58.s7.e0'}, 'e2': {'word': 'omega-agatoxin IVA', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d58.s7.e2'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that DRUG are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an DRUGUNRELATED - sensitive ( N - type ) channel , an DRUGOTHER - sensitive ( P - type ) channel and DRUGUNRELATED / DRUGUNRELATED / DRUGUNRELATED - resistant ( presumptive Q - type ) channel .
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	ginsenosides	nimodipine	none	{'e1': {'word': 'ginsenosides', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d58.s7.e0'}, 'e2': {'word': 'nimodipine', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d58.s7.e3'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that DRUG are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an DRUGUNRELATED - sensitive ( N - type ) channel , an DRUGUNRELATED - sensitive ( P - type ) channel and DRUGOTHER / DRUGUNRELATED / DRUGUNRELATED - resistant ( presumptive Q - type ) channel .
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	ginsenosides	omega-conotoxin GVIA	none	{'e1': {'word': 'ginsenosides', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d58.s7.e0'}, 'e2': {'word': 'omega-conotoxin GVIA', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d58.s7.e4'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that DRUG are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an DRUGUNRELATED - sensitive ( N - type ) channel , an DRUGUNRELATED - sensitive ( P - type ) channel and DRUGUNRELATED / DRUGOTHER / DRUGUNRELATED - resistant ( presumptive Q - type ) channel .
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	ginsenosides	omega-agatoxin VIA	none	{'e1': {'word': 'ginsenosides', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d58.s7.e0'}, 'e2': {'word': 'omega-agatoxin VIA', 'word_index': [(46, 46)], 'id': 'DDI-MedLine.d58.s7.e5'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that DRUG are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an DRUGUNRELATED - sensitive ( N - type ) channel , an DRUGUNRELATED - sensitive ( P - type ) channel and DRUGUNRELATED / DRUGUNRELATED / DRUGOTHER - resistant ( presumptive Q - type ) channel .
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	omega-conotoxin GVIA	omega-agatoxin IVA	none	{'e1': {'word': 'omega-conotoxin GVIA', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d58.s7.e1'}, 'e2': {'word': 'omega-agatoxin IVA', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d58.s7.e2'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that DRUGUNRELATED are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an DRUG - sensitive ( N - type ) channel , an DRUGOTHER - sensitive ( P - type ) channel and DRUGUNRELATED / DRUGUNRELATED / DRUGUNRELATED - resistant ( presumptive Q - type ) channel .
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	omega-conotoxin GVIA	nimodipine	none	{'e1': {'word': 'omega-conotoxin GVIA', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d58.s7.e1'}, 'e2': {'word': 'nimodipine', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d58.s7.e3'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that DRUGUNRELATED are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an DRUG - sensitive ( N - type ) channel , an DRUGUNRELATED - sensitive ( P - type ) channel and DRUGOTHER / DRUGUNRELATED / DRUGUNRELATED - resistant ( presumptive Q - type ) channel .
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	omega-conotoxin GVIA	omega-conotoxin GVIA	none	{'e1': {'word': 'omega-conotoxin GVIA', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d58.s7.e1'}, 'e2': {'word': 'omega-conotoxin GVIA', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d58.s7.e4'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that DRUGUNRELATED are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an DRUG - sensitive ( N - type ) channel , an DRUGUNRELATED - sensitive ( P - type ) channel and DRUGUNRELATED / DRUGOTHER / DRUGUNRELATED - resistant ( presumptive Q - type ) channel .
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	omega-conotoxin GVIA	omega-agatoxin VIA	none	{'e1': {'word': 'omega-conotoxin GVIA', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d58.s7.e1'}, 'e2': {'word': 'omega-agatoxin VIA', 'word_index': [(46, 46)], 'id': 'DDI-MedLine.d58.s7.e5'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that DRUGUNRELATED are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an DRUG - sensitive ( N - type ) channel , an DRUGUNRELATED - sensitive ( P - type ) channel and DRUGUNRELATED / DRUGUNRELATED / DRUGOTHER - resistant ( presumptive Q - type ) channel .
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	omega-agatoxin IVA	nimodipine	none	{'e1': {'word': 'omega-agatoxin IVA', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d58.s7.e2'}, 'e2': {'word': 'nimodipine', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d58.s7.e3'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that DRUGUNRELATED are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an DRUGUNRELATED - sensitive ( N - type ) channel , an DRUG - sensitive ( P - type ) channel and DRUGOTHER / DRUGUNRELATED / DRUGUNRELATED - resistant ( presumptive Q - type ) channel .
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	omega-agatoxin IVA	omega-conotoxin GVIA	none	{'e1': {'word': 'omega-agatoxin IVA', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d58.s7.e2'}, 'e2': {'word': 'omega-conotoxin GVIA', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d58.s7.e4'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that DRUGUNRELATED are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an DRUGUNRELATED - sensitive ( N - type ) channel , an DRUG - sensitive ( P - type ) channel and DRUGUNRELATED / DRUGOTHER / DRUGUNRELATED - resistant ( presumptive Q - type ) channel .
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	omega-agatoxin IVA	omega-agatoxin VIA	none	{'e1': {'word': 'omega-agatoxin IVA', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d58.s7.e2'}, 'e2': {'word': 'omega-agatoxin VIA', 'word_index': [(46, 46)], 'id': 'DDI-MedLine.d58.s7.e5'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that DRUGUNRELATED are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an DRUGUNRELATED - sensitive ( N - type ) channel , an DRUG - sensitive ( P - type ) channel and DRUGUNRELATED / DRUGUNRELATED / DRUGOTHER - resistant ( presumptive Q - type ) channel .
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	nimodipine	omega-conotoxin GVIA	none	{'e1': {'word': 'nimodipine', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d58.s7.e3'}, 'e2': {'word': 'omega-conotoxin GVIA', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d58.s7.e4'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that DRUGUNRELATED are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an DRUGUNRELATED - sensitive ( N - type ) channel , an DRUGUNRELATED - sensitive ( P - type ) channel and DRUG / DRUGOTHER / DRUGUNRELATED - resistant ( presumptive Q - type ) channel .
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	nimodipine	omega-agatoxin VIA	none	{'e1': {'word': 'nimodipine', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d58.s7.e3'}, 'e2': {'word': 'omega-agatoxin VIA', 'word_index': [(46, 46)], 'id': 'DDI-MedLine.d58.s7.e5'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that DRUGUNRELATED are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an DRUGUNRELATED - sensitive ( N - type ) channel , an DRUGUNRELATED - sensitive ( P - type ) channel and DRUG / DRUGUNRELATED / DRUGOTHER - resistant ( presumptive Q - type ) channel .
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	omega-conotoxin GVIA	omega-agatoxin VIA	none	{'e1': {'word': 'omega-conotoxin GVIA', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d58.s7.e4'}, 'e2': {'word': 'omega-agatoxin VIA', 'word_index': [(46, 46)], 'id': 'DDI-MedLine.d58.s7.e5'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that DRUGUNRELATED are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an DRUGUNRELATED - sensitive ( N - type ) channel , an DRUGUNRELATED - sensitive ( P - type ) channel and DRUGUNRELATED / DRUG / DRUGOTHER - resistant ( presumptive Q - type ) channel .
Thus, the selective regulation of voltage-dependent Ca(2+) subtypes by ginsenosides in bovine chromaffin cell could be the cellular basis of antistress effects induced by ginseng.	ginsenosides	ginseng	none	{'e1': {'word': 'ginsenosides', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d58.s8.e0'}, 'e2': {'word': 'ginseng', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d58.s8.e1'}, 'sentence_id': 'DDI-MedLine.d58.s8'}	Thus , the selective regulation of voltage - dependent Ca ( 2 + ) subtypes by DRUG in bovine chromaffin cell could be the cellular basis of antistress effects induced by DRUGOTHER .
Acid-catalyzed ethanolysis of temazepam in anhydrous and aqueous ethanol solutions.	temazepam	ethanol	mechanism	{'e1': {'word': 'temazepam', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d113.s0.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d113.s0.e1'}, 'sentence_id': 'DDI-MedLine.d113.s0'}	Acid - catalyzed ethanolysis of DRUG in anhydrous and aqueous DRUGOTHER solutions .
The benzodiazepines are a family of anxiolytic and hypnotic drugs. 	benzodiazepines	anxiolytic	none	{'e1': {'word': 'benzodiazepines', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d113.s1.e0'}, 'e2': {'word': 'anxiolytic', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d113.s1.e1'}, 'sentence_id': 'DDI-MedLine.d113.s1'}	The DRUG are a family of DRUGOTHER and DRUGUNRELATED .
The benzodiazepines are a family of anxiolytic and hypnotic drugs. 	benzodiazepines	hypnotic drugs	none	{'e1': {'word': 'benzodiazepines', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d113.s1.e0'}, 'e2': {'word': 'hypnotic drugs', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d113.s1.e2'}, 'sentence_id': 'DDI-MedLine.d113.s1'}	The DRUG are a family of DRUGUNRELATED and DRUGOTHER .
The benzodiazepines are a family of anxiolytic and hypnotic drugs. 	anxiolytic	hypnotic drugs	none	{'e1': {'word': 'anxiolytic', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d113.s1.e1'}, 'e2': {'word': 'hypnotic drugs', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d113.s1.e2'}, 'sentence_id': 'DDI-MedLine.d113.s1'}	The DRUGUNRELATED are a family of DRUG and DRUGOTHER .
In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a benzodiazepine) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product. 	temazepam	benzodiazepine	none	{'e1': {'word': 'temazepam', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d113.s3.e0'}, 'e2': {'word': 'benzodiazepine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d113.s3.e1'}, 'sentence_id': 'DDI-MedLine.d113.s3'}	In addition to this pharmacological interaction , this report describes a novel chemical reaction between DRUG ( a DRUGOTHER ) and DRUGUNRELATED under acidic conditions similar to those found in vivo , resulting in a 3 - ethoxylated product .
In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a benzodiazepine) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product. 	temazepam	ethanol	mechanism	{'e1': {'word': 'temazepam', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d113.s3.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d113.s3.e2'}, 'sentence_id': 'DDI-MedLine.d113.s3'}	In addition to this pharmacological interaction , this report describes a novel chemical reaction between DRUG ( a DRUGUNRELATED ) and DRUGOTHER under acidic conditions similar to those found in vivo , resulting in a 3 - ethoxylated product .
In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a benzodiazepine) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product. 	benzodiazepine	ethanol	none	{'e1': {'word': 'benzodiazepine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d113.s3.e1'}, 'e2': {'word': 'ethanol', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d113.s3.e2'}, 'sentence_id': 'DDI-MedLine.d113.s3'}	In addition to this pharmacological interaction , this report describes a novel chemical reaction between DRUGUNRELATED ( a DRUG ) and DRUGOTHER under acidic conditions similar to those found in vivo , resulting in a 3 - ethoxylated product .
The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume alcohol and 3-hydroxy-1,4-benzodiazepine on a regular basis. 	alcohol	3-hydroxy-1,4-benzodiazepine	mechanism	{'e1': {'word': 'alcohol', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d113.s5.e0'}, 'e2': {'word': '3-hydroxy-1,4-benzodiazepine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d113.s5.e1'}, 'sentence_id': 'DDI-MedLine.d113.s5'}	The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume DRUG and DRUGOTHER on a regular basis .
[The effect of sandimmune on the activity of mixed-function mono-oxidases in the liver microsomes] The effects of the immunodepressant--the drug sandimmune--on hepatic microsomal monooxygenase activities were studied. 	sandimmune	immunodepressant	none	{'e1': {'word': 'sandimmune', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d4.s0.e0'}, 'e2': {'word': 'immunodepressant', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d4.s0.e1'}, 'sentence_id': 'DDI-MedLine.d4.s0'}	[ The effect of DRUG on the activity of mixed - function mono-oxidases in the liver microsomes ] The effects of the DRUGOTHER - - the drug DRUGUNRELATED - - on hepatic microsomal monooxygenase activities were studied .
[The effect of sandimmune on the activity of mixed-function mono-oxidases in the liver microsomes] The effects of the immunodepressant--the drug sandimmune--on hepatic microsomal monooxygenase activities were studied. 	sandimmune	sandimmune	none	{'e1': {'word': 'sandimmune', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d4.s0.e0'}, 'e2': {'word': 'sandimmune', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d4.s0.e2'}, 'sentence_id': 'DDI-MedLine.d4.s0'}	[ The effect of DRUG on the activity of mixed - function mono-oxidases in the liver microsomes ] The effects of the DRUGUNRELATED - - the drug DRUGOTHER - - on hepatic microsomal monooxygenase activities were studied .
[The effect of sandimmune on the activity of mixed-function mono-oxidases in the liver microsomes] The effects of the immunodepressant--the drug sandimmune--on hepatic microsomal monooxygenase activities were studied. 	immunodepressant	sandimmune	none	{'e1': {'word': 'immunodepressant', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d4.s0.e1'}, 'e2': {'word': 'sandimmune', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d4.s0.e2'}, 'sentence_id': 'DDI-MedLine.d4.s0'}	[ The effect of DRUGUNRELATED on the activity of mixed - function mono-oxidases in the liver microsomes ] The effects of the DRUG - - the drug DRUGOTHER - - on hepatic microsomal monooxygenase activities were studied .
"In vitro interaction of prostaglandin F2alpha and oxytocin in placental vessels.
"	prostaglandin F2alpha	oxytocin	int	{'e1': {'word': 'prostaglandin F2alpha', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d17.s0.e0'}, 'e2': {'word': 'oxytocin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d17.s0.e1'}, 'sentence_id': 'DDI-MedLine.d17.s0'}	In vitro interaction of DRUG and DRUGOTHER in placental vessels .
The interaction of prostaglandin F2alpha and synthetic oxytocin on placental vessels was studied in vitro. 	prostaglandin F2alpha	oxytocin	none	{'e1': {'word': 'prostaglandin F2alpha', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d17.s1.e0'}, 'e2': {'word': 'oxytocin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d17.s1.e1'}, 'sentence_id': 'DDI-MedLine.d17.s1'}	The interaction of DRUG and synthetic DRUGOTHER on placental vessels was studied in vitro .
In seven experiments reactions to norepinephrine and oxytocin were PGF2alpha. 	norepinephrine	oxytocin	none	{'e1': {'word': 'norepinephrine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d17.s3.e0'}, 'e2': {'word': 'oxytocin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d17.s3.e1'}, 'sentence_id': 'DDI-MedLine.d17.s3'}	In seven experiments reactions to DRUG and DRUGOTHER were DRUGUNRELATED .
In seven experiments reactions to norepinephrine and oxytocin were PGF2alpha. 	norepinephrine	PGF2alpha	none	{'e1': {'word': 'norepinephrine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d17.s3.e0'}, 'e2': {'word': 'PGF2alpha', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d17.s3.e2'}, 'sentence_id': 'DDI-MedLine.d17.s3'}	In seven experiments reactions to DRUG and DRUGUNRELATED were DRUGOTHER .
In seven experiments reactions to norepinephrine and oxytocin were PGF2alpha. 	oxytocin	PGF2alpha	none	{'e1': {'word': 'oxytocin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d17.s3.e1'}, 'e2': {'word': 'PGF2alpha', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d17.s3.e2'}, 'sentence_id': 'DDI-MedLine.d17.s3'}	In seven experiments reactions to DRUGUNRELATED and DRUG were DRUGOTHER .
PGF2alpha produced significantly increased vasoconstriction after a single administration of oxytocin. 	PGF2alpha	oxytocin	effect	{'e1': {'word': 'PGF2alpha', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d17.s4.e0'}, 'e2': {'word': 'oxytocin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d17.s4.e1'}, 'sentence_id': 'DDI-MedLine.d17.s4'}	DRUG produced significantly increased vasoconstriction after a single administration of DRUGOTHER .
There is thus an enhancement effect of PGF2alpha upon the reaction of placental vessels to oxytocin in vitro.	PGF2alpha	oxytocin	effect	{'e1': {'word': 'PGF2alpha', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d17.s9.e0'}, 'e2': {'word': 'oxytocin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d17.s9.e1'}, 'sentence_id': 'DDI-MedLine.d17.s9'}	There is thus an enhancement effect of DRUG upon the reaction of placental vessels to DRUGOTHER in vitro .
"Interaction of ketamine and halothane in rats.
"	ketamine	halothane	int	{'e1': {'word': 'ketamine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d16.s0.e0'}, 'e2': {'word': 'halothane', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d16.s0.e1'}, 'sentence_id': 'DDI-MedLine.d16.s0'}	Interaction of DRUG and DRUGOTHER in rats .
The interaction of intramuscularly injected ketamine and its N-demethylated metabolite (metabolite I) with halothane was evaluated in rats. 	ketamine	halothane	none	{'e1': {'word': 'ketamine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d16.s1.e0'}, 'e2': {'word': 'halothane', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d16.s1.e1'}, 'sentence_id': 'DDI-MedLine.d16.s1'}	The interaction of intramuscularly injected DRUG and its N - demethylated metabolite ( metabolite I ) with DRUGOTHER was evaluated in rats .
However, halothane anesthetic requirement (i.e., MAC) was depressed in a dose-dependent fashion as much as 56% 1-2 hours and as much as 14% 5-6 hours after injection of ketamine, 50 mg/kg, im. 	halothane	ketamine	mechanism	{'e1': {'word': 'halothane', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d16.s3.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d16.s3.e1'}, 'sentence_id': 'DDI-MedLine.d16.s3'}	However , DRUG anesthetic requirement ( i.e. , MAC ) was depressed in a dose - dependent fashion as much as 56 % 1 - 2 hours and as much as 14 % 5 - 6 hours after injection of DRUGOTHER , 50 mg / kg , im .
The reduction in MAC was correlated with brain levels of ketamine or metabolite I, suggesting a ketamine:metabolite I potency ration of 3:1. 	ketamine	ketamine	none	{'e1': {'word': 'ketamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d16.s4.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d16.s4.e1'}, 'sentence_id': 'DDI-MedLine.d16.s4'}	The reduction in MAC was correlated with brain levels of DRUG or metabolite I , suggesting a DRUGOTHER : metabolite I potency ration of 3 : 1 .
The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone. 	ketamine	halothane	mechanism	{'e1': {'word': 'ketamine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d16.s5.e0'}, 'e2': {'word': 'halothane', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d16.s5.e1'}, 'sentence_id': 'DDI-MedLine.d16.s5'}	The half - life of DRUG in plasma and brain was longer in the presence of DRUGOTHER than when DRUGUNRELATED was given alone .
The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone. 	ketamine	ketamine	none	{'e1': {'word': 'ketamine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d16.s5.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d16.s5.e2'}, 'sentence_id': 'DDI-MedLine.d16.s5'}	The half - life of DRUG in plasma and brain was longer in the presence of DRUGUNRELATED than when DRUGOTHER was given alone .
The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone. 	halothane	ketamine	none	{'e1': {'word': 'halothane', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d16.s5.e1'}, 'e2': {'word': 'ketamine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d16.s5.e2'}, 'sentence_id': 'DDI-MedLine.d16.s5'}	The half - life of DRUGUNRELATED in plasma and brain was longer in the presence of DRUG than when DRUGOTHER was given alone .
It is concluded that ketamine is not a short-acting drug and that concomitant use with halothane would be expected to prolong further the duration of its action on the central nervous system.	ketamine	halothane	effect	{'e1': {'word': 'ketamine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d16.s6.e0'}, 'e2': {'word': 'halothane', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d16.s6.e1'}, 'sentence_id': 'DDI-MedLine.d16.s6'}	It is concluded that DRUG is not a short - acting drug and that concomitant use with DRUGOTHER would be expected to prolong further the duration of its action on the central nervous system .
The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. 	N-allylnormetazocine	NANM	none	{'e1': {'word': 'N-allylnormetazocine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d30.s1.e0'}, 'e2': {'word': 'NANM', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d30.s1.e1'}, 'sentence_id': 'DDI-MedLine.d30.s1'}	The behavioral effects of the stereoisomers of DRUG ( DRUGOTHER ) were compared with those of DRUGUNRELATED ( DRUGUNRELATED ) in pigeons and squirrel monkeys responding under a multiple fixed - interval fixed - ratio ( FI FR ) schedule of food presentation .
The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. 	N-allylnormetazocine	phencyclidine	none	{'e1': {'word': 'N-allylnormetazocine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d30.s1.e0'}, 'e2': {'word': 'phencyclidine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d30.s1.e2'}, 'sentence_id': 'DDI-MedLine.d30.s1'}	The behavioral effects of the stereoisomers of DRUG ( DRUGUNRELATED ) were compared with those of DRUGOTHER ( DRUGUNRELATED ) in pigeons and squirrel monkeys responding under a multiple fixed - interval fixed - ratio ( FI FR ) schedule of food presentation .
The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. 	N-allylnormetazocine	PCP	none	{'e1': {'word': 'N-allylnormetazocine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d30.s1.e0'}, 'e2': {'word': 'PCP', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d30.s1.e3'}, 'sentence_id': 'DDI-MedLine.d30.s1'}	The behavioral effects of the stereoisomers of DRUG ( DRUGUNRELATED ) were compared with those of DRUGUNRELATED ( DRUGOTHER ) in pigeons and squirrel monkeys responding under a multiple fixed - interval fixed - ratio ( FI FR ) schedule of food presentation .
The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. 	NANM	phencyclidine	none	{'e1': {'word': 'NANM', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d30.s1.e1'}, 'e2': {'word': 'phencyclidine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d30.s1.e2'}, 'sentence_id': 'DDI-MedLine.d30.s1'}	The behavioral effects of the stereoisomers of DRUGUNRELATED ( DRUG ) were compared with those of DRUGOTHER ( DRUGUNRELATED ) in pigeons and squirrel monkeys responding under a multiple fixed - interval fixed - ratio ( FI FR ) schedule of food presentation .
The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. 	NANM	PCP	none	{'e1': {'word': 'NANM', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d30.s1.e1'}, 'e2': {'word': 'PCP', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d30.s1.e3'}, 'sentence_id': 'DDI-MedLine.d30.s1'}	The behavioral effects of the stereoisomers of DRUGUNRELATED ( DRUG ) were compared with those of DRUGUNRELATED ( DRUGOTHER ) in pigeons and squirrel monkeys responding under a multiple fixed - interval fixed - ratio ( FI FR ) schedule of food presentation .
The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. 	phencyclidine	PCP	none	{'e1': {'word': 'phencyclidine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d30.s1.e2'}, 'e2': {'word': 'PCP', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d30.s1.e3'}, 'sentence_id': 'DDI-MedLine.d30.s1'}	The behavioral effects of the stereoisomers of DRUGUNRELATED ( DRUGUNRELATED ) were compared with those of DRUG ( DRUGOTHER ) in pigeons and squirrel monkeys responding under a multiple fixed - interval fixed - ratio ( FI FR ) schedule of food presentation .
Intermediate doses of (+)-NANM or PCP produced transient increases in FI responding in monkeys and sustained increases in FI responding in pigeons; 	(+)-NANM	PCP	none	{'e1': {'word': '(+)-NANM', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d30.s2.e0'}, 'e2': {'word': 'PCP', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d30.s2.e1'}, 'sentence_id': 'DDI-MedLine.d30.s2'}	Intermediate doses of DRUG or DRUGOTHER produced transient increases in FI responding in monkeys and sustained increases in FI responding in pigeons ;
In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM. 	(-)-NANM	(+)-NANM	none	{'e1': {'word': '(-)-NANM', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d30.s6.e0'}, 'e2': {'word': '(+)-NANM', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d30.s6.e1'}, 'sentence_id': 'DDI-MedLine.d30.s6'}	In monkeys , DRUG was about 10 times more potent than DRUGOTHER in decreasing responding , whereas in pigeons DRUGUNRELATED was about equipotent with DRUGUNRELATED .
In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM. 	(-)-NANM	(-)-NANM	none	{'e1': {'word': '(-)-NANM', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d30.s6.e0'}, 'e2': {'word': '(-)-NANM', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d30.s6.e2'}, 'sentence_id': 'DDI-MedLine.d30.s6'}	In monkeys , DRUG was about 10 times more potent than DRUGUNRELATED in decreasing responding , whereas in pigeons DRUGOTHER was about equipotent with DRUGUNRELATED .
In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM. 	(-)-NANM	(+)-NANM	none	{'e1': {'word': '(-)-NANM', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d30.s6.e0'}, 'e2': {'word': '(+)-NANM', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d30.s6.e3'}, 'sentence_id': 'DDI-MedLine.d30.s6'}	In monkeys , DRUG was about 10 times more potent than DRUGUNRELATED in decreasing responding , whereas in pigeons DRUGUNRELATED was about equipotent with DRUGOTHER .
In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM. 	(+)-NANM	(-)-NANM	none	{'e1': {'word': '(+)-NANM', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d30.s6.e1'}, 'e2': {'word': '(-)-NANM', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d30.s6.e2'}, 'sentence_id': 'DDI-MedLine.d30.s6'}	In monkeys , DRUGUNRELATED was about 10 times more potent than DRUG in decreasing responding , whereas in pigeons DRUGOTHER was about equipotent with DRUGUNRELATED .
In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM. 	(+)-NANM	(+)-NANM	none	{'e1': {'word': '(+)-NANM', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d30.s6.e1'}, 'e2': {'word': '(+)-NANM', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d30.s6.e3'}, 'sentence_id': 'DDI-MedLine.d30.s6'}	In monkeys , DRUGUNRELATED was about 10 times more potent than DRUG in decreasing responding , whereas in pigeons DRUGUNRELATED was about equipotent with DRUGOTHER .
In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM. 	(-)-NANM	(+)-NANM	none	{'e1': {'word': '(-)-NANM', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d30.s6.e2'}, 'e2': {'word': '(+)-NANM', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d30.s6.e3'}, 'sentence_id': 'DDI-MedLine.d30.s6'}	In monkeys , DRUGUNRELATED was about 10 times more potent than DRUGUNRELATED in decreasing responding , whereas in pigeons DRUG was about equipotent with DRUGOTHER .
In both species, (-)-NANM, but not (+)-NANM, antagonized the rate-decreasing effects of morphine on FI and FR responding. 	(-)-NANM	(+)-NANM	none	{'e1': {'word': '(-)-NANM', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d30.s7.e0'}, 'e2': {'word': '(+)-NANM', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d30.s7.e1'}, 'sentence_id': 'DDI-MedLine.d30.s7'}	In both species , DRUG , but not DRUGOTHER , antagonized the rate - decreasing effects of DRUGUNRELATED on FI and FR responding .
In both species, (-)-NANM, but not (+)-NANM, antagonized the rate-decreasing effects of morphine on FI and FR responding. 	(-)-NANM	morphine	effect	{'e1': {'word': '(-)-NANM', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d30.s7.e0'}, 'e2': {'word': 'morphine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d30.s7.e2'}, 'sentence_id': 'DDI-MedLine.d30.s7'}	In both species , DRUG , but not DRUGUNRELATED , antagonized the rate - decreasing effects of DRUGOTHER on FI and FR responding .
In both species, (-)-NANM, but not (+)-NANM, antagonized the rate-decreasing effects of morphine on FI and FR responding. 	(+)-NANM	morphine	none	{'e1': {'word': '(+)-NANM', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d30.s7.e1'}, 'e2': {'word': 'morphine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d30.s7.e2'}, 'sentence_id': 'DDI-MedLine.d30.s7'}	In both species , DRUGUNRELATED , but not DRUG , antagonized the rate - decreasing effects of DRUGOTHER on FI and FR responding .
In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; 	(-)-NANM	(+)-NANM	none	{'e1': {'word': '(-)-NANM', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d30.s8.e0'}, 'e2': {'word': '(+)-NANM', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d30.s8.e1'}, 'sentence_id': 'DDI-MedLine.d30.s8'}	In monkeys , the effects of DRUG , but not DRUGOTHER or DRUGUNRELATED , were antagonized by DRUGUNRELATED ;
In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; 	(-)-NANM	PCP	none	{'e1': {'word': '(-)-NANM', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d30.s8.e0'}, 'e2': {'word': 'PCP', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d30.s8.e2'}, 'sentence_id': 'DDI-MedLine.d30.s8'}	In monkeys , the effects of DRUG , but not DRUGUNRELATED or DRUGOTHER , were antagonized by DRUGUNRELATED ;
In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; 	(-)-NANM	naloxone	effect	{'e1': {'word': '(-)-NANM', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d30.s8.e0'}, 'e2': {'word': 'naloxone', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d30.s8.e3'}, 'sentence_id': 'DDI-MedLine.d30.s8'}	In monkeys , the effects of DRUG , but not DRUGUNRELATED or DRUGUNRELATED , were antagonized by DRUGOTHER ;
In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; 	(+)-NANM	PCP	none	{'e1': {'word': '(+)-NANM', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d30.s8.e1'}, 'e2': {'word': 'PCP', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d30.s8.e2'}, 'sentence_id': 'DDI-MedLine.d30.s8'}	In monkeys , the effects of DRUGUNRELATED , but not DRUG or DRUGOTHER , were antagonized by DRUGUNRELATED ;
In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; 	(+)-NANM	naloxone	none	{'e1': {'word': '(+)-NANM', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d30.s8.e1'}, 'e2': {'word': 'naloxone', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d30.s8.e3'}, 'sentence_id': 'DDI-MedLine.d30.s8'}	In monkeys , the effects of DRUGUNRELATED , but not DRUG or DRUGUNRELATED , were antagonized by DRUGOTHER ;
In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; 	PCP	naloxone	none	{'e1': {'word': 'PCP', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d30.s8.e2'}, 'e2': {'word': 'naloxone', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d30.s8.e3'}, 'sentence_id': 'DDI-MedLine.d30.s8'}	In monkeys , the effects of DRUGUNRELATED , but not DRUGUNRELATED or DRUG , were antagonized by DRUGOTHER ;
the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine. 	naloxone	(-)-NANM	effect	{'e1': {'word': 'naloxone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d30.s9.e0'}, 'e2': {'word': '(-)-NANM', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d30.s9.e1'}, 'sentence_id': 'DDI-MedLine.d30.s9'}	the doses of DRUG required to antagonize the effects of DRUGOTHER were more than 100 times higher than those required to antagonize the effects of DRUGUNRELATED .
the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine. 	naloxone	morphine	effect	{'e1': {'word': 'naloxone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d30.s9.e0'}, 'e2': {'word': 'morphine', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d30.s9.e2'}, 'sentence_id': 'DDI-MedLine.d30.s9'}	the doses of DRUG required to antagonize the effects of DRUGUNRELATED were more than 100 times higher than those required to antagonize the effects of DRUGOTHER .
the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine. 	(-)-NANM	morphine	none	{'e1': {'word': '(-)-NANM', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d30.s9.e1'}, 'e2': {'word': 'morphine', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d30.s9.e2'}, 'sentence_id': 'DDI-MedLine.d30.s9'}	the doses of DRUGUNRELATED required to antagonize the effects of DRUG were more than 100 times higher than those required to antagonize the effects of DRUGOTHER .
In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP. 	naloxone	(-)-NANM	none	{'e1': {'word': 'naloxone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d30.s10.e0'}, 'e2': {'word': '(-)-NANM', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d30.s10.e1'}, 'sentence_id': 'DDI-MedLine.d30.s10'}	In pigeons , DRUG did not systematically alter the effects of DRUGOTHER , DRUGUNRELATED or DRUGUNRELATED .
In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP. 	naloxone	(+)-NANM	none	{'e1': {'word': 'naloxone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d30.s10.e0'}, 'e2': {'word': '(+)-NANM', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d30.s10.e2'}, 'sentence_id': 'DDI-MedLine.d30.s10'}	In pigeons , DRUG did not systematically alter the effects of DRUGUNRELATED , DRUGOTHER or DRUGUNRELATED .
In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP. 	naloxone	PCP	none	{'e1': {'word': 'naloxone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d30.s10.e0'}, 'e2': {'word': 'PCP', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d30.s10.e3'}, 'sentence_id': 'DDI-MedLine.d30.s10'}	In pigeons , DRUG did not systematically alter the effects of DRUGUNRELATED , DRUGUNRELATED or DRUGOTHER .
In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP. 	(-)-NANM	(+)-NANM	none	{'e1': {'word': '(-)-NANM', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d30.s10.e1'}, 'e2': {'word': '(+)-NANM', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d30.s10.e2'}, 'sentence_id': 'DDI-MedLine.d30.s10'}	In pigeons , DRUGUNRELATED did not systematically alter the effects of DRUG , DRUGOTHER or DRUGUNRELATED .
In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP. 	(-)-NANM	PCP	none	{'e1': {'word': '(-)-NANM', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d30.s10.e1'}, 'e2': {'word': 'PCP', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d30.s10.e3'}, 'sentence_id': 'DDI-MedLine.d30.s10'}	In pigeons , DRUGUNRELATED did not systematically alter the effects of DRUG , DRUGUNRELATED or DRUGOTHER .
In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP. 	(+)-NANM	PCP	none	{'e1': {'word': '(+)-NANM', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d30.s10.e2'}, 'e2': {'word': 'PCP', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d30.s10.e3'}, 'sentence_id': 'DDI-MedLine.d30.s10'}	In pigeons , DRUGUNRELATED did not systematically alter the effects of DRUGUNRELATED , DRUG or DRUGOTHER .
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. 	Haloperidol	(+)-NANM	effect	{'e1': {'word': 'Haloperidol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d30.s11.e0'}, 'e2': {'word': '(+)-NANM', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d30.s11.e1'}, 'sentence_id': 'DDI-MedLine.d30.s11'}	DRUG reduced or eliminated the increases in FI responding produced by intermediate doses of either DRUGOTHER or DRUGUNRELATED in pigeons , but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of DRUGUNRELATED .
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. 	Haloperidol	PCP	effect	{'e1': {'word': 'Haloperidol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d30.s11.e0'}, 'e2': {'word': 'PCP', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d30.s11.e2'}, 'sentence_id': 'DDI-MedLine.d30.s11'}	DRUG reduced or eliminated the increases in FI responding produced by intermediate doses of either DRUGUNRELATED or DRUGOTHER in pigeons , but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of DRUGUNRELATED .
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. 	Haloperidol	NANM	none	{'e1': {'word': 'Haloperidol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d30.s11.e0'}, 'e2': {'word': 'NANM', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d30.s11.e3'}, 'sentence_id': 'DDI-MedLine.d30.s11'}	DRUG reduced or eliminated the increases in FI responding produced by intermediate doses of either DRUGUNRELATED or DRUGUNRELATED in pigeons , but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of DRUGOTHER .
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. 	(+)-NANM	PCP	none	{'e1': {'word': '(+)-NANM', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d30.s11.e1'}, 'e2': {'word': 'PCP', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d30.s11.e2'}, 'sentence_id': 'DDI-MedLine.d30.s11'}	DRUGUNRELATED reduced or eliminated the increases in FI responding produced by intermediate doses of either DRUG or DRUGOTHER in pigeons , but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of DRUGUNRELATED .
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. 	(+)-NANM	NANM	none	{'e1': {'word': '(+)-NANM', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d30.s11.e1'}, 'e2': {'word': 'NANM', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d30.s11.e3'}, 'sentence_id': 'DDI-MedLine.d30.s11'}	DRUGUNRELATED reduced or eliminated the increases in FI responding produced by intermediate doses of either DRUG or DRUGUNRELATED in pigeons , but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of DRUGOTHER .
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. 	PCP	NANM	none	{'e1': {'word': 'PCP', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d30.s11.e2'}, 'e2': {'word': 'NANM', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d30.s11.e3'}, 'sentence_id': 'DDI-MedLine.d30.s11'}	DRUGUNRELATED reduced or eliminated the increases in FI responding produced by intermediate doses of either DRUGUNRELATED or DRUG in pigeons , but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of DRUGOTHER .
In this study, the effects of etofibrate upon chylomicron metabolism was tested by determination of the plasma kinetics of a chylomicron-like emulsion model in 12 patients with coronary artery disease, aged 59+/-11 years, (total cholesterol: 240+/-41 mg/dl; triglycerides: 188+/-42 mg/dl) submitted to a randomized, crossover, double-blind, placebo-controlled study with administration of 1 g per day etofibrate or placebo for 1-month. 	etofibrate	etofibrate	none	{'e1': {'word': 'etofibrate', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d44.s2.e0'}, 'e2': {'word': 'etofibrate', 'word_index': [(88, 88)], 'id': 'DDI-MedLine.d44.s2.e1'}, 'sentence_id': 'DDI-MedLine.d44.s2'}	In this study , the effects of DRUG upon chylomicron metabolism was tested by determination of the plasma kinetics of a chylomicron - like emulsion model in 12 patients with coronary artery disease , aged 59 + / - 11 years , ( total cholesterol : 240 + / - 41 mg / dl ; triglycerides : 188 + / - 42 mg / dl ) submitted to a randomized , crossover , double - blind , placebo - controlled study with administration of 1 g per day DRUGOTHER or placebo for 1 - month .
Etofibrate elicited 62% enhancement of post-heparin lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment. 	Etofibrate	heparin	effect	{'e1': {'word': 'Etofibrate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d44.s6.e0'}, 'e2': {'word': 'heparin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d44.s6.e1'}, 'sentence_id': 'DDI-MedLine.d44.s6'}	DRUG elicited 62 % enhancement of post - DRUGOTHER lipolytic activity and 100 % increase of 3H - triglyceride fractional clearance rate compared with placebo treatment .
"Carbamazepine overdose recognized by a tricyclic antidepressant assay.
"	Carbamazepine	tricyclic antidepressant	none	{'e1': {'word': 'Carbamazepine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d36.s0.e0'}, 'e2': {'word': 'tricyclic antidepressant', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d36.s0.e1'}, 'sentence_id': 'DDI-MedLine.d36.s0'}	DRUG overdose recognized by a DRUGOTHER assay .
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.	carbamazepine	tricyclic antidepressant	effect	{'e1': {'word': 'carbamazepine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d36.s2.e0'}, 'e2': {'word': 'tricyclic antidepressant', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d36.s2.e1'}, 'sentence_id': 'DDI-MedLine.d36.s2'}	We report the case of an adolescent with altered consciousness caused by DRUG overdose with a positive DRUGOTHER level to alert clinicians to the cross-reactivity of DRUGUNRELATED with a toxicology screen for DRUGUNRELATED .
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.	carbamazepine	carbamazepine	none	{'e1': {'word': 'carbamazepine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d36.s2.e0'}, 'e2': {'word': 'carbamazepine', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d36.s2.e2'}, 'sentence_id': 'DDI-MedLine.d36.s2'}	We report the case of an adolescent with altered consciousness caused by DRUG overdose with a positive DRUGUNRELATED level to alert clinicians to the cross-reactivity of DRUGOTHER with a toxicology screen for DRUGUNRELATED .
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.	carbamazepine	tricyclic antidepressants	none	{'e1': {'word': 'carbamazepine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d36.s2.e0'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d36.s2.e3'}, 'sentence_id': 'DDI-MedLine.d36.s2'}	We report the case of an adolescent with altered consciousness caused by DRUG overdose with a positive DRUGUNRELATED level to alert clinicians to the cross-reactivity of DRUGUNRELATED with a toxicology screen for DRUGOTHER .
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.	tricyclic antidepressant	carbamazepine	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d36.s2.e1'}, 'e2': {'word': 'carbamazepine', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d36.s2.e2'}, 'sentence_id': 'DDI-MedLine.d36.s2'}	We report the case of an adolescent with altered consciousness caused by DRUGUNRELATED overdose with a positive DRUG level to alert clinicians to the cross-reactivity of DRUGOTHER with a toxicology screen for DRUGUNRELATED .
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.	tricyclic antidepressant	tricyclic antidepressants	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d36.s2.e1'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d36.s2.e3'}, 'sentence_id': 'DDI-MedLine.d36.s2'}	We report the case of an adolescent with altered consciousness caused by DRUGUNRELATED overdose with a positive DRUG level to alert clinicians to the cross-reactivity of DRUGUNRELATED with a toxicology screen for DRUGOTHER .
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.	carbamazepine	tricyclic antidepressants	advise	{'e1': {'word': 'carbamazepine', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d36.s2.e2'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d36.s2.e3'}, 'sentence_id': 'DDI-MedLine.d36.s2'}	We report the case of an adolescent with altered consciousness caused by DRUGUNRELATED overdose with a positive DRUGUNRELATED level to alert clinicians to the cross-reactivity of DRUG with a toxicology screen for DRUGOTHER .
The 16,16-dimethylprostaglandin E2 (dmPGE2)-induced diarrhea was analyzed in cecectomized rats prepared by resecting the cecum and its vasculature without disturbing the ileocecal junction. 	16,16-dimethylprostaglandin E2	dmPGE2	none	{'e1': {'word': '16,16-dimethylprostaglandin E2', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d128.s1.e0'}, 'e2': {'word': 'dmPGE2', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d128.s1.e1'}, 'sentence_id': 'DDI-MedLine.d128.s1'}	The DRUG ( DRUGOTHER ) - induced diarrhea was analyzed in cecectomized rats prepared by resecting the cecum and its vasculature without disturbing the ileocecal junction .
On the other hand, the enhanced secretion of colonic fluid by dmPGE2, given intraluminally, was only half of that in control rats, whereas the colonic transit-enhancing effect of dmPGE2 in cecectomized rats was more pronounced than in control rats at 15 but not at 30 min after its administration. 	dmPGE2	dmPGE2	none	{'e1': {'word': 'dmPGE2', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d128.s10.e0'}, 'e2': {'word': 'dmPGE2', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d128.s10.e1'}, 'sentence_id': 'DDI-MedLine.d128.s10'}	On the other hand , the enhanced secretion of colonic fluid by DRUG , given intraluminally , was only half of that in control rats , whereas the colonic transit - enhancing effect of DRUGOTHER in cecectomized rats was more pronounced than in control rats at 15 but not at 30 min after its administration .
Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) 	Loperamide	morphine	none	{'e1': {'word': 'Loperamide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d128.s12.e0'}, 'e2': {'word': 'morphine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d128.s12.e1'}, 'sentence_id': 'DDI-MedLine.d128.s12'}	DRUG and DRUGOTHER ( 0.1 and 1.0 mg / kg , s.c. )
Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. 	Loperamide	morphine	none	{'e1': {'word': 'Loperamide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d128.s13.e0'}, 'e2': {'word': 'morphine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d128.s13.e1'}, 'sentence_id': 'DDI-MedLine.d128.s13'}	DRUG and DRUGOTHER ( 0.1 and 1.0 mg / kg , s.c. ) inhibited the DRUGUNRELATED ( 0.3 mg / kg , p.o. ) - induced diarrhea in cecectomized rats .
Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. 	Loperamide	dmPGE2	effect	{'e1': {'word': 'Loperamide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d128.s13.e0'}, 'e2': {'word': 'dmPGE2', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d128.s13.e2'}, 'sentence_id': 'DDI-MedLine.d128.s13'}	DRUG and DRUGUNRELATED ( 0.1 and 1.0 mg / kg , s.c. ) inhibited the DRUGOTHER ( 0.3 mg / kg , p.o. ) - induced diarrhea in cecectomized rats .
Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. 	morphine	dmPGE2	effect	{'e1': {'word': 'morphine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d128.s13.e1'}, 'e2': {'word': 'dmPGE2', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d128.s13.e2'}, 'sentence_id': 'DDI-MedLine.d128.s13'}	DRUGUNRELATED and DRUG ( 0.1 and 1.0 mg / kg , s.c. ) inhibited the DRUGOTHER ( 0.3 mg / kg , p.o. ) - induced diarrhea in cecectomized rats .
N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine. 	N-methyllevallorphan	loperamide	effect	{'e1': {'word': 'N-methyllevallorphan', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d128.s15.e0'}, 'e2': {'word': 'loperamide', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d128.s15.e1'}, 'sentence_id': 'DDI-MedLine.d128.s15'}	DRUG ( 5 mg / kg , s.c. ) completely antagonized the inhibitory effect of DRUGOTHER and partly antagonized the effect of DRUGUNRELATED .
N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine. 	N-methyllevallorphan	morphine	effect	{'e1': {'word': 'N-methyllevallorphan', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d128.s15.e0'}, 'e2': {'word': 'morphine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d128.s15.e2'}, 'sentence_id': 'DDI-MedLine.d128.s15'}	DRUG ( 5 mg / kg , s.c. ) completely antagonized the inhibitory effect of DRUGUNRELATED and partly antagonized the effect of DRUGOTHER .
N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine. 	loperamide	morphine	none	{'e1': {'word': 'loperamide', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d128.s15.e1'}, 'e2': {'word': 'morphine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d128.s15.e2'}, 'sentence_id': 'DDI-MedLine.d128.s15'}	DRUGUNRELATED ( 5 mg / kg , s.c. ) completely antagonized the inhibitory effect of DRUG and partly antagonized the effect of DRUGOTHER .
Cytochalasin D at 10 microM preferentially blocked the secretory effect of carbachol and its synergism with cAMP, whereas it had no effect on histamine- or cAMP-stimulated acid secretion within 15 min. 	Cytochalasin D	carbachol	effect	{'e1': {'word': 'Cytochalasin D', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d59.s4.e0'}, 'e2': {'word': 'carbachol', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d59.s4.e1'}, 'sentence_id': 'DDI-MedLine.d59.s4'}	DRUG at 10 microM preferentially blocked the secretory effect of DRUGOTHER and its synergism with cAMP , whereas it had no effect on histamine - or cAMP - stimulated acid secretion within 15 min .
Cytochalasin D inhibited the carbachol-stimulated intracellular Ca(2+) concentration ([Ca(2+)](i)) increase due to release from the Ca(2+) store. 	Cytochalasin D	carbachol	effect	{'e1': {'word': 'Cytochalasin D', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d59.s5.e0'}, 'e2': {'word': 'carbachol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d59.s5.e1'}, 'sentence_id': 'DDI-MedLine.d59.s5'}	DRUG inhibited the DRUGOTHER - stimulated intracellular Ca ( 2 + ) concentration ( [ Ca ( 2 + ) ] ( i ) ) increase due to release from the Ca ( 2 + ) store .
"Antimicrobial activity of Ganoderma lucidum extract alone and in combination with some antibiotics.
"	Ganoderma lucidum extract	antibiotics	none	{'e1': {'word': 'Ganoderma lucidum extract', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d84.s0.e0'}, 'e2': {'word': 'antibiotics', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d84.s0.e1'}, 'sentence_id': 'DDI-MedLine.d84.s0'}	Antimicrobial activity of DRUG alone and in combination with some DRUGOTHER .
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	GL	antibiotics	none	{'e1': {'word': 'GL', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d84.s3.e0'}, 'e2': {'word': 'antibiotics', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d84.s3.e1'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of DRUG with four kinds of DRUGOTHER ( DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED and DRUGUNRELATED ) , the fractional inhibitory concentration index ( FICI ) was determined by checkerboard assay for each strain .
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	GL	ampicillin	none	{'e1': {'word': 'GL', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d84.s3.e0'}, 'e2': {'word': 'ampicillin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d84.s3.e2'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of DRUG with four kinds of DRUGUNRELATED ( DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED and DRUGUNRELATED ) , the fractional inhibitory concentration index ( FICI ) was determined by checkerboard assay for each strain .
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	GL	cefazolin	none	{'e1': {'word': 'GL', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d84.s3.e0'}, 'e2': {'word': 'cefazolin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d84.s3.e3'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of DRUG with four kinds of DRUGUNRELATED ( DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED and DRUGUNRELATED ) , the fractional inhibitory concentration index ( FICI ) was determined by checkerboard assay for each strain .
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	GL	oxytetracycline	none	{'e1': {'word': 'GL', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d84.s3.e0'}, 'e2': {'word': 'oxytetracycline', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d84.s3.e4'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of DRUG with four kinds of DRUGUNRELATED ( DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER and DRUGUNRELATED ) , the fractional inhibitory concentration index ( FICI ) was determined by checkerboard assay for each strain .
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	GL	chloramphenicol	none	{'e1': {'word': 'GL', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d84.s3.e0'}, 'e2': {'word': 'chloramphenicol', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d84.s3.e5'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of DRUG with four kinds of DRUGUNRELATED ( DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED and DRUGOTHER ) , the fractional inhibitory concentration index ( FICI ) was determined by checkerboard assay for each strain .
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	antibiotics	ampicillin	none	{'e1': {'word': 'antibiotics', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d84.s3.e1'}, 'e2': {'word': 'ampicillin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d84.s3.e2'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of DRUGUNRELATED with four kinds of DRUG ( DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED and DRUGUNRELATED ) , the fractional inhibitory concentration index ( FICI ) was determined by checkerboard assay for each strain .
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	antibiotics	cefazolin	none	{'e1': {'word': 'antibiotics', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d84.s3.e1'}, 'e2': {'word': 'cefazolin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d84.s3.e3'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of DRUGUNRELATED with four kinds of DRUG ( DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED and DRUGUNRELATED ) , the fractional inhibitory concentration index ( FICI ) was determined by checkerboard assay for each strain .
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	antibiotics	oxytetracycline	none	{'e1': {'word': 'antibiotics', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d84.s3.e1'}, 'e2': {'word': 'oxytetracycline', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d84.s3.e4'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of DRUGUNRELATED with four kinds of DRUG ( DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER and DRUGUNRELATED ) , the fractional inhibitory concentration index ( FICI ) was determined by checkerboard assay for each strain .
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	antibiotics	chloramphenicol	none	{'e1': {'word': 'antibiotics', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d84.s3.e1'}, 'e2': {'word': 'chloramphenicol', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d84.s3.e5'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of DRUGUNRELATED with four kinds of DRUG ( DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED and DRUGOTHER ) , the fractional inhibitory concentration index ( FICI ) was determined by checkerboard assay for each strain .
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	ampicillin	cefazolin	none	{'e1': {'word': 'ampicillin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d84.s3.e2'}, 'e2': {'word': 'cefazolin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d84.s3.e3'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of DRUGUNRELATED with four kinds of DRUGUNRELATED ( DRUG , DRUGOTHER , DRUGUNRELATED and DRUGUNRELATED ) , the fractional inhibitory concentration index ( FICI ) was determined by checkerboard assay for each strain .
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	ampicillin	oxytetracycline	none	{'e1': {'word': 'ampicillin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d84.s3.e2'}, 'e2': {'word': 'oxytetracycline', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d84.s3.e4'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of DRUGUNRELATED with four kinds of DRUGUNRELATED ( DRUG , DRUGUNRELATED , DRUGOTHER and DRUGUNRELATED ) , the fractional inhibitory concentration index ( FICI ) was determined by checkerboard assay for each strain .
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	ampicillin	chloramphenicol	none	{'e1': {'word': 'ampicillin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d84.s3.e2'}, 'e2': {'word': 'chloramphenicol', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d84.s3.e5'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of DRUGUNRELATED with four kinds of DRUGUNRELATED ( DRUG , DRUGUNRELATED , DRUGUNRELATED and DRUGOTHER ) , the fractional inhibitory concentration index ( FICI ) was determined by checkerboard assay for each strain .
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	cefazolin	oxytetracycline	none	{'e1': {'word': 'cefazolin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d84.s3.e3'}, 'e2': {'word': 'oxytetracycline', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d84.s3.e4'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of DRUGUNRELATED with four kinds of DRUGUNRELATED ( DRUGUNRELATED , DRUG , DRUGOTHER and DRUGUNRELATED ) , the fractional inhibitory concentration index ( FICI ) was determined by checkerboard assay for each strain .
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	cefazolin	chloramphenicol	none	{'e1': {'word': 'cefazolin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d84.s3.e3'}, 'e2': {'word': 'chloramphenicol', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d84.s3.e5'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of DRUGUNRELATED with four kinds of DRUGUNRELATED ( DRUGUNRELATED , DRUG , DRUGUNRELATED and DRUGOTHER ) , the fractional inhibitory concentration index ( FICI ) was determined by checkerboard assay for each strain .
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	oxytetracycline	chloramphenicol	none	{'e1': {'word': 'oxytetracycline', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d84.s3.e4'}, 'e2': {'word': 'chloramphenicol', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d84.s3.e5'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of DRUGUNRELATED with four kinds of DRUGUNRELATED ( DRUGUNRELATED , DRUGUNRELATED , DRUG and DRUGOTHER ) , the fractional inhibitory concentration index ( FICI ) was determined by checkerboard assay for each strain .
The antimicrobial combinations of GL with four antibiotics resulted in additive effect in most instances, synergism in two instances, and antagonism in two instances. 	GL	antibiotics	effect	{'e1': {'word': 'GL', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d84.s4.e0'}, 'e2': {'word': 'antibiotics', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d84.s4.e1'}, 'sentence_id': 'DDI-MedLine.d84.s4'}	The antimicrobial combinations of DRUG with four DRUGOTHER resulted in additive effect in most instances , synergism in two instances , and antagonism in two instances .
Synergism was observed when GL was combined with cefazolin against Bacillus subtilis and Klebsiella oxytoca.	GL	cefazolin	effect	{'e1': {'word': 'GL', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d84.s5.e0'}, 'e2': {'word': 'cefazolin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d84.s5.e1'}, 'sentence_id': 'DDI-MedLine.d84.s5'}	Synergism was observed when DRUG was combined with DRUGOTHER against Bacillus subtilis and Klebsiella oxytoca .
Here we show that a combination of galangin or 3,7-dihydroxyflavone with vancomycin may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus faecium to the level of vancomycin-sensitive strains. 	galangin	vancomycin	none	{'e1': {'word': 'galangin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d123.s2.e0'}, 'e2': {'word': 'vancomycin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d123.s2.e1'}, 'sentence_id': 'DDI-MedLine.d123.s2'}	Here we show that a combination of DRUG or 3 , 7 - dihydroxyflavone with DRUGOTHER may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus faecium to the level of vancomycin - sensitive strains .
METHODS: Clinical studies, case reports, and commentaries and editorials concerning sildenafil published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms sildenafil, Viagra, and erectile dysfunction. 	sildenafil	sildenafil	none	{'e1': {'word': 'sildenafil', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d42.s4.e0'}, 'e2': {'word': 'sildenafil', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d42.s4.e1'}, 'sentence_id': 'DDI-MedLine.d42.s4'}	METHODS : Clinical studies , case reports , and commentaries and editorials concerning DRUG published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE , PREMEDLINE , and International Pharmaceutical Abstracts , using the terms DRUGOTHER , DRUGUNRELATED , and erectile dysfunction .
METHODS: Clinical studies, case reports, and commentaries and editorials concerning sildenafil published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms sildenafil, Viagra, and erectile dysfunction. 	sildenafil	Viagra	none	{'e1': {'word': 'sildenafil', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d42.s4.e0'}, 'e2': {'word': 'Viagra', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d42.s4.e2'}, 'sentence_id': 'DDI-MedLine.d42.s4'}	METHODS : Clinical studies , case reports , and commentaries and editorials concerning DRUG published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE , PREMEDLINE , and International Pharmaceutical Abstracts , using the terms DRUGUNRELATED , DRUGOTHER , and erectile dysfunction .
METHODS: Clinical studies, case reports, and commentaries and editorials concerning sildenafil published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms sildenafil, Viagra, and erectile dysfunction. 	sildenafil	Viagra	none	{'e1': {'word': 'sildenafil', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d42.s4.e1'}, 'e2': {'word': 'Viagra', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d42.s4.e2'}, 'sentence_id': 'DDI-MedLine.d42.s4'}	METHODS : Clinical studies , case reports , and commentaries and editorials concerning DRUGUNRELATED published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE , PREMEDLINE , and International Pharmaceutical Abstracts , using the terms DRUG , DRUGOTHER , and erectile dysfunction .
RESULTS: Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, selective serotonin reuptake inhibitors [SSRIs]). 	Sildenafil	selective serotonin reuptake inhibitors	none	{'e1': {'word': 'Sildenafil', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d42.s5.e0'}, 'e2': {'word': 'selective serotonin reuptake inhibitors', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d42.s5.e1'}, 'sentence_id': 'DDI-MedLine.d42.s5'}	RESULTS : DRUG has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy , radiation therapy , diabetes mellitus , certain neurologic disorders , and drug therapy ( eg , DRUGOTHER [ DRUGUNRELATED ] ) .
RESULTS: Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, selective serotonin reuptake inhibitors [SSRIs]). 	Sildenafil	SSRIs	none	{'e1': {'word': 'Sildenafil', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d42.s5.e0'}, 'e2': {'word': 'SSRIs', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d42.s5.e2'}, 'sentence_id': 'DDI-MedLine.d42.s5'}	RESULTS : DRUG has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy , radiation therapy , diabetes mellitus , certain neurologic disorders , and drug therapy ( eg , DRUGUNRELATED [ DRUGOTHER ] ) .
RESULTS: Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, selective serotonin reuptake inhibitors [SSRIs]). 	selective serotonin reuptake inhibitors	SSRIs	none	{'e1': {'word': 'selective serotonin reuptake inhibitors', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d42.s5.e1'}, 'e2': {'word': 'SSRIs', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d42.s5.e2'}, 'sentence_id': 'DDI-MedLine.d42.s5'}	RESULTS : DRUGUNRELATED has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy , radiation therapy , diabetes mellitus , certain neurologic disorders , and drug therapy ( eg , DRUG [ DRUGOTHER ] ) .
however, patients with moderate to severe cardiovascular disease or those taking nitrate therapy are at increased risk for potentially serious cardiovascular adverse effects with sildenafil therapy. 	nitrate	sildenafil	effect	{'e1': {'word': 'nitrate', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d42.s9.e0'}, 'e2': {'word': 'sildenafil', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d42.s9.e1'}, 'sentence_id': 'DDI-MedLine.d42.s9'}	however , patients with moderate to severe cardiovascular disease or those taking DRUG therapy are at increased risk for potentially serious cardiovascular adverse effects with DRUGOTHER therapy .
In addition, patients taking drugs that inhibit the cytochrome P450 3A4 isozyme, which metabolizes sildenafil, may experience increased drug concentrations and possible toxicity from normal doses of sildenafil. 	sildenafil	sildenafil	none	{'e1': {'word': 'sildenafil', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d42.s10.e0'}, 'e2': {'word': 'sildenafil', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d42.s10.e1'}, 'sentence_id': 'DDI-MedLine.d42.s10'}	In addition , patients taking drugs that inhibit the cytochrome P450 3A4 isozyme , which metabolizes DRUG , may experience increased drug concentrations and possible toxicity from normal doses of DRUGOTHER .
Little has been studied of the adverse effects of the exposure of the liver to the interaction of ethanol with its congeners and acetaldehyde, coexisting in the contents of alcoholic beverages. 	ethanol	acetaldehyde	none	{'e1': {'word': 'ethanol', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d107.s1.e0'}, 'e2': {'word': 'acetaldehyde', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d107.s1.e1'}, 'sentence_id': 'DDI-MedLine.d107.s1'}	Little has been studied of the adverse effects of the exposure of the liver to the interaction of DRUG with its congeners and DRUGOTHER , coexisting in the contents of alcoholic beverages .
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages; 	ethanol	methanol	none	{'e1': {'word': 'ethanol', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d107.s3.e0'}, 'e2': {'word': 'methanol', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d107.s3.e1'}, 'sentence_id': 'DDI-MedLine.d107.s3'}	Two groups ( SH / DA ; SH / FA ) were submitted to daily treatment with synthetic hydroalcoholic solutions containing DRUG , DRUGOTHER , higher DRUGUNRELATED and DRUGUNRELATED in the same proportions as those found in most common distilled and fermented alcoholic beverages ;
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages; 	ethanol	alcohols	none	{'e1': {'word': 'ethanol', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d107.s3.e0'}, 'e2': {'word': 'alcohols', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d107.s3.e2'}, 'sentence_id': 'DDI-MedLine.d107.s3'}	Two groups ( SH / DA ; SH / FA ) were submitted to daily treatment with synthetic hydroalcoholic solutions containing DRUG , DRUGUNRELATED , higher DRUGOTHER and DRUGUNRELATED in the same proportions as those found in most common distilled and fermented alcoholic beverages ;
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages; 	ethanol	acetaldehyde	none	{'e1': {'word': 'ethanol', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d107.s3.e0'}, 'e2': {'word': 'acetaldehyde', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d107.s3.e3'}, 'sentence_id': 'DDI-MedLine.d107.s3'}	Two groups ( SH / DA ; SH / FA ) were submitted to daily treatment with synthetic hydroalcoholic solutions containing DRUG , DRUGUNRELATED , higher DRUGUNRELATED and DRUGOTHER in the same proportions as those found in most common distilled and fermented alcoholic beverages ;
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages; 	methanol	alcohols	none	{'e1': {'word': 'methanol', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d107.s3.e1'}, 'e2': {'word': 'alcohols', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d107.s3.e2'}, 'sentence_id': 'DDI-MedLine.d107.s3'}	Two groups ( SH / DA ; SH / FA ) were submitted to daily treatment with synthetic hydroalcoholic solutions containing DRUGUNRELATED , DRUG , higher DRUGOTHER and DRUGUNRELATED in the same proportions as those found in most common distilled and fermented alcoholic beverages ;
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages; 	methanol	acetaldehyde	none	{'e1': {'word': 'methanol', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d107.s3.e1'}, 'e2': {'word': 'acetaldehyde', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d107.s3.e3'}, 'sentence_id': 'DDI-MedLine.d107.s3'}	Two groups ( SH / DA ; SH / FA ) were submitted to daily treatment with synthetic hydroalcoholic solutions containing DRUGUNRELATED , DRUG , higher DRUGUNRELATED and DRUGOTHER in the same proportions as those found in most common distilled and fermented alcoholic beverages ;
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages; 	alcohols	acetaldehyde	none	{'e1': {'word': 'alcohols', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d107.s3.e2'}, 'e2': {'word': 'acetaldehyde', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d107.s3.e3'}, 'sentence_id': 'DDI-MedLine.d107.s3'}	Two groups ( SH / DA ; SH / FA ) were submitted to daily treatment with synthetic hydroalcoholic solutions containing DRUGUNRELATED , DRUGUNRELATED , higher DRUG and DRUGOTHER in the same proportions as those found in most common distilled and fermented alcoholic beverages ;
These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde; 	ethanol	acetaldehyde	effect	{'e1': {'word': 'ethanol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d107.s9.e0'}, 'e2': {'word': 'acetaldehyde', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d107.s9.e1'}, 'sentence_id': 'DDI-MedLine.d107.s9'}	These results suggest that the hepatoxicity of DRUG in alcoholic beverages is enhanced by interaction with its congeners and DRUGOTHER ;
The fluoroquinolones are a rapidly growing class of antibiotics with a broad spectrum of activity against gram-negative and some gram-positive aerobic bacteria. 	fluoroquinolones	antibiotics	none	{'e1': {'word': 'fluoroquinolones', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d78.s1.e0'}, 'e2': {'word': 'antibiotics', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d78.s1.e1'}, 'sentence_id': 'DDI-MedLine.d78.s1'}	The DRUG are a rapidly growing class of DRUGOTHER with a broad spectrum of activity against gram - negative and some gram - positive aerobic bacteria .
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	norfloxacin	ciprofloxacin	none	{'e1': {'word': 'norfloxacin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d78.s2.e0'}, 'e2': {'word': 'ciprofloxacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d78.s2.e1'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	These agents , including DRUG , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED , have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis .
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	norfloxacin	ofloxacin	none	{'e1': {'word': 'norfloxacin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d78.s2.e0'}, 'e2': {'word': 'ofloxacin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d78.s2.e2'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	These agents , including DRUG , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , and DRUGUNRELATED , have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis .
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	norfloxacin	enoxacin	none	{'e1': {'word': 'norfloxacin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d78.s2.e0'}, 'e2': {'word': 'enoxacin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d78.s2.e3'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	These agents , including DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , and DRUGUNRELATED , have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis .
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	norfloxacin	lomefloxacin	none	{'e1': {'word': 'norfloxacin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d78.s2.e0'}, 'e2': {'word': 'lomefloxacin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d78.s2.e4'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	These agents , including DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUGOTHER , have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis .
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	ciprofloxacin	ofloxacin	none	{'e1': {'word': 'ciprofloxacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d78.s2.e1'}, 'e2': {'word': 'ofloxacin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d78.s2.e2'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	These agents , including DRUGUNRELATED , DRUG , DRUGOTHER , DRUGUNRELATED , and DRUGUNRELATED , have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis .
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	ciprofloxacin	enoxacin	none	{'e1': {'word': 'ciprofloxacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d78.s2.e1'}, 'e2': {'word': 'enoxacin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d78.s2.e3'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	These agents , including DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGOTHER , and DRUGUNRELATED , have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis .
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	ciprofloxacin	lomefloxacin	none	{'e1': {'word': 'ciprofloxacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d78.s2.e1'}, 'e2': {'word': 'lomefloxacin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d78.s2.e4'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	These agents , including DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGUNRELATED , and DRUGOTHER , have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis .
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	ofloxacin	enoxacin	none	{'e1': {'word': 'ofloxacin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d78.s2.e2'}, 'e2': {'word': 'enoxacin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d78.s2.e3'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	These agents , including DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGOTHER , and DRUGUNRELATED , have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis .
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	ofloxacin	lomefloxacin	none	{'e1': {'word': 'ofloxacin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d78.s2.e2'}, 'e2': {'word': 'lomefloxacin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d78.s2.e4'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	These agents , including DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGUNRELATED , and DRUGOTHER , have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis .
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	enoxacin	lomefloxacin	none	{'e1': {'word': 'enoxacin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d78.s2.e3'}, 'e2': {'word': 'lomefloxacin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d78.s2.e4'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	These agents , including DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUG , and DRUGOTHER , have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis .
Advantages offered by this class of antibiotics include optimal pharmacokinetics, effectiveness against multidrug-resistant organisms, and oral administration even when parenteral antibiotics are generally used. 	antibiotics	antibiotics	none	{'e1': {'word': 'antibiotics', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d78.s3.e0'}, 'e2': {'word': 'antibiotics', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d78.s3.e1'}, 'sentence_id': 'DDI-MedLine.d78.s3'}	Advantages offered by this class of DRUG include optimal pharmacokinetics , effectiveness against multidrug - resistant organisms , and oral administration even when parenteral DRUGOTHER are generally used .
"Effect of probenecid on the apparent volume of distribution and elimination of cloxacillin.
"	probenecid	cloxacillin	none	{'e1': {'word': 'probenecid', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d29.s0.e0'}, 'e2': {'word': 'cloxacillin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d29.s0.e1'}, 'sentence_id': 'DDI-MedLine.d29.s0'}	Effect of DRUG on the apparent volume of distribution and elimination of DRUGOTHER .
(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body. 	penicillins	cephaloridine	none	{'e1': {'word': 'penicillins', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d29.s2.e0'}, 'e2': {'word': 'cephaloridine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d29.s2.e1'}, 'sentence_id': 'DDI-MedLine.d29.s2'}	( 1968 , 1970 ) , the higher serum concentrations of DRUG and DRUGOTHER reached after administration of DRUGUNRELATED are due not only to slower renal elimination but also to an altered distribution in the body .
(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body. 	penicillins	probenecid	mechanism	{'e1': {'word': 'penicillins', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d29.s2.e0'}, 'e2': {'word': 'probenecid', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d29.s2.e2'}, 'sentence_id': 'DDI-MedLine.d29.s2'}	( 1968 , 1970 ) , the higher serum concentrations of DRUG and DRUGUNRELATED reached after administration of DRUGOTHER are due not only to slower renal elimination but also to an altered distribution in the body .
(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body. 	cephaloridine	probenecid	mechanism	{'e1': {'word': 'cephaloridine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d29.s2.e1'}, 'e2': {'word': 'probenecid', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d29.s2.e2'}, 'sentence_id': 'DDI-MedLine.d29.s2'}	( 1968 , 1970 ) , the higher serum concentrations of DRUGUNRELATED and DRUG reached after administration of DRUGOTHER are due not only to slower renal elimination but also to an altered distribution in the body .
To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. 	probenecid	cloxacillin	none	{'e1': {'word': 'probenecid', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d29.s3.e0'}, 'e2': {'word': 'cloxacillin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d29.s3.e1'}, 'sentence_id': 'DDI-MedLine.d29.s3'}	To determine whether DRUG has a direct effect on the distribution of DRUGOTHER , the elimination and distribution of DRUGUNRELATED was studied in six patients , five lacking kidney function and one with a partially impaired renal function , in the presence or absence of DRUGUNRELATED .
To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. 	probenecid	cloxacillin	none	{'e1': {'word': 'probenecid', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d29.s3.e0'}, 'e2': {'word': 'cloxacillin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d29.s3.e2'}, 'sentence_id': 'DDI-MedLine.d29.s3'}	To determine whether DRUG has a direct effect on the distribution of DRUGUNRELATED , the elimination and distribution of DRUGOTHER was studied in six patients , five lacking kidney function and one with a partially impaired renal function , in the presence or absence of DRUGUNRELATED .
To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. 	probenecid	probenecid	none	{'e1': {'word': 'probenecid', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d29.s3.e0'}, 'e2': {'word': 'probenecid', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d29.s3.e3'}, 'sentence_id': 'DDI-MedLine.d29.s3'}	To determine whether DRUG has a direct effect on the distribution of DRUGUNRELATED , the elimination and distribution of DRUGUNRELATED was studied in six patients , five lacking kidney function and one with a partially impaired renal function , in the presence or absence of DRUGOTHER .
To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. 	cloxacillin	cloxacillin	none	{'e1': {'word': 'cloxacillin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d29.s3.e1'}, 'e2': {'word': 'cloxacillin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d29.s3.e2'}, 'sentence_id': 'DDI-MedLine.d29.s3'}	To determine whether DRUGUNRELATED has a direct effect on the distribution of DRUG , the elimination and distribution of DRUGOTHER was studied in six patients , five lacking kidney function and one with a partially impaired renal function , in the presence or absence of DRUGUNRELATED .
To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. 	cloxacillin	probenecid	none	{'e1': {'word': 'cloxacillin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d29.s3.e1'}, 'e2': {'word': 'probenecid', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d29.s3.e3'}, 'sentence_id': 'DDI-MedLine.d29.s3'}	To determine whether DRUGUNRELATED has a direct effect on the distribution of DRUG , the elimination and distribution of DRUGUNRELATED was studied in six patients , five lacking kidney function and one with a partially impaired renal function , in the presence or absence of DRUGOTHER .
To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. 	cloxacillin	probenecid	none	{'e1': {'word': 'cloxacillin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d29.s3.e2'}, 'e2': {'word': 'probenecid', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d29.s3.e3'}, 'sentence_id': 'DDI-MedLine.d29.s3'}	To determine whether DRUGUNRELATED has a direct effect on the distribution of DRUGUNRELATED , the elimination and distribution of DRUG was studied in six patients , five lacking kidney function and one with a partially impaired renal function , in the presence or absence of DRUGOTHER .
No significant difference was found between the mean values of the volume of distribution of cloxacillin with and without probenecid (13.0 and 12.6 liters, respectively). 	cloxacillin	probenecid	none	{'e1': {'word': 'cloxacillin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d29.s4.e0'}, 'e2': {'word': 'probenecid', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d29.s4.e1'}, 'sentence_id': 'DDI-MedLine.d29.s4'}	No significant difference was found between the mean values of the volume of distribution of DRUG with and without DRUGOTHER ( 13.0 and 12.6 liters , respectively ) .
This might be explained by a blockade by probenecid of the elimination of cloxacillin by the liver.	probenecid	cloxacillin	mechanism	{'e1': {'word': 'probenecid', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d29.s8.e0'}, 'e2': {'word': 'cloxacillin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d29.s8.e1'}, 'sentence_id': 'DDI-MedLine.d29.s8'}	This might be explained by a blockade by DRUG of the elimination of DRUGOTHER by the liver .
"The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are ""insulin sensitizers"" "	thiazolidinediones	rosiglitazone	none	{'e1': {'word': 'thiazolidinediones', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d28.s7.e0'}, 'e2': {'word': 'rosiglitazone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d28.s7.e1'}, 'sentence_id': 'DDI-MedLine.d28.s7'}	"The DRUG ( DRUGOTHER and DRUGUNRELATED ) , a new class of oral DRUGUNRELATED , are "" insulin sensitizers """
"The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are ""insulin sensitizers"" "	thiazolidinediones	pioglitazone	none	{'e1': {'word': 'thiazolidinediones', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d28.s7.e0'}, 'e2': {'word': 'pioglitazone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d28.s7.e2'}, 'sentence_id': 'DDI-MedLine.d28.s7'}	"The DRUG ( DRUGUNRELATED and DRUGOTHER ) , a new class of oral DRUGUNRELATED , are "" insulin sensitizers """
"The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are ""insulin sensitizers"" "	thiazolidinediones	antidiabetic agents	none	{'e1': {'word': 'thiazolidinediones', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d28.s7.e0'}, 'e2': {'word': 'antidiabetic agents', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d28.s7.e3'}, 'sentence_id': 'DDI-MedLine.d28.s7'}	"The DRUG ( DRUGUNRELATED and DRUGUNRELATED ) , a new class of oral DRUGOTHER , are "" insulin sensitizers """
"The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are ""insulin sensitizers"" "	rosiglitazone	pioglitazone	none	{'e1': {'word': 'rosiglitazone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d28.s7.e1'}, 'e2': {'word': 'pioglitazone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d28.s7.e2'}, 'sentence_id': 'DDI-MedLine.d28.s7'}	"The DRUGUNRELATED ( DRUG and DRUGOTHER ) , a new class of oral DRUGUNRELATED , are "" insulin sensitizers """
"The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are ""insulin sensitizers"" "	rosiglitazone	antidiabetic agents	none	{'e1': {'word': 'rosiglitazone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d28.s7.e1'}, 'e2': {'word': 'antidiabetic agents', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d28.s7.e3'}, 'sentence_id': 'DDI-MedLine.d28.s7'}	"The DRUGUNRELATED ( DRUG and DRUGUNRELATED ) , a new class of oral DRUGOTHER , are "" insulin sensitizers """
"The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are ""insulin sensitizers"" "	pioglitazone	antidiabetic agents	none	{'e1': {'word': 'pioglitazone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d28.s7.e2'}, 'e2': {'word': 'antidiabetic agents', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d28.s7.e3'}, 'sentence_id': 'DDI-MedLine.d28.s7'}	"The DRUGUNRELATED ( DRUGUNRELATED and DRUG ) , a new class of oral DRUGOTHER , are "" insulin sensitizers """
Concomitantly given thiazide diuretics did not interfere with the absorption of a tablet of digoxin. 	thiazide diuretics	digoxin	none	{'e1': {'word': 'thiazide diuretics', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d127.s6.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d127.s6.e1'}, 'sentence_id': 'DDI-MedLine.d127.s6'}	Concomitantly given DRUG did not interfere with the absorption of a tablet of DRUGOTHER .
"Glucose and insulin exert additive ocular and renal vasodilator effects on healthy humans.
"	Glucose	insulin	none	{'e1': {'word': 'Glucose', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d137.s0.e0'}, 'e2': {'word': 'insulin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d137.s0.e1'}, 'sentence_id': 'DDI-MedLine.d137.s0'}	DRUG and DRUGOTHER exert additive ocular and renal vasodilator effects on healthy humans .
AIMS/HYPOTHESIS: There is evidence that insulin and glucose cause renal and ocular vasodilation. 	insulin	glucose	none	{'e1': {'word': 'insulin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d137.s1.e0'}, 'e2': {'word': 'glucose', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d137.s1.e1'}, 'sentence_id': 'DDI-MedLine.d137.s1'}	AIMS / HYPOTHESIS : There is evidence that DRUG and DRUGOTHER cause renal and ocular vasodilation .
Haemodynamic effects of glucose and insulin were additive when somatostatin was co-administered but not under basal conditions. 	glucose	insulin	none	{'e1': {'word': 'glucose', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d137.s9.e0'}, 'e2': {'word': 'insulin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d137.s9.e1'}, 'sentence_id': 'DDI-MedLine.d137.s9'}	Haemodynamic effects of DRUG and DRUGOTHER were additive when DRUGUNRELATED was co-administered but not under basal conditions .
Haemodynamic effects of glucose and insulin were additive when somatostatin was co-administered but not under basal conditions. 	glucose	somatostatin	none	{'e1': {'word': 'glucose', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d137.s9.e0'}, 'e2': {'word': 'somatostatin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d137.s9.e2'}, 'sentence_id': 'DDI-MedLine.d137.s9'}	Haemodynamic effects of DRUG and DRUGUNRELATED were additive when DRUGOTHER was co-administered but not under basal conditions .
Haemodynamic effects of glucose and insulin were additive when somatostatin was co-administered but not under basal conditions. 	insulin	somatostatin	none	{'e1': {'word': 'insulin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d137.s9.e1'}, 'e2': {'word': 'somatostatin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d137.s9.e2'}, 'sentence_id': 'DDI-MedLine.d137.s9'}	Haemodynamic effects of DRUGUNRELATED and DRUG were additive when DRUGOTHER was co-administered but not under basal conditions .
CONCLUSIONS/INTERPRETATION: Glucose and insulin can exert additive vasodilator properties on renal and ocular circulation. 	Glucose	insulin	none	{'e1': {'word': 'Glucose', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d137.s10.e0'}, 'e2': {'word': 'insulin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d137.s10.e1'}, 'sentence_id': 'DDI-MedLine.d137.s10'}	CONCLUSIONS / INTERPRETATION : DRUG and DRUGOTHER can exert additive vasodilator properties on renal and ocular circulation .
"Studies on the mechanism of action of miconazole: effect of miconazole on respiration and cell permeability of Candida albicans.
"	miconazole	miconazole	none	{'e1': {'word': 'miconazole', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d40.s0.e0'}, 'e2': {'word': 'miconazole', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d40.s0.e1'}, 'sentence_id': 'DDI-MedLine.d40.s0'}	Studies on the mechanism of action of DRUG : effect of DRUGOTHER on respiration and cell permeability of Candida albicans .
The antifungal drug, miconazole nitrate, inhibits the growth of several species of Candida. 	antifungal drug	miconazole nitrate	none	{'e1': {'word': 'antifungal drug', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d40.s1.e0'}, 'e2': {'word': 'miconazole nitrate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d40.s1.e1'}, 'sentence_id': 'DDI-MedLine.d40.s1'}	The DRUG , DRUGOTHER , inhibits the growth of several species of Candida .
The percentage of neurons hyperpolarized by mu-, delta(1)-, and kappa-selective opioids was significantly reduced when 1% but not < 	mu-selective opioids	delta(1)-selective opioids	none	{'e1': {'word': 'mu-selective opioids', 'word_index': [(6, 6), (12, 12)], 'id': 'DDI-MedLine.d75.s3.e0'}, 'e2': {'word': 'delta(1)-selective opioids', 'word_index': [(8, 8), (12, 12)], 'id': 'DDI-MedLine.d75.s3.e1'}, 'sentence_id': 'DDI-MedLine.d75.s3'}	The percentage of neurons hyperpolarized by DRUG , DRUGOTHER , and DRUGUNRELATED DRUGEITHER was significantly reduced when 1 % but not <
The percentage of neurons hyperpolarized by mu-, delta(1)-, and kappa-selective opioids was significantly reduced when 1% but not < 	mu-selective opioids	kappa-selective opioids	none	{'e1': {'word': 'mu-selective opioids', 'word_index': [(6, 6), (12, 12)], 'id': 'DDI-MedLine.d75.s3.e0'}, 'e2': {'word': 'kappa-selective opioids', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d75.s3.e2'}, 'sentence_id': 'DDI-MedLine.d75.s3'}	The percentage of neurons hyperpolarized by DRUG , DRUGUNRELATED , and DRUGOTHER DRUG was significantly reduced when 1 % but not <
The percentage of neurons hyperpolarized by mu-, delta(1)-, and kappa-selective opioids was significantly reduced when 1% but not < 	delta(1)-selective opioids	kappa-selective opioids	none	{'e1': {'word': 'delta(1)-selective opioids', 'word_index': [(8, 8), (12, 12)], 'id': 'DDI-MedLine.d75.s3.e1'}, 'e2': {'word': 'kappa-selective opioids', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d75.s3.e2'}, 'sentence_id': 'DDI-MedLine.d75.s3'}	The percentage of neurons hyperpolarized by DRUGUNRELATED , DRUG , and DRUGOTHER DRUG was significantly reduced when 1 % but not <
Among the risk factors studied, two appear to increase the risk of ARE: the prescription of thiabendazole to treat strongyloidiasis during the melarsoprol cure and the bad general clinical conditions of patients. 	thiabendazole	melarsoprol	effect	{'e1': {'word': 'thiabendazole', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d97.s8.e0'}, 'e2': {'word': 'melarsoprol', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d97.s8.e1'}, 'sentence_id': 'DDI-MedLine.d97.s8'}	Among the risk factors studied , two appear to increase the risk of ARE : the prescription of DRUG to treat strongyloidiasis during the DRUGOTHER cure and the bad general clinical conditions of patients .
Recommendations were to avoid administration of diffusible anti-helminthic treatment during the cure, and to improve the general conditions of patients before the cure of melarsoprol.	anti-helminthic	melarsoprol	none	{'e1': {'word': 'anti-helminthic', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d97.s10.e0'}, 'e2': {'word': 'melarsoprol', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d97.s10.e1'}, 'sentence_id': 'DDI-MedLine.d97.s10'}	Recommendations were to avoid administration of diffusible DRUG treatment during the cure , and to improve the general conditions of patients before the cure of DRUGOTHER .
"Effect of dofetillide on the pharmacokinetics of digoxin.
"	dofetillide	digoxin	none	{'e1': {'word': 'dofetillide', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d112.s0.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d112.s0.e1'}, 'sentence_id': 'DDI-MedLine.d112.s0'}	Effect of DRUG on the pharmacokinetics of DRUGOTHER .
The effect of dofetilide on the steady-state pharmacokinetics of digoxin was evaluated in a randomized, double-blind study. 	dofetilide	digoxin	none	{'e1': {'word': 'dofetilide', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d112.s1.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d112.s1.e1'}, 'sentence_id': 'DDI-MedLine.d112.s1'}	The effect of DRUG on the steady - state pharmacokinetics of DRUGOTHER was evaluated in a randomized , double - blind study .
Five days of dofetilide treatment did not significantly affect steady-state pharmacokinetic variables of digoxin compared with placebo; 	dofetilide	digoxin	none	{'e1': {'word': 'dofetilide', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d112.s2.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d112.s2.e1'}, 'sentence_id': 'DDI-MedLine.d112.s2'}	Five days of DRUG treatment did not significantly affect steady - state pharmacokinetic variables of DRUGOTHER compared with placebo ;
therefore, the use of dofetilide does not necessitate an adjustment in digoxin dose to maintain therapeutic digoxin levels.	dofetilide	digoxin	none	{'e1': {'word': 'dofetilide', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d112.s3.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d112.s3.e1'}, 'sentence_id': 'DDI-MedLine.d112.s3'}	therefore , the use of DRUG does not necessitate an adjustment in DRUGOTHER dose to maintain therapeutic digoxin levels .
"The mode of toxic action of the pesticide gliftor: the metabolism of 1,3-difluoroacetone to (-)-erythro-fluorocitrate.
"	gliftor	1,3-difluoroacetone	none	{'e1': {'word': 'gliftor', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d125.s0.e0'}, 'e2': {'word': '1,3-difluoroacetone', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d125.s0.e1'}, 'sentence_id': 'DDI-MedLine.d125.s0'}	The mode of toxic action of the pesticide DRUG : the metabolism of DRUGOTHER to DRUGUNRELATED .
"The mode of toxic action of the pesticide gliftor: the metabolism of 1,3-difluoroacetone to (-)-erythro-fluorocitrate.
"	gliftor	(-)-erythro-fluorocitrate	none	{'e1': {'word': 'gliftor', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d125.s0.e0'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d125.s0.e2'}, 'sentence_id': 'DDI-MedLine.d125.s0'}	The mode of toxic action of the pesticide DRUG : the metabolism of DRUGUNRELATED to DRUGOTHER .
"The mode of toxic action of the pesticide gliftor: the metabolism of 1,3-difluoroacetone to (-)-erythro-fluorocitrate.
"	1,3-difluoroacetone	(-)-erythro-fluorocitrate	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d125.s0.e1'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d125.s0.e2'}, 'sentence_id': 'DDI-MedLine.d125.s0'}	The mode of toxic action of the pesticide DRUGUNRELATED : the metabolism of DRUG to DRUGOTHER .
The biochemical toxicology of 1,3-difluoroacetone, a known metabolite of the major ingredient of the pesticide Gliftor (1,3-difluoro-2-propanol), was investigated in vivo and in vitro. 	1,3-difluoroacetone	Gliftor	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d125.s1.e0'}, 'e2': {'word': 'Gliftor', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d125.s1.e1'}, 'sentence_id': 'DDI-MedLine.d125.s1'}	The biochemical toxicology of DRUG , a known metabolite of the major ingredient of the pesticide DRUGOTHER ( DRUGUNRELATED ) , was investigated in vivo and in vitro .
The biochemical toxicology of 1,3-difluoroacetone, a known metabolite of the major ingredient of the pesticide Gliftor (1,3-difluoro-2-propanol), was investigated in vivo and in vitro. 	1,3-difluoroacetone	1,3-difluoro-2-propanol	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d125.s1.e0'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d125.s1.e2'}, 'sentence_id': 'DDI-MedLine.d125.s1'}	The biochemical toxicology of DRUG , a known metabolite of the major ingredient of the pesticide DRUGUNRELATED ( DRUGOTHER ) , was investigated in vivo and in vitro .
The biochemical toxicology of 1,3-difluoroacetone, a known metabolite of the major ingredient of the pesticide Gliftor (1,3-difluoro-2-propanol), was investigated in vivo and in vitro. 	Gliftor	1,3-difluoro-2-propanol	none	{'e1': {'word': 'Gliftor', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d125.s1.e1'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d125.s1.e2'}, 'sentence_id': 'DDI-MedLine.d125.s1'}	The biochemical toxicology of DRUGUNRELATED , a known metabolite of the major ingredient of the pesticide DRUG ( DRUGOTHER ) , was investigated in vivo and in vitro .
Rat kidney homogenates supplemented with coenzyme A, ATP, oxaloacetate, and Mg2+ converted 1,3-difluoroacetone to (-)-erythro-fluorocitrate in vitro. 	1,3-difluoroacetone	(-)-erythro-fluorocitrate	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d125.s2.e0'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d125.s2.e1'}, 'sentence_id': 'DDI-MedLine.d125.s2'}	Rat kidney homogenates supplemented with coenzyme A , ATP , oxaloacetate , and Mg2 + converted DRUG to DRUGOTHER in vitro .
Administration of 1,3-difluoroacetone (100 mg kg(-1) body weight) to rats in vivo resulted in (-)-erythro-fluorocitrate synthesis in the kidney, which was preceded by an elevation in fluoride levels and followed by citrate accumulation. 	1,3-difluoroacetone	(-)-erythro-fluorocitrate	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d125.s3.e0'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d125.s3.e1'}, 'sentence_id': 'DDI-MedLine.d125.s3'}	Administration of DRUG ( 100 mg kg ( - 1 ) body weight ) to rats in vivo resulted in DRUGOTHER synthesis in the kidney , which was preceded by an elevation in fluoride levels and followed by citrate accumulation .
Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol. 	1,3-difluoroacetone	(-)-erythro-fluorocitrate	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d125.s4.e0'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d125.s4.e1'}, 'sentence_id': 'DDI-MedLine.d125.s4'}	Animals dosed with DRUG did not display the 2 - 3 hour lag phase in either DRUGOTHER synthesis or in citrate and fluoride accumulation characteristic of animals dosed with DRUGUNRELATED .
Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol. 	1,3-difluoroacetone	1,3-difluoro-2-propanol	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d125.s4.e0'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d125.s4.e2'}, 'sentence_id': 'DDI-MedLine.d125.s4'}	Animals dosed with DRUG did not display the 2 - 3 hour lag phase in either DRUGUNRELATED synthesis or in citrate and fluoride accumulation characteristic of animals dosed with DRUGOTHER .
Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol. 	(-)-erythro-fluorocitrate	1,3-difluoro-2-propanol	none	{'e1': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d125.s4.e1'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d125.s4.e2'}, 'sentence_id': 'DDI-MedLine.d125.s4'}	Animals dosed with DRUGUNRELATED did not display the 2 - 3 hour lag phase in either DRUG synthesis or in citrate and fluoride accumulation characteristic of animals dosed with DRUGOTHER .
We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. 	1,3-difluoro-2-propanol	1,3-difluoroacetone	none	{'e1': {'word': '1,3-difluoro-2-propanol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d125.s5.e0'}, 'e2': {'word': '1,3-difluoroacetone', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d125.s5.e1'}, 'sentence_id': 'DDI-MedLine.d125.s5'}	We demonstrate that the conversion of DRUG to DRUGOTHER by an NAD+ - dependent oxidation is the rate - limiting step in the synthesis of the toxic product , DRUGUNRELATED from DRUGUNRELATED .
We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. 	1,3-difluoro-2-propanol	(-)-erythro-fluorocitrate	none	{'e1': {'word': '1,3-difluoro-2-propanol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d125.s5.e0'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d125.s5.e2'}, 'sentence_id': 'DDI-MedLine.d125.s5'}	We demonstrate that the conversion of DRUG to DRUGUNRELATED by an NAD+ - dependent oxidation is the rate - limiting step in the synthesis of the toxic product , DRUGOTHER from DRUGUNRELATED .
We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. 	1,3-difluoro-2-propanol	1,3-difluoro-2-propanol	none	{'e1': {'word': '1,3-difluoro-2-propanol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d125.s5.e0'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d125.s5.e3'}, 'sentence_id': 'DDI-MedLine.d125.s5'}	We demonstrate that the conversion of DRUG to DRUGUNRELATED by an NAD+ - dependent oxidation is the rate - limiting step in the synthesis of the toxic product , DRUGUNRELATED from DRUGOTHER .
We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. 	1,3-difluoroacetone	(-)-erythro-fluorocitrate	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d125.s5.e1'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d125.s5.e2'}, 'sentence_id': 'DDI-MedLine.d125.s5'}	We demonstrate that the conversion of DRUGUNRELATED to DRUG by an NAD+ - dependent oxidation is the rate - limiting step in the synthesis of the toxic product , DRUGOTHER from DRUGUNRELATED .
We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. 	1,3-difluoroacetone	1,3-difluoro-2-propanol	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d125.s5.e1'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d125.s5.e3'}, 'sentence_id': 'DDI-MedLine.d125.s5'}	We demonstrate that the conversion of DRUGUNRELATED to DRUG by an NAD+ - dependent oxidation is the rate - limiting step in the synthesis of the toxic product , DRUGUNRELATED from DRUGOTHER .
We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. 	(-)-erythro-fluorocitrate	1,3-difluoro-2-propanol	none	{'e1': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d125.s5.e2'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d125.s5.e3'}, 'sentence_id': 'DDI-MedLine.d125.s5'}	We demonstrate that the conversion of DRUGUNRELATED to DRUGUNRELATED by an NAD+ - dependent oxidation is the rate - limiting step in the synthesis of the toxic product , DRUG from DRUGOTHER .
Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 	4-methylpyrazole	1,3-difluoro-2-propanol	effect	{'e1': {'word': '4-methylpyrazole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d125.s6.e0'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d125.s6.e1'}, 'sentence_id': 'DDI-MedLine.d125.s6'}	Prior administration of DRUG ( 90 mg kg ( - 1 ) body weight ) was shown to prevent the conversion of DRUGOTHER ( 100 mg kg ( - 1 ) body weight ) to DRUGUNRELATED in vivo and to eliminate the fluoride and citrate elevations seen in DRUGUNRELATED - intoxicated animals .
Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 	4-methylpyrazole	(-)-erythro-fluorocitrate	none	{'e1': {'word': '4-methylpyrazole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d125.s6.e0'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d125.s6.e2'}, 'sentence_id': 'DDI-MedLine.d125.s6'}	Prior administration of DRUG ( 90 mg kg ( - 1 ) body weight ) was shown to prevent the conversion of DRUGUNRELATED ( 100 mg kg ( - 1 ) body weight ) to DRUGOTHER in vivo and to eliminate the fluoride and citrate elevations seen in DRUGUNRELATED - intoxicated animals .
Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 	4-methylpyrazole	1,3-difluoro-2-propanol	none	{'e1': {'word': '4-methylpyrazole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d125.s6.e0'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(48, 48)], 'id': 'DDI-MedLine.d125.s6.e3'}, 'sentence_id': 'DDI-MedLine.d125.s6'}	Prior administration of DRUG ( 90 mg kg ( - 1 ) body weight ) was shown to prevent the conversion of DRUGUNRELATED ( 100 mg kg ( - 1 ) body weight ) to DRUGUNRELATED in vivo and to eliminate the fluoride and citrate elevations seen in DRUGOTHER - intoxicated animals .
Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 	1,3-difluoro-2-propanol	(-)-erythro-fluorocitrate	none	{'e1': {'word': '1,3-difluoro-2-propanol', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d125.s6.e1'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d125.s6.e2'}, 'sentence_id': 'DDI-MedLine.d125.s6'}	Prior administration of DRUGUNRELATED ( 90 mg kg ( - 1 ) body weight ) was shown to prevent the conversion of DRUG ( 100 mg kg ( - 1 ) body weight ) to DRUGOTHER in vivo and to eliminate the fluoride and citrate elevations seen in DRUGUNRELATED - intoxicated animals .
Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 	1,3-difluoro-2-propanol	1,3-difluoro-2-propanol	none	{'e1': {'word': '1,3-difluoro-2-propanol', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d125.s6.e1'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(48, 48)], 'id': 'DDI-MedLine.d125.s6.e3'}, 'sentence_id': 'DDI-MedLine.d125.s6'}	Prior administration of DRUGUNRELATED ( 90 mg kg ( - 1 ) body weight ) was shown to prevent the conversion of DRUG ( 100 mg kg ( - 1 ) body weight ) to DRUGUNRELATED in vivo and to eliminate the fluoride and citrate elevations seen in DRUGOTHER - intoxicated animals .
Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 	(-)-erythro-fluorocitrate	1,3-difluoro-2-propanol	none	{'e1': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d125.s6.e2'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(48, 48)], 'id': 'DDI-MedLine.d125.s6.e3'}, 'sentence_id': 'DDI-MedLine.d125.s6'}	Prior administration of DRUGUNRELATED ( 90 mg kg ( - 1 ) body weight ) was shown to prevent the conversion of DRUGUNRELATED ( 100 mg kg ( - 1 ) body weight ) to DRUG in vivo and to eliminate the fluoride and citrate elevations seen in DRUGOTHER - intoxicated animals .
However, administration of 4-methylpyrazole (90 mg kg(-1) body weight) to rats 2 hours prior to 1,3-difluoroacetone (100 mg kg(-1) body weight) was ineffective in preventing (-)-erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo. 	4-methylpyrazole	1,3-difluoroacetone	none	{'e1': {'word': '4-methylpyrazole', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d125.s7.e0'}, 'e2': {'word': '1,3-difluoroacetone', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d125.s7.e1'}, 'sentence_id': 'DDI-MedLine.d125.s7'}	However , administration of DRUG ( 90 mg kg ( - 1 ) body weight ) to rats 2 hours prior to DRUGOTHER ( 100 mg kg ( - 1 ) body weight ) was ineffective in preventing DRUGUNRELATED synthesis and did not diminish fluoride or citrate accumulation in vivo .
However, administration of 4-methylpyrazole (90 mg kg(-1) body weight) to rats 2 hours prior to 1,3-difluoroacetone (100 mg kg(-1) body weight) was ineffective in preventing (-)-erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo. 	4-methylpyrazole	(-)-erythro-fluorocitrate	none	{'e1': {'word': '4-methylpyrazole', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d125.s7.e0'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d125.s7.e2'}, 'sentence_id': 'DDI-MedLine.d125.s7'}	However , administration of DRUG ( 90 mg kg ( - 1 ) body weight ) to rats 2 hours prior to DRUGUNRELATED ( 100 mg kg ( - 1 ) body weight ) was ineffective in preventing DRUGOTHER synthesis and did not diminish fluoride or citrate accumulation in vivo .
However, administration of 4-methylpyrazole (90 mg kg(-1) body weight) to rats 2 hours prior to 1,3-difluoroacetone (100 mg kg(-1) body weight) was ineffective in preventing (-)-erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo. 	1,3-difluoroacetone	(-)-erythro-fluorocitrate	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d125.s7.e1'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d125.s7.e2'}, 'sentence_id': 'DDI-MedLine.d125.s7'}	However , administration of DRUGUNRELATED ( 90 mg kg ( - 1 ) body weight ) to rats 2 hours prior to DRUG ( 100 mg kg ( - 1 ) body weight ) was ineffective in preventing DRUGOTHER synthesis and did not diminish fluoride or citrate accumulation in vivo .
We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.	4-methylpyrazole	1,3-difluoro-2-propanol	effect	{'e1': {'word': '4-methylpyrazole', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d125.s8.e0'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d125.s8.e1'}, 'sentence_id': 'DDI-MedLine.d125.s8'}	We conclude that the prophylactic and antidotal properties of DRUG seen in animals treated with DRUGOTHER derive from its capacity to inhibit the NAD+ - dependent oxidation responsible for converting DRUGUNRELATED to DRUGUNRELATED in the committed step of the toxic pathway .
We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.	4-methylpyrazole	1,3-difluoro-2-propanol	none	{'e1': {'word': '4-methylpyrazole', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d125.s8.e0'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d125.s8.e2'}, 'sentence_id': 'DDI-MedLine.d125.s8'}	We conclude that the prophylactic and antidotal properties of DRUG seen in animals treated with DRUGUNRELATED derive from its capacity to inhibit the NAD+ - dependent oxidation responsible for converting DRUGOTHER to DRUGUNRELATED in the committed step of the toxic pathway .
We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.	4-methylpyrazole	1,3-difluoroacetone	none	{'e1': {'word': '4-methylpyrazole', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d125.s8.e0'}, 'e2': {'word': '1,3-difluoroacetone', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d125.s8.e3'}, 'sentence_id': 'DDI-MedLine.d125.s8'}	We conclude that the prophylactic and antidotal properties of DRUG seen in animals treated with DRUGUNRELATED derive from its capacity to inhibit the NAD+ - dependent oxidation responsible for converting DRUGUNRELATED to DRUGOTHER in the committed step of the toxic pathway .
We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.	1,3-difluoro-2-propanol	1,3-difluoro-2-propanol	none	{'e1': {'word': '1,3-difluoro-2-propanol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d125.s8.e1'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d125.s8.e2'}, 'sentence_id': 'DDI-MedLine.d125.s8'}	We conclude that the prophylactic and antidotal properties of DRUGUNRELATED seen in animals treated with DRUG derive from its capacity to inhibit the NAD+ - dependent oxidation responsible for converting DRUGOTHER to DRUGUNRELATED in the committed step of the toxic pathway .
We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.	1,3-difluoro-2-propanol	1,3-difluoroacetone	none	{'e1': {'word': '1,3-difluoro-2-propanol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d125.s8.e1'}, 'e2': {'word': '1,3-difluoroacetone', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d125.s8.e3'}, 'sentence_id': 'DDI-MedLine.d125.s8'}	We conclude that the prophylactic and antidotal properties of DRUGUNRELATED seen in animals treated with DRUG derive from its capacity to inhibit the NAD+ - dependent oxidation responsible for converting DRUGUNRELATED to DRUGOTHER in the committed step of the toxic pathway .
We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.	1,3-difluoro-2-propanol	1,3-difluoroacetone	none	{'e1': {'word': '1,3-difluoro-2-propanol', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d125.s8.e2'}, 'e2': {'word': '1,3-difluoroacetone', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d125.s8.e3'}, 'sentence_id': 'DDI-MedLine.d125.s8'}	We conclude that the prophylactic and antidotal properties of DRUGUNRELATED seen in animals treated with DRUGUNRELATED derive from its capacity to inhibit the NAD+ - dependent oxidation responsible for converting DRUG to DRUGOTHER in the committed step of the toxic pathway .
Effect of estradiol on endotoxin-induced changes in steroid hormone levels and lethality in male rats.	estradiol	endotoxin	none	{'e1': {'word': 'estradiol', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d39.s0.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d39.s0.e1'}, 'sentence_id': 'DDI-MedLine.d39.s0'}	Effect of DRUG on DRUGOTHER - induced changes in steroid hormone levels and lethality in male rats .
We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin. 	estradiol	endotoxin	none	{'e1': {'word': 'estradiol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d39.s1.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d39.s1.e1'}, 'sentence_id': 'DDI-MedLine.d39.s1'}	We examined the effect of exogenous DRUG on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli DRUGOTHER in male rats and the deaths due to nonlethal and lethal doses of DRUGUNRELATED .
We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin. 	estradiol	endotoxin	none	{'e1': {'word': 'estradiol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d39.s1.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d39.s1.e2'}, 'sentence_id': 'DDI-MedLine.d39.s1'}	We examined the effect of exogenous DRUG on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli DRUGUNRELATED in male rats and the deaths due to nonlethal and lethal doses of DRUGOTHER .
We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin. 	endotoxin	endotoxin	none	{'e1': {'word': 'endotoxin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d39.s1.e1'}, 'e2': {'word': 'endotoxin', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d39.s1.e2'}, 'sentence_id': 'DDI-MedLine.d39.s1'}	We examined the effect of exogenous DRUGUNRELATED on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli DRUG in male rats and the deaths due to nonlethal and lethal doses of DRUGOTHER .
Injection of estradiol 5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin. 	estradiol	endotoxin	effect	{'e1': {'word': 'estradiol', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d39.s2.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d39.s2.e1'}, 'sentence_id': 'DDI-MedLine.d39.s2'}	Injection of DRUG 5 min before a nonlethal dose of DRUGOTHER changed the serum sex steroid hormone response of male rats to DRUGUNRELATED .
Injection of estradiol 5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin. 	estradiol	endotoxin	none	{'e1': {'word': 'estradiol', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d39.s2.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d39.s2.e2'}, 'sentence_id': 'DDI-MedLine.d39.s2'}	Injection of DRUG 5 min before a nonlethal dose of DRUGUNRELATED changed the serum sex steroid hormone response of male rats to DRUGOTHER .
Injection of estradiol 5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin. 	endotoxin	endotoxin	none	{'e1': {'word': 'endotoxin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d39.s2.e1'}, 'e2': {'word': 'endotoxin', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d39.s2.e2'}, 'sentence_id': 'DDI-MedLine.d39.s2'}	Injection of DRUGUNRELATED 5 min before a nonlethal dose of DRUG changed the serum sex steroid hormone response of male rats to DRUGOTHER .
The serum estrogen concentrations of estradiol + endotoxin-treated rats decreased by 50%, while those of the endotoxin-treated rats increased (2- to 5-fold). 	estradiol	endotoxin	mechanism	{'e1': {'word': 'estradiol', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d39.s3.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d39.s3.e1'}, 'sentence_id': 'DDI-MedLine.d39.s3'}	The serum estrogen concentrations of DRUG + DRUGOTHER - treated rats decreased by 50 % , while those of the DRUGUNRELATED - treated rats increased ( 2 - to 5-fold ) .
The serum estrogen concentrations of estradiol + endotoxin-treated rats decreased by 50%, while those of the endotoxin-treated rats increased (2- to 5-fold). 	estradiol	endotoxin	none	{'e1': {'word': 'estradiol', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d39.s3.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d39.s3.e2'}, 'sentence_id': 'DDI-MedLine.d39.s3'}	The serum estrogen concentrations of DRUG + DRUGUNRELATED - treated rats decreased by 50 % , while those of the DRUGOTHER - treated rats increased ( 2 - to 5-fold ) .
The serum estrogen concentrations of estradiol + endotoxin-treated rats decreased by 50%, while those of the endotoxin-treated rats increased (2- to 5-fold). 	endotoxin	endotoxin	none	{'e1': {'word': 'endotoxin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d39.s3.e1'}, 'e2': {'word': 'endotoxin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d39.s3.e2'}, 'sentence_id': 'DDI-MedLine.d39.s3'}	The serum estrogen concentrations of DRUGUNRELATED + DRUG - treated rats decreased by 50 % , while those of the DRUGOTHER - treated rats increased ( 2 - to 5-fold ) .
The serum androgen concentrations of estradiol + endotoxin-treated rats did not change significantly, while those of endotoxin-treated rats dropped to 30-40%	estradiol	endotoxin	none	{'e1': {'word': 'estradiol', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d39.s4.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d39.s4.e1'}, 'sentence_id': 'DDI-MedLine.d39.s4'}	The serum androgen concentrations of DRUG + DRUGOTHER - treated rats did not change significantly , while those of DRUGUNRELATED - treated rats dropped to 30 - 40 %
The serum androgen concentrations of estradiol + endotoxin-treated rats did not change significantly, while those of endotoxin-treated rats dropped to 30-40%	estradiol	endotoxin	none	{'e1': {'word': 'estradiol', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d39.s4.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d39.s4.e2'}, 'sentence_id': 'DDI-MedLine.d39.s4'}	The serum androgen concentrations of DRUG + DRUGUNRELATED - treated rats did not change significantly , while those of DRUGOTHER - treated rats dropped to 30 - 40 %
The serum androgen concentrations of estradiol + endotoxin-treated rats did not change significantly, while those of endotoxin-treated rats dropped to 30-40%	endotoxin	endotoxin	none	{'e1': {'word': 'endotoxin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d39.s4.e1'}, 'e2': {'word': 'endotoxin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d39.s4.e2'}, 'sentence_id': 'DDI-MedLine.d39.s4'}	The serum androgen concentrations of DRUGUNRELATED + DRUG - treated rats did not change significantly , while those of DRUGOTHER - treated rats dropped to 30 - 40 %
Exogenous estradiol also appeared to influence the percentage of endotoxin-induced deaths in a dose-dependent manner. 	estradiol	endotoxin	effect	{'e1': {'word': 'estradiol', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d39.s6.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d39.s6.e1'}, 'sentence_id': 'DDI-MedLine.d39.s6'}	Exogenous DRUG also appeared to influence the percentage of DRUGOTHER - induced deaths in a dose - dependent manner .
These results, together with the known relationships between estrogen and the immune response, suggest that estrogens affect the course of septic shock in a complex fashion and may have either protective or deleterious effect.	estrogen	estrogens	none	{'e1': {'word': 'estrogen', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d39.s8.e0'}, 'e2': {'word': 'estrogens', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d39.s8.e1'}, 'sentence_id': 'DDI-MedLine.d39.s8'}	These results , together with the known relationships between DRUG and the immune response , suggest that DRUGOTHER affect the course of septic shock in a complex fashion and may have either protective or deleterious effect .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium carboxymethylcellulose	NaCMC	none	{'e1': {'word': 'sodium carboxymethylcellulose', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d76.s1.e0'}, 'e2': {'word': 'NaCMC', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d76.s1.e1'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUG ( DRUGOTHER ) and DRUGUNRELATED ( DRUGUNRELATED ) conjugates on the intestinal permeation of DRUGUNRELATED ( DRUGUNRELATED ) and model peptide drugs , DRUGUNRELATED and DRUGUNRELATED .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium carboxymethylcellulose	carboxymethylcellulose-cysteine	none	{'e1': {'word': 'sodium carboxymethylcellulose', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d76.s1.e0'}, 'e2': {'word': 'carboxymethylcellulose-cysteine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d76.s1.e2'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUG ( DRUGUNRELATED ) and DRUGOTHER ( DRUGUNRELATED ) conjugates on the intestinal permeation of DRUGUNRELATED ( DRUGUNRELATED ) and model peptide drugs , DRUGUNRELATED and DRUGUNRELATED .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium carboxymethylcellulose	CMC-Cys	none	{'e1': {'word': 'sodium carboxymethylcellulose', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d76.s1.e0'}, 'e2': {'word': 'CMC-Cys', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d76.s1.e3'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUG ( DRUGUNRELATED ) and DRUGUNRELATED ( DRUGOTHER ) conjugates on the intestinal permeation of DRUGUNRELATED ( DRUGUNRELATED ) and model peptide drugs , DRUGUNRELATED and DRUGUNRELATED .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium carboxymethylcellulose	sodium fluorescein	none	{'e1': {'word': 'sodium carboxymethylcellulose', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d76.s1.e0'}, 'e2': {'word': 'sodium fluorescein', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d76.s1.e4'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUG ( DRUGUNRELATED ) and DRUGUNRELATED ( DRUGUNRELATED ) conjugates on the intestinal permeation of DRUGOTHER ( DRUGUNRELATED ) and model peptide drugs , DRUGUNRELATED and DRUGUNRELATED .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium carboxymethylcellulose	NaFlu	none	{'e1': {'word': 'sodium carboxymethylcellulose', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d76.s1.e0'}, 'e2': {'word': 'NaFlu', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d76.s1.e5'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUG ( DRUGUNRELATED ) and DRUGUNRELATED ( DRUGUNRELATED ) conjugates on the intestinal permeation of DRUGUNRELATED ( DRUGOTHER ) and model peptide drugs , DRUGUNRELATED and DRUGUNRELATED .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium carboxymethylcellulose	bacitracin	none	{'e1': {'word': 'sodium carboxymethylcellulose', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d76.s1.e0'}, 'e2': {'word': 'bacitracin', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d76.s1.e6'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUG ( DRUGUNRELATED ) and DRUGUNRELATED ( DRUGUNRELATED ) conjugates on the intestinal permeation of DRUGUNRELATED ( DRUGUNRELATED ) and model peptide drugs , DRUGOTHER and DRUGUNRELATED .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium carboxymethylcellulose	insulin	none	{'e1': {'word': 'sodium carboxymethylcellulose', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d76.s1.e0'}, 'e2': {'word': 'insulin', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d76.s1.e7'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUG ( DRUGUNRELATED ) and DRUGUNRELATED ( DRUGUNRELATED ) conjugates on the intestinal permeation of DRUGUNRELATED ( DRUGUNRELATED ) and model peptide drugs , DRUGUNRELATED and DRUGOTHER .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	NaCMC	carboxymethylcellulose-cysteine	none	{'e1': {'word': 'NaCMC', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d76.s1.e1'}, 'e2': {'word': 'carboxymethylcellulose-cysteine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d76.s1.e2'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUGUNRELATED ( DRUG ) and DRUGOTHER ( DRUGUNRELATED ) conjugates on the intestinal permeation of DRUGUNRELATED ( DRUGUNRELATED ) and model peptide drugs , DRUGUNRELATED and DRUGUNRELATED .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	NaCMC	CMC-Cys	none	{'e1': {'word': 'NaCMC', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d76.s1.e1'}, 'e2': {'word': 'CMC-Cys', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d76.s1.e3'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUGUNRELATED ( DRUG ) and DRUGUNRELATED ( DRUGOTHER ) conjugates on the intestinal permeation of DRUGUNRELATED ( DRUGUNRELATED ) and model peptide drugs , DRUGUNRELATED and DRUGUNRELATED .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	NaCMC	sodium fluorescein	none	{'e1': {'word': 'NaCMC', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d76.s1.e1'}, 'e2': {'word': 'sodium fluorescein', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d76.s1.e4'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUGUNRELATED ( DRUG ) and DRUGUNRELATED ( DRUGUNRELATED ) conjugates on the intestinal permeation of DRUGOTHER ( DRUGUNRELATED ) and model peptide drugs , DRUGUNRELATED and DRUGUNRELATED .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	NaCMC	NaFlu	none	{'e1': {'word': 'NaCMC', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d76.s1.e1'}, 'e2': {'word': 'NaFlu', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d76.s1.e5'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUGUNRELATED ( DRUG ) and DRUGUNRELATED ( DRUGUNRELATED ) conjugates on the intestinal permeation of DRUGUNRELATED ( DRUGOTHER ) and model peptide drugs , DRUGUNRELATED and DRUGUNRELATED .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	NaCMC	bacitracin	none	{'e1': {'word': 'NaCMC', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d76.s1.e1'}, 'e2': {'word': 'bacitracin', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d76.s1.e6'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUGUNRELATED ( DRUG ) and DRUGUNRELATED ( DRUGUNRELATED ) conjugates on the intestinal permeation of DRUGUNRELATED ( DRUGUNRELATED ) and model peptide drugs , DRUGOTHER and DRUGUNRELATED .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	NaCMC	insulin	none	{'e1': {'word': 'NaCMC', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d76.s1.e1'}, 'e2': {'word': 'insulin', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d76.s1.e7'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUGUNRELATED ( DRUG ) and DRUGUNRELATED ( DRUGUNRELATED ) conjugates on the intestinal permeation of DRUGUNRELATED ( DRUGUNRELATED ) and model peptide drugs , DRUGUNRELATED and DRUGOTHER .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	carboxymethylcellulose-cysteine	CMC-Cys	none	{'e1': {'word': 'carboxymethylcellulose-cysteine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d76.s1.e2'}, 'e2': {'word': 'CMC-Cys', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d76.s1.e3'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUGUNRELATED ( DRUGUNRELATED ) and DRUG ( DRUGOTHER ) conjugates on the intestinal permeation of DRUGUNRELATED ( DRUGUNRELATED ) and model peptide drugs , DRUGUNRELATED and DRUGUNRELATED .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	carboxymethylcellulose-cysteine	sodium fluorescein	none	{'e1': {'word': 'carboxymethylcellulose-cysteine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d76.s1.e2'}, 'e2': {'word': 'sodium fluorescein', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d76.s1.e4'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUGUNRELATED ( DRUGUNRELATED ) and DRUG ( DRUGUNRELATED ) conjugates on the intestinal permeation of DRUGOTHER ( DRUGUNRELATED ) and model peptide drugs , DRUGUNRELATED and DRUGUNRELATED .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	carboxymethylcellulose-cysteine	NaFlu	none	{'e1': {'word': 'carboxymethylcellulose-cysteine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d76.s1.e2'}, 'e2': {'word': 'NaFlu', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d76.s1.e5'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUGUNRELATED ( DRUGUNRELATED ) and DRUG ( DRUGUNRELATED ) conjugates on the intestinal permeation of DRUGUNRELATED ( DRUGOTHER ) and model peptide drugs , DRUGUNRELATED and DRUGUNRELATED .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	carboxymethylcellulose-cysteine	bacitracin	none	{'e1': {'word': 'carboxymethylcellulose-cysteine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d76.s1.e2'}, 'e2': {'word': 'bacitracin', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d76.s1.e6'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUGUNRELATED ( DRUGUNRELATED ) and DRUG ( DRUGUNRELATED ) conjugates on the intestinal permeation of DRUGUNRELATED ( DRUGUNRELATED ) and model peptide drugs , DRUGOTHER and DRUGUNRELATED .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	carboxymethylcellulose-cysteine	insulin	none	{'e1': {'word': 'carboxymethylcellulose-cysteine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d76.s1.e2'}, 'e2': {'word': 'insulin', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d76.s1.e7'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUGUNRELATED ( DRUGUNRELATED ) and DRUG ( DRUGUNRELATED ) conjugates on the intestinal permeation of DRUGUNRELATED ( DRUGUNRELATED ) and model peptide drugs , DRUGUNRELATED and DRUGOTHER .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	CMC-Cys	sodium fluorescein	none	{'e1': {'word': 'CMC-Cys', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d76.s1.e3'}, 'e2': {'word': 'sodium fluorescein', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d76.s1.e4'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUGUNRELATED ( DRUGUNRELATED ) and DRUGUNRELATED ( DRUG ) conjugates on the intestinal permeation of DRUGOTHER ( DRUGUNRELATED ) and model peptide drugs , DRUGUNRELATED and DRUGUNRELATED .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	CMC-Cys	NaFlu	none	{'e1': {'word': 'CMC-Cys', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d76.s1.e3'}, 'e2': {'word': 'NaFlu', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d76.s1.e5'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUGUNRELATED ( DRUGUNRELATED ) and DRUGUNRELATED ( DRUG ) conjugates on the intestinal permeation of DRUGUNRELATED ( DRUGOTHER ) and model peptide drugs , DRUGUNRELATED and DRUGUNRELATED .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	CMC-Cys	bacitracin	none	{'e1': {'word': 'CMC-Cys', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d76.s1.e3'}, 'e2': {'word': 'bacitracin', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d76.s1.e6'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUGUNRELATED ( DRUGUNRELATED ) and DRUGUNRELATED ( DRUG ) conjugates on the intestinal permeation of DRUGUNRELATED ( DRUGUNRELATED ) and model peptide drugs , DRUGOTHER and DRUGUNRELATED .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	CMC-Cys	insulin	none	{'e1': {'word': 'CMC-Cys', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d76.s1.e3'}, 'e2': {'word': 'insulin', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d76.s1.e7'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUGUNRELATED ( DRUGUNRELATED ) and DRUGUNRELATED ( DRUG ) conjugates on the intestinal permeation of DRUGUNRELATED ( DRUGUNRELATED ) and model peptide drugs , DRUGUNRELATED and DRUGOTHER .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium fluorescein	NaFlu	none	{'e1': {'word': 'sodium fluorescein', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d76.s1.e4'}, 'e2': {'word': 'NaFlu', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d76.s1.e5'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUGUNRELATED ( DRUGUNRELATED ) and DRUGUNRELATED ( DRUGUNRELATED ) conjugates on the intestinal permeation of DRUG ( DRUGOTHER ) and model peptide drugs , DRUGUNRELATED and DRUGUNRELATED .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium fluorescein	bacitracin	none	{'e1': {'word': 'sodium fluorescein', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d76.s1.e4'}, 'e2': {'word': 'bacitracin', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d76.s1.e6'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUGUNRELATED ( DRUGUNRELATED ) and DRUGUNRELATED ( DRUGUNRELATED ) conjugates on the intestinal permeation of DRUG ( DRUGUNRELATED ) and model peptide drugs , DRUGOTHER and DRUGUNRELATED .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium fluorescein	insulin	none	{'e1': {'word': 'sodium fluorescein', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d76.s1.e4'}, 'e2': {'word': 'insulin', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d76.s1.e7'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUGUNRELATED ( DRUGUNRELATED ) and DRUGUNRELATED ( DRUGUNRELATED ) conjugates on the intestinal permeation of DRUG ( DRUGUNRELATED ) and model peptide drugs , DRUGUNRELATED and DRUGOTHER .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	NaFlu	bacitracin	none	{'e1': {'word': 'NaFlu', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d76.s1.e5'}, 'e2': {'word': 'bacitracin', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d76.s1.e6'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUGUNRELATED ( DRUGUNRELATED ) and DRUGUNRELATED ( DRUGUNRELATED ) conjugates on the intestinal permeation of DRUGUNRELATED ( DRUG ) and model peptide drugs , DRUGOTHER and DRUGUNRELATED .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	NaFlu	insulin	none	{'e1': {'word': 'NaFlu', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d76.s1.e5'}, 'e2': {'word': 'insulin', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d76.s1.e7'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUGUNRELATED ( DRUGUNRELATED ) and DRUGUNRELATED ( DRUGUNRELATED ) conjugates on the intestinal permeation of DRUGUNRELATED ( DRUG ) and model peptide drugs , DRUGUNRELATED and DRUGOTHER .
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	bacitracin	insulin	none	{'e1': {'word': 'bacitracin', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d76.s1.e6'}, 'e2': {'word': 'insulin', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d76.s1.e7'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of DRUGUNRELATED ( DRUGUNRELATED ) and DRUGUNRELATED ( DRUGUNRELATED ) conjugates on the intestinal permeation of DRUGUNRELATED ( DRUGUNRELATED ) and model peptide drugs , DRUG and DRUGOTHER .
Cysteine was covalently linked to carbodiimide activated NaCMC. 	Cysteine	NaCMC	none	{'e1': {'word': 'Cysteine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s2.e0'}, 'e2': {'word': 'NaCMC', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d76.s2.e1'}, 'sentence_id': 'DDI-MedLine.d76.s2'}	DRUG was covalently linked to carbodiimide activated DRUGOTHER .
Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. 	NaCMC	NaFlu	none	{'e1': {'word': 'NaCMC', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d76.s5.e0'}, 'e2': {'word': 'NaFlu', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d76.s5.e1'}, 'sentence_id': 'DDI-MedLine.d76.s5'}	Unmodified DRUG ( 1 % m / v ) significantly improved the transport ratio ( R = P ( app ) polymer / P ( app ) control ) of DRUGOTHER to 1.3 and 1 % ( m / v ) DRUGUNRELATED conjugated with DRUGUNRELATED further enhanced the permeation .
Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. 	NaCMC	NaCMC	none	{'e1': {'word': 'NaCMC', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d76.s5.e0'}, 'e2': {'word': 'NaCMC', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d76.s5.e2'}, 'sentence_id': 'DDI-MedLine.d76.s5'}	Unmodified DRUG ( 1 % m / v ) significantly improved the transport ratio ( R = P ( app ) polymer / P ( app ) control ) of DRUGUNRELATED to 1.3 and 1 % ( m / v ) DRUGOTHER conjugated with DRUGUNRELATED further enhanced the permeation .
Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. 	NaCMC	cysteine	none	{'e1': {'word': 'NaCMC', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d76.s5.e0'}, 'e2': {'word': 'cysteine', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d76.s5.e3'}, 'sentence_id': 'DDI-MedLine.d76.s5'}	Unmodified DRUG ( 1 % m / v ) significantly improved the transport ratio ( R = P ( app ) polymer / P ( app ) control ) of DRUGUNRELATED to 1.3 and 1 % ( m / v ) DRUGUNRELATED conjugated with DRUGOTHER further enhanced the permeation .
Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. 	NaFlu	NaCMC	none	{'e1': {'word': 'NaFlu', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d76.s5.e1'}, 'e2': {'word': 'NaCMC', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d76.s5.e2'}, 'sentence_id': 'DDI-MedLine.d76.s5'}	Unmodified DRUGUNRELATED ( 1 % m / v ) significantly improved the transport ratio ( R = P ( app ) polymer / P ( app ) control ) of DRUG to 1.3 and 1 % ( m / v ) DRUGOTHER conjugated with DRUGUNRELATED further enhanced the permeation .
Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. 	NaFlu	cysteine	none	{'e1': {'word': 'NaFlu', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d76.s5.e1'}, 'e2': {'word': 'cysteine', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d76.s5.e3'}, 'sentence_id': 'DDI-MedLine.d76.s5'}	Unmodified DRUGUNRELATED ( 1 % m / v ) significantly improved the transport ratio ( R = P ( app ) polymer / P ( app ) control ) of DRUG to 1.3 and 1 % ( m / v ) DRUGUNRELATED conjugated with DRUGOTHER further enhanced the permeation .
Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. 	NaCMC	cysteine	none	{'e1': {'word': 'NaCMC', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d76.s5.e2'}, 'e2': {'word': 'cysteine', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d76.s5.e3'}, 'sentence_id': 'DDI-MedLine.d76.s5'}	Unmodified DRUGUNRELATED ( 1 % m / v ) significantly improved the transport ratio ( R = P ( app ) polymer / P ( app ) control ) of DRUGUNRELATED to 1.3 and 1 % ( m / v ) DRUG conjugated with DRUGOTHER further enhanced the permeation .
Decreasing the concentration of CMC-Cys, exhibiting 7.3% (m/m) of immobilised cysteine (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of NaFlu from 1.8 to 1.2. 	CMC-Cys	cysteine	none	{'e1': {'word': 'CMC-Cys', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d76.s7.e0'}, 'e2': {'word': 'cysteine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d76.s7.e1'}, 'sentence_id': 'DDI-MedLine.d76.s7'}	Decreasing the concentration of DRUG , exhibiting 7.3 % ( m / m ) of immobilised DRUGOTHER ( CMC - Cys7.3 ) from 1 % ( m / v ) to 0.5 % ( m / v ) decreased the R - value of DRUGUNRELATED from 1.8 to 1.2 .
Decreasing the concentration of CMC-Cys, exhibiting 7.3% (m/m) of immobilised cysteine (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of NaFlu from 1.8 to 1.2. 	CMC-Cys	NaFlu	none	{'e1': {'word': 'CMC-Cys', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d76.s7.e0'}, 'e2': {'word': 'NaFlu', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d76.s7.e2'}, 'sentence_id': 'DDI-MedLine.d76.s7'}	Decreasing the concentration of DRUG , exhibiting 7.3 % ( m / m ) of immobilised DRUGUNRELATED ( CMC - Cys7.3 ) from 1 % ( m / v ) to 0.5 % ( m / v ) decreased the R - value of DRUGOTHER from 1.8 to 1.2 .
Decreasing the concentration of CMC-Cys, exhibiting 7.3% (m/m) of immobilised cysteine (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of NaFlu from 1.8 to 1.2. 	cysteine	NaFlu	none	{'e1': {'word': 'cysteine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d76.s7.e1'}, 'e2': {'word': 'NaFlu', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d76.s7.e2'}, 'sentence_id': 'DDI-MedLine.d76.s7'}	Decreasing the concentration of DRUGUNRELATED , exhibiting 7.3 % ( m / m ) of immobilised DRUG ( CMC - Cys7.3 ) from 1 % ( m / v ) to 0.5 % ( m / v ) decreased the R - value of DRUGOTHER from 1.8 to 1.2 .
NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. 	NaCMC	cysteine	none	{'e1': {'word': 'NaCMC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s8.e0'}, 'e2': {'word': 'cysteine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d76.s8.e1'}, 'sentence_id': 'DDI-MedLine.d76.s8'}	DRUG at 1 % ( m / v ) in the presence of free DRUGOTHER had no significant effect on the R - value of DRUGUNRELATED compared to DRUGUNRELATED alone .
NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. 	NaCMC	NaFlu	none	{'e1': {'word': 'NaCMC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s8.e0'}, 'e2': {'word': 'NaFlu', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d76.s8.e2'}, 'sentence_id': 'DDI-MedLine.d76.s8'}	DRUG at 1 % ( m / v ) in the presence of free DRUGUNRELATED had no significant effect on the R - value of DRUGOTHER compared to DRUGUNRELATED alone .
NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. 	NaCMC	NaCMC	none	{'e1': {'word': 'NaCMC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s8.e0'}, 'e2': {'word': 'NaCMC', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d76.s8.e3'}, 'sentence_id': 'DDI-MedLine.d76.s8'}	DRUG at 1 % ( m / v ) in the presence of free DRUGUNRELATED had no significant effect on the R - value of DRUGUNRELATED compared to DRUGOTHER alone .
NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. 	cysteine	NaFlu	none	{'e1': {'word': 'cysteine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d76.s8.e1'}, 'e2': {'word': 'NaFlu', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d76.s8.e2'}, 'sentence_id': 'DDI-MedLine.d76.s8'}	DRUGUNRELATED at 1 % ( m / v ) in the presence of free DRUG had no significant effect on the R - value of DRUGOTHER compared to DRUGUNRELATED alone .
NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. 	cysteine	NaCMC	none	{'e1': {'word': 'cysteine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d76.s8.e1'}, 'e2': {'word': 'NaCMC', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d76.s8.e3'}, 'sentence_id': 'DDI-MedLine.d76.s8'}	DRUGUNRELATED at 1 % ( m / v ) in the presence of free DRUG had no significant effect on the R - value of DRUGUNRELATED compared to DRUGOTHER alone .
NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. 	NaFlu	NaCMC	none	{'e1': {'word': 'NaFlu', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d76.s8.e2'}, 'e2': {'word': 'NaCMC', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d76.s8.e3'}, 'sentence_id': 'DDI-MedLine.d76.s8'}	DRUGUNRELATED at 1 % ( m / v ) in the presence of free DRUGUNRELATED had no significant effect on the R - value of DRUG compared to DRUGOTHER alone .
Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). 	bacitracin	insulin	none	{'e1': {'word': 'bacitracin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d76.s9.e0'}, 'e2': {'word': 'insulin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d76.s9.e1'}, 'sentence_id': 'DDI-MedLine.d76.s9'}	Formulation of fluorescence labelled DRUG and DRUGOTHER in unconjugated DRUGUNRELATED ( 1 % m / v ) did not significantly improve the permeation , however in the presence of 1 % ( m / v ) DRUGUNRELATED 7.3 a significantly improved permeation was observed ( R = 1.3 ) .
Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). 	bacitracin	NaCMC	none	{'e1': {'word': 'bacitracin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d76.s9.e0'}, 'e2': {'word': 'NaCMC', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d76.s9.e2'}, 'sentence_id': 'DDI-MedLine.d76.s9'}	Formulation of fluorescence labelled DRUG and DRUGUNRELATED in unconjugated DRUGOTHER ( 1 % m / v ) did not significantly improve the permeation , however in the presence of 1 % ( m / v ) DRUGUNRELATED 7.3 a significantly improved permeation was observed ( R = 1.3 ) .
Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). 	bacitracin	CMC-Cys	none	{'e1': {'word': 'bacitracin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d76.s9.e0'}, 'e2': {'word': 'CMC-Cys', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d76.s9.e3'}, 'sentence_id': 'DDI-MedLine.d76.s9'}	Formulation of fluorescence labelled DRUG and DRUGUNRELATED in unconjugated DRUGUNRELATED ( 1 % m / v ) did not significantly improve the permeation , however in the presence of 1 % ( m / v ) DRUGOTHER 7.3 a significantly improved permeation was observed ( R = 1.3 ) .
Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). 	insulin	NaCMC	none	{'e1': {'word': 'insulin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d76.s9.e1'}, 'e2': {'word': 'NaCMC', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d76.s9.e2'}, 'sentence_id': 'DDI-MedLine.d76.s9'}	Formulation of fluorescence labelled DRUGUNRELATED and DRUG in unconjugated DRUGOTHER ( 1 % m / v ) did not significantly improve the permeation , however in the presence of 1 % ( m / v ) DRUGUNRELATED 7.3 a significantly improved permeation was observed ( R = 1.3 ) .
Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). 	insulin	CMC-Cys	none	{'e1': {'word': 'insulin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d76.s9.e1'}, 'e2': {'word': 'CMC-Cys', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d76.s9.e3'}, 'sentence_id': 'DDI-MedLine.d76.s9'}	Formulation of fluorescence labelled DRUGUNRELATED and DRUG in unconjugated DRUGUNRELATED ( 1 % m / v ) did not significantly improve the permeation , however in the presence of 1 % ( m / v ) DRUGOTHER 7.3 a significantly improved permeation was observed ( R = 1.3 ) .
Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). 	NaCMC	CMC-Cys	none	{'e1': {'word': 'NaCMC', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d76.s9.e2'}, 'e2': {'word': 'CMC-Cys', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d76.s9.e3'}, 'sentence_id': 'DDI-MedLine.d76.s9'}	Formulation of fluorescence labelled DRUGUNRELATED and DRUGUNRELATED in unconjugated DRUG ( 1 % m / v ) did not significantly improve the permeation , however in the presence of 1 % ( m / v ) DRUGOTHER 7.3 a significantly improved permeation was observed ( R = 1.3 ) .
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	NaCMC	cysteine	none	{'e1': {'word': 'NaCMC', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d76.s10.e0'}, 'e2': {'word': 'cysteine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d76.s10.e1'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	Conjugation at DRUG with DRUGOTHER moieties significantly improves the intestinal permeation of the hydrophilic molecule DRUGUNRELATED and the model peptide drugs DRUGUNRELATED and DRUGUNRELATED in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	NaCMC	NaFlu	none	{'e1': {'word': 'NaCMC', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d76.s10.e0'}, 'e2': {'word': 'NaFlu', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d76.s10.e2'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	Conjugation at DRUG with DRUGUNRELATED moieties significantly improves the intestinal permeation of the hydrophilic molecule DRUGOTHER and the model peptide drugs DRUGUNRELATED and DRUGUNRELATED in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	NaCMC	bacitracin	none	{'e1': {'word': 'NaCMC', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d76.s10.e0'}, 'e2': {'word': 'bacitracin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s10.e3'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	Conjugation at DRUG with DRUGUNRELATED moieties significantly improves the intestinal permeation of the hydrophilic molecule DRUGUNRELATED and the model peptide drugs DRUGOTHER and DRUGUNRELATED in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	NaCMC	insulin	none	{'e1': {'word': 'NaCMC', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d76.s10.e0'}, 'e2': {'word': 'insulin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d76.s10.e4'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	Conjugation at DRUG with DRUGUNRELATED moieties significantly improves the intestinal permeation of the hydrophilic molecule DRUGUNRELATED and the model peptide drugs DRUGUNRELATED and DRUGOTHER in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	cysteine	NaFlu	none	{'e1': {'word': 'cysteine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d76.s10.e1'}, 'e2': {'word': 'NaFlu', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d76.s10.e2'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	Conjugation at DRUGUNRELATED with DRUG moieties significantly improves the intestinal permeation of the hydrophilic molecule DRUGOTHER and the model peptide drugs DRUGUNRELATED and DRUGUNRELATED in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	cysteine	bacitracin	none	{'e1': {'word': 'cysteine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d76.s10.e1'}, 'e2': {'word': 'bacitracin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s10.e3'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	Conjugation at DRUGUNRELATED with DRUG moieties significantly improves the intestinal permeation of the hydrophilic molecule DRUGUNRELATED and the model peptide drugs DRUGOTHER and DRUGUNRELATED in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	cysteine	insulin	none	{'e1': {'word': 'cysteine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d76.s10.e1'}, 'e2': {'word': 'insulin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d76.s10.e4'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	Conjugation at DRUGUNRELATED with DRUG moieties significantly improves the intestinal permeation of the hydrophilic molecule DRUGUNRELATED and the model peptide drugs DRUGUNRELATED and DRUGOTHER in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	NaFlu	bacitracin	none	{'e1': {'word': 'NaFlu', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d76.s10.e2'}, 'e2': {'word': 'bacitracin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s10.e3'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	Conjugation at DRUGUNRELATED with DRUGUNRELATED moieties significantly improves the intestinal permeation of the hydrophilic molecule DRUG and the model peptide drugs DRUGOTHER and DRUGUNRELATED in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	NaFlu	insulin	none	{'e1': {'word': 'NaFlu', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d76.s10.e2'}, 'e2': {'word': 'insulin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d76.s10.e4'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	Conjugation at DRUGUNRELATED with DRUGUNRELATED moieties significantly improves the intestinal permeation of the hydrophilic molecule DRUG and the model peptide drugs DRUGUNRELATED and DRUGOTHER in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	bacitracin	insulin	none	{'e1': {'word': 'bacitracin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s10.e3'}, 'e2': {'word': 'insulin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d76.s10.e4'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	Conjugation at DRUGUNRELATED with DRUGUNRELATED moieties significantly improves the intestinal permeation of the hydrophilic molecule DRUGUNRELATED and the model peptide drugs DRUG and DRUGOTHER in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .
"ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia.
"	ADL 8-2698	morphine	effect	{'e1': {'word': 'ADL 8-2698', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d87.s0.e0'}, 'e2': {'word': 'morphine', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d87.s0.e1'}, 'sentence_id': 'DDI-MedLine.d87.s0'}	DRUG , a trans - 3 , 4 - dimethyl - 4 - ( 3 - hydroxyphenyl ) piperidine , prevents gastrointestinal effects of intravenous DRUGOTHER without affecting analgesia .
ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia. 	ADL-8-2698	peripherally restricted opioid antagonist	none	{'e1': {'word': 'ADL-8-2698', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d87.s1.e0'}, 'e2': {'word': 'peripherally restricted opioid antagonist', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d87.s1.e1'}, 'sentence_id': 'DDI-MedLine.d87.s1'}	DRUG is a novel DRUGOTHER that may selectively prevent DRUGUNRELATED - induced gastrointestinal effects without reversing analgesia .
ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia. 	ADL-8-2698	opioid	effect	{'e1': {'word': 'ADL-8-2698', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d87.s1.e0'}, 'e2': {'word': 'opioid', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d87.s1.e2'}, 'sentence_id': 'DDI-MedLine.d87.s1'}	DRUG is a novel DRUGUNRELATED that may selectively prevent DRUGOTHER - induced gastrointestinal effects without reversing analgesia .
ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia. 	peripherally restricted opioid antagonist	opioid	none	{'e1': {'word': 'peripherally restricted opioid antagonist', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d87.s1.e1'}, 'e2': {'word': 'opioid', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d87.s1.e2'}, 'sentence_id': 'DDI-MedLine.d87.s1'}	DRUGUNRELATED is a novel DRUG that may selectively prevent DRUGOTHER - induced gastrointestinal effects without reversing analgesia .
Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (0.05 mg x kg(-1)), and oral ADL 8-2698 (4 mg) and intravenous morphine (0.05 mg x kg(-1)) in a double blind, cross-over study. 	morphine	ADL 8-2698	none	{'e1': {'word': 'morphine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d87.s2.e0'}, 'e2': {'word': 'ADL 8-2698', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d87.s2.e1'}, 'sentence_id': 'DDI-MedLine.d87.s2'}	Gastrointestinal transit time ( lactulose hydrogen breath test ) was measured in 14 volunteers with oral and intravenous placebo , oral placebo and intravenous DRUG ( 0.05 mg x kg ( - 1 ) ) , and oral DRUGOTHER ( 4 mg ) and intravenous DRUGUNRELATED ( 0.05 mg x kg ( - 1 ) ) in a double blind , cross-over study .
Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (0.05 mg x kg(-1)), and oral ADL 8-2698 (4 mg) and intravenous morphine (0.05 mg x kg(-1)) in a double blind, cross-over study. 	morphine	morphine	none	{'e1': {'word': 'morphine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d87.s2.e0'}, 'e2': {'word': 'morphine', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d87.s2.e2'}, 'sentence_id': 'DDI-MedLine.d87.s2'}	Gastrointestinal transit time ( lactulose hydrogen breath test ) was measured in 14 volunteers with oral and intravenous placebo , oral placebo and intravenous DRUG ( 0.05 mg x kg ( - 1 ) ) , and oral DRUGUNRELATED ( 4 mg ) and intravenous DRUGOTHER ( 0.05 mg x kg ( - 1 ) ) in a double blind , cross-over study .
Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (0.05 mg x kg(-1)), and oral ADL 8-2698 (4 mg) and intravenous morphine (0.05 mg x kg(-1)) in a double blind, cross-over study. 	ADL 8-2698	morphine	none	{'e1': {'word': 'ADL 8-2698', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d87.s2.e1'}, 'e2': {'word': 'morphine', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d87.s2.e2'}, 'sentence_id': 'DDI-MedLine.d87.s2'}	Gastrointestinal transit time ( lactulose hydrogen breath test ) was measured in 14 volunteers with oral and intravenous placebo , oral placebo and intravenous DRUGUNRELATED ( 0.05 mg x kg ( - 1 ) ) , and oral DRUG ( 4 mg ) and intravenous DRUGOTHER ( 0.05 mg x kg ( - 1 ) ) in a double blind , cross-over study .
Morphine prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005); this was prevented by ADL 8-2698 (P = .004). 	Morphine	ADL 8-2698	effect	{'e1': {'word': 'Morphine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d87.s4.e0'}, 'e2': {'word': 'ADL 8-2698', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d87.s4.e1'}, 'sentence_id': 'DDI-MedLine.d87.s4'}	DRUG prolonged gastrointestinal transit time from 69 to 103 minutes ( P = .005 ) ; this was prevented by DRUGOTHER ( P = .004 ) .
Postoperatively, 45 patients were randomly assigned in a double-blind fashion to receive ADL 8-2698 (4 mg) or placebo and intravenous morphine (0.15 mg/kg) or to receive oral and intravenous placebo. 	ADL 8-2698	morphine	none	{'e1': {'word': 'ADL 8-2698', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d87.s5.e0'}, 'e2': {'word': 'morphine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d87.s5.e1'}, 'sentence_id': 'DDI-MedLine.d87.s5'}	Postoperatively , 45 patients were randomly assigned in a double - blind fashion to receive DRUG ( 4 mg ) or placebo and intravenous DRUGOTHER ( 0.15 mg / kg ) or to receive oral and intravenous placebo .
Morphine analgesia and pupil constriction were unaffected by ADL 8-2698 and differed from placebo (P < .002). 	Morphine	ADL 8-2698	none	{'e1': {'word': 'Morphine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d87.s7.e0'}, 'e2': {'word': 'ADL 8-2698', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d87.s7.e1'}, 'sentence_id': 'DDI-MedLine.d87.s7'}	DRUG analgesia and pupil constriction were unaffected by DRUGOTHER and differed from placebo ( P < .002 ) .
We conclude that ADL 8-2698 prevents morphine-induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia.	ADL 8-2698	morphine	effect	{'e1': {'word': 'ADL 8-2698', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d87.s8.e0'}, 'e2': {'word': 'morphine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d87.s8.e1'}, 'sentence_id': 'DDI-MedLine.d87.s8'}	We conclude that DRUG prevents DRUGOTHER - induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia .
Fluvastatin is the first synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor to be approved for clinical use, and has been studied extensively in humans since 1986. 	Fluvastatin	synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor	none	{'e1': {'word': 'Fluvastatin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d119.s1.e0'}, 'e2': {'word': 'synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d119.s1.e1'}, 'sentence_id': 'DDI-MedLine.d119.s1'}	DRUG is the first DRUGOTHER to be approved for clinical use , and has been studied extensively in humans since 1986 .
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 	HMGCoA reductase inhibitors	lovastatin	none	{'e1': {'word': 'HMGCoA reductase inhibitors', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d119.s2.e0'}, 'e2': {'word': 'lovastatin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d119.s2.e1'}, 'sentence_id': 'DDI-MedLine.d119.s2'}	It is structurally distinct from the other currently available DRUG ( DRUGOTHER , DRUGUNRELATED , and DRUGUNRELATED ) , leading to unique biopharmaceutical properties relative to the other agents of this class .
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 	HMGCoA reductase inhibitors	simvastatin	none	{'e1': {'word': 'HMGCoA reductase inhibitors', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d119.s2.e0'}, 'e2': {'word': 'simvastatin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d119.s2.e2'}, 'sentence_id': 'DDI-MedLine.d119.s2'}	It is structurally distinct from the other currently available DRUG ( DRUGUNRELATED , DRUGOTHER , and DRUGUNRELATED ) , leading to unique biopharmaceutical properties relative to the other agents of this class .
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 	HMGCoA reductase inhibitors	pravastatin	none	{'e1': {'word': 'HMGCoA reductase inhibitors', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d119.s2.e0'}, 'e2': {'word': 'pravastatin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d119.s2.e3'}, 'sentence_id': 'DDI-MedLine.d119.s2'}	It is structurally distinct from the other currently available DRUG ( DRUGUNRELATED , DRUGUNRELATED , and DRUGOTHER ) , leading to unique biopharmaceutical properties relative to the other agents of this class .
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 	lovastatin	simvastatin	none	{'e1': {'word': 'lovastatin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d119.s2.e1'}, 'e2': {'word': 'simvastatin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d119.s2.e2'}, 'sentence_id': 'DDI-MedLine.d119.s2'}	It is structurally distinct from the other currently available DRUGUNRELATED ( DRUG , DRUGOTHER , and DRUGUNRELATED ) , leading to unique biopharmaceutical properties relative to the other agents of this class .
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 	lovastatin	pravastatin	none	{'e1': {'word': 'lovastatin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d119.s2.e1'}, 'e2': {'word': 'pravastatin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d119.s2.e3'}, 'sentence_id': 'DDI-MedLine.d119.s2'}	It is structurally distinct from the other currently available DRUGUNRELATED ( DRUG , DRUGUNRELATED , and DRUGOTHER ) , leading to unique biopharmaceutical properties relative to the other agents of this class .
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 	simvastatin	pravastatin	none	{'e1': {'word': 'simvastatin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d119.s2.e2'}, 'e2': {'word': 'pravastatin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d119.s2.e3'}, 'sentence_id': 'DDI-MedLine.d119.s2'}	It is structurally distinct from the other currently available DRUGUNRELATED ( DRUGUNRELATED , DRUG , and DRUGOTHER ) , leading to unique biopharmaceutical properties relative to the other agents of this class .
Cholestyramine, an anionic-binding resin, has a considerable effect in lowering the rate and extent of fluvastatin bioavailability. 	Cholestyramine	fluvastatin	mechanism	{'e1': {'word': 'Cholestyramine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d119.s15.e0'}, 'e2': {'word': 'fluvastatin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d119.s15.e1'}, 'sentence_id': 'DDI-MedLine.d119.s15'}	DRUG , an anionic - binding resin , has a considerable effect in lowering the rate and extent of DRUGOTHER bioavailability .
Although this effect was noted even when cholestyramine was given 4 hours prior to fluvastatin, this regimen did not result in diminished efficacy. 	cholestyramine	fluvastatin	effect	{'e1': {'word': 'cholestyramine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d119.s16.e0'}, 'e2': {'word': 'fluvastatin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d119.s16.e1'}, 'sentence_id': 'DDI-MedLine.d119.s16'}	Although this effect was noted even when DRUG was given 4 hours prior to DRUGOTHER , this regimen did not result in diminished efficacy .
Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of warfarin and fluvastatin. 	warfarin	warfarin	none	{'e1': {'word': 'warfarin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d119.s17.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d119.s17.e1'}, 'sentence_id': 'DDI-MedLine.d119.s17'}	Further , no effects on either DRUG levels or prothrombin times were observed in a study involving concomitant administration of DRUGOTHER and DRUGUNRELATED .
Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of warfarin and fluvastatin. 	warfarin	fluvastatin	none	{'e1': {'word': 'warfarin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d119.s17.e0'}, 'e2': {'word': 'fluvastatin', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d119.s17.e2'}, 'sentence_id': 'DDI-MedLine.d119.s17'}	Further , no effects on either DRUG levels or prothrombin times were observed in a study involving concomitant administration of DRUGUNRELATED and DRUGOTHER .
Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of warfarin and fluvastatin. 	warfarin	fluvastatin	none	{'e1': {'word': 'warfarin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d119.s17.e1'}, 'e2': {'word': 'fluvastatin', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d119.s17.e2'}, 'sentence_id': 'DDI-MedLine.d119.s17'}	Further , no effects on either DRUGUNRELATED levels or prothrombin times were observed in a study involving concomitant administration of DRUG and DRUGOTHER .
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	niacin	propranolol	none	{'e1': {'word': 'niacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d119.s18.e0'}, 'e2': {'word': 'propranolol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d119.s18.e1'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	Moreover , additional interaction studies with DRUG and DRUGOTHER have not demonstrated any effect on DRUGUNRELATED plasma levels , and administration to a patient population chronically receiving DRUGUNRELATED resulted in no difference in the extent of bioavailability of DRUGUNRELATED relative to control data .
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	niacin	fluvastatin	none	{'e1': {'word': 'niacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d119.s18.e0'}, 'e2': {'word': 'fluvastatin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d119.s18.e2'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	Moreover , additional interaction studies with DRUG and DRUGUNRELATED have not demonstrated any effect on DRUGOTHER plasma levels , and administration to a patient population chronically receiving DRUGUNRELATED resulted in no difference in the extent of bioavailability of DRUGUNRELATED relative to control data .
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	niacin	digoxin	none	{'e1': {'word': 'niacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d119.s18.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d119.s18.e3'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	Moreover , additional interaction studies with DRUG and DRUGUNRELATED have not demonstrated any effect on DRUGUNRELATED plasma levels , and administration to a patient population chronically receiving DRUGOTHER resulted in no difference in the extent of bioavailability of DRUGUNRELATED relative to control data .
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	niacin	digoxin	none	{'e1': {'word': 'niacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d119.s18.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d119.s18.e4'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	Moreover , additional interaction studies with DRUG and DRUGUNRELATED have not demonstrated any effect on DRUGUNRELATED plasma levels , and administration to a patient population chronically receiving DRUGUNRELATED resulted in no difference in the extent of bioavailability of DRUGOTHER relative to control data .
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	propranolol	fluvastatin	none	{'e1': {'word': 'propranolol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d119.s18.e1'}, 'e2': {'word': 'fluvastatin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d119.s18.e2'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	Moreover , additional interaction studies with DRUGUNRELATED and DRUG have not demonstrated any effect on DRUGOTHER plasma levels , and administration to a patient population chronically receiving DRUGUNRELATED resulted in no difference in the extent of bioavailability of DRUGUNRELATED relative to control data .
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	propranolol	digoxin	none	{'e1': {'word': 'propranolol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d119.s18.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d119.s18.e3'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	Moreover , additional interaction studies with DRUGUNRELATED and DRUG have not demonstrated any effect on DRUGUNRELATED plasma levels , and administration to a patient population chronically receiving DRUGOTHER resulted in no difference in the extent of bioavailability of DRUGUNRELATED relative to control data .
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	propranolol	digoxin	none	{'e1': {'word': 'propranolol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d119.s18.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d119.s18.e4'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	Moreover , additional interaction studies with DRUGUNRELATED and DRUG have not demonstrated any effect on DRUGUNRELATED plasma levels , and administration to a patient population chronically receiving DRUGUNRELATED resulted in no difference in the extent of bioavailability of DRUGOTHER relative to control data .
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	fluvastatin	digoxin	none	{'e1': {'word': 'fluvastatin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d119.s18.e2'}, 'e2': {'word': 'digoxin', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d119.s18.e3'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	Moreover , additional interaction studies with DRUGUNRELATED and DRUGUNRELATED have not demonstrated any effect on DRUG plasma levels , and administration to a patient population chronically receiving DRUGOTHER resulted in no difference in the extent of bioavailability of DRUGUNRELATED relative to control data .
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	fluvastatin	digoxin	none	{'e1': {'word': 'fluvastatin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d119.s18.e2'}, 'e2': {'word': 'digoxin', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d119.s18.e4'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	Moreover , additional interaction studies with DRUGUNRELATED and DRUGUNRELATED have not demonstrated any effect on DRUG plasma levels , and administration to a patient population chronically receiving DRUGUNRELATED resulted in no difference in the extent of bioavailability of DRUGOTHER relative to control data .
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d119.s18.e3'}, 'e2': {'word': 'digoxin', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d119.s18.e4'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	Moreover , additional interaction studies with DRUGUNRELATED and DRUGUNRELATED have not demonstrated any effect on DRUGUNRELATED plasma levels , and administration to a patient population chronically receiving DRUG resulted in no difference in the extent of bioavailability of DRUGOTHER relative to control data .
Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats. 	Resveratrol	noradrenaline	none	{'e1': {'word': 'Resveratrol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d95.s4.e0'}, 'e2': {'word': 'noradrenaline', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d95.s4.e1'}, 'sentence_id': 'DDI-MedLine.d95.s4'}	DRUG ( 5 - 35 micromol / l ) induced concentration - dependent relaxation of mesenteric arteries preconstricted with DRUGOTHER ( 8 micromol / l ) or DRUGUNRELATED ( 125 mmol / l ) from both lean and dietary - obese rats .
Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats. 	Resveratrol	KCl	none	{'e1': {'word': 'Resveratrol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d95.s4.e0'}, 'e2': {'word': 'KCl', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d95.s4.e2'}, 'sentence_id': 'DDI-MedLine.d95.s4'}	DRUG ( 5 - 35 micromol / l ) induced concentration - dependent relaxation of mesenteric arteries preconstricted with DRUGUNRELATED ( 8 micromol / l ) or DRUGOTHER ( 125 mmol / l ) from both lean and dietary - obese rats .
Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats. 	noradrenaline	KCl	none	{'e1': {'word': 'noradrenaline', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d95.s4.e1'}, 'e2': {'word': 'KCl', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d95.s4.e2'}, 'sentence_id': 'DDI-MedLine.d95.s4'}	DRUGUNRELATED ( 5 - 35 micromol / l ) induced concentration - dependent relaxation of mesenteric arteries preconstricted with DRUG ( 8 micromol / l ) or DRUGOTHER ( 125 mmol / l ) from both lean and dietary - obese rats .
However, L-NAME (100 and 300 micromol/l) did not alter the effects of reseveratrol on arteries from dietary-obese rats, giving superimposed concentration-responses curves. 	L-NAME	reseveratrol	none	{'e1': {'word': 'L-NAME', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d95.s6.e0'}, 'e2': {'word': 'reseveratrol', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d95.s6.e1'}, 'sentence_id': 'DDI-MedLine.d95.s6'}	However , DRUG ( 100 and 300 micromol / l ) did not alter the effects of DRUGOTHER on arteries from dietary - obese rats , giving superimposed concentration - responses curves .
Indomethacin was also ineffective in altering resveratrol activity in arteries from both lean and dietary-obese rats. 	Indomethacin	resveratrol	none	{'e1': {'word': 'Indomethacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d95.s7.e0'}, 'e2': {'word': 'resveratrol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d95.s7.e1'}, 'sentence_id': 'DDI-MedLine.d95.s7'}	DRUG was also ineffective in altering DRUGOTHER activity in arteries from both lean and dietary - obese rats .
In noradrenaline-precontracted arteries from dietary-obese rats, responses to resveratrol were not attenuated by endothelial denudation, indicating an action independent of the endothelium. 	noradrenaline	resveratrol	none	{'e1': {'word': 'noradrenaline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d95.s8.e0'}, 'e2': {'word': 'resveratrol', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d95.s8.e1'}, 'sentence_id': 'DDI-MedLine.d95.s8'}	In DRUG - precontracted arteries from dietary - obese rats , responses to DRUGOTHER were not attenuated by endothelial denudation , indicating an action independent of the endothelium .
This study indicates that: (a) the maximal effects of resveratrol on resistance arteries from lean and dietary-obese rats are not effected by endothelial dysfunction, and (b) the effects of resveratrol in lean animals (where endothelial function is not impaired), but not in dietary-obese rats, are mediated via NO.	resveratrol	resveratrol	none	{'e1': {'word': 'resveratrol', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d95.s9.e0'}, 'e2': {'word': 'resveratrol', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d95.s9.e1'}, 'sentence_id': 'DDI-MedLine.d95.s9'}	This study indicates that : ( a ) the maximal effects of DRUG on resistance arteries from lean and dietary - obese rats are not effected by endothelial dysfunction , and ( b ) the effects of DRUGOTHER in lean animals ( where endothelial function is not impaired ) , but not in dietary - obese rats , are mediated via NO .
On the basis of the estimated number of regular users of intravenous amphetamine in Ontario, the mortality rate in such users is at least four times as high as in the general population of the same age, and is comparable to that in alcoholics and heroin addicts. 	amphetamine	heroin	none	{'e1': {'word': 'amphetamine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d13.s7.e0'}, 'e2': {'word': 'heroin', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d13.s7.e1'}, 'sentence_id': 'DDI-MedLine.d13.s7'}	On the basis of the estimated number of regular users of intravenous DRUG in Ontario , the mortality rate in such users is at least four times as high as in the general population of the same age , and is comparable to that in alcoholics and DRUGOTHER addicts .
However, the absolute number of alcohol-related deaths is far greater than the number of deaths in amphetamine or heroin users.	alcohol	amphetamine	none	{'e1': {'word': 'alcohol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d13.s8.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d13.s8.e1'}, 'sentence_id': 'DDI-MedLine.d13.s8'}	However , the absolute number of DRUG - related deaths is far greater than the number of deaths in DRUGOTHER or DRUGUNRELATED users .
However, the absolute number of alcohol-related deaths is far greater than the number of deaths in amphetamine or heroin users.	alcohol	heroin	none	{'e1': {'word': 'alcohol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d13.s8.e0'}, 'e2': {'word': 'heroin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d13.s8.e2'}, 'sentence_id': 'DDI-MedLine.d13.s8'}	However , the absolute number of DRUG - related deaths is far greater than the number of deaths in DRUGUNRELATED or DRUGOTHER users .
However, the absolute number of alcohol-related deaths is far greater than the number of deaths in amphetamine or heroin users.	amphetamine	heroin	none	{'e1': {'word': 'amphetamine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d13.s8.e1'}, 'e2': {'word': 'heroin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d13.s8.e2'}, 'sentence_id': 'DDI-MedLine.d13.s8'}	However , the absolute number of DRUGUNRELATED - related deaths is far greater than the number of deaths in DRUG or DRUGOTHER users .
"The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine.
"	phenytoin	quetiapine	none	{'e1': {'word': 'phenytoin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d0.s0.e0'}, 'e2': {'word': 'quetiapine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d0.s0.e1'}, 'sentence_id': 'DDI-MedLine.d0.s0'}	The effects of concomitant DRUG administration on the steady - state pharmacokinetics of DRUGOTHER .
Quetiapine fumarate ('Seroquel') is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia. 	Quetiapine fumarate	Seroquel	none	{'e1': {'word': 'Quetiapine fumarate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d0.s1.e0'}, 'e2': {'word': 'Seroquel', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d0.s1.e1'}, 'sentence_id': 'DDI-MedLine.d0.s1'}	DRUG ( ' DRUGOTHER ' ) is a newly introduced DRUGUNRELATED with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia .
Quetiapine fumarate ('Seroquel') is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia. 	Quetiapine fumarate	atypical antipsychotic	none	{'e1': {'word': 'Quetiapine fumarate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d0.s1.e0'}, 'e2': {'word': 'atypical antipsychotic', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d0.s1.e2'}, 'sentence_id': 'DDI-MedLine.d0.s1'}	DRUG ( ' DRUGUNRELATED ' ) is a newly introduced DRUGOTHER with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia .
Quetiapine fumarate ('Seroquel') is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia. 	Seroquel	atypical antipsychotic	none	{'e1': {'word': 'Seroquel', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d0.s1.e1'}, 'e2': {'word': 'atypical antipsychotic', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d0.s1.e2'}, 'sentence_id': 'DDI-MedLine.d0.s1'}	DRUGUNRELATED ( ' DRUG ' ) is a newly introduced DRUGOTHER with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia .
This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder. 	phenytoin	quetiapine	mechanism	{'e1': {'word': 'phenytoin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d0.s4.e0'}, 'e2': {'word': 'quetiapine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d0.s4.e1'}, 'sentence_id': 'DDI-MedLine.d0.s4'}	This study demonstrated that the potent cytochrome P450 enzyme - inducer DRUG did indeed have a marked effect on the metabolism of DRUGOTHER , resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM - IV - diagnosed schizophrenia , schizoaffective disorder , or bipolar disorder .
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	caffeine	theophylline	none	{'e1': {'word': 'caffeine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d51.s1.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d51.s1.e1'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	We investigated the effects of adenosine receptor antagonists , DRUG , DRUGOTHER , DRUGUNRELATED , and DRUGUNRELATED ( DRUGUNRELATED ) , in a light / dark test in mice .
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	caffeine	8-phenyltheophylline	none	{'e1': {'word': 'caffeine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d51.s1.e0'}, 'e2': {'word': '8-phenyltheophylline', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d51.s1.e2'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	We investigated the effects of adenosine receptor antagonists , DRUG , DRUGUNRELATED , DRUGOTHER , and DRUGUNRELATED ( DRUGUNRELATED ) , in a light / dark test in mice .
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	caffeine	8-cyclopentyl-1,3-dipropylxanthine	none	{'e1': {'word': 'caffeine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d51.s1.e0'}, 'e2': {'word': '8-cyclopentyl-1,3-dipropylxanthine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d51.s1.e3'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	We investigated the effects of adenosine receptor antagonists , DRUG , DRUGUNRELATED , DRUGUNRELATED , and DRUGOTHER ( DRUGUNRELATED ) , in a light / dark test in mice .
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	caffeine	DPCPX	none	{'e1': {'word': 'caffeine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d51.s1.e0'}, 'e2': {'word': 'DPCPX', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d51.s1.e4'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	We investigated the effects of adenosine receptor antagonists , DRUG , DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED ( DRUGOTHER ) , in a light / dark test in mice .
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	theophylline	8-phenyltheophylline	none	{'e1': {'word': 'theophylline', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d51.s1.e1'}, 'e2': {'word': '8-phenyltheophylline', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d51.s1.e2'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	We investigated the effects of adenosine receptor antagonists , DRUGUNRELATED , DRUG , DRUGOTHER , and DRUGUNRELATED ( DRUGUNRELATED ) , in a light / dark test in mice .
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	theophylline	8-cyclopentyl-1,3-dipropylxanthine	none	{'e1': {'word': 'theophylline', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d51.s1.e1'}, 'e2': {'word': '8-cyclopentyl-1,3-dipropylxanthine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d51.s1.e3'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	We investigated the effects of adenosine receptor antagonists , DRUGUNRELATED , DRUG , DRUGUNRELATED , and DRUGOTHER ( DRUGUNRELATED ) , in a light / dark test in mice .
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	theophylline	DPCPX	none	{'e1': {'word': 'theophylline', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d51.s1.e1'}, 'e2': {'word': 'DPCPX', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d51.s1.e4'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	We investigated the effects of adenosine receptor antagonists , DRUGUNRELATED , DRUG , DRUGUNRELATED , and DRUGUNRELATED ( DRUGOTHER ) , in a light / dark test in mice .
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	8-phenyltheophylline	8-cyclopentyl-1,3-dipropylxanthine	none	{'e1': {'word': '8-phenyltheophylline', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d51.s1.e2'}, 'e2': {'word': '8-cyclopentyl-1,3-dipropylxanthine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d51.s1.e3'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	We investigated the effects of adenosine receptor antagonists , DRUGUNRELATED , DRUGUNRELATED , DRUG , and DRUGOTHER ( DRUGUNRELATED ) , in a light / dark test in mice .
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	8-phenyltheophylline	DPCPX	none	{'e1': {'word': '8-phenyltheophylline', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d51.s1.e2'}, 'e2': {'word': 'DPCPX', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d51.s1.e4'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	We investigated the effects of adenosine receptor antagonists , DRUGUNRELATED , DRUGUNRELATED , DRUG , and DRUGUNRELATED ( DRUGOTHER ) , in a light / dark test in mice .
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	8-cyclopentyl-1,3-dipropylxanthine	DPCPX	none	{'e1': {'word': '8-cyclopentyl-1,3-dipropylxanthine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d51.s1.e3'}, 'e2': {'word': 'DPCPX', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d51.s1.e4'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	We investigated the effects of adenosine receptor antagonists , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , and DRUG ( DRUGOTHER ) , in a light / dark test in mice .
The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. 	theophylline	CGS 21680	effect	{'e1': {'word': 'theophylline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d51.s3.e0'}, 'e2': {'word': 'CGS 21680', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d51.s3.e1'}, 'sentence_id': 'DDI-MedLine.d51.s3'}	The anxiogenic effects of DRUG were reduced by pretreatment with DRUGOTHER , an A2 - selective agonist , but not by DRUGUNRELATED ( DRUGUNRELATED ) , an A1 - selective agonist .
The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. 	theophylline	N6-cyclopentyladenosine	none	{'e1': {'word': 'theophylline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d51.s3.e0'}, 'e2': {'word': 'N6-cyclopentyladenosine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d51.s3.e2'}, 'sentence_id': 'DDI-MedLine.d51.s3'}	The anxiogenic effects of DRUG were reduced by pretreatment with DRUGUNRELATED , an A2 - selective agonist , but not by DRUGOTHER ( DRUGUNRELATED ) , an A1 - selective agonist .
The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. 	theophylline	CPA	none	{'e1': {'word': 'theophylline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d51.s3.e0'}, 'e2': {'word': 'CPA', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d51.s3.e3'}, 'sentence_id': 'DDI-MedLine.d51.s3'}	The anxiogenic effects of DRUG were reduced by pretreatment with DRUGUNRELATED , an A2 - selective agonist , but not by DRUGUNRELATED ( DRUGOTHER ) , an A1 - selective agonist .
The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. 	CGS 21680	N6-cyclopentyladenosine	none	{'e1': {'word': 'CGS 21680', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d51.s3.e1'}, 'e2': {'word': 'N6-cyclopentyladenosine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d51.s3.e2'}, 'sentence_id': 'DDI-MedLine.d51.s3'}	The anxiogenic effects of DRUGUNRELATED were reduced by pretreatment with DRUG , an A2 - selective agonist , but not by DRUGOTHER ( DRUGUNRELATED ) , an A1 - selective agonist .
The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. 	CGS 21680	CPA	none	{'e1': {'word': 'CGS 21680', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d51.s3.e1'}, 'e2': {'word': 'CPA', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d51.s3.e3'}, 'sentence_id': 'DDI-MedLine.d51.s3'}	The anxiogenic effects of DRUGUNRELATED were reduced by pretreatment with DRUG , an A2 - selective agonist , but not by DRUGUNRELATED ( DRUGOTHER ) , an A1 - selective agonist .
The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. 	N6-cyclopentyladenosine	CPA	none	{'e1': {'word': 'N6-cyclopentyladenosine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d51.s3.e2'}, 'e2': {'word': 'CPA', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d51.s3.e3'}, 'sentence_id': 'DDI-MedLine.d51.s3'}	The anxiogenic effects of DRUGUNRELATED were reduced by pretreatment with DRUGUNRELATED , an A2 - selective agonist , but not by DRUG ( DRUGOTHER ) , an A1 - selective agonist .
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	theophylline	CGS21680	effect	{'e1': {'word': 'theophylline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d51.s4.e0'}, 'e2': {'word': 'CGS21680', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d51.s4.e1'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	However , the antagonism of the DRUG - induced anxiogenic effects by DRUGOTHER was only observed in the time spent in the light zone , and DRUGUNRELATED - induced anxiogenic effects were neither reversed by DRUGUNRELATED nor by DRUGUNRELATED .
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	theophylline	DPCPX	none	{'e1': {'word': 'theophylline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d51.s4.e0'}, 'e2': {'word': 'DPCPX', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d51.s4.e2'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	However , the antagonism of the DRUG - induced anxiogenic effects by DRUGUNRELATED was only observed in the time spent in the light zone , and DRUGOTHER - induced anxiogenic effects were neither reversed by DRUGUNRELATED nor by DRUGUNRELATED .
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	theophylline	CGS 21680	none	{'e1': {'word': 'theophylline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d51.s4.e0'}, 'e2': {'word': 'CGS 21680', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d51.s4.e3'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	However , the antagonism of the DRUG - induced anxiogenic effects by DRUGUNRELATED was only observed in the time spent in the light zone , and DRUGUNRELATED - induced anxiogenic effects were neither reversed by DRUGOTHER nor by DRUGUNRELATED .
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	theophylline	CPA	none	{'e1': {'word': 'theophylline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d51.s4.e0'}, 'e2': {'word': 'CPA', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d51.s4.e4'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	However , the antagonism of the DRUG - induced anxiogenic effects by DRUGUNRELATED was only observed in the time spent in the light zone , and DRUGUNRELATED - induced anxiogenic effects were neither reversed by DRUGUNRELATED nor by DRUGOTHER .
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	CGS21680	DPCPX	none	{'e1': {'word': 'CGS21680', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d51.s4.e1'}, 'e2': {'word': 'DPCPX', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d51.s4.e2'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	However , the antagonism of the DRUGUNRELATED - induced anxiogenic effects by DRUG was only observed in the time spent in the light zone , and DRUGOTHER - induced anxiogenic effects were neither reversed by DRUGUNRELATED nor by DRUGUNRELATED .
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	CGS21680	CGS 21680	none	{'e1': {'word': 'CGS21680', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d51.s4.e1'}, 'e2': {'word': 'CGS 21680', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d51.s4.e3'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	However , the antagonism of the DRUGUNRELATED - induced anxiogenic effects by DRUG was only observed in the time spent in the light zone , and DRUGUNRELATED - induced anxiogenic effects were neither reversed by DRUGOTHER nor by DRUGUNRELATED .
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	CGS21680	CPA	none	{'e1': {'word': 'CGS21680', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d51.s4.e1'}, 'e2': {'word': 'CPA', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d51.s4.e4'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	However , the antagonism of the DRUGUNRELATED - induced anxiogenic effects by DRUG was only observed in the time spent in the light zone , and DRUGUNRELATED - induced anxiogenic effects were neither reversed by DRUGUNRELATED nor by DRUGOTHER .
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	DPCPX	CGS 21680	none	{'e1': {'word': 'DPCPX', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d51.s4.e2'}, 'e2': {'word': 'CGS 21680', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d51.s4.e3'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	However , the antagonism of the DRUGUNRELATED - induced anxiogenic effects by DRUGUNRELATED was only observed in the time spent in the light zone , and DRUG - induced anxiogenic effects were neither reversed by DRUGOTHER nor by DRUGUNRELATED .
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	DPCPX	CPA	none	{'e1': {'word': 'DPCPX', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d51.s4.e2'}, 'e2': {'word': 'CPA', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d51.s4.e4'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	However , the antagonism of the DRUGUNRELATED - induced anxiogenic effects by DRUGUNRELATED was only observed in the time spent in the light zone , and DRUG - induced anxiogenic effects were neither reversed by DRUGUNRELATED nor by DRUGOTHER .
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	CGS 21680	CPA	none	{'e1': {'word': 'CGS 21680', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d51.s4.e3'}, 'e2': {'word': 'CPA', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d51.s4.e4'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	However , the antagonism of the DRUGUNRELATED - induced anxiogenic effects by DRUGUNRELATED was only observed in the time spent in the light zone , and DRUGUNRELATED - induced anxiogenic effects were neither reversed by DRUG nor by DRUGOTHER .
"Interactions of cobalt and iron in absorption and retention.
"	cobalt	iron	mechanism	{'e1': {'word': 'cobalt', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d34.s0.e0'}, 'e2': {'word': 'iron', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d34.s0.e1'}, 'sentence_id': 'DDI-MedLine.d34.s0'}	Interactions of DRUG and DRUGOTHER in absorption and retention .
The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. 	cobalt	iron	none	{'e1': {'word': 'cobalt', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d34.s1.e0'}, 'e2': {'word': 'iron', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d34.s1.e1'}, 'sentence_id': 'DDI-MedLine.d34.s1'}	The effects of supplementary oral DRUG and DRUGOTHER , as well as the interaction between both at the absorption site , fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms / kg of DRUGUNRELATED and 48 or 446 mg / kg of DRUGUNRELATED over a period of 19 days in a total of 24 rats .
The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. 	cobalt	Co	none	{'e1': {'word': 'cobalt', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d34.s1.e0'}, 'e2': {'word': 'Co', 'word_index': [(49, 49)], 'id': 'DDI-MedLine.d34.s1.e2'}, 'sentence_id': 'DDI-MedLine.d34.s1'}	The effects of supplementary oral DRUG and DRUGUNRELATED , as well as the interaction between both at the absorption site , fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms / kg of DRUGOTHER and 48 or 446 mg / kg of DRUGUNRELATED over a period of 19 days in a total of 24 rats .
The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. 	cobalt	Fe	none	{'e1': {'word': 'cobalt', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d34.s1.e0'}, 'e2': {'word': 'Fe', 'word_index': [(58, 58)], 'id': 'DDI-MedLine.d34.s1.e3'}, 'sentence_id': 'DDI-MedLine.d34.s1'}	The effects of supplementary oral DRUG and DRUGUNRELATED , as well as the interaction between both at the absorption site , fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms / kg of DRUGUNRELATED and 48 or 446 mg / kg of DRUGOTHER over a period of 19 days in a total of 24 rats .
The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. 	iron	Co	none	{'e1': {'word': 'iron', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d34.s1.e1'}, 'e2': {'word': 'Co', 'word_index': [(49, 49)], 'id': 'DDI-MedLine.d34.s1.e2'}, 'sentence_id': 'DDI-MedLine.d34.s1'}	The effects of supplementary oral DRUGUNRELATED and DRUG , as well as the interaction between both at the absorption site , fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms / kg of DRUGOTHER and 48 or 446 mg / kg of DRUGUNRELATED over a period of 19 days in a total of 24 rats .
The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. 	iron	Fe	none	{'e1': {'word': 'iron', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d34.s1.e1'}, 'e2': {'word': 'Fe', 'word_index': [(58, 58)], 'id': 'DDI-MedLine.d34.s1.e3'}, 'sentence_id': 'DDI-MedLine.d34.s1'}	The effects of supplementary oral DRUGUNRELATED and DRUG , as well as the interaction between both at the absorption site , fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms / kg of DRUGUNRELATED and 48 or 446 mg / kg of DRUGOTHER over a period of 19 days in a total of 24 rats .
The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. 	Co	Fe	none	{'e1': {'word': 'Co', 'word_index': [(49, 49)], 'id': 'DDI-MedLine.d34.s1.e2'}, 'e2': {'word': 'Fe', 'word_index': [(58, 58)], 'id': 'DDI-MedLine.d34.s1.e3'}, 'sentence_id': 'DDI-MedLine.d34.s1'}	The effects of supplementary oral DRUGUNRELATED and DRUGUNRELATED , as well as the interaction between both at the absorption site , fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms / kg of DRUG and 48 or 446 mg / kg of DRUGOTHER over a period of 19 days in a total of 24 rats .
Cobalt excretion was enhanced by supplementary cobalt; 	Cobalt	cobalt	none	{'e1': {'word': 'Cobalt', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d34.s4.e0'}, 'e2': {'word': 'cobalt', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d34.s4.e1'}, 'sentence_id': 'DDI-MedLine.d34.s4'}	DRUG excretion was enhanced by supplementary DRUGOTHER ;
Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments. 	iron	cobalt	mechanism	{'e1': {'word': 'iron', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d34.s7.e0'}, 'e2': {'word': 'cobalt', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d34.s7.e1'}, 'sentence_id': 'DDI-MedLine.d34.s7'}	Additional DRUG significantly inhibited the absorption of DRUGOTHER in both dietary DRUGUNRELATED treatments .
Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments. 	iron	cobalt	mechanism	{'e1': {'word': 'iron', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d34.s7.e0'}, 'e2': {'word': 'cobalt', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d34.s7.e2'}, 'sentence_id': 'DDI-MedLine.d34.s7'}	Additional DRUG significantly inhibited the absorption of DRUGUNRELATED in both dietary DRUGOTHER treatments .
Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments. 	cobalt	cobalt	none	{'e1': {'word': 'cobalt', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d34.s7.e1'}, 'e2': {'word': 'cobalt', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d34.s7.e2'}, 'sentence_id': 'DDI-MedLine.d34.s7'}	Additional DRUGUNRELATED significantly inhibited the absorption of DRUG in both dietary DRUGOTHER treatments .
The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of cobalt. 	Fe	Fe	none	{'e1': {'word': 'Fe', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d34.s8.e0'}, 'e2': {'word': 'Fe', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d34.s8.e1'}, 'sentence_id': 'DDI-MedLine.d34.s8'}	The lower rate of absorption in the groups receiving 446 mg DRUG instead of 48 mg of DRUGOTHER per kg diet resulted in a decreased renal excretion of DRUGUNRELATED .
The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of cobalt. 	Fe	cobalt	mechanism	{'e1': {'word': 'Fe', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d34.s8.e0'}, 'e2': {'word': 'cobalt', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d34.s8.e2'}, 'sentence_id': 'DDI-MedLine.d34.s8'}	The lower rate of absorption in the groups receiving 446 mg DRUG instead of 48 mg of DRUGUNRELATED per kg diet resulted in a decreased renal excretion of DRUGOTHER .
The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of cobalt. 	Fe	cobalt	none	{'e1': {'word': 'Fe', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d34.s8.e1'}, 'e2': {'word': 'cobalt', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d34.s8.e2'}, 'sentence_id': 'DDI-MedLine.d34.s8'}	The lower rate of absorption in the groups receiving 446 mg DRUGUNRELATED instead of 48 mg of DRUG per kg diet resulted in a decreased renal excretion of DRUGOTHER .
Consequently, the effect of iron on the retention of cobalt was lower than on absorption. 	iron	cobalt	mechanism	{'e1': {'word': 'iron', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d34.s9.e0'}, 'e2': {'word': 'cobalt', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d34.s9.e1'}, 'sentence_id': 'DDI-MedLine.d34.s9'}	Consequently , the effect of DRUG on the retention of DRUGOTHER was lower than on absorption .
Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. 	cobalt	iron	none	{'e1': {'word': 'cobalt', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d34.s11.e0'}, 'e2': {'word': 'iron', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d34.s11.e1'}, 'sentence_id': 'DDI-MedLine.d34.s11'}	Because of the low dietary DRUG concentration as compared to the DRUGOTHER contents of the diets , no effect of DRUGUNRELATED on DRUGUNRELATED absorption and excretion occurred .
Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. 	cobalt	cobalt	none	{'e1': {'word': 'cobalt', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d34.s11.e0'}, 'e2': {'word': 'cobalt', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d34.s11.e2'}, 'sentence_id': 'DDI-MedLine.d34.s11'}	Because of the low dietary DRUG concentration as compared to the DRUGUNRELATED contents of the diets , no effect of DRUGOTHER on DRUGUNRELATED absorption and excretion occurred .
Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. 	cobalt	iron	none	{'e1': {'word': 'cobalt', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d34.s11.e0'}, 'e2': {'word': 'iron', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d34.s11.e3'}, 'sentence_id': 'DDI-MedLine.d34.s11'}	Because of the low dietary DRUG concentration as compared to the DRUGUNRELATED contents of the diets , no effect of DRUGUNRELATED on DRUGOTHER absorption and excretion occurred .
Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. 	iron	cobalt	none	{'e1': {'word': 'iron', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d34.s11.e1'}, 'e2': {'word': 'cobalt', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d34.s11.e2'}, 'sentence_id': 'DDI-MedLine.d34.s11'}	Because of the low dietary DRUGUNRELATED concentration as compared to the DRUG contents of the diets , no effect of DRUGOTHER on DRUGUNRELATED absorption and excretion occurred .
Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. 	iron	iron	none	{'e1': {'word': 'iron', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d34.s11.e1'}, 'e2': {'word': 'iron', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d34.s11.e3'}, 'sentence_id': 'DDI-MedLine.d34.s11'}	Because of the low dietary DRUGUNRELATED concentration as compared to the DRUG contents of the diets , no effect of DRUGUNRELATED on DRUGOTHER absorption and excretion occurred .
Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. 	cobalt	iron	none	{'e1': {'word': 'cobalt', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d34.s11.e2'}, 'e2': {'word': 'iron', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d34.s11.e3'}, 'sentence_id': 'DDI-MedLine.d34.s11'}	Because of the low dietary DRUGUNRELATED concentration as compared to the DRUGUNRELATED contents of the diets , no effect of DRUG on DRUGOTHER absorption and excretion occurred .
Differences in iron balance were only observed between both dietary concentrations, showing a higher absolute but a lower relative absorption as well as retention in the groups fed further Fe.(ABSTRACT TRUNCATED AT 250 WORDS)	iron	Fe	none	{'e1': {'word': 'iron', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d34.s12.e0'}, 'e2': {'word': 'Fe', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d34.s12.e1'}, 'sentence_id': 'DDI-MedLine.d34.s12'}	Differences in DRUG balance were only observed between both dietary concentrations , showing a higher absolute but a lower relative absorption as well as retention in the groups fed further DRUGOTHER . ( ABSTRACT TRUNCATED AT 250 WORDS )
By contrast, spermidine (1 mM) and putrescine (1 mM) had no significant effect on the translocation when added alone. 	spermidine	putrescine	none	{'e1': {'word': 'spermidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d22.s2.e0'}, 'e2': {'word': 'putrescine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d22.s2.e1'}, 'sentence_id': 'DDI-MedLine.d22.s2'}	By contrast , DRUG ( 1 mM ) and DRUGOTHER ( 1 mM ) had no significant effect on the translocation when added alone .
Spermine, and to a lesser extent, spermidine, enhanced the translocating action of oleate and increased its effectiveness in transferring the phosphohydrolase from the soluble to the microsomal fraction. 	Spermine	spermidine	none	{'e1': {'word': 'Spermine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d22.s3.e0'}, 'e2': {'word': 'spermidine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d22.s3.e1'}, 'sentence_id': 'DDI-MedLine.d22.s3'}	DRUG , and to a lesser extent , DRUGOTHER , enhanced the translocating action of oleate and increased its effectiveness in transferring the phosphohydrolase from the soluble to the microsomal fraction .
In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.  	progestin-only oral contraceptives	POC	none	{'e1': {'word': 'progestin-only oral contraceptives', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d80.s1.e0'}, 'e2': {'word': 'POC', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d80.s1.e1'}, 'sentence_id': 'DDI-MedLine.d80.s1'}	In order to provide information for the appropriate package insert labeling of DRUG ( DRUGOTHER ) in the US , a comprehensive review was made of DRUGUNRELATED ( 0.075 mg ) and DRUGUNRELATED ( 0.35 mg ) , with the clinical differences indicated where applicable .
In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.  	progestin-only oral contraceptives	norgestrel	none	{'e1': {'word': 'progestin-only oral contraceptives', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d80.s1.e0'}, 'e2': {'word': 'norgestrel', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d80.s1.e2'}, 'sentence_id': 'DDI-MedLine.d80.s1'}	In order to provide information for the appropriate package insert labeling of DRUG ( DRUGUNRELATED ) in the US , a comprehensive review was made of DRUGOTHER ( 0.075 mg ) and DRUGUNRELATED ( 0.35 mg ) , with the clinical differences indicated where applicable .
In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.  	progestin-only oral contraceptives	norethindrone	none	{'e1': {'word': 'progestin-only oral contraceptives', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d80.s1.e0'}, 'e2': {'word': 'norethindrone', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d80.s1.e3'}, 'sentence_id': 'DDI-MedLine.d80.s1'}	In order to provide information for the appropriate package insert labeling of DRUG ( DRUGUNRELATED ) in the US , a comprehensive review was made of DRUGUNRELATED ( 0.075 mg ) and DRUGOTHER ( 0.35 mg ) , with the clinical differences indicated where applicable .
In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.  	POC	norgestrel	none	{'e1': {'word': 'POC', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d80.s1.e1'}, 'e2': {'word': 'norgestrel', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d80.s1.e2'}, 'sentence_id': 'DDI-MedLine.d80.s1'}	In order to provide information for the appropriate package insert labeling of DRUGUNRELATED ( DRUG ) in the US , a comprehensive review was made of DRUGOTHER ( 0.075 mg ) and DRUGUNRELATED ( 0.35 mg ) , with the clinical differences indicated where applicable .
In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.  	POC	norethindrone	none	{'e1': {'word': 'POC', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d80.s1.e1'}, 'e2': {'word': 'norethindrone', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d80.s1.e3'}, 'sentence_id': 'DDI-MedLine.d80.s1'}	In order to provide information for the appropriate package insert labeling of DRUGUNRELATED ( DRUG ) in the US , a comprehensive review was made of DRUGUNRELATED ( 0.075 mg ) and DRUGOTHER ( 0.35 mg ) , with the clinical differences indicated where applicable .
In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.  	norgestrel	norethindrone	none	{'e1': {'word': 'norgestrel', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d80.s1.e2'}, 'e2': {'word': 'norethindrone', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d80.s1.e3'}, 'sentence_id': 'DDI-MedLine.d80.s1'}	In order to provide information for the appropriate package insert labeling of DRUGUNRELATED ( DRUGUNRELATED ) in the US , a comprehensive review was made of DRUG ( 0.075 mg ) and DRUGOTHER ( 0.35 mg ) , with the clinical differences indicated where applicable .
"Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant.
"	budesonide	Survanta	none	{'e1': {'word': 'budesonide', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d18.s0.e0'}, 'e2': {'word': 'Survanta', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d18.s0.e1'}, 'sentence_id': 'DDI-MedLine.d18.s0'}	Note : dissolution of aerosol particles of DRUG in DRUGOTHER , a model DRUGUNRELATED .
"Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant.
"	budesonide	lung surfactant	none	{'e1': {'word': 'budesonide', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d18.s0.e0'}, 'e2': {'word': 'lung surfactant', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d18.s0.e2'}, 'sentence_id': 'DDI-MedLine.d18.s0'}	Note : dissolution of aerosol particles of DRUG in DRUGUNRELATED , a model DRUGOTHER .
"Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant.
"	Survanta	lung surfactant	none	{'e1': {'word': 'Survanta', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d18.s0.e1'}, 'e2': {'word': 'lung surfactant', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d18.s0.e2'}, 'sentence_id': 'DDI-MedLine.d18.s0'}	Note : dissolution of aerosol particles of DRUGUNRELATED in DRUG , a model DRUGOTHER .
The effect of a pulmonary surfactant extract from bovine lung, Survanta, on the dissolution rate of aerosol particles of budesonide was determined. 	pulmonary surfactant	Survanta	none	{'e1': {'word': 'pulmonary surfactant', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d18.s1.e0'}, 'e2': {'word': 'Survanta', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d18.s1.e1'}, 'sentence_id': 'DDI-MedLine.d18.s1'}	The effect of a DRUG extract from bovine lung , DRUGOTHER , on the dissolution rate of aerosol particles of DRUGUNRELATED was determined .
The effect of a pulmonary surfactant extract from bovine lung, Survanta, on the dissolution rate of aerosol particles of budesonide was determined. 	pulmonary surfactant	budesonide	none	{'e1': {'word': 'pulmonary surfactant', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d18.s1.e0'}, 'e2': {'word': 'budesonide', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d18.s1.e2'}, 'sentence_id': 'DDI-MedLine.d18.s1'}	The effect of a DRUG extract from bovine lung , DRUGUNRELATED , on the dissolution rate of aerosol particles of DRUGOTHER was determined .
The effect of a pulmonary surfactant extract from bovine lung, Survanta, on the dissolution rate of aerosol particles of budesonide was determined. 	Survanta	budesonide	none	{'e1': {'word': 'Survanta', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d18.s1.e1'}, 'e2': {'word': 'budesonide', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d18.s1.e2'}, 'sentence_id': 'DDI-MedLine.d18.s1'}	The effect of a DRUGUNRELATED extract from bovine lung , DRUG , on the dissolution rate of aerosol particles of DRUGOTHER was determined .
Aerosol particles of budesonide were generated from an ethanol solution, dried, and collected by a cascade impactor for characterization or by a liquid impinger for dissolution experiments. 	budesonide	ethanol	none	{'e1': {'word': 'budesonide', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d18.s2.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d18.s2.e1'}, 'sentence_id': 'DDI-MedLine.d18.s2'}	Aerosol particles of DRUG were generated from an DRUGOTHER solution , dried , and collected by a cascade impactor for characterization or by a liquid impinger for dissolution experiments .
Survanta increased the extent of dissolution of budesonide in proportion to the added concentration, which was also verified by equilibrium solubilization studies. 	Survanta	budesonide	none	{'e1': {'word': 'Survanta', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d18.s6.e0'}, 'e2': {'word': 'budesonide', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d18.s6.e1'}, 'sentence_id': 'DDI-MedLine.d18.s6'}	DRUG increased the extent of dissolution of DRUGOTHER in proportion to the added concentration , which was also verified by equilibrium solubilization studies .
Survanta also increased rate of dissolution, in a manner similar to sodium dodecyl sulfate. 	Survanta	sodium dodecyl sulfate	none	{'e1': {'word': 'Survanta', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d18.s7.e0'}, 'e2': {'word': 'sodium dodecyl sulfate', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d18.s7.e1'}, 'sentence_id': 'DDI-MedLine.d18.s7'}	DRUG also increased rate of dissolution , in a manner similar to DRUGOTHER .
Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of budesonide between the Survanta and aqueous phase. 	budesonide	budesonide	none	{'e1': {'word': 'budesonide', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d18.s8.e0'}, 'e2': {'word': 'budesonide', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d18.s8.e1'}, 'sentence_id': 'DDI-MedLine.d18.s8'}	Analysis of the concentration of DRUG following ultracentrifugation indicated that there is rapid equilibration of DRUGOTHER between the DRUGUNRELATED and aqueous phase .
Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of budesonide between the Survanta and aqueous phase. 	budesonide	Survanta	none	{'e1': {'word': 'budesonide', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d18.s8.e0'}, 'e2': {'word': 'Survanta', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d18.s8.e2'}, 'sentence_id': 'DDI-MedLine.d18.s8'}	Analysis of the concentration of DRUG following ultracentrifugation indicated that there is rapid equilibration of DRUGUNRELATED between the DRUGOTHER and aqueous phase .
Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of budesonide between the Survanta and aqueous phase. 	budesonide	Survanta	none	{'e1': {'word': 'budesonide', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d18.s8.e1'}, 'e2': {'word': 'Survanta', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d18.s8.e2'}, 'sentence_id': 'DDI-MedLine.d18.s8'}	Analysis of the concentration of DRUGUNRELATED following ultracentrifugation indicated that there is rapid equilibration of DRUG between the DRUGOTHER and aqueous phase .
"Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.
"	diltiazem	sirolimus	mechanism	{'e1': {'word': 'diltiazem', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d86.s0.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d86.s0.e1'}, 'sentence_id': 'DDI-MedLine.d86.s0'}	Pharmacokinetic interaction between single oral doses of DRUG and DRUGOTHER in healthy volunteers .
AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. 	sirolimus	macrolide immunosuppressant	none	{'e1': {'word': 'sirolimus', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d86.s1.e0'}, 'e2': {'word': 'macrolide immunosuppressant', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d86.s1.e1'}, 'sentence_id': 'DDI-MedLine.d86.s1'}	AIM AND BACKGROUND : The pharmacokinetic interaction between DRUG , a DRUGOTHER metabolized by CYP3A4 , and the DRUGUNRELATED DRUGUNRELATED was studied in 18 healthy subjects .
AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. 	sirolimus	calcium channel blocker	none	{'e1': {'word': 'sirolimus', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d86.s1.e0'}, 'e2': {'word': 'calcium channel blocker', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d86.s1.e2'}, 'sentence_id': 'DDI-MedLine.d86.s1'}	AIM AND BACKGROUND : The pharmacokinetic interaction between DRUG , a DRUGUNRELATED metabolized by CYP3A4 , and the DRUGOTHER DRUGUNRELATED was studied in 18 healthy subjects .
AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. 	sirolimus	diltiazem	none	{'e1': {'word': 'sirolimus', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d86.s1.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d86.s1.e3'}, 'sentence_id': 'DDI-MedLine.d86.s1'}	AIM AND BACKGROUND : The pharmacokinetic interaction between DRUG , a DRUGUNRELATED metabolized by CYP3A4 , and the DRUGUNRELATED DRUGOTHER was studied in 18 healthy subjects .
AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. 	macrolide immunosuppressant	calcium channel blocker	none	{'e1': {'word': 'macrolide immunosuppressant', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d86.s1.e1'}, 'e2': {'word': 'calcium channel blocker', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d86.s1.e2'}, 'sentence_id': 'DDI-MedLine.d86.s1'}	AIM AND BACKGROUND : The pharmacokinetic interaction between DRUGUNRELATED , a DRUG metabolized by CYP3A4 , and the DRUGOTHER DRUGUNRELATED was studied in 18 healthy subjects .
AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. 	macrolide immunosuppressant	diltiazem	none	{'e1': {'word': 'macrolide immunosuppressant', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d86.s1.e1'}, 'e2': {'word': 'diltiazem', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d86.s1.e3'}, 'sentence_id': 'DDI-MedLine.d86.s1'}	AIM AND BACKGROUND : The pharmacokinetic interaction between DRUGUNRELATED , a DRUG metabolized by CYP3A4 , and the DRUGUNRELATED DRUGOTHER was studied in 18 healthy subjects .
AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. 	calcium channel blocker	diltiazem	none	{'e1': {'word': 'calcium channel blocker', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d86.s1.e2'}, 'e2': {'word': 'diltiazem', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d86.s1.e3'}, 'sentence_id': 'DDI-MedLine.d86.s1'}	AIM AND BACKGROUND : The pharmacokinetic interaction between DRUGUNRELATED , a DRUGUNRELATED metabolized by CYP3A4 , and the DRUG DRUGOTHER was studied in 18 healthy subjects .
Several clinically important interactions have previously been reported for other immunosuppressive drugs that are metabolized by the same enzyme and for calcium antagonists. 	immunosuppressive drugs	calcium antagonists	none	{'e1': {'word': 'immunosuppressive drugs', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d86.s2.e0'}, 'e2': {'word': 'calcium antagonists', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d86.s2.e1'}, 'sentence_id': 'DDI-MedLine.d86.s2'}	Several clinically important interactions have previously been reported for other DRUG that are metabolized by the same enzyme and for DRUGOTHER .
METHODS: Healthy subjects who were 20 to 43 years old participated in an open, three-period, randomized, crossover study of the pharmacokinetics of a single 10-mg oral dose of sirolimus, a single oral 120-mg dose of diltiazem, and the two drugs given together. 	sirolimus	diltiazem	none	{'e1': {'word': 'sirolimus', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d86.s3.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(46, 46)], 'id': 'DDI-MedLine.d86.s3.e1'}, 'sentence_id': 'DDI-MedLine.d86.s3'}	METHODS : Healthy subjects who were 20 to 43 years old participated in an open , three - period , randomized , crossover study of the pharmacokinetics of a single 10 - mg oral dose of DRUG , a single oral 120 - mg dose of DRUGOTHER , and the two drugs given together .
RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. 	sirolimus	diltiazem	mechanism	{'e1': {'word': 'sirolimus', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d86.s5.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(66, 66)], 'id': 'DDI-MedLine.d86.s5.e1'}, 'sentence_id': 'DDI-MedLine.d86.s5'}	RESULTS : The geometric mean ( 90 % confidence interval ) whole blood DRUG area under the plasma concentration time - curve increased 60 % ( 35 % - 90 % ) , from 736 to 1178 ng x h / mL , and maximum concentration increased 43 % ( 14 % - 81 % ) , from 67 to 96 ng / mL , with DRUGOTHER coadministration , whereas the mean elimination half - life of DRUGUNRELATED decreased slightly , from 79 to 67 hours .
RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. 	sirolimus	sirolimus	none	{'e1': {'word': 'sirolimus', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d86.s5.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(77, 77)], 'id': 'DDI-MedLine.d86.s5.e2'}, 'sentence_id': 'DDI-MedLine.d86.s5'}	RESULTS : The geometric mean ( 90 % confidence interval ) whole blood DRUG area under the plasma concentration time - curve increased 60 % ( 35 % - 90 % ) , from 736 to 1178 ng x h / mL , and maximum concentration increased 43 % ( 14 % - 81 % ) , from 67 to 96 ng / mL , with DRUGUNRELATED coadministration , whereas the mean elimination half - life of DRUGOTHER decreased slightly , from 79 to 67 hours .
RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. 	diltiazem	sirolimus	none	{'e1': {'word': 'diltiazem', 'word_index': [(66, 66)], 'id': 'DDI-MedLine.d86.s5.e1'}, 'e2': {'word': 'sirolimus', 'word_index': [(77, 77)], 'id': 'DDI-MedLine.d86.s5.e2'}, 'sentence_id': 'DDI-MedLine.d86.s5'}	RESULTS : The geometric mean ( 90 % confidence interval ) whole blood DRUGUNRELATED area under the plasma concentration time - curve increased 60 % ( 35 % - 90 % ) , from 736 to 1178 ng x h / mL , and maximum concentration increased 43 % ( 14 % - 81 % ) , from 67 to 96 ng / mL , with DRUG coadministration , whereas the mean elimination half - life of DRUGOTHER decreased slightly , from 79 to 67 hours .
Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem. 	sirolimus	sirolimus	none	{'e1': {'word': 'sirolimus', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d86.s6.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d86.s6.e1'}, 'sentence_id': 'DDI-MedLine.d86.s6'}	Apparent oral clearance and volume of distribution of DRUG decreased with 38 % and 45 % , respectively , when DRUGOTHER was given with DRUGUNRELATED .
Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem. 	sirolimus	diltiazem	none	{'e1': {'word': 'sirolimus', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d86.s6.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d86.s6.e2'}, 'sentence_id': 'DDI-MedLine.d86.s6'}	Apparent oral clearance and volume of distribution of DRUG decreased with 38 % and 45 % , respectively , when DRUGUNRELATED was given with DRUGOTHER .
Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem. 	sirolimus	diltiazem	mechanism	{'e1': {'word': 'sirolimus', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d86.s6.e1'}, 'e2': {'word': 'diltiazem', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d86.s6.e2'}, 'sentence_id': 'DDI-MedLine.d86.s6'}	Apparent oral clearance and volume of distribution of DRUGUNRELATED decreased with 38 % and 45 % , respectively , when DRUG was given with DRUGOTHER .
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	diltiazem	desacetyldiltiazem	none	{'e1': {'word': 'diltiazem', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d86.s7.e0'}, 'e2': {'word': 'desacetyldiltiazem', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d86.s7.e1'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	The plasma maximum concentration and area under the plasma concentration - time curve of DRUG , DRUGOTHER , and DRUGUNRELATED were unchanged after coadministration of DRUGUNRELATED , and no potentiation of the effects of DRUGUNRELATED on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen .
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	diltiazem	desmethyldiltiazem	none	{'e1': {'word': 'diltiazem', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d86.s7.e0'}, 'e2': {'word': 'desmethyldiltiazem', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d86.s7.e2'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	The plasma maximum concentration and area under the plasma concentration - time curve of DRUG , DRUGUNRELATED , and DRUGOTHER were unchanged after coadministration of DRUGUNRELATED , and no potentiation of the effects of DRUGUNRELATED on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen .
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	diltiazem	sirolimus	none	{'e1': {'word': 'diltiazem', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d86.s7.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d86.s7.e3'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	The plasma maximum concentration and area under the plasma concentration - time curve of DRUG , DRUGUNRELATED , and DRUGUNRELATED were unchanged after coadministration of DRUGOTHER , and no potentiation of the effects of DRUGUNRELATED on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen .
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	diltiazem	diltiazem	none	{'e1': {'word': 'diltiazem', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d86.s7.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d86.s7.e4'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	The plasma maximum concentration and area under the plasma concentration - time curve of DRUG , DRUGUNRELATED , and DRUGUNRELATED were unchanged after coadministration of DRUGUNRELATED , and no potentiation of the effects of DRUGOTHER on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen .
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	desacetyldiltiazem	desmethyldiltiazem	none	{'e1': {'word': 'desacetyldiltiazem', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d86.s7.e1'}, 'e2': {'word': 'desmethyldiltiazem', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d86.s7.e2'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	The plasma maximum concentration and area under the plasma concentration - time curve of DRUGUNRELATED , DRUG , and DRUGOTHER were unchanged after coadministration of DRUGUNRELATED , and no potentiation of the effects of DRUGUNRELATED on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen .
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	desacetyldiltiazem	sirolimus	none	{'e1': {'word': 'desacetyldiltiazem', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d86.s7.e1'}, 'e2': {'word': 'sirolimus', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d86.s7.e3'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	The plasma maximum concentration and area under the plasma concentration - time curve of DRUGUNRELATED , DRUG , and DRUGUNRELATED were unchanged after coadministration of DRUGOTHER , and no potentiation of the effects of DRUGUNRELATED on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen .
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	desacetyldiltiazem	diltiazem	none	{'e1': {'word': 'desacetyldiltiazem', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d86.s7.e1'}, 'e2': {'word': 'diltiazem', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d86.s7.e4'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	The plasma maximum concentration and area under the plasma concentration - time curve of DRUGUNRELATED , DRUG , and DRUGUNRELATED were unchanged after coadministration of DRUGUNRELATED , and no potentiation of the effects of DRUGOTHER on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen .
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	desmethyldiltiazem	sirolimus	none	{'e1': {'word': 'desmethyldiltiazem', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d86.s7.e2'}, 'e2': {'word': 'sirolimus', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d86.s7.e3'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	The plasma maximum concentration and area under the plasma concentration - time curve of DRUGUNRELATED , DRUGUNRELATED , and DRUG were unchanged after coadministration of DRUGOTHER , and no potentiation of the effects of DRUGUNRELATED on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen .
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	desmethyldiltiazem	diltiazem	none	{'e1': {'word': 'desmethyldiltiazem', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d86.s7.e2'}, 'e2': {'word': 'diltiazem', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d86.s7.e4'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	The plasma maximum concentration and area under the plasma concentration - time curve of DRUGUNRELATED , DRUGUNRELATED , and DRUG were unchanged after coadministration of DRUGUNRELATED , and no potentiation of the effects of DRUGOTHER on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen .
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	sirolimus	diltiazem	none	{'e1': {'word': 'sirolimus', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d86.s7.e3'}, 'e2': {'word': 'diltiazem', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d86.s7.e4'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	The plasma maximum concentration and area under the plasma concentration - time curve of DRUGUNRELATED , DRUGUNRELATED , and DRUGUNRELATED were unchanged after coadministration of DRUG , and no potentiation of the effects of DRUGOTHER on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen .
CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus. 	diltiazem	sirolimus	mechanism	{'e1': {'word': 'diltiazem', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d86.s8.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d86.s8.e1'}, 'sentence_id': 'DDI-MedLine.d86.s8'}	CONCLUSIONS : Single - dose DRUG coadministration leads to higher DRUGOTHER exposure , presumably by inhibition of the first - pass metabolism of DRUGUNRELATED .
CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus. 	diltiazem	sirolimus	none	{'e1': {'word': 'diltiazem', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d86.s8.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d86.s8.e2'}, 'sentence_id': 'DDI-MedLine.d86.s8'}	CONCLUSIONS : Single - dose DRUG coadministration leads to higher DRUGUNRELATED exposure , presumably by inhibition of the first - pass metabolism of DRUGOTHER .
CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus. 	sirolimus	sirolimus	none	{'e1': {'word': 'sirolimus', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d86.s8.e1'}, 'e2': {'word': 'sirolimus', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d86.s8.e2'}, 'sentence_id': 'DDI-MedLine.d86.s8'}	CONCLUSIONS : Single - dose DRUGUNRELATED coadministration leads to higher DRUG exposure , presumably by inhibition of the first - pass metabolism of DRUGOTHER .
Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.	sirolimus	diltiazem	advise	{'e1': {'word': 'sirolimus', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d86.s9.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d86.s9.e1'}, 'sentence_id': 'DDI-MedLine.d86.s9'}	Because of the pronounced intersubject variability in the extent of the DRUG - DRUGOTHER interaction , whole blood DRUGUNRELATED concentrations should be monitored closely in patients treated with the two drugs .
Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.	sirolimus	sirolimus	none	{'e1': {'word': 'sirolimus', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d86.s9.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d86.s9.e2'}, 'sentence_id': 'DDI-MedLine.d86.s9'}	Because of the pronounced intersubject variability in the extent of the DRUG - DRUGUNRELATED interaction , whole blood DRUGOTHER concentrations should be monitored closely in patients treated with the two drugs .
Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.	diltiazem	sirolimus	none	{'e1': {'word': 'diltiazem', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d86.s9.e1'}, 'e2': {'word': 'sirolimus', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d86.s9.e2'}, 'sentence_id': 'DDI-MedLine.d86.s9'}	Because of the pronounced intersubject variability in the extent of the DRUGUNRELATED - DRUG interaction , whole blood DRUGOTHER concentrations should be monitored closely in patients treated with the two drugs .
Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents. 	antidepressant drugs	hypoglycemic agents	int	{'e1': {'word': 'antidepressant drugs', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d21.s2.e0'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d21.s2.e1'}, 'sentence_id': 'DDI-MedLine.d21.s2'}	Treatment with DRUG can directly interfere with blood glucose levels or may interact with DRUGOTHER .
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	Imipramine	moclobemide	none	{'e1': {'word': 'Imipramine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s6.e0'}, 'e2': {'word': 'moclobemide', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d21.s6.e1'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	DRUG ( 5 mg / kg ) , DRUGOTHER ( 30 mg / kg ) , DRUGUNRELATED ( 0.25 mg / kg ) , DRUGUNRELATED ( 20 mg / kg ) DRUGUNRELATED ( 30 mg / kg ) or vehicle was administered .
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	Imipramine	clonazepam	none	{'e1': {'word': 'Imipramine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s6.e0'}, 'e2': {'word': 'clonazepam', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d21.s6.e2'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	DRUG ( 5 mg / kg ) , DRUGUNRELATED ( 30 mg / kg ) , DRUGOTHER ( 0.25 mg / kg ) , DRUGUNRELATED ( 20 mg / kg ) DRUGUNRELATED ( 30 mg / kg ) or vehicle was administered .
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	Imipramine	fluoxetine	none	{'e1': {'word': 'Imipramine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s6.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d21.s6.e3'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	DRUG ( 5 mg / kg ) , DRUGUNRELATED ( 30 mg / kg ) , DRUGUNRELATED ( 0.25 mg / kg ) , DRUGOTHER ( 20 mg / kg ) DRUGUNRELATED ( 30 mg / kg ) or vehicle was administered .
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	Imipramine	sertraline	none	{'e1': {'word': 'Imipramine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s6.e0'}, 'e2': {'word': 'sertraline', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d21.s6.e4'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	DRUG ( 5 mg / kg ) , DRUGUNRELATED ( 30 mg / kg ) , DRUGUNRELATED ( 0.25 mg / kg ) , DRUGUNRELATED ( 20 mg / kg ) DRUGOTHER ( 30 mg / kg ) or vehicle was administered .
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	moclobemide	clonazepam	none	{'e1': {'word': 'moclobemide', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d21.s6.e1'}, 'e2': {'word': 'clonazepam', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d21.s6.e2'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	DRUGUNRELATED ( 5 mg / kg ) , DRUG ( 30 mg / kg ) , DRUGOTHER ( 0.25 mg / kg ) , DRUGUNRELATED ( 20 mg / kg ) DRUGUNRELATED ( 30 mg / kg ) or vehicle was administered .
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	moclobemide	fluoxetine	none	{'e1': {'word': 'moclobemide', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d21.s6.e1'}, 'e2': {'word': 'fluoxetine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d21.s6.e3'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	DRUGUNRELATED ( 5 mg / kg ) , DRUG ( 30 mg / kg ) , DRUGUNRELATED ( 0.25 mg / kg ) , DRUGOTHER ( 20 mg / kg ) DRUGUNRELATED ( 30 mg / kg ) or vehicle was administered .
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	moclobemide	sertraline	none	{'e1': {'word': 'moclobemide', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d21.s6.e1'}, 'e2': {'word': 'sertraline', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d21.s6.e4'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	DRUGUNRELATED ( 5 mg / kg ) , DRUG ( 30 mg / kg ) , DRUGUNRELATED ( 0.25 mg / kg ) , DRUGUNRELATED ( 20 mg / kg ) DRUGOTHER ( 30 mg / kg ) or vehicle was administered .
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	clonazepam	fluoxetine	none	{'e1': {'word': 'clonazepam', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d21.s6.e2'}, 'e2': {'word': 'fluoxetine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d21.s6.e3'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	DRUGUNRELATED ( 5 mg / kg ) , DRUGUNRELATED ( 30 mg / kg ) , DRUG ( 0.25 mg / kg ) , DRUGOTHER ( 20 mg / kg ) DRUGUNRELATED ( 30 mg / kg ) or vehicle was administered .
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	clonazepam	sertraline	none	{'e1': {'word': 'clonazepam', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d21.s6.e2'}, 'e2': {'word': 'sertraline', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d21.s6.e4'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	DRUGUNRELATED ( 5 mg / kg ) , DRUGUNRELATED ( 30 mg / kg ) , DRUG ( 0.25 mg / kg ) , DRUGUNRELATED ( 20 mg / kg ) DRUGOTHER ( 30 mg / kg ) or vehicle was administered .
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	fluoxetine	sertraline	none	{'e1': {'word': 'fluoxetine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d21.s6.e3'}, 'e2': {'word': 'sertraline', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d21.s6.e4'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	DRUGUNRELATED ( 5 mg / kg ) , DRUGUNRELATED ( 30 mg / kg ) , DRUGUNRELATED ( 0.25 mg / kg ) , DRUG ( 20 mg / kg ) DRUGOTHER ( 30 mg / kg ) or vehicle was administered .
An oral glucose overload of 1 ml of a 50% glucose solution was given to rats and blood glucose was determined after 30, 60 and 90 min. 	glucose	glucose	none	{'e1': {'word': 'glucose', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d21.s8.e0'}, 'e2': {'word': 'glucose', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d21.s8.e1'}, 'sentence_id': 'DDI-MedLine.d21.s8'}	An oral DRUG overload of 1 ml of a 50 % DRUGOTHER solution was given to rats and blood glucose was determined after 30 , 60 and 90 min .
Imipramine and clonazepam did not change fasting or overload glycemia. 	Imipramine	clonazepam	none	{'e1': {'word': 'Imipramine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s9.e0'}, 'e2': {'word': 'clonazepam', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d21.s9.e1'}, 'sentence_id': 'DDI-MedLine.d21.s9'}	DRUG and DRUGOTHER did not change fasting or overload glycemia .
Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. 	Fluoxetine	moclobemide	none	{'e1': {'word': 'Fluoxetine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s10.e0'}, 'e2': {'word': 'moclobemide', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d21.s10.e1'}, 'sentence_id': 'DDI-MedLine.d21.s10'}	DRUG and DRUGOTHER increased blood DRUGUNRELATED at different times after the glucose overload .
Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. 	Fluoxetine	glucose	none	{'e1': {'word': 'Fluoxetine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s10.e0'}, 'e2': {'word': 'glucose', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d21.s10.e2'}, 'sentence_id': 'DDI-MedLine.d21.s10'}	DRUG and DRUGUNRELATED increased blood DRUGOTHER at different times after the glucose overload .
Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. 	moclobemide	glucose	none	{'e1': {'word': 'moclobemide', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d21.s10.e1'}, 'e2': {'word': 'glucose', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d21.s10.e2'}, 'sentence_id': 'DDI-MedLine.d21.s10'}	DRUGUNRELATED and DRUG increased blood DRUGOTHER at different times after the glucose overload .
Sertraline neutralized the increase of glycemia induced by oral glucose overload. 	Sertraline	glucose	none	{'e1': {'word': 'Sertraline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s11.e0'}, 'e2': {'word': 'glucose', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d21.s11.e1'}, 'sentence_id': 'DDI-MedLine.d21.s11'}	DRUG neutralized the increase of glycemia induced by oral DRUGOTHER overload .
In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of glucose tolerance 30 min after glucose overload. 	glucose	glucose	none	{'e1': {'word': 'glucose', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d21.s12.e0'}, 'e2': {'word': 'glucose', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d21.s12.e1'}, 'sentence_id': 'DDI-MedLine.d21.s12'}	In the second experiment , non-diabetic and streptozotocin - induced diabetic rats were fasted , and the same procedures were followed for estimation of DRUG tolerance 30 min after DRUGOTHER overload .
Again, sertraline neutralized the increase in glycemia after glucose overload both in diabetic and non-diabetic rats. 	sertraline	glucose	none	{'e1': {'word': 'sertraline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d21.s13.e0'}, 'e2': {'word': 'glucose', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d21.s13.e1'}, 'sentence_id': 'DDI-MedLine.d21.s13'}	Again , DRUG neutralized the increase in glycemia after DRUGOTHER overload both in diabetic and non-diabetic rats .
"18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
"	18-Methoxycoronaridine	18-MC	none	{'e1': {'word': '18-Methoxycoronaridine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s0.e0'}, 'e2': {'word': '18-MC', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d110.s0.e1'}, 'sentence_id': 'DDI-MedLine.d110.s0'}	DRUG ( DRUGOTHER ) and DRUGUNRELATED : comparison of antiaddictive efficacy , toxicity , and mechanisms of action .
"18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
"	18-Methoxycoronaridine	ibogaine	none	{'e1': {'word': '18-Methoxycoronaridine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s0.e0'}, 'e2': {'word': 'ibogaine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d110.s0.e2'}, 'sentence_id': 'DDI-MedLine.d110.s0'}	DRUG ( DRUGUNRELATED ) and DRUGOTHER : comparison of antiaddictive efficacy , toxicity , and mechanisms of action .
"18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
"	18-MC	ibogaine	none	{'e1': {'word': '18-MC', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d110.s0.e1'}, 'e2': {'word': 'ibogaine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d110.s0.e2'}, 'sentence_id': 'DDI-MedLine.d110.s0'}	DRUGUNRELATED ( DRUG ) and DRUGOTHER : comparison of antiaddictive efficacy , toxicity , and mechanisms of action .
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s2.e0'}, 'e2': {'word': '18-MC', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d110.s2.e1'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like DRUG ( 40 mg / kg ) , DRUGOTHER ( 40 mg / kg ) decreases the intravenous self - administration of DRUGUNRELATED and DRUGUNRELATED and the oral self - administration of DRUGUNRELATED and DRUGUNRELATED in rats ;
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	ibogaine	morphine	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s2.e0'}, 'e2': {'word': 'morphine', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d110.s2.e2'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like DRUG ( 40 mg / kg ) , DRUGUNRELATED ( 40 mg / kg ) decreases the intravenous self - administration of DRUGOTHER and DRUGUNRELATED and the oral self - administration of DRUGUNRELATED and DRUGUNRELATED in rats ;
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	ibogaine	cocaine	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s2.e0'}, 'e2': {'word': 'cocaine', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d110.s2.e3'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like DRUG ( 40 mg / kg ) , DRUGUNRELATED ( 40 mg / kg ) decreases the intravenous self - administration of DRUGUNRELATED and DRUGOTHER and the oral self - administration of DRUGUNRELATED and DRUGUNRELATED in rats ;
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	ibogaine	ethanol	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s2.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d110.s2.e4'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like DRUG ( 40 mg / kg ) , DRUGUNRELATED ( 40 mg / kg ) decreases the intravenous self - administration of DRUGUNRELATED and DRUGUNRELATED and the oral self - administration of DRUGOTHER and DRUGUNRELATED in rats ;
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	ibogaine	nicotine	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s2.e0'}, 'e2': {'word': 'nicotine', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d110.s2.e5'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like DRUG ( 40 mg / kg ) , DRUGUNRELATED ( 40 mg / kg ) decreases the intravenous self - administration of DRUGUNRELATED and DRUGUNRELATED and the oral self - administration of DRUGUNRELATED and DRUGOTHER in rats ;
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	18-MC	morphine	none	{'e1': {'word': '18-MC', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d110.s2.e1'}, 'e2': {'word': 'morphine', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d110.s2.e2'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like DRUGUNRELATED ( 40 mg / kg ) , DRUG ( 40 mg / kg ) decreases the intravenous self - administration of DRUGOTHER and DRUGUNRELATED and the oral self - administration of DRUGUNRELATED and DRUGUNRELATED in rats ;
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	18-MC	cocaine	none	{'e1': {'word': '18-MC', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d110.s2.e1'}, 'e2': {'word': 'cocaine', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d110.s2.e3'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like DRUGUNRELATED ( 40 mg / kg ) , DRUG ( 40 mg / kg ) decreases the intravenous self - administration of DRUGUNRELATED and DRUGOTHER and the oral self - administration of DRUGUNRELATED and DRUGUNRELATED in rats ;
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	18-MC	ethanol	none	{'e1': {'word': '18-MC', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d110.s2.e1'}, 'e2': {'word': 'ethanol', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d110.s2.e4'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like DRUGUNRELATED ( 40 mg / kg ) , DRUG ( 40 mg / kg ) decreases the intravenous self - administration of DRUGUNRELATED and DRUGUNRELATED and the oral self - administration of DRUGOTHER and DRUGUNRELATED in rats ;
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	18-MC	nicotine	none	{'e1': {'word': '18-MC', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d110.s2.e1'}, 'e2': {'word': 'nicotine', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d110.s2.e5'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like DRUGUNRELATED ( 40 mg / kg ) , DRUG ( 40 mg / kg ) decreases the intravenous self - administration of DRUGUNRELATED and DRUGUNRELATED and the oral self - administration of DRUGUNRELATED and DRUGOTHER in rats ;
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	morphine	cocaine	none	{'e1': {'word': 'morphine', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d110.s2.e2'}, 'e2': {'word': 'cocaine', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d110.s2.e3'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like DRUGUNRELATED ( 40 mg / kg ) , DRUGUNRELATED ( 40 mg / kg ) decreases the intravenous self - administration of DRUG and DRUGOTHER and the oral self - administration of DRUGUNRELATED and DRUGUNRELATED in rats ;
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	morphine	ethanol	none	{'e1': {'word': 'morphine', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d110.s2.e2'}, 'e2': {'word': 'ethanol', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d110.s2.e4'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like DRUGUNRELATED ( 40 mg / kg ) , DRUGUNRELATED ( 40 mg / kg ) decreases the intravenous self - administration of DRUG and DRUGUNRELATED and the oral self - administration of DRUGOTHER and DRUGUNRELATED in rats ;
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	morphine	nicotine	none	{'e1': {'word': 'morphine', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d110.s2.e2'}, 'e2': {'word': 'nicotine', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d110.s2.e5'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like DRUGUNRELATED ( 40 mg / kg ) , DRUGUNRELATED ( 40 mg / kg ) decreases the intravenous self - administration of DRUG and DRUGUNRELATED and the oral self - administration of DRUGUNRELATED and DRUGOTHER in rats ;
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	cocaine	ethanol	none	{'e1': {'word': 'cocaine', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d110.s2.e3'}, 'e2': {'word': 'ethanol', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d110.s2.e4'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like DRUGUNRELATED ( 40 mg / kg ) , DRUGUNRELATED ( 40 mg / kg ) decreases the intravenous self - administration of DRUGUNRELATED and DRUG and the oral self - administration of DRUGOTHER and DRUGUNRELATED in rats ;
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	cocaine	nicotine	none	{'e1': {'word': 'cocaine', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d110.s2.e3'}, 'e2': {'word': 'nicotine', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d110.s2.e5'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like DRUGUNRELATED ( 40 mg / kg ) , DRUGUNRELATED ( 40 mg / kg ) decreases the intravenous self - administration of DRUGUNRELATED and DRUG and the oral self - administration of DRUGUNRELATED and DRUGOTHER in rats ;
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	ethanol	nicotine	none	{'e1': {'word': 'ethanol', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d110.s2.e4'}, 'e2': {'word': 'nicotine', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d110.s2.e5'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like DRUGUNRELATED ( 40 mg / kg ) , DRUGUNRELATED ( 40 mg / kg ) decreases the intravenous self - administration of DRUGUNRELATED and DRUGUNRELATED and the oral self - administration of DRUG and DRUGOTHER in rats ;
unlike ibogaine, 18-MC does not affect responding for a nondrug reinforcer (water). 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s3.e0'}, 'e2': {'word': '18-MC', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s3.e1'}, 'sentence_id': 'DDI-MedLine.d110.s3'}	unlike DRUG , DRUGOTHER does not affect responding for a nondrug reinforcer ( water ) .
Both ibogaine and 18-MC ameliorate opioid withdrawal signs. 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s4.e0'}, 'e2': {'word': '18-MC', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s4.e1'}, 'sentence_id': 'DDI-MedLine.d110.s4'}	Both DRUG and DRUGOTHER ameliorate DRUGUNRELATED withdrawal signs .
Both ibogaine and 18-MC ameliorate opioid withdrawal signs. 	ibogaine	opioid	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s4.e0'}, 'e2': {'word': 'opioid', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d110.s4.e2'}, 'sentence_id': 'DDI-MedLine.d110.s4'}	Both DRUG and DRUGUNRELATED ameliorate DRUGOTHER withdrawal signs .
Both ibogaine and 18-MC ameliorate opioid withdrawal signs. 	18-MC	opioid	none	{'e1': {'word': '18-MC', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s4.e1'}, 'e2': {'word': 'opioid', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d110.s4.e2'}, 'sentence_id': 'DDI-MedLine.d110.s4'}	Both DRUGUNRELATED and DRUG ameliorate DRUGOTHER withdrawal signs .
Both ibogaine and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens. 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s5.e0'}, 'e2': {'word': '18-MC', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s5.e1'}, 'sentence_id': 'DDI-MedLine.d110.s5'}	Both DRUG and DRUGOTHER decrease extracellular levels of dopamine in the nucleus accumbens , but only DRUGUNRELATED increases extracellular levels of serotonin in the nucleus accumbens .
Both ibogaine and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens. 	ibogaine	ibogaine	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s5.e0'}, 'e2': {'word': 'ibogaine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d110.s5.e2'}, 'sentence_id': 'DDI-MedLine.d110.s5'}	Both DRUG and DRUGUNRELATED decrease extracellular levels of dopamine in the nucleus accumbens , but only DRUGOTHER increases extracellular levels of serotonin in the nucleus accumbens .
Both ibogaine and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens. 	18-MC	ibogaine	none	{'e1': {'word': '18-MC', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s5.e1'}, 'e2': {'word': 'ibogaine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d110.s5.e2'}, 'sentence_id': 'DDI-MedLine.d110.s5'}	Both DRUGUNRELATED and DRUG decrease extracellular levels of dopamine in the nucleus accumbens , but only DRUGOTHER increases extracellular levels of serotonin in the nucleus accumbens .
Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s6.e0'}, 'e2': {'word': '18-MC', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s6.e1'}, 'sentence_id': 'DDI-MedLine.d110.s6'}	Both DRUG and DRUGOTHER block DRUGUNRELATED - induced and DRUGUNRELATED - induced dopamine release in the nucleus accumbens ;
Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; 	ibogaine	morphine	effect	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s6.e0'}, 'e2': {'word': 'morphine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d110.s6.e2'}, 'sentence_id': 'DDI-MedLine.d110.s6'}	Both DRUG and DRUGUNRELATED block DRUGOTHER - induced and DRUGUNRELATED - induced dopamine release in the nucleus accumbens ;
Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; 	ibogaine	nicotine	effect	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s6.e0'}, 'e2': {'word': 'nicotine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d110.s6.e3'}, 'sentence_id': 'DDI-MedLine.d110.s6'}	Both DRUG and DRUGUNRELATED block DRUGUNRELATED - induced and DRUGOTHER - induced dopamine release in the nucleus accumbens ;
Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; 	18-MC	morphine	effect	{'e1': {'word': '18-MC', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s6.e1'}, 'e2': {'word': 'morphine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d110.s6.e2'}, 'sentence_id': 'DDI-MedLine.d110.s6'}	Both DRUGUNRELATED and DRUG block DRUGOTHER - induced and DRUGUNRELATED - induced dopamine release in the nucleus accumbens ;
Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; 	18-MC	nicotine	effect	{'e1': {'word': '18-MC', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s6.e1'}, 'e2': {'word': 'nicotine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d110.s6.e3'}, 'sentence_id': 'DDI-MedLine.d110.s6'}	Both DRUGUNRELATED and DRUG block DRUGUNRELATED - induced and DRUGOTHER - induced dopamine release in the nucleus accumbens ;
Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; 	morphine	nicotine	none	{'e1': {'word': 'morphine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d110.s6.e2'}, 'e2': {'word': 'nicotine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d110.s6.e3'}, 'sentence_id': 'DDI-MedLine.d110.s6'}	Both DRUGUNRELATED and DRUGUNRELATED block DRUG - induced and DRUGOTHER - induced dopamine release in the nucleus accumbens ;
only ibogaine enhances cocaine-induced increases in accumbal dopamine. 	ibogaine	cocaine	effect	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s7.e0'}, 'e2': {'word': 'cocaine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s7.e1'}, 'sentence_id': 'DDI-MedLine.d110.s7'}	only DRUG enhances DRUGOTHER - induced increases in accumbal dopamine .
Both ibogaine and 18-MC enhance the locomotor and/or stereotypic effects of stimulants. 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s8.e0'}, 'e2': {'word': '18-MC', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s8.e1'}, 'sentence_id': 'DDI-MedLine.d110.s8'}	Both DRUG and DRUGOTHER enhance the locomotor and / or stereotypic effects of stimulants .
Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine; 	Ibogaine	18-MC	none	{'e1': {'word': 'Ibogaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s9.e0'}, 'e2': {'word': '18-MC', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d110.s9.e1'}, 'sentence_id': 'DDI-MedLine.d110.s9'}	DRUG attenuates , but DRUGOTHER potentiates , the acute locomotor effects of DRUGUNRELATED ;
Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine; 	Ibogaine	morphine	effect	{'e1': {'word': 'Ibogaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s9.e0'}, 'e2': {'word': 'morphine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d110.s9.e2'}, 'sentence_id': 'DDI-MedLine.d110.s9'}	DRUG attenuates , but DRUGUNRELATED potentiates , the acute locomotor effects of DRUGOTHER ;
Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine; 	18-MC	morphine	effect	{'e1': {'word': '18-MC', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d110.s9.e1'}, 'e2': {'word': 'morphine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d110.s9.e2'}, 'sentence_id': 'DDI-MedLine.d110.s9'}	DRUGUNRELATED attenuates , but DRUG potentiates , the acute locomotor effects of DRUGOTHER ;
both compounds attenuate morphine-induced locomotion in morphine-experienced rats. 	morphine	morphine	none	{'e1': {'word': 'morphine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s10.e0'}, 'e2': {'word': 'morphine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d110.s10.e1'}, 'sentence_id': 'DDI-MedLine.d110.s10'}	both compounds attenuate DRUG - induced locomotion in DRUGOTHER - experienced rats .
Ibogaine, but not 18-MC, decreases heart rate at high doses. 	Ibogaine	18-MC	none	{'e1': {'word': 'Ibogaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s13.e0'}, 'e2': {'word': '18-MC', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d110.s13.e1'}, 'sentence_id': 'DDI-MedLine.d110.s13'}	DRUG , but not DRUGOTHER , decreases heart rate at high doses .
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	18-MC	ibogaine	none	{'e1': {'word': '18-MC', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s14.e0'}, 'e2': {'word': 'ibogaine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s14.e1'}, 'sentence_id': 'DDI-MedLine.d110.s14'}	While DRUG and DRUGOTHER have similar affinities for kappa opioid and possibly nicotinic receptors , DRUGUNRELATED has much lower affinities than DRUGUNRELATED for NMDA and sigma - 2 receptors , sodium channels , and the 5 - HT transporter .
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	18-MC	18-MC	none	{'e1': {'word': '18-MC', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s14.e0'}, 'e2': {'word': '18-MC', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d110.s14.e2'}, 'sentence_id': 'DDI-MedLine.d110.s14'}	While DRUG and DRUGUNRELATED have similar affinities for kappa opioid and possibly nicotinic receptors , DRUGOTHER has much lower affinities than DRUGUNRELATED for NMDA and sigma - 2 receptors , sodium channels , and the 5 - HT transporter .
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	18-MC	ibogaine	none	{'e1': {'word': '18-MC', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s14.e0'}, 'e2': {'word': 'ibogaine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d110.s14.e3'}, 'sentence_id': 'DDI-MedLine.d110.s14'}	While DRUG and DRUGUNRELATED have similar affinities for kappa opioid and possibly nicotinic receptors , DRUGUNRELATED has much lower affinities than DRUGOTHER for NMDA and sigma - 2 receptors , sodium channels , and the 5 - HT transporter .
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s14.e1'}, 'e2': {'word': '18-MC', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d110.s14.e2'}, 'sentence_id': 'DDI-MedLine.d110.s14'}	While DRUGUNRELATED and DRUG have similar affinities for kappa opioid and possibly nicotinic receptors , DRUGOTHER has much lower affinities than DRUGUNRELATED for NMDA and sigma - 2 receptors , sodium channels , and the 5 - HT transporter .
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	ibogaine	ibogaine	none	{'e1': {'word': 'ibogaine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s14.e1'}, 'e2': {'word': 'ibogaine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d110.s14.e3'}, 'sentence_id': 'DDI-MedLine.d110.s14'}	While DRUGUNRELATED and DRUG have similar affinities for kappa opioid and possibly nicotinic receptors , DRUGUNRELATED has much lower affinities than DRUGOTHER for NMDA and sigma - 2 receptors , sodium channels , and the 5 - HT transporter .
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	18-MC	ibogaine	none	{'e1': {'word': '18-MC', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d110.s14.e2'}, 'e2': {'word': 'ibogaine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d110.s14.e3'}, 'sentence_id': 'DDI-MedLine.d110.s14'}	While DRUGUNRELATED and DRUGUNRELATED have similar affinities for kappa opioid and possibly nicotinic receptors , DRUG has much lower affinities than DRUGOTHER for NMDA and sigma - 2 receptors , sodium channels , and the 5 - HT transporter .
Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. 	18-MC	ibogaine	none	{'e1': {'word': '18-MC', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s15.e0'}, 'e2': {'word': 'ibogaine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s15.e1'}, 'sentence_id': 'DDI-MedLine.d110.s15'}	Both DRUG and DRUGOTHER are sequestered in fat and , like DRUGUNRELATED , DRUGUNRELATED probably has an active metabolite .
Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. 	18-MC	ibogaine	none	{'e1': {'word': '18-MC', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s15.e0'}, 'e2': {'word': 'ibogaine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d110.s15.e2'}, 'sentence_id': 'DDI-MedLine.d110.s15'}	Both DRUG and DRUGUNRELATED are sequestered in fat and , like DRUGOTHER , DRUGUNRELATED probably has an active metabolite .
Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. 	18-MC	18-MC	none	{'e1': {'word': '18-MC', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s15.e0'}, 'e2': {'word': '18-MC', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d110.s15.e3'}, 'sentence_id': 'DDI-MedLine.d110.s15'}	Both DRUG and DRUGUNRELATED are sequestered in fat and , like DRUGUNRELATED , DRUGOTHER probably has an active metabolite .
Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. 	ibogaine	ibogaine	none	{'e1': {'word': 'ibogaine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s15.e1'}, 'e2': {'word': 'ibogaine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d110.s15.e2'}, 'sentence_id': 'DDI-MedLine.d110.s15'}	Both DRUGUNRELATED and DRUG are sequestered in fat and , like DRUGOTHER , DRUGUNRELATED probably has an active metabolite .
Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s15.e1'}, 'e2': {'word': '18-MC', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d110.s15.e3'}, 'sentence_id': 'DDI-MedLine.d110.s15'}	Both DRUGUNRELATED and DRUG are sequestered in fat and , like DRUGUNRELATED , DRUGOTHER probably has an active metabolite .
Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d110.s15.e2'}, 'e2': {'word': '18-MC', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d110.s15.e3'}, 'sentence_id': 'DDI-MedLine.d110.s15'}	Both DRUGUNRELATED and DRUGUNRELATED are sequestered in fat and , like DRUG , DRUGOTHER probably has an active metabolite .
The data suggest that 18-MC has a narrower spectrum of actions and will have a substantially greater therapeutic index than ibogaine.	18-MC	ibogaine	none	{'e1': {'word': '18-MC', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d110.s16.e0'}, 'e2': {'word': 'ibogaine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d110.s16.e1'}, 'sentence_id': 'DDI-MedLine.d110.s16'}	The data suggest that DRUG has a narrower spectrum of actions and will have a substantially greater therapeutic index than DRUGOTHER .
"Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline.
"	estradiol	progesterone	none	{'e1': {'word': 'estradiol', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d102.s0.e0'}, 'e2': {'word': 'progesterone', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d102.s0.e1'}, 'sentence_id': 'DDI-MedLine.d102.s0'}	Influence of DRUG and DRUGOTHER on the sensitivity of rat thoracic aorta to DRUGUNRELATED .
"Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline.
"	estradiol	noradrenaline	none	{'e1': {'word': 'estradiol', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d102.s0.e0'}, 'e2': {'word': 'noradrenaline', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d102.s0.e2'}, 'sentence_id': 'DDI-MedLine.d102.s0'}	Influence of DRUG and DRUGUNRELATED on the sensitivity of rat thoracic aorta to DRUGOTHER .
"Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline.
"	progesterone	noradrenaline	none	{'e1': {'word': 'progesterone', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d102.s0.e1'}, 'e2': {'word': 'noradrenaline', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d102.s0.e2'}, 'sentence_id': 'DDI-MedLine.d102.s0'}	Influence of DRUGUNRELATED and DRUG on the sensitivity of rat thoracic aorta to DRUGOTHER .
The aim of this study was to investigate the effects of low and high doses of estradiol, and of progesterone on the response to noradrenaline in rat thoracic aorta. 	estradiol	progesterone	none	{'e1': {'word': 'estradiol', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d102.s1.e0'}, 'e2': {'word': 'progesterone', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d102.s1.e1'}, 'sentence_id': 'DDI-MedLine.d102.s1'}	The aim of this study was to investigate the effects of low and high doses of DRUG , and of DRUGOTHER on the response to DRUGUNRELATED in rat thoracic aorta .
The aim of this study was to investigate the effects of low and high doses of estradiol, and of progesterone on the response to noradrenaline in rat thoracic aorta. 	estradiol	noradrenaline	none	{'e1': {'word': 'estradiol', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d102.s1.e0'}, 'e2': {'word': 'noradrenaline', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d102.s1.e2'}, 'sentence_id': 'DDI-MedLine.d102.s1'}	The aim of this study was to investigate the effects of low and high doses of DRUG , and of DRUGUNRELATED on the response to DRUGOTHER in rat thoracic aorta .
The aim of this study was to investigate the effects of low and high doses of estradiol, and of progesterone on the response to noradrenaline in rat thoracic aorta. 	progesterone	noradrenaline	none	{'e1': {'word': 'progesterone', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d102.s1.e1'}, 'e2': {'word': 'noradrenaline', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d102.s1.e2'}, 'sentence_id': 'DDI-MedLine.d102.s1'}	The aim of this study was to investigate the effects of low and high doses of DRUGUNRELATED , and of DRUG on the response to DRUGOTHER in rat thoracic aorta .
injection of vehicle (corn oil, 0.1 mL/day), estradiol (10 microg/kg/day or 4 mg/kg/day) and/or progesterone (20 mg/kg/day), for eight days. 	estradiol	progesterone	none	{'e1': {'word': 'estradiol', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d102.s3.e0'}, 'e2': {'word': 'progesterone', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d102.s3.e1'}, 'sentence_id': 'DDI-MedLine.d102.s3'}	injection of vehicle ( corn oil , 0.1 mL / day ) , DRUG ( 10 microg / kg / day or 4 mg / kg / day ) and / or DRUGOTHER ( 20 mg / kg / day ) , for eight days .
Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively). 	estradiol	noradrenaline	effect	{'e1': {'word': 'estradiol', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d102.s5.e0'}, 'e2': {'word': 'noradrenaline', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d102.s5.e1'}, 'sentence_id': 'DDI-MedLine.d102.s5'}	Aortic rings with intact endothelium from the high - dose ( 4 mg / kg / day ) DRUG group were supersensitive to DRUGOTHER compared to the vehicle or low - dose ( 10 microg / kg / day ) estradiol groups ( pD2 values = 7.86 + / - 0.09 , 7.30 + / - 0.11 and 7.35 + / - 0.04 , respectively ) .
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	estradiol	noradrenaline	effect	{'e1': {'word': 'estradiol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d102.s6.e0'}, 'e2': {'word': 'noradrenaline', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d102.s6.e1'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	Endothelium - intact aortic rings from high - DRUG rats were supersensitive to DRUGOTHER when compared to vehicle - , DRUGUNRELATED - and DRUGUNRELATED + high - DRUGUNRELATED - treated rats ( pD2 values = 7.77 + / - 0.12 , 7.21+/-0.13 , 6.93+/-0.04 and 7.22 + / - 0.18 , respectively ) .
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	estradiol	progesterone	none	{'e1': {'word': 'estradiol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d102.s6.e0'}, 'e2': {'word': 'progesterone', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d102.s6.e2'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	Endothelium - intact aortic rings from high - DRUG rats were supersensitive to DRUGUNRELATED when compared to vehicle - , DRUGOTHER - and DRUGUNRELATED + high - DRUGUNRELATED - treated rats ( pD2 values = 7.77 + / - 0.12 , 7.21+/-0.13 , 6.93+/-0.04 and 7.22 + / - 0.18 , respectively ) .
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	estradiol	progesterone	none	{'e1': {'word': 'estradiol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d102.s6.e0'}, 'e2': {'word': 'progesterone', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d102.s6.e3'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	Endothelium - intact aortic rings from high - DRUG rats were supersensitive to DRUGUNRELATED when compared to vehicle - , DRUGUNRELATED - and DRUGOTHER + high - DRUGUNRELATED - treated rats ( pD2 values = 7.77 + / - 0.12 , 7.21+/-0.13 , 6.93+/-0.04 and 7.22 + / - 0.18 , respectively ) .
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	estradiol	estradiol	none	{'e1': {'word': 'estradiol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d102.s6.e0'}, 'e2': {'word': 'estradiol', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d102.s6.e4'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	Endothelium - intact aortic rings from high - DRUG rats were supersensitive to DRUGUNRELATED when compared to vehicle - , DRUGUNRELATED - and DRUGUNRELATED + high - DRUGOTHER - treated rats ( pD2 values = 7.77 + / - 0.12 , 7.21+/-0.13 , 6.93+/-0.04 and 7.22 + / - 0.18 , respectively ) .
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	noradrenaline	progesterone	none	{'e1': {'word': 'noradrenaline', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d102.s6.e1'}, 'e2': {'word': 'progesterone', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d102.s6.e2'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	Endothelium - intact aortic rings from high - DRUGUNRELATED rats were supersensitive to DRUG when compared to vehicle - , DRUGOTHER - and DRUGUNRELATED + high - DRUGUNRELATED - treated rats ( pD2 values = 7.77 + / - 0.12 , 7.21+/-0.13 , 6.93+/-0.04 and 7.22 + / - 0.18 , respectively ) .
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	noradrenaline	progesterone	none	{'e1': {'word': 'noradrenaline', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d102.s6.e1'}, 'e2': {'word': 'progesterone', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d102.s6.e3'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	Endothelium - intact aortic rings from high - DRUGUNRELATED rats were supersensitive to DRUG when compared to vehicle - , DRUGUNRELATED - and DRUGOTHER + high - DRUGUNRELATED - treated rats ( pD2 values = 7.77 + / - 0.12 , 7.21+/-0.13 , 6.93+/-0.04 and 7.22 + / - 0.18 , respectively ) .
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	noradrenaline	estradiol	none	{'e1': {'word': 'noradrenaline', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d102.s6.e1'}, 'e2': {'word': 'estradiol', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d102.s6.e4'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	Endothelium - intact aortic rings from high - DRUGUNRELATED rats were supersensitive to DRUG when compared to vehicle - , DRUGUNRELATED - and DRUGUNRELATED + high - DRUGOTHER - treated rats ( pD2 values = 7.77 + / - 0.12 , 7.21+/-0.13 , 6.93+/-0.04 and 7.22 + / - 0.18 , respectively ) .
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	progesterone	progesterone	none	{'e1': {'word': 'progesterone', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d102.s6.e2'}, 'e2': {'word': 'progesterone', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d102.s6.e3'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	Endothelium - intact aortic rings from high - DRUGUNRELATED rats were supersensitive to DRUGUNRELATED when compared to vehicle - , DRUG - and DRUGOTHER + high - DRUGUNRELATED - treated rats ( pD2 values = 7.77 + / - 0.12 , 7.21+/-0.13 , 6.93+/-0.04 and 7.22 + / - 0.18 , respectively ) .
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	progesterone	estradiol	none	{'e1': {'word': 'progesterone', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d102.s6.e2'}, 'e2': {'word': 'estradiol', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d102.s6.e4'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	Endothelium - intact aortic rings from high - DRUGUNRELATED rats were supersensitive to DRUGUNRELATED when compared to vehicle - , DRUG - and DRUGUNRELATED + high - DRUGOTHER - treated rats ( pD2 values = 7.77 + / - 0.12 , 7.21+/-0.13 , 6.93+/-0.04 and 7.22 + / - 0.18 , respectively ) .
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	progesterone	estradiol	none	{'e1': {'word': 'progesterone', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d102.s6.e3'}, 'e2': {'word': 'estradiol', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d102.s6.e4'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	Endothelium - intact aortic rings from high - DRUGUNRELATED rats were supersensitive to DRUGUNRELATED when compared to vehicle - , DRUGUNRELATED - and DRUG + high - DRUGOTHER - treated rats ( pD2 values = 7.77 + / - 0.12 , 7.21+/ -0.13 , 6.93+/-0.04 and 7.22 + / - 0.18 , respectively ) .
"Rifampin and warfarin: a drug interaction.
"	Rifampin	warfarin	int	{'e1': {'word': 'Rifampin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d116.s0.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d116.s0.e1'}, 'sentence_id': 'DDI-MedLine.d116.s0'}	DRUG and DRUGOTHER : a drug interaction .
The drug interaction between warfarin and rifampin is not well known. 	warfarin	rifampin	int	{'e1': {'word': 'warfarin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d116.s1.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d116.s1.e1'}, 'sentence_id': 'DDI-MedLine.d116.s1'}	The drug interaction between DRUG and DRUGOTHER is not well known .
Rifampin has been reported to increase the warfarin requirements in human subjects ingesting these agents simultaneously. 	Rifampin	warfarin	mechanism	{'e1': {'word': 'Rifampin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d116.s2.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d116.s2.e1'}, 'sentence_id': 'DDI-MedLine.d116.s2'}	DRUG has been reported to increase the DRUGOTHER requirements in human subjects ingesting these agents simultaneously .
The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. 	rifampin	warfarin	mechanism	{'e1': {'word': 'rifampin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d116.s3.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d116.s3.e1'}, 'sentence_id': 'DDI-MedLine.d116.s3'}	The concomitant administration of DRUG and DRUGOTHER resulted in the need for an unusually high maintenance dose of DRUGUNRELATED ( 20 mg per day ) in order to produce a therapeutic effect .
The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. 	rifampin	warfarin	none	{'e1': {'word': 'rifampin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d116.s3.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d116.s3.e2'}, 'sentence_id': 'DDI-MedLine.d116.s3'}	The concomitant administration of DRUG and DRUGUNRELATED resulted in the need for an unusually high maintenance dose of DRUGOTHER ( 20 mg per day ) in order to produce a therapeutic effect .
The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. 	warfarin	warfarin	none	{'e1': {'word': 'warfarin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d116.s3.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d116.s3.e2'}, 'sentence_id': 'DDI-MedLine.d116.s3'}	The concomitant administration of DRUGUNRELATED and DRUG resulted in the need for an unusually high maintenance dose of DRUGOTHER ( 20 mg per day ) in order to produce a therapeutic effect .
Withdrawal of rifampin decreased the warfarin requirement by 50%. 	rifampin	warfarin	mechanism	{'e1': {'word': 'rifampin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d116.s4.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d116.s4.e1'}, 'sentence_id': 'DDI-MedLine.d116.s4'}	Withdrawal of DRUG decreased the DRUGOTHER requirement by 50 % .
This effect may be mediated by the ability of rifampin to induce microsomal enzymes and, thus, the catabolism of warfarin. 	rifampin	warfarin	mechanism	{'e1': {'word': 'rifampin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d116.s5.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d116.s5.e1'}, 'sentence_id': 'DDI-MedLine.d116.s5'}	This effect may be mediated by the ability of DRUG to induce microsomal enzymes and , thus , the catabolism of DRUGOTHER .
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. 	rifampin	warfarin	effect	{'e1': {'word': 'rifampin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d116.s6.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d116.s6.e1'}, 'sentence_id': 'DDI-MedLine.d116.s6'}	The effect of DRUG on the DRUGOTHER requirement of our patient appeared to be maximal 5 to 7 days after the initiation of DRUGUNRELATED and extended a similar length of time after DRUGUNRELATED withdrawal .
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. 	rifampin	rifampin	none	{'e1': {'word': 'rifampin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d116.s6.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d116.s6.e2'}, 'sentence_id': 'DDI-MedLine.d116.s6'}	The effect of DRUG on the DRUGUNRELATED requirement of our patient appeared to be maximal 5 to 7 days after the initiation of DRUGOTHER and extended a similar length of time after DRUGUNRELATED withdrawal .
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. 	rifampin	rifampin	none	{'e1': {'word': 'rifampin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d116.s6.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d116.s6.e3'}, 'sentence_id': 'DDI-MedLine.d116.s6'}	The effect of DRUG on the DRUGUNRELATED requirement of our patient appeared to be maximal 5 to 7 days after the initiation of DRUGUNRELATED and extended a similar length of time after DRUGOTHER withdrawal .
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. 	warfarin	rifampin	none	{'e1': {'word': 'warfarin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d116.s6.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d116.s6.e2'}, 'sentence_id': 'DDI-MedLine.d116.s6'}	The effect of DRUGUNRELATED on the DRUG requirement of our patient appeared to be maximal 5 to 7 days after the initiation of DRUGOTHER and extended a similar length of time after DRUGUNRELATED withdrawal .
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. 	warfarin	rifampin	none	{'e1': {'word': 'warfarin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d116.s6.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d116.s6.e3'}, 'sentence_id': 'DDI-MedLine.d116.s6'}	The effect of DRUGUNRELATED on the DRUG requirement of our patient appeared to be maximal 5 to 7 days after the initiation of DRUGUNRELATED and extended a similar length of time after DRUGOTHER withdrawal .
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. 	rifampin	rifampin	none	{'e1': {'word': 'rifampin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d116.s6.e2'}, 'e2': {'word': 'rifampin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d116.s6.e3'}, 'sentence_id': 'DDI-MedLine.d116.s6'}	The effect of DRUGUNRELATED on the DRUGUNRELATED requirement of our patient appeared to be maximal 5 to 7 days after the initiation of DRUG and extended a similar length of time after DRUGOTHER withdrawal .
"Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.
"	Misonidazole	CCNU	effect	{'e1': {'word': 'Misonidazole', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d85.s0.e0'}, 'e2': {'word': 'CCNU', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d85.s0.e1'}, 'sentence_id': 'DDI-MedLine.d85.s0'}	DRUG protects mouse tumour and normal tissues from the toxicity of oral DRUGOTHER .
Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. 	nitrosourea	CCNU	none	{'e1': {'word': 'nitrosourea', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d85.s1.e0'}, 'e2': {'word': 'CCNU', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d85.s1.e1'}, 'sentence_id': 'DDI-MedLine.d85.s1'}	Because the DRUG DRUGOTHER is given exclusively by the oral route in man , we have carried out studies in mice on the antitumour activity , acute toxicity and pharmacokinetics of oral DRUGUNRELATED , either alone or in combination with the chemosensitizer DRUGUNRELATED .
Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. 	nitrosourea	CCNU	none	{'e1': {'word': 'nitrosourea', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d85.s1.e0'}, 'e2': {'word': 'CCNU', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d85.s1.e2'}, 'sentence_id': 'DDI-MedLine.d85.s1'}	Because the DRUG DRUGUNRELATED is given exclusively by the oral route in man , we have carried out studies in mice on the antitumour activity , acute toxicity and pharmacokinetics of oral DRUGOTHER , either alone or in combination with the chemosensitizer DRUGUNRELATED .
Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. 	nitrosourea	misonidazole	none	{'e1': {'word': 'nitrosourea', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d85.s1.e0'}, 'e2': {'word': 'misonidazole', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d85.s1.e3'}, 'sentence_id': 'DDI-MedLine.d85.s1'}	Because the DRUG DRUGUNRELATED is given exclusively by the oral route in man , we have carried out studies in mice on the antitumour activity , acute toxicity and pharmacokinetics of oral DRUGUNRELATED , either alone or in combination with the chemosensitizer DRUGOTHER .
Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. 	CCNU	CCNU	none	{'e1': {'word': 'CCNU', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d85.s1.e1'}, 'e2': {'word': 'CCNU', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d85.s1.e2'}, 'sentence_id': 'DDI-MedLine.d85.s1'}	Because the DRUGUNRELATED DRUG is given exclusively by the oral route in man , we have carried out studies in mice on the antitumour activity , acute toxicity and pharmacokinetics of oral DRUGOTHER , either alone or in combination with the chemosensitizer DRUGUNRELATED .
Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. 	CCNU	misonidazole	none	{'e1': {'word': 'CCNU', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d85.s1.e1'}, 'e2': {'word': 'misonidazole', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d85.s1.e3'}, 'sentence_id': 'DDI-MedLine.d85.s1'}	Because the DRUGUNRELATED DRUG is given exclusively by the oral route in man , we have carried out studies in mice on the antitumour activity , acute toxicity and pharmacokinetics of oral DRUGUNRELATED , either alone or in combination with the chemosensitizer DRUGOTHER .
Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. 	CCNU	misonidazole	none	{'e1': {'word': 'CCNU', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d85.s1.e2'}, 'e2': {'word': 'misonidazole', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d85.s1.e3'}, 'sentence_id': 'DDI-MedLine.d85.s1'}	Because the DRUGUNRELATED DRUGUNRELATED is given exclusively by the oral route in man , we have carried out studies in mice on the antitumour activity , acute toxicity and pharmacokinetics of oral DRUG , either alone or in combination with the chemosensitizer DRUGOTHER .
Misonidazole reduced the antitumour activity of oral CCNU by dose modifying factors (DMF) of 0.58-0.71. 	Misonidazole	CCNU	effect	{'e1': {'word': 'Misonidazole', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d85.s7.e0'}, 'e2': {'word': 'CCNU', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d85.s7.e1'}, 'sentence_id': 'DDI-MedLine.d85.s7'}	DRUG reduced the antitumour activity of oral DRUGOTHER by dose modifying factors ( DMF ) of 0.58 - 0.71.
Misonidazole has a complex effect on oral CCNU pharmacokinetics. 	Misonidazole	CCNU	mechanism	{'e1': {'word': 'Misonidazole', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d85.s9.e0'}, 'e2': {'word': 'CCNU', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d85.s9.e1'}, 'sentence_id': 'DDI-MedLine.d85.s9'}	DRUG has a complex effect on oral DRUGOTHER pharmacokinetics .
We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral CCNU cytotoxicity by misonidazole. 	CCNU	misonidazole	mechanism	{'e1': {'word': 'CCNU', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d85.s14.e0'}, 'e2': {'word': 'misonidazole', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d85.s14.e1'}, 'sentence_id': 'DDI-MedLine.d85.s14'}	We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral DRUG cytotoxicity by DRUGOTHER .
[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration] The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 	radiopertechnetate	sodium perchlorate	none	{'e1': {'word': 'radiopertechnetate', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d134.s0.e0'}, 'e2': {'word': 'sodium perchlorate', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d134.s0.e1'}, 'sentence_id': 'DDI-MedLine.d134.s0'}	[ Dose - time effects of competitive displacement of DRUG by DRUGOTHER following oral and intravenous administration ] The effect of various doses of DRUGUNRELATED in several dose fractions on the extent and the time scale of displacement of DRUGUNRELATED , in dependence on application mode , was studied .
[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration] The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 	radiopertechnetate	sodium perchlorate	none	{'e1': {'word': 'radiopertechnetate', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d134.s0.e0'}, 'e2': {'word': 'sodium perchlorate', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d134.s0.e2'}, 'sentence_id': 'DDI-MedLine.d134.s0'}	[ Dose - time effects of competitive displacement of DRUG by DRUGUNRELATED following oral and intravenous administration ] The effect of various doses of DRUGOTHER in several dose fractions on the extent and the time scale of displacement of DRUGUNRELATED , in dependence on application mode , was studied .
[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration] The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 	radiopertechnetate	radiopertechnetate	none	{'e1': {'word': 'radiopertechnetate', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d134.s0.e0'}, 'e2': {'word': 'radiopertechnetate', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d134.s0.e3'}, 'sentence_id': 'DDI-MedLine.d134.s0'}	[ Dose - time effects of competitive displacement of DRUG by DRUGUNRELATED following oral and intravenous administration ] The effect of various doses of DRUGUNRELATED in several dose fractions on the extent and the time scale of displacement of DRUGOTHER , in dependence on application mode , was studied .
[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration] The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 	sodium perchlorate	sodium perchlorate	none	{'e1': {'word': 'sodium perchlorate', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d134.s0.e1'}, 'e2': {'word': 'sodium perchlorate', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d134.s0.e2'}, 'sentence_id': 'DDI-MedLine.d134.s0'}	[ Dose - time effects of competitive displacement of DRUGUNRELATED by DRUG following oral and intravenous administration ] The effect of various doses of DRUGOTHER in several dose fractions on the extent and the time scale of displacement of DRUGUNRELATED , in dependence on application mode , was studied .
[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration] The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 	sodium perchlorate	radiopertechnetate	none	{'e1': {'word': 'sodium perchlorate', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d134.s0.e1'}, 'e2': {'word': 'radiopertechnetate', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d134.s0.e3'}, 'sentence_id': 'DDI-MedLine.d134.s0'}	[ Dose - time effects of competitive displacement of DRUGUNRELATED by DRUG following oral and intravenous administration ] The effect of various doses of DRUGUNRELATED in several dose fractions on the extent and the time scale of displacement of DRUGOTHER , in dependence on application mode , was studied .
[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration] The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 	sodium perchlorate	radiopertechnetate	none	{'e1': {'word': 'sodium perchlorate', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d134.s0.e2'}, 'e2': {'word': 'radiopertechnetate', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d134.s0.e3'}, 'sentence_id': 'DDI-MedLine.d134.s0'}	[ Dose - time effects of competitive displacement of DRUGUNRELATED by DRUGUNRELATED following oral and intravenous administration ] The effect of various doses of DRUG in several dose fractions on the extent and the time scale of displacement of DRUGOTHER , in dependence on application mode , was studied .
An intravenous dose of 50 mg perchlorate was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of radiopertechnetate. 	perchlorate	pertechnetate	none	{'e1': {'word': 'perchlorate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d134.s1.e0'}, 'e2': {'word': 'pertechnetate', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d134.s1.e1'}, 'sentence_id': 'DDI-MedLine.d134.s1'}	An intravenous dose of 50 mg DRUG was in respect of competitive suppression of organs actively concentrating DRUGOTHER as effective as intravenous 1000 mg ClO - 4 - simultaneously or 1000 mg orally 30 min before the injection of DRUGUNRELATED .
An intravenous dose of 50 mg perchlorate was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of radiopertechnetate. 	perchlorate	radiopertechnetate	none	{'e1': {'word': 'perchlorate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d134.s1.e0'}, 'e2': {'word': 'radiopertechnetate', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d134.s1.e2'}, 'sentence_id': 'DDI-MedLine.d134.s1'}	An intravenous dose of 50 mg DRUG was in respect of competitive suppression of organs actively concentrating DRUGUNRELATED as effective as intravenous 1000 mg ClO - 4 - simultaneously or 1000 mg orally 30 min before the injection of DRUGOTHER .
An intravenous dose of 50 mg perchlorate was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of radiopertechnetate. 	pertechnetate	radiopertechnetate	none	{'e1': {'word': 'pertechnetate', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d134.s1.e1'}, 'e2': {'word': 'radiopertechnetate', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d134.s1.e2'}, 'sentence_id': 'DDI-MedLine.d134.s1'}	An intravenous dose of 50 mg DRUGUNRELATED was in respect of competitive suppression of organs actively concentrating DRUG as effective as intravenous 1000 mg ClO - 4 - simultaneously or 1000 mg orally 30 min before the injection of DRUGOTHER .
An intravenous injection of perchlorate given later also produces a complete and immediately beginning depletion of pertechnetate already accumulated in the thyroid, within a period of 195 min after 99m-TcO-4-injection with a corresponding increase in blood levels. 	perchlorate	pertechnetate	mechanism	{'e1': {'word': 'perchlorate', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d134.s2.e0'}, 'e2': {'word': 'pertechnetate', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d134.s2.e1'}, 'sentence_id': 'DDI-MedLine.d134.s2'}	An intravenous injection of DRUG given later also produces a complete and immediately beginning depletion of DRUGOTHER already accumulated in the thyroid , within a period of 195 min after 99 m - TcO - 4 - injection with a corresponding increase in blood levels .
"Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.
"	amprenavir	rifabutin	none	{'e1': {'word': 'amprenavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s0.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d3.s0.e1'}, 'sentence_id': 'DDI-MedLine.d3.s0'}	Pharmacokinetic Interaction between DRUG and DRUGOTHER or DRUGUNRELATED in healthy males .
"Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.
"	amprenavir	rifampin	none	{'e1': {'word': 'amprenavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s0.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d3.s0.e2'}, 'sentence_id': 'DDI-MedLine.d3.s0'}	Pharmacokinetic Interaction between DRUG and DRUGUNRELATED or DRUGOTHER in healthy males .
"Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.
"	rifabutin	rifampin	none	{'e1': {'word': 'rifabutin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d3.s0.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d3.s0.e2'}, 'sentence_id': 'DDI-MedLine.d3.s0'}	Pharmacokinetic Interaction between DRUGUNRELATED and DRUG or DRUGOTHER in healthy males .
The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). 	amprenavir	rifabutin	none	{'e1': {'word': 'amprenavir', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d3.s1.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d3.s1.e1'}, 'sentence_id': 'DDI-MedLine.d3.s1'}	The objective of this study was to determine if there is a pharmacokinetic interaction when DRUG is given with DRUGOTHER or DRUGUNRELATED and to determine the effects of these drugs on the erythromycin breath test ( ERMBT ) .
The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). 	amprenavir	rifampin	none	{'e1': {'word': 'amprenavir', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d3.s1.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d3.s1.e2'}, 'sentence_id': 'DDI-MedLine.d3.s1'}	The objective of this study was to determine if there is a pharmacokinetic interaction when DRUG is given with DRUGUNRELATED or DRUGOTHER and to determine the effects of these drugs on the erythromycin breath test ( ERMBT ) .
The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). 	rifabutin	rifampin	none	{'e1': {'word': 'rifabutin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d3.s1.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d3.s1.e2'}, 'sentence_id': 'DDI-MedLine.d3.s1'}	The objective of this study was to determine if there is a pharmacokinetic interaction when DRUGUNRELATED is given with DRUG or DRUGOTHER and to determine the effects of these drugs on the erythromycin breath test ( ERMBT ) .
All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. 	amprenavir	rifabutin	none	{'e1': {'word': 'amprenavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s3.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d3.s3.e1'}, 'sentence_id': 'DDI-MedLine.d3.s3'}	All subjects received DRUG ( 1,200 mg twice a day ) for 4 days , followed by a 7 - day washout period , followed by either DRUGOTHER ( 300 mg once a day [ QD ] ) ( cohort 1 ) or DRUGUNRELATED ( 600 mg QD ) ( cohort 2 ) for 14 days .
All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. 	amprenavir	rifampin	none	{'e1': {'word': 'amprenavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s3.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d3.s3.e2'}, 'sentence_id': 'DDI-MedLine.d3.s3'}	All subjects received DRUG ( 1,200 mg twice a day ) for 4 days , followed by a 7 - day washout period , followed by either DRUGUNRELATED ( 300 mg once a day [ QD ] ) ( cohort 1 ) or DRUGOTHER ( 600 mg QD ) ( cohort 2 ) for 14 days .
All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. 	rifabutin	rifampin	none	{'e1': {'word': 'rifabutin', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d3.s3.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d3.s3.e2'}, 'sentence_id': 'DDI-MedLine.d3.s3'}	All subjects received DRUGUNRELATED ( 1,200 mg twice a day ) for 4 days , followed by a 7 - day washout period , followed by either DRUG ( 300 mg once a day [ QD ] ) ( cohort 1 ) or DRUGOTHER ( 600 mg QD ) ( cohort 2 ) for 14 days .
Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. 	amprenavir	rifabutin	none	{'e1': {'word': 'amprenavir', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d3.s4.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d3.s4.e1'}, 'sentence_id': 'DDI-MedLine.d3.s4'}	Cohort 1 then received DRUG plus DRUGOTHER for 10 days , and cohort 2 received DRUGUNRELATED plus DRUGUNRELATED for 4 days .
Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. 	amprenavir	amprenavir	none	{'e1': {'word': 'amprenavir', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d3.s4.e0'}, 'e2': {'word': 'amprenavir', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d3.s4.e2'}, 'sentence_id': 'DDI-MedLine.d3.s4'}	Cohort 1 then received DRUG plus DRUGUNRELATED for 10 days , and cohort 2 received DRUGOTHER plus DRUGUNRELATED for 4 days .
Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. 	amprenavir	rifampin	none	{'e1': {'word': 'amprenavir', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d3.s4.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d3.s4.e3'}, 'sentence_id': 'DDI-MedLine.d3.s4'}	Cohort 1 then received DRUG plus DRUGUNRELATED for 10 days , and cohort 2 received DRUGUNRELATED plus DRUGOTHER for 4 days .
Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. 	rifabutin	amprenavir	none	{'e1': {'word': 'rifabutin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d3.s4.e1'}, 'e2': {'word': 'amprenavir', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d3.s4.e2'}, 'sentence_id': 'DDI-MedLine.d3.s4'}	Cohort 1 then received DRUGUNRELATED plus DRUG for 10 days , and cohort 2 received DRUGOTHER plus DRUGUNRELATED for 4 days .
Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. 	rifabutin	rifampin	none	{'e1': {'word': 'rifabutin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d3.s4.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d3.s4.e3'}, 'sentence_id': 'DDI-MedLine.d3.s4'}	Cohort 1 then received DRUGUNRELATED plus DRUG for 10 days , and cohort 2 received DRUGUNRELATED plus DRUGOTHER for 4 days .
Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. 	amprenavir	rifampin	none	{'e1': {'word': 'amprenavir', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d3.s4.e2'}, 'e2': {'word': 'rifampin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d3.s4.e3'}, 'sentence_id': 'DDI-MedLine.d3.s4'}	Cohort 1 then received DRUGUNRELATED plus DRUGUNRELATED for 10 days , and cohort 2 received DRUG plus DRUGOTHER for 4 days .
Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. 	amprenavir	rifabutin	none	{'e1': {'word': 'amprenavir', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d3.s5.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d3.s5.e1'}, 'sentence_id': 'DDI-MedLine.d3.s5'}	Serial plasma and urine samples for measurement of DRUG , DRUGOTHER , and DRUGUNRELATED and their DRUGUNRELATED , were measured by high - performance liquid chromatography .
Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. 	amprenavir	rifampin	none	{'e1': {'word': 'amprenavir', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d3.s5.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d3.s5.e2'}, 'sentence_id': 'DDI-MedLine.d3.s5'}	Serial plasma and urine samples for measurement of DRUG , DRUGUNRELATED , and DRUGOTHER and their DRUGUNRELATED , were measured by high - performance liquid chromatography .
Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. 	amprenavir	25-O-desacetyl metabolites	none	{'e1': {'word': 'amprenavir', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d3.s5.e0'}, 'e2': {'word': '25-O-desacetyl metabolites', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d3.s5.e3'}, 'sentence_id': 'DDI-MedLine.d3.s5'}	Serial plasma and urine samples for measurement of DRUG , DRUGUNRELATED , and DRUGUNRELATED and their DRUGOTHER , were measured by high - performance liquid chromatography .
Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. 	rifabutin	rifampin	none	{'e1': {'word': 'rifabutin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d3.s5.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d3.s5.e2'}, 'sentence_id': 'DDI-MedLine.d3.s5'}	Serial plasma and urine samples for measurement of DRUGUNRELATED , DRUG , and DRUGOTHER and their DRUGUNRELATED , were measured by high - performance liquid chromatography .
Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. 	rifabutin	25-O-desacetyl metabolites	none	{'e1': {'word': 'rifabutin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d3.s5.e1'}, 'e2': {'word': '25-O-desacetyl metabolites', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d3.s5.e3'}, 'sentence_id': 'DDI-MedLine.d3.s5'}	Serial plasma and urine samples for measurement of DRUGUNRELATED , DRUG , and DRUGUNRELATED and their DRUGOTHER , were measured by high - performance liquid chromatography .
Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. 	rifampin	25-O-desacetyl metabolites	none	{'e1': {'word': 'rifampin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d3.s5.e2'}, 'e2': {'word': '25-O-desacetyl metabolites', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d3.s5.e3'}, 'sentence_id': 'DDI-MedLine.d3.s5'}	Serial plasma and urine samples for measurement of DRUGUNRELATED , DRUGUNRELATED , and DRUG and their DRUGOTHER , were measured by high - performance liquid chromatography .
Rifabutin did not significantly affect amprenavir's pharmacokinetics. 	Rifabutin	amprenavir	none	{'e1': {'word': 'Rifabutin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s6.e0'}, 'e2': {'word': 'amprenavir', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d3.s6.e1'}, 'sentence_id': 'DDI-MedLine.d3.s6'}	DRUG did not significantly affect DRUGOTHER 's pharmacokinetics .
Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. 	Amprenavir	rifabutin	mechanism	{'e1': {'word': 'Amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s7.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d3.s7.e1'}, 'sentence_id': 'DDI-MedLine.d3.s7'}	DRUG significantly increased the area under the curve at steady state ( AUC ( ss ) ) of DRUGOTHER by 2.93 - fold and the AUC ( ss ) of DRUGUNRELATED by 13.3-fold .
Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. 	Amprenavir	25-O-desacetylrifabutin	mechanism	{'e1': {'word': 'Amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s7.e0'}, 'e2': {'word': '25-O-desacetylrifabutin', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d3.s7.e2'}, 'sentence_id': 'DDI-MedLine.d3.s7'}	DRUG significantly increased the area under the curve at steady state ( AUC ( ss ) ) of DRUGUNRELATED by 2.93 - fold and the AUC ( ss ) of DRUGOTHER by 13.3-fold .
Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. 	rifabutin	25-O-desacetylrifabutin	none	{'e1': {'word': 'rifabutin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d3.s7.e1'}, 'e2': {'word': '25-O-desacetylrifabutin', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d3.s7.e2'}, 'sentence_id': 'DDI-MedLine.d3.s7'}	DRUGUNRELATED significantly increased the area under the curve at steady state ( AUC ( ss ) ) of DRUG by 2.93- fold and the AUC ( ss ) of DRUGOTHER by 13.3-fold .
Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. 	Rifampin	amprenavir	mechanism	{'e1': {'word': 'Rifampin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s8.e0'}, 'e2': {'word': 'amprenavir', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d3.s8.e1'}, 'sentence_id': 'DDI-MedLine.d3.s8'}	DRUG significantly decreased the AUC ( ss ) of DRUGOTHER by 82 % , but DRUGUNRELATED had no effect on DRUGUNRELATED pharmacokinetics .
Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. 	Rifampin	amprenavir	none	{'e1': {'word': 'Rifampin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s8.e0'}, 'e2': {'word': 'amprenavir', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d3.s8.e2'}, 'sentence_id': 'DDI-MedLine.d3.s8'}	DRUG significantly decreased the AUC ( ss ) of DRUGUNRELATED by 82 % , but DRUGOTHER had no effect on DRUGUNRELATED pharmacokinetics .
Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. 	Rifampin	rifampin	none	{'e1': {'word': 'Rifampin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s8.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d3.s8.e3'}, 'sentence_id': 'DDI-MedLine.d3.s8'}	DRUG significantly decreased the AUC ( ss ) of DRUGUNRELATED by 82 % , but DRUGUNRELATED had no effect on DRUGOTHER pharmacokinetics .
Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. 	amprenavir	amprenavir	none	{'e1': {'word': 'amprenavir', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d3.s8.e1'}, 'e2': {'word': 'amprenavir', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d3.s8.e2'}, 'sentence_id': 'DDI-MedLine.d3.s8'}	DRUGUNRELATED significantly decreased the AUC ( ss ) of DRUG by 82 % , but DRUGOTHER had no effect on DRUGUNRELATED pharmacokinetics .
Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. 	amprenavir	rifampin	none	{'e1': {'word': 'amprenavir', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d3.s8.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d3.s8.e3'}, 'sentence_id': 'DDI-MedLine.d3.s8'}	DRUGUNRELATED significantly decreased the AUC ( ss ) of DRUG by 82 % , but DRUGUNRELATED had no effect on DRUGOTHER pharmacokinetics .
Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. 	amprenavir	rifampin	none	{'e1': {'word': 'amprenavir', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d3.s8.e2'}, 'e2': {'word': 'rifampin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d3.s8.e3'}, 'sentence_id': 'DDI-MedLine.d3.s8'}	DRUGUNRELATED significantly decreased the AUC ( ss ) of DRUGUNRELATED by 82 % , but DRUG had no effect on DRUGOTHER pharmacokinetics .
The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively. 	rifabutin	rifampin	none	{'e1': {'word': 'rifabutin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d3.s10.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d3.s10.e1'}, 'sentence_id': 'DDI-MedLine.d3.s10'}	The results of the ERMBT after 2 weeks of DRUG and DRUGOTHER therapy were increased 187 and 156 % , respectively .
Amprenavir plus rifampin was well tolerated. 	Amprenavir	rifampin	none	{'e1': {'word': 'Amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s11.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d3.s11.e1'}, 'sentence_id': 'DDI-MedLine.d3.s11'}	DRUG plus DRUGOTHER was well tolerated .
Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. 	Amprenavir	rifabutin	effect	{'e1': {'word': 'Amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s12.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d3.s12.e1'}, 'sentence_id': 'DDI-MedLine.d3.s12'}	DRUG plus DRUGOTHER was poorly tolerated , and 5 of 11 subjects discontinued therapy .
Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. 	Rifampin	amprenavir	mechanism	{'e1': {'word': 'Rifampin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s13.e0'}, 'e2': {'word': 'amprenavir', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d3.s13.e1'}, 'sentence_id': 'DDI-MedLine.d3.s13'}	DRUG markedly increases the metabolic clearance of DRUGOTHER , and coadministration is contraindicated .
Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. 	Amprenavir	rifabutin	mechanism	{'e1': {'word': 'Amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s14.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d3.s14.e1'}, 'sentence_id': 'DDI-MedLine.d3.s14'}	DRUG significantly decreases clearance of DRUGOTHER and DRUGUNRELATED , and the combination is poorly tolerated .
Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. 	Amprenavir	25-O-desacetylrifabutin	mechanism	{'e1': {'word': 'Amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s14.e0'}, 'e2': {'word': '25-O-desacetylrifabutin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d3.s14.e2'}, 'sentence_id': 'DDI-MedLine.d3.s14'}	DRUG significantly decreases clearance of DRUGUNRELATED and DRUGOTHER , and the combination is poorly tolerated .
Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. 	rifabutin	25-O-desacetylrifabutin	none	{'e1': {'word': 'rifabutin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d3.s14.e1'}, 'e2': {'word': '25-O-desacetylrifabutin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d3.s14.e2'}, 'sentence_id': 'DDI-MedLine.d3.s14'}	DRUGUNRELATED significantly decreases clearance of DRUG and DRUGOTHER , and the combination is poorly tolerated .
Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.	Amprenavir	rifampin	none	{'e1': {'word': 'Amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s15.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d3.s15.e1'}, 'sentence_id': 'DDI-MedLine.d3.s15'}	DRUG inhibits the ERMBT , and DRUGOTHER and DRUGUNRELATED are equipotent inducers of the ERMBT .
Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.	Amprenavir	rifabutin	none	{'e1': {'word': 'Amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s15.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d3.s15.e2'}, 'sentence_id': 'DDI-MedLine.d3.s15'}	DRUG inhibits the ERMBT , and DRUGUNRELATED and DRUGOTHER are equipotent inducers of the ERMBT .
Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.	rifampin	rifabutin	none	{'e1': {'word': 'rifampin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d3.s15.e1'}, 'e2': {'word': 'rifabutin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d3.s15.e2'}, 'sentence_id': 'DDI-MedLine.d3.s15'}	DRUGUNRELATED inhibits the ERMBT , and DRUG and DRUGOTHER are equipotent inducers of the ERMBT .
"Behavioral responses to repeated cocaine exposure in mice selectively bred for differential sensitivity to pentobarbital.
"	cocaine	pentobarbital	none	{'e1': {'word': 'cocaine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d98.s0.e0'}, 'e2': {'word': 'pentobarbital', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d98.s0.e1'}, 'sentence_id': 'DDI-MedLine.d98.s0'}	Behavioral responses to repeated DRUG exposure in mice selectively bred for differential sensitivity to DRUGOTHER .
Mice from the 20th generation of three lines divergently selected for response to pentobarbital-induced sedation times [long-sedation time (LST), short sedation time (SST), and randomly bred control (RBC)] were used to study cocaine-induced behavioral sensitization. 	pentobarbital	cocaine	none	{'e1': {'word': 'pentobarbital', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d98.s1.e0'}, 'e2': {'word': 'cocaine', 'word_index': [(46, 46)], 'id': 'DDI-MedLine.d98.s1.e1'}, 'sentence_id': 'DDI-MedLine.d98.s1'}	Mice from the 20th generation of three lines divergently selected for response to DRUG - induced sedation times [ long - sedation time ( LST ) , short sedation time ( SST ) , and randomly bred control ( RBC ) ] were used to study DRUGOTHER - induced behavioral sensitization .
Changes in urinary homocysteine following synthetic steroidal estrogen and progestogen administration to rats.	synthetic steroidal estrogen	synthetic steroidal progestogen	none	{'e1': {'word': 'synthetic steroidal estrogen', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d66.s0.e0'}, 'e2': {'word': 'synthetic steroidal progestogen', 'word_index': [(6, 6), (9, 9)], 'id': 'DDI-MedLine.d66.s0.e1'}, 'sentence_id': 'DDI-MedLine.d66.s0'}	Changes in urinary homocysteine following DRUG DRUGOTHER estrogen and DRUGOTHER administration to rats .
The present work involved the administration of both ethynyl estradiol and levonorgestrel to groups of rats, followed by determination of the homocysteine excretion rate in urine. 	ethynyl estradiol	levonorgestrel	none	{'e1': {'word': 'ethynyl estradiol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d66.s1.e0'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d66.s1.e1'}, 'sentence_id': 'DDI-MedLine.d66.s1'}	The present work involved the administration of both DRUG and DRUGOTHER to groups of rats , followed by determination of the homocysteine excretion rate in urine .
The results indicate that a statistically significant difference exists between the excreted levels of homocysteine in the urine of both control and levonorgestrel-treated rats and the levels shown by rats treated with ethynyl estradiol. 	levonorgestrel	ethynyl estradiol	none	{'e1': {'word': 'levonorgestrel', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d66.s2.e0'}, 'e2': {'word': 'ethynyl estradiol', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d66.s2.e1'}, 'sentence_id': 'DDI-MedLine.d66.s2'}	The results indicate that a statistically significant difference exists between the excreted levels of homocysteine in the urine of both control and DRUG - treated rats and the levels shown by rats treated with DRUGOTHER .
"Therapeutic drug monitoring can avoid iatrogenic alterations caused by 99mTc-methylene diphosphonate (MDP)-gentamicin interaction.
"	99mTc-methylene diphosphonate	gentamicin	effect	{'e1': {'word': '99mTc-methylene diphosphonate', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d89.s0.e0'}, 'e2': {'word': 'gentamicin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d89.s0.e1'}, 'sentence_id': 'DDI-MedLine.d89.s0'}	Therapeutic drug monitoring can avoid iatrogenic alterations caused by DRUG ( MDP ) - DRUGOTHER interaction .
Gentamicin is an aminoglycoside antibiotic used to treat a wide variety of infections caused by gram-negative organisms, but it is potentially toxic to the kidneys. 	Gentamicin	aminoglycoside antibiotic	none	{'e1': {'word': 'Gentamicin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d89.s1.e0'}, 'e2': {'word': 'aminoglycoside antibiotic', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d89.s1.e1'}, 'sentence_id': 'DDI-MedLine.d89.s1'}	DRUG is an DRUGOTHER used to treat a wide variety of infections caused by gram - negative organisms , but it is potentially toxic to the kidneys .
Due to its nephrotoxicity, gentamicin may cause abnormal renal uptake to be seen on 99mTc-MDP bone scintigraphy. 	gentamicin	99mTc-MDP	mechanism	{'e1': {'word': 'gentamicin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d89.s2.e0'}, 'e2': {'word': '99mTc-MDP', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d89.s2.e1'}, 'sentence_id': 'DDI-MedLine.d89.s2'}	Due to its nephrotoxicity , DRUG may cause abnormal renal uptake to be seen on DRUGOTHER bone scintigraphy .
Therapeutic drug monitoring (TDM) of gentamicin therapy, and bone scintigraphy employing 99mTc-MDP as the radiopharmaceutical was carried out in 22 patients. 	gentamicin	99mTc-MDP	none	{'e1': {'word': 'gentamicin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d89.s7.e0'}, 'e2': {'word': '99mTc-MDP', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d89.s7.e1'}, 'sentence_id': 'DDI-MedLine.d89.s7'}	Therapeutic drug monitoring ( TDM ) of DRUG therapy , and bone scintigraphy employing DRUGOTHER as the DRUGUNRELATED was carried out in 22 patients .
Therapeutic drug monitoring (TDM) of gentamicin therapy, and bone scintigraphy employing 99mTc-MDP as the radiopharmaceutical was carried out in 22 patients. 	gentamicin	radiopharmaceutical	none	{'e1': {'word': 'gentamicin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d89.s7.e0'}, 'e2': {'word': 'radiopharmaceutical', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d89.s7.e2'}, 'sentence_id': 'DDI-MedLine.d89.s7'}	Therapeutic drug monitoring ( TDM ) of DRUG therapy , and bone scintigraphy employing DRUGUNRELATED as the DRUGOTHER was carried out in 22 patients .
Therapeutic drug monitoring (TDM) of gentamicin therapy, and bone scintigraphy employing 99mTc-MDP as the radiopharmaceutical was carried out in 22 patients. 	99mTc-MDP	radiopharmaceutical	none	{'e1': {'word': '99mTc-MDP', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d89.s7.e1'}, 'e2': {'word': 'radiopharmaceutical', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d89.s7.e2'}, 'sentence_id': 'DDI-MedLine.d89.s7'}	Therapeutic drug monitoring ( TDM ) of DRUGUNRELATED therapy , and bone scintigraphy employing DRUG as the DRUGOTHER was carried out in 22 patients .
The data presented here demonstrate that with serial pharmacokinetic dosing of gentamicin, the iatrogenic alteration caused by gentamicin therapy can be avoided.	gentamicin	gentamicin	none	{'e1': {'word': 'gentamicin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d89.s8.e0'}, 'e2': {'word': 'gentamicin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d89.s8.e1'}, 'sentence_id': 'DDI-MedLine.d89.s8'}	The data presented here demonstrate that with serial pharmacokinetic dosing of DRUG , the iatrogenic alteration caused by DRUGOTHER therapy can be avoided .
Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.	Dexamethasone	retinyl acetate	none	{'e1': {'word': 'Dexamethasone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s0.e0'}, 'e2': {'word': 'retinyl acetate', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d12.s0.e1'}, 'sentence_id': 'DDI-MedLine.d12.s0'}	DRUG and DRUGOTHER similarly inhibit and stimulate DRUGUNRELATED - or DRUGUNRELATED - induced proliferation of prostatic epithelium .
Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.	Dexamethasone	EGF	effect	{'e1': {'word': 'Dexamethasone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s0.e0'}, 'e2': {'word': 'EGF', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d12.s0.e2'}, 'sentence_id': 'DDI-MedLine.d12.s0'}	DRUG and DRUGUNRELATED similarly inhibit and stimulate DRUGOTHER - or DRUGUNRELATED - induced proliferation of prostatic epithelium .
Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.	Dexamethasone	insulin	effect	{'e1': {'word': 'Dexamethasone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s0.e0'}, 'e2': {'word': 'insulin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d12.s0.e3'}, 'sentence_id': 'DDI-MedLine.d12.s0'}	DRUG and DRUGUNRELATED similarly inhibit and stimulate DRUGUNRELATED - or DRUGOTHER - induced proliferation of prostatic epithelium .
Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.	retinyl acetate	EGF	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d12.s0.e1'}, 'e2': {'word': 'EGF', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d12.s0.e2'}, 'sentence_id': 'DDI-MedLine.d12.s0'}	DRUGUNRELATED and DRUG similarly inhibit and stimulate DRUGOTHER - or DRUGUNRELATED - induced proliferation of prostatic epithelium .
Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.	retinyl acetate	insulin	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d12.s0.e1'}, 'e2': {'word': 'insulin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d12.s0.e3'}, 'sentence_id': 'DDI-MedLine.d12.s0'}	DRUGUNRELATED and DRUG similarly inhibit and stimulate DRUGUNRELATED - or DRUGOTHER - induced proliferation of prostatic epithelium .
Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.	EGF	insulin	none	{'e1': {'word': 'EGF', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d12.s0.e2'}, 'e2': {'word': 'insulin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d12.s0.e3'}, 'sentence_id': 'DDI-MedLine.d12.s0'}	DRUGUNRELATED and DRUGUNRELATED similarly inhibit and stimulate DRUG - or DRUGOTHER - induced proliferation of prostatic epithelium .
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin (1 microgram/ml), EGF (10 ng/ml), and insulin (3.7 micrograms/ml or 0.1 IU/ml). 	transferrin	EGF	none	{'e1': {'word': 'transferrin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d12.s1.e0'}, 'e2': {'word': 'EGF', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d12.s1.e1'}, 'sentence_id': 'DDI-MedLine.d12.s1'}	Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing DRUG ( 1 microgram / ml ) , DRUGOTHER ( 10 ng / ml ) , and DRUGUNRELATED ( 3.7 micrograms / ml or 0.1 IU / ml ) .
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin (1 microgram/ml), EGF (10 ng/ml), and insulin (3.7 micrograms/ml or 0.1 IU/ml). 	transferrin	insulin	none	{'e1': {'word': 'transferrin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d12.s1.e0'}, 'e2': {'word': 'insulin', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d12.s1.e2'}, 'sentence_id': 'DDI-MedLine.d12.s1'}	Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing DRUG ( 1 microgram / ml ) , DRUGUNRELATED ( 10 ng / ml ) , and DRUGOTHER ( 3.7 micrograms / ml or 0.1 IU / ml ) .
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin (1 microgram/ml), EGF (10 ng/ml), and insulin (3.7 micrograms/ml or 0.1 IU/ml). 	EGF	insulin	none	{'e1': {'word': 'EGF', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d12.s1.e1'}, 'e2': {'word': 'insulin', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d12.s1.e2'}, 'sentence_id': 'DDI-MedLine.d12.s1'}	Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing DRUGUNRELATED ( 1 microgram / ml ) , DRUG ( 10 ng / ml ) , and DRUGOTHER ( 3.7 micrograms / ml or 0.1 IU / ml ) .
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	dexamethasone	retinyl acetate	none	{'e1': {'word': 'dexamethasone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d12.s2.e0'}, 'e2': {'word': 'retinyl acetate', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d12.s2.e1'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	Although neither DRUG nor DRUGOTHER affected the proliferation of prostatic epithelium in RPMI1640 containing DRUGUNRELATED alone , they modify the mitogenic effect of DRUGUNRELATED and DRUGUNRELATED .
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	dexamethasone	transferrin	none	{'e1': {'word': 'dexamethasone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d12.s2.e0'}, 'e2': {'word': 'transferrin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d12.s2.e2'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	Although neither DRUG nor DRUGUNRELATED affected the proliferation of prostatic epithelium in RPMI1640 containing DRUGOTHER alone , they modify the mitogenic effect of DRUGUNRELATED and DRUGUNRELATED .
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	dexamethasone	EGF	effect	{'e1': {'word': 'dexamethasone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d12.s2.e0'}, 'e2': {'word': 'EGF', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d12.s2.e3'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	Although neither DRUG nor DRUGUNRELATED affected the proliferation of prostatic epithelium in RPMI1640 containing DRUGUNRELATED alone , they modify the mitogenic effect of DRUGOTHER and DRUGUNRELATED .
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	dexamethasone	insulin	effect	{'e1': {'word': 'dexamethasone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d12.s2.e0'}, 'e2': {'word': 'insulin', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d12.s2.e4'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	Although neither DRUG nor DRUGUNRELATED affected the proliferation of prostatic epithelium in RPMI1640 containing DRUGUNRELATED alone , they modify the mitogenic effect of DRUGUNRELATED and DRUGOTHER .
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	retinyl acetate	transferrin	none	{'e1': {'word': 'retinyl acetate', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d12.s2.e1'}, 'e2': {'word': 'transferrin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d12.s2.e2'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	Although neither DRUGUNRELATED nor DRUG affected the proliferation of prostatic epithelium in RPMI1640 containing DRUGOTHER alone , they modify the mitogenic effect of DRUGUNRELATED and DRUGUNRELATED .
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	retinyl acetate	EGF	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d12.s2.e1'}, 'e2': {'word': 'EGF', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d12.s2.e3'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	Although neither DRUGUNRELATED nor DRUG affected the proliferation of prostatic epithelium in RPMI1640 containing DRUGUNRELATED alone , they modify the mitogenic effect of DRUGOTHER and DRUGUNRELATED .
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	retinyl acetate	insulin	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d12.s2.e1'}, 'e2': {'word': 'insulin', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d12.s2.e4'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	Although neither DRUGUNRELATED nor DRUG affected the proliferation of prostatic epithelium in RPMI1640 containing DRUGUNRELATED alone , they modify the mitogenic effect of DRUGUNRELATED and DRUGOTHER .
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	transferrin	EGF	none	{'e1': {'word': 'transferrin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d12.s2.e2'}, 'e2': {'word': 'EGF', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d12.s2.e3'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	Although neither DRUGUNRELATED nor DRUGUNRELATED affected the proliferation of prostatic epithelium in RPMI1640 containing DRUG alone , they modify the mitogenic effect of DRUGOTHER and DRUGUNRELATED .
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	transferrin	insulin	none	{'e1': {'word': 'transferrin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d12.s2.e2'}, 'e2': {'word': 'insulin', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d12.s2.e4'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	Although neither DRUGUNRELATED nor DRUGUNRELATED affected the proliferation of prostatic epithelium in RPMI1640 containing DRUG alone , they modify the mitogenic effect of DRUGUNRELATED and DRUGOTHER .
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	EGF	insulin	none	{'e1': {'word': 'EGF', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d12.s2.e3'}, 'e2': {'word': 'insulin', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d12.s2.e4'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	Although neither DRUGUNRELATED nor DRUGUNRELATED affected the proliferation of prostatic epithelium in RPMI1640 containing DRUGUNRELATED alone , they modify the mitogenic effect of DRUG and DRUGOTHER .
Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF. 	Dexamethasone	retinyl acetate	none	{'e1': {'word': 'Dexamethasone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s3.e0'}, 'e2': {'word': 'retinyl acetate', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d12.s3.e1'}, 'sentence_id': 'DDI-MedLine.d12.s3'}	DRUG at 10 ( - 10 ) M or DRUGOTHER at about 3 X 10 ( - 9 ) M inhibits proliferation stimulated by DRUGUNRELATED .
Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF. 	Dexamethasone	EGF	effect	{'e1': {'word': 'Dexamethasone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s3.e0'}, 'e2': {'word': 'EGF', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d12.s3.e2'}, 'sentence_id': 'DDI-MedLine.d12.s3'}	DRUG at 10 ( - 10 ) M or DRUGUNRELATED at about 3 X 10 ( - 9 ) M inhibits proliferation stimulated by DRUGOTHER .
Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF. 	retinyl acetate	EGF	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d12.s3.e1'}, 'e2': {'word': 'EGF', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d12.s3.e2'}, 'sentence_id': 'DDI-MedLine.d12.s3'}	DRUGUNRELATED at 10 ( - 10 ) M or DRUG at about 3 X 10 ( - 9 ) M inhibits proliferation stimulated by DRUGOTHER .
Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF. 	dexamethasone	retinyl acetate	none	{'e1': {'word': 'dexamethasone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d12.s4.e0'}, 'e2': {'word': 'retinyl acetate', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d12.s4.e1'}, 'sentence_id': 'DDI-MedLine.d12.s4'}	Higher concentrations of DRUG ( 10 ( - 8 ) - 10 ( - 6 ) M ) or DRUGOTHER ( 3 X 10 ( - 8 ) - 10 ( - 7 ) M ) enhance the mitogenic activity of DRUGUNRELATED .
Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF. 	dexamethasone	EGF	effect	{'e1': {'word': 'dexamethasone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d12.s4.e0'}, 'e2': {'word': 'EGF', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d12.s4.e2'}, 'sentence_id': 'DDI-MedLine.d12.s4'}	Higher concentrations of DRUG ( 10 ( - 8 ) - 10 ( - 6 ) M ) or DRUGUNRELATED ( 3 X 10 ( - 8 ) - 10 ( - 7 ) M ) enhance the mitogenic activity of DRUGOTHER .
Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF. 	retinyl acetate	EGF	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d12.s4.e1'}, 'e2': {'word': 'EGF', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d12.s4.e2'}, 'sentence_id': 'DDI-MedLine.d12.s4'}	Higher concentrations of DRUGUNRELATED ( 10 ( - 8 ) - 10 ( - 6 ) M ) or DRUG ( 3 X 10 ( - 8 ) - 10 ( - 7 ) M ) enhance the mitogenic activity of DRUGOTHER .
Dexamethasone had a similar effect in the presence of insulin. 	Dexamethasone	insulin	none	{'e1': {'word': 'Dexamethasone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s5.e0'}, 'e2': {'word': 'insulin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d12.s5.e1'}, 'sentence_id': 'DDI-MedLine.d12.s5'}	DRUG had a similar effect in the presence of DRUGOTHER .
However, retinyl acetate stimulated, but did not significantly inhibit, proliferation in the presence of insulin. 	retinyl acetate	insulin	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d12.s6.e0'}, 'e2': {'word': 'insulin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d12.s6.e1'}, 'sentence_id': 'DDI-MedLine.d12.s6'}	However , DRUG stimulated , but did not significantly inhibit , proliferation in the presence of DRUGOTHER .
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	dexamethasone	retinyl acetate	none	{'e1': {'word': 'dexamethasone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d12.s7.e0'}, 'e2': {'word': 'retinyl acetate', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d12.s7.e1'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both DRUG and DRUGOTHER , and possibly other DRUGUNRELATED and DRUGUNRELATED , may regulate the proliferation of prostate epithelium by a dose - dependent modification of the activity of DRUGUNRELATED and DRUGUNRELATED .
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	dexamethasone	glucocorticoids	none	{'e1': {'word': 'dexamethasone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d12.s7.e0'}, 'e2': {'word': 'glucocorticoids', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d12.s7.e2'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both DRUG and DRUGUNRELATED , and possibly other DRUGOTHER and DRUGUNRELATED , may regulate the proliferation of prostate epithelium by a dose - dependent modification of the activity of DRUGUNRELATED and DRUGUNRELATED .
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	dexamethasone	retinoids	none	{'e1': {'word': 'dexamethasone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d12.s7.e0'}, 'e2': {'word': 'retinoids', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d12.s7.e3'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both DRUG and DRUGUNRELATED , and possibly other DRUGUNRELATED and DRUGOTHER , may regulate the proliferation of prostate epithelium by a dose - dependent modification of the activity of DRUGUNRELATED and DRUGUNRELATED .
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	dexamethasone	insulin	effect	{'e1': {'word': 'dexamethasone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d12.s7.e0'}, 'e2': {'word': 'insulin', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d12.s7.e4'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both DRUG and DRUGUNRELATED , and possibly other DRUGUNRELATED and DRUGUNRELATED , may regulate the proliferation of prostate epithelium by a dose - dependent modification of the activity of DRUGOTHER and DRUGUNRELATED .
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	dexamethasone	EGF	effect	{'e1': {'word': 'dexamethasone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d12.s7.e0'}, 'e2': {'word': 'EGF', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d12.s7.e5'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both DRUG and DRUGUNRELATED , and possibly other DRUGUNRELATED and DRUGUNRELATED , may regulate the proliferation of prostate epithelium by a dose - dependent modification of the activity of DRUGUNRELATED and DRUGOTHER .
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	retinyl acetate	glucocorticoids	none	{'e1': {'word': 'retinyl acetate', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d12.s7.e1'}, 'e2': {'word': 'glucocorticoids', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d12.s7.e2'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both DRUGUNRELATED and DRUG , and possibly other DRUGOTHER and DRUGUNRELATED , may regulate the proliferation of prostate epithelium by a dose - dependent modification of the activity of DRUGUNRELATED and DRUGUNRELATED .
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	retinyl acetate	retinoids	none	{'e1': {'word': 'retinyl acetate', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d12.s7.e1'}, 'e2': {'word': 'retinoids', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d12.s7.e3'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both DRUGUNRELATED and DRUG , and possibly other DRUGUNRELATED and DRUGOTHER , may regulate the proliferation of prostate epithelium by a dose - dependent modification of the activity of DRUGUNRELATED and DRUGUNRELATED .
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	retinyl acetate	insulin	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d12.s7.e1'}, 'e2': {'word': 'insulin', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d12.s7.e4'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both DRUGUNRELATED and DRUG , and possibly other DRUGUNRELATED and DRUGUNRELATED , may regulate the proliferation of prostate epithelium by a dose - dependent modification of the activity of DRUGOTHER and DRUGUNRELATED .
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	retinyl acetate	EGF	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d12.s7.e1'}, 'e2': {'word': 'EGF', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d12.s7.e5'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both DRUGUNRELATED and DRUG , and possibly other DRUGUNRELATED and DRUGUNRELATED , may regulate the proliferation of prostate epithelium by a dose - dependent modification of the activity of DRUGUNRELATED and DRUGOTHER .
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	glucocorticoids	retinoids	none	{'e1': {'word': 'glucocorticoids', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d12.s7.e2'}, 'e2': {'word': 'retinoids', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d12.s7.e3'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both DRUGUNRELATED and DRUGUNRELATED , and possibly other DRUG and DRUGOTHER , may regulate the proliferation of prostate epithelium by a dose - dependent modification of the activity of DRUGUNRELATED and DRUGUNRELATED .
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	glucocorticoids	insulin	effect	{'e1': {'word': 'glucocorticoids', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d12.s7.e2'}, 'e2': {'word': 'insulin', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d12.s7.e4'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both DRUGUNRELATED and DRUGUNRELATED , and possibly other DRUG and DRUGUNRELATED , may regulate the proliferation of prostate epithelium by a dose - dependent modification of the activity of DRUGOTHER and DRUGUNRELATED .
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	glucocorticoids	EGF	effect	{'e1': {'word': 'glucocorticoids', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d12.s7.e2'}, 'e2': {'word': 'EGF', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d12.s7.e5'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both DRUGUNRELATED and DRUGUNRELATED , and possibly other DRUG and DRUGUNRELATED , may regulate the proliferation of prostate epithelium by a dose - dependent modification of the activity of DRUGUNRELATED and DRUGOTHER .
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	retinoids	insulin	effect	{'e1': {'word': 'retinoids', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d12.s7.e3'}, 'e2': {'word': 'insulin', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d12.s7.e4'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both DRUGUNRELATED and DRUGUNRELATED , and possibly other DRUGUNRELATED and DRUG , may regulate the proliferation of prostate epithelium by a dose - dependent modification of the activity of DRUGOTHER and DRUGUNRELATED .
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	retinoids	EGF	effect	{'e1': {'word': 'retinoids', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d12.s7.e3'}, 'e2': {'word': 'EGF', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d12.s7.e5'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both DRUGUNRELATED and DRUGUNRELATED , and possibly other DRUGUNRELATED and DRUG , may regulate the proliferation of prostate epithelium by a dose - dependent modification of the activity of DRUGUNRELATED and DRUGOTHER .
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	insulin	EGF	none	{'e1': {'word': 'insulin', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d12.s7.e4'}, 'e2': {'word': 'EGF', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d12.s7.e5'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both DRUGUNRELATED and DRUGUNRELATED , and possibly other DRUGUNRELATED and DRUGUNRELATED , may regulate the proliferation of prostate epithelium by a dose - dependent modification of the activity of DRUG and DRUGOTHER .
Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat.	acetaminophen	caffeine	effect	{'e1': {'word': 'acetaminophen', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d55.s0.e0'}, 'e2': {'word': 'caffeine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d55.s0.e1'}, 'sentence_id': 'DDI-MedLine.d55.s0'}	Increased hepatotoxicity of DRUG by concomitant administration of DRUGOTHER in the rat .
Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. 	caffeine	acetaminophen	none	{'e1': {'word': 'caffeine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d55.s1.e0'}, 'e2': {'word': 'acetaminophen', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d55.s1.e1'}, 'sentence_id': 'DDI-MedLine.d55.s1'}	Since DRUG is frequently co-administered with DRUGOTHER , it is of clinical interest to study the effect of DRUGUNRELATED on the hepatotoxicity of DRUGUNRELATED .
Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. 	caffeine	caffeine	none	{'e1': {'word': 'caffeine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d55.s1.e0'}, 'e2': {'word': 'caffeine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d55.s1.e2'}, 'sentence_id': 'DDI-MedLine.d55.s1'}	Since DRUG is frequently co-administered with DRUGUNRELATED , it is of clinical interest to study the effect of DRUGOTHER on the hepatotoxicity of DRUGUNRELATED .
Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. 	caffeine	acetaminophen	none	{'e1': {'word': 'caffeine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d55.s1.e0'}, 'e2': {'word': 'acetaminophen', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d55.s1.e3'}, 'sentence_id': 'DDI-MedLine.d55.s1'}	Since DRUG is frequently co-administered with DRUGUNRELATED , it is of clinical interest to study the effect of DRUGUNRELATED on the hepatotoxicity of DRUGOTHER .
Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. 	acetaminophen	caffeine	none	{'e1': {'word': 'acetaminophen', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d55.s1.e1'}, 'e2': {'word': 'caffeine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d55.s1.e2'}, 'sentence_id': 'DDI-MedLine.d55.s1'}	Since DRUGUNRELATED is frequently co-administered with DRUG , it is of clinical interest to study the effect of DRUGOTHER on the hepatotoxicity of DRUGUNRELATED .
Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. 	acetaminophen	acetaminophen	none	{'e1': {'word': 'acetaminophen', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d55.s1.e1'}, 'e2': {'word': 'acetaminophen', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d55.s1.e3'}, 'sentence_id': 'DDI-MedLine.d55.s1'}	Since DRUGUNRELATED is frequently co-administered with DRUG , it is of clinical interest to study the effect of DRUGUNRELATED on the hepatotoxicity of DRUGOTHER .
Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. 	caffeine	acetaminophen	none	{'e1': {'word': 'caffeine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d55.s1.e2'}, 'e2': {'word': 'acetaminophen', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d55.s1.e3'}, 'sentence_id': 'DDI-MedLine.d55.s1'}	Since DRUGUNRELATED is frequently co-administered with DRUGUNRELATED , it is of clinical interest to study the effect of DRUG on the hepatotoxicity of DRUGOTHER .
Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.	acetaminophen	caffeine	effect	{'e1': {'word': 'acetaminophen', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d55.s4.e0'}, 'e2': {'word': 'caffeine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d55.s4.e1'}, 'sentence_id': 'DDI-MedLine.d55.s4'}	Careful observations on hepatotoxicity are suggested when DRUG is prescribed with DRUGOTHER .
Failure of neomycin to modify ACTH induced hypertension in sheep.	neomycin	ACTH	none	{'e1': {'word': 'neomycin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d2.s0.e0'}, 'e2': {'word': 'ACTH', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d2.s0.e1'}, 'sentence_id': 'DDI-MedLine.d2.s0'}	Failure of DRUG to modify DRUGOTHER induced hypertension in sheep .
Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension. 	neomycin	adrenocortical steroid	none	{'e1': {'word': 'neomycin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d2.s1.e0'}, 'e2': {'word': 'adrenocortical steroid', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d2.s1.e1'}, 'sentence_id': 'DDI-MedLine.d2.s1'}	Studies in rats have shown that DRUG administration attenuates certain types of DRUGOTHER dependent hypertension , including DRUGUNRELATED hypertension .
Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension. 	neomycin	ACTH	effect	{'e1': {'word': 'neomycin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d2.s1.e0'}, 'e2': {'word': 'ACTH', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d2.s1.e2'}, 'sentence_id': 'DDI-MedLine.d2.s1'}	Studies in rats have shown that DRUG administration attenuates certain types of DRUGUNRELATED dependent hypertension , including DRUGOTHER hypertension .
Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension. 	adrenocortical steroid	ACTH	none	{'e1': {'word': 'adrenocortical steroid', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d2.s1.e1'}, 'e2': {'word': 'ACTH', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d2.s1.e2'}, 'sentence_id': 'DDI-MedLine.d2.s1'}	Studies in rats have shown that DRUGUNRELATED administration attenuates certain types of DRUG dependent hypertension , including DRUGOTHER hypertension .
The effects of oral neomycin on ACTH induced hypertension were examined in conscious sheep. 	neomycin	ACTH	none	{'e1': {'word': 'neomycin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d2.s2.e0'}, 'e2': {'word': 'ACTH', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d2.s2.e1'}, 'sentence_id': 'DDI-MedLine.d2.s2'}	The effects of oral DRUG on DRUGOTHER induced hypertension were examined in conscious sheep .
Neomycin has no effect on the blood pressure or metabolic responses to ACTH in sheep.	Neomycin	ACTH	none	{'e1': {'word': 'Neomycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d2.s3.e0'}, 'e2': {'word': 'ACTH', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d2.s3.e1'}, 'sentence_id': 'DDI-MedLine.d2.s3'}	DRUG has no effect on the blood pressure or metabolic responses to DRUGOTHER in sheep .
For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved. 	calcium-entry blocking agents	verapamil	none	{'e1': {'word': 'calcium-entry blocking agents', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d9.s3.e0'}, 'e2': {'word': 'verapamil', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d9.s3.e1'}, 'sentence_id': 'DDI-MedLine.d9.s3'}	For the DRUG now available in the United States ( DRUGOTHER , DRUGUNRELATED and DRUGUNRELATED ) , these data appeared well after clinical patterns of use evolved .
For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved. 	calcium-entry blocking agents	nifedipine	none	{'e1': {'word': 'calcium-entry blocking agents', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d9.s3.e0'}, 'e2': {'word': 'nifedipine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d9.s3.e2'}, 'sentence_id': 'DDI-MedLine.d9.s3'}	For the DRUG now available in the United States ( DRUGUNRELATED , DRUGOTHER and DRUGUNRELATED ) , these data appeared well after clinical patterns of use evolved .
For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved. 	calcium-entry blocking agents	diltiazem	none	{'e1': {'word': 'calcium-entry blocking agents', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d9.s3.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d9.s3.e3'}, 'sentence_id': 'DDI-MedLine.d9.s3'}	For the DRUG now available in the United States ( DRUGUNRELATED , DRUGUNRELATED and DRUGOTHER ) , these data appeared well after clinical patterns of use evolved .
For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved. 	verapamil	nifedipine	none	{'e1': {'word': 'verapamil', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d9.s3.e1'}, 'e2': {'word': 'nifedipine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d9.s3.e2'}, 'sentence_id': 'DDI-MedLine.d9.s3'}	For the DRUGUNRELATED now available in the United States ( DRUG , DRUGOTHER and DRUGUNRELATED ) , these data appeared well after clinical patterns of use evolved .
For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved. 	verapamil	diltiazem	none	{'e1': {'word': 'verapamil', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d9.s3.e1'}, 'e2': {'word': 'diltiazem', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d9.s3.e3'}, 'sentence_id': 'DDI-MedLine.d9.s3'}	For the DRUGUNRELATED now available in the United States ( DRUG , DRUGUNRELATED and DRUGOTHER ) , these data appeared well after clinical patterns of use evolved .
For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved. 	nifedipine	diltiazem	none	{'e1': {'word': 'nifedipine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d9.s3.e2'}, 'e2': {'word': 'diltiazem', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d9.s3.e3'}, 'sentence_id': 'DDI-MedLine.d9.s3'}	For the DRUGUNRELATED now available in the United States ( DRUGUNRELATED , DRUG and DRUGOTHER ) , these data appeared well after clinical patterns of use evolved .
by the nonlinear kinetic characteristics for verapamil and diltiazem (and probably for nifedipine, as well) and the derivative implications for decreased dosing frequency requirements; 	verapamil	diltiazem	none	{'e1': {'word': 'verapamil', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d9.s5.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d9.s5.e1'}, 'sentence_id': 'DDI-MedLine.d9.s5'}	by the nonlinear kinetic characteristics for DRUG and DRUGOTHER ( and probably for DRUGUNRELATED , as well ) and the derivative implications for decreased dosing frequency requirements ;
by the nonlinear kinetic characteristics for verapamil and diltiazem (and probably for nifedipine, as well) and the derivative implications for decreased dosing frequency requirements; 	verapamil	nifedipine	none	{'e1': {'word': 'verapamil', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d9.s5.e0'}, 'e2': {'word': 'nifedipine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d9.s5.e2'}, 'sentence_id': 'DDI-MedLine.d9.s5'}	by the nonlinear kinetic characteristics for DRUG and DRUGUNRELATED ( and probably for DRUGOTHER , as well ) and the derivative implications for decreased dosing frequency requirements ;
by the nonlinear kinetic characteristics for verapamil and diltiazem (and probably for nifedipine, as well) and the derivative implications for decreased dosing frequency requirements; 	diltiazem	nifedipine	none	{'e1': {'word': 'diltiazem', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d9.s5.e1'}, 'e2': {'word': 'nifedipine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d9.s5.e2'}, 'sentence_id': 'DDI-MedLine.d9.s5'}	by the nonlinear kinetic characteristics for DRUGUNRELATED and DRUG ( and probably for DRUGOTHER , as well ) and the derivative implications for decreased dosing frequency requirements ;
"The effects of chlordiazepoxide, amphetamine and cocaine on bar-press behavior in normal and genetically nervous dogs.
"	chlordiazepoxide	amphetamine	none	{'e1': {'word': 'chlordiazepoxide', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d88.s0.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d88.s0.e1'}, 'sentence_id': 'DDI-MedLine.d88.s0'}	The effects of DRUG , DRUGOTHER and DRUGUNRELATED on bar - press behavior in normal and genetically nervous dogs .
"The effects of chlordiazepoxide, amphetamine and cocaine on bar-press behavior in normal and genetically nervous dogs.
"	chlordiazepoxide	cocaine	none	{'e1': {'word': 'chlordiazepoxide', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d88.s0.e0'}, 'e2': {'word': 'cocaine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d88.s0.e2'}, 'sentence_id': 'DDI-MedLine.d88.s0'}	The effects of DRUG , DRUGUNRELATED and DRUGOTHER on bar - press behavior in normal and genetically nervous dogs .
"The effects of chlordiazepoxide, amphetamine and cocaine on bar-press behavior in normal and genetically nervous dogs.
"	amphetamine	cocaine	none	{'e1': {'word': 'amphetamine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d88.s0.e1'}, 'e2': {'word': 'cocaine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d88.s0.e2'}, 'sentence_id': 'DDI-MedLine.d88.s0'}	The effects of DRUGUNRELATED , DRUG and DRUGOTHER on bar - press behavior in normal and genetically nervous dogs .
"Studies on two strains of pointer dogs have demonstrated that administration of a benzodiazepine (chlordiazepoxide) facilitates acquisition of goal-directed behavior in ""genetically nervous"""	benzodiazepine	chlordiazepoxide	none	{'e1': {'word': 'benzodiazepine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d88.s1.e0'}, 'e2': {'word': 'chlordiazepoxide', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d88.s1.e1'}, 'sentence_id': 'DDI-MedLine.d88.s1'}	"Studies on two strains of pointer dogs have demonstrated that administration of a DRUG ( DRUGOTHER ) facilitates acquisition of goal - directed behavior in "" genetically nervous """
The concomitant administration of either cocaine or amphetamine, compounds which inhibit neuronal reuptake of norepinephrine, disrupts the behavioral response of the genetically nervous E-strain subjects to a far greater extent than the stable A-strain subjects. 	cocaine	amphetamine	none	{'e1': {'word': 'cocaine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d88.s4.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d88.s4.e1'}, 'sentence_id': 'DDI-MedLine.d88.s4'}	The concomitant administration of either DRUG or DRUGOTHER , compounds which inhibit neuronal reuptake of norepinephrine , disrupts the behavioral response of the genetically nervous E - strain subjects to a far greater extent than the stable A - strain subjects .
"Interaction of clindamycin and gentamicin in vitro.
"	clindamycin	gentamicin	int	{'e1': {'word': 'clindamycin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d49.s0.e0'}, 'e2': {'word': 'gentamicin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d49.s0.e1'}, 'sentence_id': 'DDI-MedLine.d49.s0'}	Interaction of DRUG and DRUGOTHER in vitro .
The minimal inhibitory concentrations of clindamycin and gentamicin alone and in combinations were determined by a microdilution method for 163 aerobic, facultative, and anaerobic clinical isolates. 	clindamycin	gentamicin	none	{'e1': {'word': 'clindamycin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d49.s1.e0'}, 'e2': {'word': 'gentamicin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d49.s1.e1'}, 'sentence_id': 'DDI-MedLine.d49.s1'}	The minimal inhibitory concentrations of DRUG and DRUGOTHER alone and in combinations were determined by a microdilution method for 163 aerobic , facultative , and anaerobic clinical isolates .
Gentamicin did not interfere with the activity of clindamycin within the range of concentrations tested (0.1 to 100 mug/ml); 	Gentamicin	clindamycin	none	{'e1': {'word': 'Gentamicin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d49.s3.e0'}, 'e2': {'word': 'clindamycin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d49.s3.e1'}, 'sentence_id': 'DDI-MedLine.d49.s3'}	DRUG did not interfere with the activity of DRUGOTHER within the range of concentrations tested ( 0.1 to 100 mug / ml ) ;
Combinations of clindamycin and gentamicin were indifferent for 29 strains and synergistic for 33 strains. 	clindamycin	gentamicin	effect	{'e1': {'word': 'clindamycin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d49.s6.e0'}, 'e2': {'word': 'gentamicin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d49.s6.e1'}, 'sentence_id': 'DDI-MedLine.d49.s6'}	Combinations of DRUG and DRUGOTHER were indifferent for 29 strains and synergistic for 33 strains .
All 20 strains of enterococcus, three strains of Clostridium, three strains of Escherichia coli, and one strain of Proteus rettgeri were resistant to both clindamycin (minimal inhibitory concentration greater than 3.1 mug/ml) and gentamicin (minimal inhibitory concentration greater than 6.2 mug/ml). 	clindamycin	gentamicin	none	{'e1': {'word': 'clindamycin', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d49.s7.e0'}, 'e2': {'word': 'gentamicin', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d49.s7.e1'}, 'sentence_id': 'DDI-MedLine.d49.s7'}	All 20 strains of enterococcus , three strains of Clostridium , three strains of Escherichia coli , and one strain of Proteus rettgeri were resistant to both DRUG ( minimal inhibitory concentration greater than 3.1 mug / ml ) and DRUGOTHER ( minimal inhibitory concentration greater than 6.2 mug / ml ) .
Combinations of clindamycin and gentamicin were indifferent for 16 and synergistic for 11 of the resistant strains. 	clindamycin	gentamicin	effect	{'e1': {'word': 'clindamycin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d49.s8.e0'}, 'e2': {'word': 'gentamicin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d49.s8.e1'}, 'sentence_id': 'DDI-MedLine.d49.s8'}	Combinations of DRUG and DRUGOTHER were indifferent for 16 and synergistic for 11 of the resistant strains .
"Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
"	neurotensin	enkephalins	effect	{'e1': {'word': 'neurotensin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d131.s0.e0'}, 'e2': {'word': 'enkephalins', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d131.s0.e1'}, 'sentence_id': 'DDI-MedLine.d131.s0'}	Interaction on the antinociceptive effect between DRUG and DRUGOTHER or DRUGUNRELATED .
"Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
"	neurotensin	tuftsin	effect	{'e1': {'word': 'neurotensin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d131.s0.e0'}, 'e2': {'word': 'tuftsin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d131.s0.e2'}, 'sentence_id': 'DDI-MedLine.d131.s0'}	Interaction on the antinociceptive effect between DRUG and DRUGUNRELATED or DRUGOTHER .
"Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
"	enkephalins	tuftsin	none	{'e1': {'word': 'enkephalins', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d131.s0.e1'}, 'e2': {'word': 'tuftsin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d131.s0.e2'}, 'sentence_id': 'DDI-MedLine.d131.s0'}	Interaction on the antinociceptive effect between DRUGUNRELATED and DRUG or DRUGOTHER .
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	neurotensin	enkephalins	none	{'e1': {'word': 'neurotensin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d131.s1.e0'}, 'e2': {'word': 'enkephalins', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d131.s1.e1'}, 'sentence_id': 'DDI-MedLine.d131.s1'}	The aim of this paper was to study the interaction between DRUG and both DRUGOTHER or its synthetic analogue DRUGUNRELATED , or DRUGUNRELATED , on the antinonciceptive effect of these peptides in mice after intracisternal injection .
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	neurotensin	D-Ala2-metenkephalinamide	none	{'e1': {'word': 'neurotensin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d131.s1.e0'}, 'e2': {'word': 'D-Ala2-metenkephalinamide', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d131.s1.e2'}, 'sentence_id': 'DDI-MedLine.d131.s1'}	The aim of this paper was to study the interaction between DRUG and both DRUGUNRELATED or its synthetic analogue DRUGOTHER , or DRUGUNRELATED , on the antinonciceptive effect of these peptides in mice after intracisternal injection .
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	neurotensin	tuftsin	none	{'e1': {'word': 'neurotensin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d131.s1.e0'}, 'e2': {'word': 'tuftsin', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d131.s1.e3'}, 'sentence_id': 'DDI-MedLine.d131.s1'}	The aim of this paper was to study the interaction between DRUG and both DRUGUNRELATED or its synthetic analogue DRUGUNRELATED , or DRUGOTHER , on the antinonciceptive effect of these peptides in mice after intracisternal injection .
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	enkephalins	D-Ala2-metenkephalinamide	none	{'e1': {'word': 'enkephalins', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d131.s1.e1'}, 'e2': {'word': 'D-Ala2-metenkephalinamide', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d131.s1.e2'}, 'sentence_id': 'DDI-MedLine.d131.s1'}	The aim of this paper was to study the interaction between DRUGUNRELATED and both DRUG or its synthetic analogue DRUGOTHER , or DRUGUNRELATED , on the antinonciceptive effect of these peptides in mice after intracisternal injection .
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	enkephalins	tuftsin	none	{'e1': {'word': 'enkephalins', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d131.s1.e1'}, 'e2': {'word': 'tuftsin', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d131.s1.e3'}, 'sentence_id': 'DDI-MedLine.d131.s1'}	The aim of this paper was to study the interaction between DRUGUNRELATED and both DRUG or its synthetic analogue DRUGUNRELATED , or DRUGOTHER , on the antinonciceptive effect of these peptides in mice after intracisternal injection .
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	D-Ala2-metenkephalinamide	tuftsin	none	{'e1': {'word': 'D-Ala2-metenkephalinamide', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d131.s1.e2'}, 'e2': {'word': 'tuftsin', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d131.s1.e3'}, 'sentence_id': 'DDI-MedLine.d131.s1'}	The aim of this paper was to study the interaction between DRUGUNRELATED and both DRUGUNRELATED or its synthetic analogue DRUG , or DRUGOTHER , on the antinonciceptive effect of these peptides in mice after intracisternal injection .
It was shown that neurotensin antagonized evidently the antinociceptive effect of enkephalins and their analogue. 	neurotensin	enkephalins	effect	{'e1': {'word': 'neurotensin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d131.s3.e0'}, 'e2': {'word': 'enkephalins', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d131.s3.e1'}, 'sentence_id': 'DDI-MedLine.d131.s3'}	It was shown that DRUG antagonized evidently the antinociceptive effect of DRUGOTHER and their analogue .
On the contrary, neurotensin and tuftsin were agonists in induction of analgesia. 	neurotensin	tuftsin	effect	{'e1': {'word': 'neurotensin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d131.s4.e0'}, 'e2': {'word': 'tuftsin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d131.s4.e1'}, 'sentence_id': 'DDI-MedLine.d131.s4'}	On the contrary , DRUG and DRUGOTHER were agonists in induction of analgesia .
It is concluded that neurotensin modulates in an opposite way the function of the enkephalinergic neurons and the central action of tuftsin.	neurotensin	tuftsin	effect	{'e1': {'word': 'neurotensin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d131.s5.e0'}, 'e2': {'word': 'tuftsin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d131.s5.e1'}, 'sentence_id': 'DDI-MedLine.d131.s5'}	It is concluded that DRUG modulates in an opposite way the function of the enkephalinergic neurons and the central action of DRUGOTHER .
"Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers.
"	rofecoxib	digoxin	none	{'e1': {'word': 'rofecoxib', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d109.s0.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d109.s0.e1'}, 'sentence_id': 'DDI-MedLine.d109.s0'}	Effect of DRUG on the pharmacokinetics of DRUGOTHER in healthy volunteers .
The authors examined the effect of the cyclooxygenase-2 (COX-2) inhibitor, rofecoxib, at steady state on the pharmacokinetics of digoxin following a single dose in healthy subjects. 	rofecoxib	digoxin	none	{'e1': {'word': 'rofecoxib', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d109.s1.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d109.s1.e1'}, 'sentence_id': 'DDI-MedLine.d109.s1'}	The authors examined the effect of the cyclooxygenase - 2 ( COX - 2 ) inhibitor , DRUG , at steady state on the pharmacokinetics of DRUGOTHER following a single dose in healthy subjects .
Samples for plasma and urine immunoreactive digoxin concentrations were collected through 120 hours following the digoxin dose. 	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d109.s5.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d109.s5.e1'}, 'sentence_id': 'DDI-MedLine.d109.s5'}	Samples for plasma and urine immunoreactive DRUG concentrations were collected through 120 hours following the DRUGOTHER dose .
For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. 	digoxin	rofecoxib	none	{'e1': {'word': 'digoxin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d109.s7.e0'}, 'e2': {'word': 'rofecoxib', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d109.s7.e1'}, 'sentence_id': 'DDI-MedLine.d109.s7'}	For DRUG AUC ( 0 - infinity ) , AUC ( 0 - 24 ) , and Cmax , the geometric mean ratios ( 90 % confidence interval ) for ( DRUGOTHER + DRUGUNRELATED / placebo + DRUGUNRELATED ) were 1.04 ( 0.94 , 1.14 ) , 1.02 ( 0.94 , 1.09 ) , and 1.00 ( 0.91 , 1.10 ) , respectively .
For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. 	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d109.s7.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d109.s7.e2'}, 'sentence_id': 'DDI-MedLine.d109.s7'}	For DRUG AUC ( 0 - infinity ) , AUC ( 0 - 24 ) , and Cmax , the geometric mean ratios ( 90 % confidence interval ) for ( DRUGUNRELATED + DRUGOTHER / placebo + DRUGUNRELATED ) were 1.04 ( 0.94 , 1.14 ) , 1.02 ( 0.94 , 1.09 ) , and 1.00 ( 0.91 , 1.10 ) , respectively .
For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. 	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d109.s7.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d109.s7.e3'}, 'sentence_id': 'DDI-MedLine.d109.s7'}	For DRUG AUC ( 0 - infinity ) , AUC ( 0 - 24 ) , and Cmax , the geometric mean ratios ( 90 % confidence interval ) for ( DRUGUNRELATED + DRUGUNRELATED / placebo + DRUGOTHER ) were 1.04 ( 0.94 , 1.14 ) , 1.02 ( 0.94 , 1.09 ) , and 1.00 ( 0.91 , 1.10 ) , respectively .
For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. 	rofecoxib	digoxin	none	{'e1': {'word': 'rofecoxib', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d109.s7.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d109.s7.e2'}, 'sentence_id': 'DDI-MedLine.d109.s7'}	For DRUGUNRELATED AUC ( 0 - infinity ) , AUC ( 0 - 24 ) , and Cmax , the geometric mean ratios ( 90 % confidence interval ) for ( DRUG + DRUGOTHER / placebo + DRUGUNRELATED ) were 1.04 ( 0.94 , 1.14 ) , 1.02 ( 0.94 , 1.09 ) , and 1.00 ( 0.91 , 1.10 ) , respectively .
For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. 	rofecoxib	digoxin	none	{'e1': {'word': 'rofecoxib', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d109.s7.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d109.s7.e3'}, 'sentence_id': 'DDI-MedLine.d109.s7'}	For DRUGUNRELATED AUC ( 0 - infinity ) , AUC ( 0 - 24 ) , and Cmax , the geometric mean ratios ( 90 % confidence interval ) for ( DRUG + DRUGUNRELATED / placebo + DRUGOTHER ) were 1.04 ( 0.94 , 1.14 ) , 1.02 ( 0.94 , 1.09 ) , and 1.00 ( 0.91 , 1.10 ) , respectively .
For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. 	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d109.s7.e2'}, 'e2': {'word': 'digoxin', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d109.s7.e3'}, 'sentence_id': 'DDI-MedLine.d109.s7'}	For DRUGUNRELATED AUC ( 0 - infinity ) , AUC ( 0 - 24 ) , and Cmax , the geometric mean ratios ( 90 % confidence interval ) for ( DRUGUNRELATED + DRUG / placebo + DRUGOTHER ) were 1.04 ( 0.94 , 1.14 ) , 1.02 ( 0.94 , 1.09 ) , and 1.00 ( 0.91 , 1.10 ) , respectively .
The harmonic mean elimination half-life was 45.7 and 43.4 hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively. 	rofecoxib	digoxin	none	{'e1': {'word': 'rofecoxib', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d109.s9.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d109.s9.e1'}, 'sentence_id': 'DDI-MedLine.d109.s9'}	The harmonic mean elimination half - life was 45.7 and 43.4 hours for DRUG + DRUGOTHER and placebo + DRUGUNRELATED treatments , respectively .
The harmonic mean elimination half-life was 45.7 and 43.4 hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively. 	rofecoxib	digoxin	none	{'e1': {'word': 'rofecoxib', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d109.s9.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d109.s9.e2'}, 'sentence_id': 'DDI-MedLine.d109.s9'}	The harmonic mean elimination half - life was 45.7 and 43.4 hours for DRUG + DRUGUNRELATED and placebo + DRUGOTHER treatments , respectively .
The harmonic mean elimination half-life was 45.7 and 43.4 hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively. 	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d109.s9.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d109.s9.e2'}, 'sentence_id': 'DDI-MedLine.d109.s9'}	The harmonic mean elimination half - life was 45.7 and 43.4 hours for DRUGUNRELATED + DRUG and placebo + DRUGOTHER treatments , respectively .
The mean (SD) cumulative urinary excretion of immunoreactive digoxin after concurrent treatment with rofecoxib or placebo was 228.2 (+/- 30.8) and 235.1 (+/- 39.1) micrograms/120 hours, respectively. 	digoxin	rofecoxib	none	{'e1': {'word': 'digoxin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d109.s11.e0'}, 'e2': {'word': 'rofecoxib', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d109.s11.e1'}, 'sentence_id': 'DDI-MedLine.d109.s11'}	The mean ( SD ) cumulative urinary excretion of immunoreactive DRUG after concurrent treatment with DRUGOTHER or placebo was 228.2 ( + / - 30.8 ) and 235.1 ( + / - 39.1 ) micrograms / 120 hours , respectively .
Rofecoxib did not influence the plasma pharmacokinetics or renal elimination of a single oral dose of digoxin.	Rofecoxib	digoxin	none	{'e1': {'word': 'Rofecoxib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d109.s13.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d109.s13.e1'}, 'sentence_id': 'DDI-MedLine.d109.s13'}	DRUG did not influence the plasma pharmacokinetics or renal elimination of a single oral dose of DRUGOTHER .
Many people use both alcohol and nicotine (i.e., cigarettes and other tobacco products). 	alcohol	nicotine	none	{'e1': {'word': 'alcohol', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d122.s1.e0'}, 'e2': {'word': 'nicotine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d122.s1.e1'}, 'sentence_id': 'DDI-MedLine.d122.s1'}	Many people use both DRUG and DRUGOTHER ( i.e. , cigarettes and other tobacco products ) .
The initiation of alcohol or nicotine use may be precipitated by similar personality characteristics in the user, such as impulsivity and sensation seeking. 	alcohol	nicotine	none	{'e1': {'word': 'alcohol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d122.s3.e0'}, 'e2': {'word': 'nicotine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d122.s3.e1'}, 'sentence_id': 'DDI-MedLine.d122.s3'}	The initiation of DRUG or DRUGOTHER use may be precipitated by similar personality characteristics in the user , such as impulsivity and sensation seeking .
Moreover, the mechanisms underlying the development of dependence may be similar for alcohol and nicotine. 	alcohol	nicotine	none	{'e1': {'word': 'alcohol', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d122.s4.e0'}, 'e2': {'word': 'nicotine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d122.s4.e1'}, 'sentence_id': 'DDI-MedLine.d122.s4'}	Moreover , the mechanisms underlying the development of dependence may be similar for DRUG and DRUGOTHER .
"Clinical implications of warfarin interactions with five sedatives.
"	warfarin	sedatives	int	{'e1': {'word': 'warfarin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s0.e0'}, 'e2': {'word': 'sedatives', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d106.s0.e1'}, 'sentence_id': 'DDI-MedLine.d106.s0'}	Clinical implications of DRUG interactions with five DRUGOTHER .
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	anticoagulant	phenobarbital	none	{'e1': {'word': 'anticoagulant', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d106.s1.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d106.s1.e1'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity , uniformity and time course of DRUG interference by DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED and DRUGUNRELATED were systematically investigated in 16 patients receiving DRUGUNRELATED therapy .
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	anticoagulant	secobarbital	none	{'e1': {'word': 'anticoagulant', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d106.s1.e0'}, 'e2': {'word': 'secobarbital', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d106.s1.e2'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity , uniformity and time course of DRUG interference by DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED and DRUGUNRELATED were systematically investigated in 16 patients receiving DRUGUNRELATED therapy .
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	anticoagulant	glutethimide	none	{'e1': {'word': 'anticoagulant', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d106.s1.e0'}, 'e2': {'word': 'glutethimide', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d106.s1.e3'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity , uniformity and time course of DRUG interference by DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED and DRUGUNRELATED were systematically investigated in 16 patients receiving DRUGUNRELATED therapy .
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	anticoagulant	chloral hydrate	none	{'e1': {'word': 'anticoagulant', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d106.s1.e0'}, 'e2': {'word': 'chloral hydrate', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d106.s1.e4'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity , uniformity and time course of DRUG interference by DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER and DRUGUNRELATED were systematically investigated in 16 patients receiving DRUGUNRELATED therapy .
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	anticoagulant	methaqualone	none	{'e1': {'word': 'anticoagulant', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d106.s1.e0'}, 'e2': {'word': 'methaqualone', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d106.s1.e5'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity , uniformity and time course of DRUG interference by DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED and DRUGOTHER were systematically investigated in 16 patients receiving DRUGUNRELATED therapy .
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	anticoagulant	coumarin	none	{'e1': {'word': 'anticoagulant', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d106.s1.e0'}, 'e2': {'word': 'coumarin', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d106.s1.e6'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity , uniformity and time course of DRUG interference by DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED and DRUGUNRELATED were systematically investigated in 16 patients receiving DRUGOTHER therapy .
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	phenobarbital	secobarbital	none	{'e1': {'word': 'phenobarbital', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d106.s1.e1'}, 'e2': {'word': 'secobarbital', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d106.s1.e2'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity , uniformity and time course of DRUGUNRELATED interference by DRUG , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED and DRUGUNRELATED were systematically investigated in 16 patients receiving DRUGUNRELATED therapy .
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	phenobarbital	glutethimide	none	{'e1': {'word': 'phenobarbital', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d106.s1.e1'}, 'e2': {'word': 'glutethimide', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d106.s1.e3'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity , uniformity and time course of DRUGUNRELATED interference by DRUG , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED and DRUGUNRELATED were systematically investigated in 16 patients receiving DRUGUNRELATED therapy .
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	phenobarbital	chloral hydrate	none	{'e1': {'word': 'phenobarbital', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d106.s1.e1'}, 'e2': {'word': 'chloral hydrate', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d106.s1.e4'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity , uniformity and time course of DRUGUNRELATED interference by DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER and DRUGUNRELATED were systematically investigated in 16 patients receiving DRUGUNRELATED therapy .
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	phenobarbital	methaqualone	none	{'e1': {'word': 'phenobarbital', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d106.s1.e1'}, 'e2': {'word': 'methaqualone', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d106.s1.e5'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity , uniformity and time course of DRUGUNRELATED interference by DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED and DRUGOTHER were systematically investigated in 16 patients receiving DRUGUNRELATED therapy .
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	phenobarbital	coumarin	none	{'e1': {'word': 'phenobarbital', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d106.s1.e1'}, 'e2': {'word': 'coumarin', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d106.s1.e6'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity , uniformity and time course of DRUGUNRELATED interference by DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED and DRUGUNRELATED were systematically investigated in 16 patients receiving DRUGOTHER therapy .
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	secobarbital	glutethimide	none	{'e1': {'word': 'secobarbital', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d106.s1.e2'}, 'e2': {'word': 'glutethimide', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d106.s1.e3'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity , uniformity and time course of DRUGUNRELATED interference by DRUGUNRELATED , DRUG , DRUGOTHER , DRUGUNRELATED and DRUGUNRELATED were systematically investigated in 16 patients receiving DRUGUNRELATED therapy .
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	secobarbital	chloral hydrate	none	{'e1': {'word': 'secobarbital', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d106.s1.e2'}, 'e2': {'word': 'chloral hydrate', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d106.s1.e4'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity , uniformity and time course of DRUGUNRELATED interference by DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGOTHER and DRUGUNRELATED were systematically investigated in 16 patients receiving DRUGUNRELATED therapy .
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	secobarbital	methaqualone	none	{'e1': {'word': 'secobarbital', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d106.s1.e2'}, 'e2': {'word': 'methaqualone', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d106.s1.e5'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity , uniformity and time course of DRUGUNRELATED interference by DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGUNRELATED and DRUGOTHER were systematically investigated in 16 patients receiving DRUGUNRELATED therapy .
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	secobarbital	coumarin	none	{'e1': {'word': 'secobarbital', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d106.s1.e2'}, 'e2': {'word': 'coumarin', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d106.s1.e6'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity , uniformity and time course of DRUGUNRELATED interference by DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGUNRELATED and DRUGUNRELATED were systematically investigated in 16 patients receiving DRUGOTHER therapy .
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	glutethimide	chloral hydrate	none	{'e1': {'word': 'glutethimide', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d106.s1.e3'}, 'e2': {'word': 'chloral hydrate', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d106.s1.e4'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity , uniformity and time course of DRUGUNRELATED interference by DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGOTHER and DRUGUNRELATED were systematically investigated in 16 patients receiving DRUGUNRELATED therapy .
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	glutethimide	methaqualone	none	{'e1': {'word': 'glutethimide', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d106.s1.e3'}, 'e2': {'word': 'methaqualone', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d106.s1.e5'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity , uniformity and time course of DRUGUNRELATED interference by DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGUNRELATED and DRUGOTHER were systematically investigated in 16 patients receiving DRUGUNRELATED therapy .
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	glutethimide	coumarin	none	{'e1': {'word': 'glutethimide', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d106.s1.e3'}, 'e2': {'word': 'coumarin', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d106.s1.e6'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity , uniformity and time course of DRUGUNRELATED interference by DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGUNRELATED and DRUGUNRELATED were systematically investigated in 16 patients receiving DRUGOTHER therapy .
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	chloral hydrate	methaqualone	none	{'e1': {'word': 'chloral hydrate', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d106.s1.e4'}, 'e2': {'word': 'methaqualone', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d106.s1.e5'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity , uniformity and time course of DRUGUNRELATED interference by DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUG and DRUGOTHER were systematically investigated in 16 patients receiving DRUGUNRELATED therapy .
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	chloral hydrate	coumarin	none	{'e1': {'word': 'chloral hydrate', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d106.s1.e4'}, 'e2': {'word': 'coumarin', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d106.s1.e6'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity , uniformity and time course of DRUGUNRELATED interference by DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUG and DRUGUNRELATED were systematically investigated in 16 patients receiving DRUGOTHER therapy .
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	methaqualone	coumarin	none	{'e1': {'word': 'methaqualone', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d106.s1.e5'}, 'e2': {'word': 'coumarin', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d106.s1.e6'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity , uniformity and time course of DRUGUNRELATED interference by DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED and DRUG were systematically investigated in 16 patients receiving DRUGOTHER therapy .
Anticoagulant inhibition was observed during the administration of phenobarbital, secobarbital and glutethimide; 	phenobarbital	secobarbital	none	{'e1': {'word': 'phenobarbital', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d106.s4.e0'}, 'e2': {'word': 'secobarbital', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d106.s4.e1'}, 'sentence_id': 'DDI-MedLine.d106.s4'}	Anticoagulant inhibition was observed during the administration of DRUG , DRUGOTHER and DRUGUNRELATED ;
Anticoagulant inhibition was observed during the administration of phenobarbital, secobarbital and glutethimide; 	phenobarbital	glutethimide	none	{'e1': {'word': 'phenobarbital', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d106.s4.e0'}, 'e2': {'word': 'glutethimide', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d106.s4.e2'}, 'sentence_id': 'DDI-MedLine.d106.s4'}	Anticoagulant inhibition was observed during the administration of DRUG , DRUGUNRELATED and DRUGOTHER ;
Anticoagulant inhibition was observed during the administration of phenobarbital, secobarbital and glutethimide; 	secobarbital	glutethimide	none	{'e1': {'word': 'secobarbital', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d106.s4.e1'}, 'e2': {'word': 'glutethimide', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d106.s4.e2'}, 'sentence_id': 'DDI-MedLine.d106.s4'}	Anticoagulant inhibition was observed during the administration of DRUGUNRELATED , DRUG and DRUGOTHER ;
there was no significant change in prothrombin test results during the trials of chloral hydrate and methaqualone. 	chloral hydrate	methaqualone	none	{'e1': {'word': 'chloral hydrate', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d106.s5.e0'}, 'e2': {'word': 'methaqualone', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d106.s5.e1'}, 'sentence_id': 'DDI-MedLine.d106.s5'}	there was no significant change in prothrombin test results during the trials of DRUG and DRUGOTHER .
Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs. 	Barbiturates	glutethimide	none	{'e1': {'word': 'Barbiturates', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d106.s6.e0'}, 'e2': {'word': 'glutethimide', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d106.s6.e1'}, 'sentence_id': 'DDI-MedLine.d106.s6'}	DRUG and DRUGOTHER should not be administered to patients receiving DRUGUNRELATED .
Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs. 	Barbiturates	coumarin drugs	advise	{'e1': {'word': 'Barbiturates', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d106.s6.e0'}, 'e2': {'word': 'coumarin drugs', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d106.s6.e2'}, 'sentence_id': 'DDI-MedLine.d106.s6'}	DRUG and DRUGUNRELATED should not be administered to patients receiving DRUGOTHER .
Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs. 	glutethimide	coumarin drugs	advise	{'e1': {'word': 'glutethimide', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d106.s6.e1'}, 'e2': {'word': 'coumarin drugs', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d106.s6.e2'}, 'sentence_id': 'DDI-MedLine.d106.s6'}	DRUGUNRELATED and DRUG should not be administered to patients receiving DRUGOTHER .
Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant. 	Chloral hydrate	methaqualone	none	{'e1': {'word': 'Chloral hydrate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d106.s8.e0'}, 'e2': {'word': 'methaqualone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d106.s8.e1'}, 'sentence_id': 'DDI-MedLine.d106.s8'}	DRUG and DRUGOTHER interact pharmacologically with orally administered DRUGUNRELATED , but the effect is not clinically significant .
Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant. 	Chloral hydrate	anticoagulant agents	int	{'e1': {'word': 'Chloral hydrate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d106.s8.e0'}, 'e2': {'word': 'anticoagulant agents', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d106.s8.e2'}, 'sentence_id': 'DDI-MedLine.d106.s8'}	DRUG and DRUGUNRELATED interact pharmacologically with orally administered DRUGOTHER , but the effect is not clinically significant .
Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant. 	methaqualone	anticoagulant agents	int	{'e1': {'word': 'methaqualone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d106.s8.e1'}, 'e2': {'word': 'anticoagulant agents', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d106.s8.e2'}, 'sentence_id': 'DDI-MedLine.d106.s8'}	DRUGUNRELATED and DRUG interact pharmacologically with orally administered DRUGOTHER , but the effect is not clinically significant .
It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.	chloral hydrate	methaqualone	none	{'e1': {'word': 'chloral hydrate', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d106.s9.e0'}, 'e2': {'word': 'methaqualone', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d106.s9.e1'}, 'sentence_id': 'DDI-MedLine.d106.s9'}	It is concluded that DRUG and DRUGOTHER may be administered safely without additional caution in prothrombin test monitoring during oral DRUGUNRELATED therapy .
It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.	chloral hydrate	anticoagulant	none	{'e1': {'word': 'chloral hydrate', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d106.s9.e0'}, 'e2': {'word': 'anticoagulant', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d106.s9.e2'}, 'sentence_id': 'DDI-MedLine.d106.s9'}	It is concluded that DRUG and DRUGUNRELATED may be administered safely without additional caution in prothrombin test monitoring during oral DRUGOTHER therapy .
It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.	methaqualone	anticoagulant	none	{'e1': {'word': 'methaqualone', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d106.s9.e1'}, 'e2': {'word': 'anticoagulant', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d106.s9.e2'}, 'sentence_id': 'DDI-MedLine.d106.s9'}	It is concluded that DRUGUNRELATED and DRUG may be administered safely without additional caution in prothrombin test monitoring during oral DRUGOTHER therapy .
"Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
"	everolimus	cyclosporine	none	{'e1': {'word': 'everolimus', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d140.s0.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d140.s0.e1'}, 'sentence_id': 'DDI-MedLine.d140.s0'}	Longitudinal assessment of DRUG in de novo renal transplant recipients over the first post-transplant year : pharmacokinetics , exposure - response relationships , and influence on DRUGOTHER .
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation. 	everolimus	cyclosporine	none	{'e1': {'word': 'everolimus', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d140.s1.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d140.s1.e1'}, 'sentence_id': 'DDI-MedLine.d140.s1'}	OBJECTIVE : Our objective was to characterize the steady - state pharmacokinetics of DRUG and DRUGOTHER ( INN , DRUGUNRELATED ) when coadministered in de novo kidney allograft recipients during the first year after transplantation .
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation. 	everolimus	ciclosporin	none	{'e1': {'word': 'everolimus', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d140.s1.e0'}, 'e2': {'word': 'ciclosporin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d140.s1.e2'}, 'sentence_id': 'DDI-MedLine.d140.s1'}	OBJECTIVE : Our objective was to characterize the steady - state pharmacokinetics of DRUG and DRUGUNRELATED ( INN , DRUGOTHER ) when coadministered in de novo kidney allograft recipients during the first year after transplantation .
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation. 	cyclosporine	ciclosporin	none	{'e1': {'word': 'cyclosporine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d140.s1.e1'}, 'e2': {'word': 'ciclosporin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d140.s1.e2'}, 'sentence_id': 'DDI-MedLine.d140.s1'}	OBJECTIVE : Our objective was to characterize the steady - state pharmacokinetics of DRUGUNRELATED and DRUG ( INN , DRUGOTHER ) when coadministered in de novo kidney allograft recipients during the first year after transplantation .
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone. 	everolimus	cyclosporine	none	{'e1': {'word': 'everolimus', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d140.s2.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d140.s2.e1'}, 'sentence_id': 'DDI-MedLine.d140.s2'}	METHOD : This study was a multicenter randomized double - blind study of 101 patients who were randomly assigned 1 : 1 : 1 to receive DRUG tablets at doses of 0.5 mg , 1 mg , or 2 mg twice daily with DRUGOTHER and DRUGUNRELATED .
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone. 	everolimus	prednisone	none	{'e1': {'word': 'everolimus', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d140.s2.e0'}, 'e2': {'word': 'prednisone', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d140.s2.e2'}, 'sentence_id': 'DDI-MedLine.d140.s2'}	METHOD : This study was a multicenter randomized double - blind study of 101 patients who were randomly assigned 1 : 1 : 1 to receive DRUG tablets at doses of 0.5 mg , 1 mg , or 2 mg twice daily with DRUGUNRELATED and DRUGOTHER .
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone. 	cyclosporine	prednisone	none	{'e1': {'word': 'cyclosporine', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d140.s2.e1'}, 'e2': {'word': 'prednisone', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d140.s2.e2'}, 'sentence_id': 'DDI-MedLine.d140.s2'}	METHOD : This study was a multicenter randomized double - blind study of 101 patients who were randomly assigned 1 : 1 : 1 to receive DRUGUNRELATED tablets at doses of 0.5 mg , 1 mg , or 2 mg twice daily with DRUG and DRUGOTHER .
Blood sampling for the pharmacokinetics of everolimus and cyclosporine was performed on day 1, on weeks 1, 2, 3, and 4, and on months 2, 3, 6, 9, and 12. 	everolimus	cyclosporine	none	{'e1': {'word': 'everolimus', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d140.s3.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d140.s3.e1'}, 'sentence_id': 'DDI-MedLine.d140.s3'}	Blood sampling for the pharmacokinetics of DRUG and DRUGOTHER was performed on day 1 , on weeks 1 , 2 , 3 , and 4 , and on months 2 , 3 , 6 , 9 , and 12 .
Potential differences in cyclosporine dosing and pharmacokinetics at different levels of everolimus exposure were assessed in the context of ANOVA. 	cyclosporine	everolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d140.s6.e0'}, 'e2': {'word': 'everolimus', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d140.s6.e1'}, 'sentence_id': 'DDI-MedLine.d140.s6'}	Potential differences in DRUG dosing and pharmacokinetics at different levels of DRUGOTHER exposure were assessed in the context of ANOVA .
Cyclosporine doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered everolimus dose level (P = .13, .82, and .76, respectively). 	Cyclosporine	everolimus	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d140.s13.e0'}, 'e2': {'word': 'everolimus', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d140.s13.e1'}, 'sentence_id': 'DDI-MedLine.d140.s13'}	DRUG doses , trough concentrations , and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered DRUGOTHER dose level ( P = .13 , .82 , and .76 , respectively ) .
For a 4-fold range of everolimus doses there were no differential effects on cyclosporine dosing or pharmacokinetics.	everolimus	cyclosporine	none	{'e1': {'word': 'everolimus', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d140.s15.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d140.s15.e1'}, 'sentence_id': 'DDI-MedLine.d140.s15'}	For a 4-fold range of DRUG doses there were no differential effects on DRUGOTHER dosing or pharmacokinetics .
